0001048477-21-000008.txt : 20210226 0001048477-21-000008.hdr.sgml : 20210226 20210226151619 ACCESSION NUMBER: 0001048477-21-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 121 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210226 DATE AS OF CHANGE: 20210226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 21687856 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 10-K 1 bmrn-20201231.htm 10-K bmrn-20201231
FALSE2020FY0001048477P1YP1Y2.25us-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrentP3Y00010484772020-01-012020-12-31iso4217:USD00010484772020-06-30xbrli:shares00010484772021-02-1200010484772020-12-3100010484772019-12-31iso4217:USDxbrli:shares0001048477us-gaap:ProductMember2020-01-012020-12-310001048477us-gaap:ProductMember2019-01-012019-12-310001048477us-gaap:ProductMember2018-01-012018-12-310001048477bmrn:RoyaltyAndOtherMember2020-01-012020-12-310001048477bmrn:RoyaltyAndOtherMember2019-01-012019-12-310001048477bmrn:RoyaltyAndOtherMember2018-01-012018-12-3100010484772019-01-012019-12-3100010484772018-01-012018-12-310001048477us-gaap:CommonStockMember2019-12-310001048477us-gaap:CommonStockMember2018-12-310001048477us-gaap:CommonStockMember2017-12-310001048477us-gaap:CommonStockMember2020-01-012020-12-310001048477us-gaap:CommonStockMember2019-01-012019-12-310001048477us-gaap:CommonStockMember2018-01-012018-12-310001048477us-gaap:CommonStockMember2020-12-3100010484772018-12-3100010484772017-12-310001048477us-gaap:AdditionalPaidInCapitalMember2019-12-310001048477us-gaap:AdditionalPaidInCapitalMember2018-12-310001048477us-gaap:AdditionalPaidInCapitalMember2017-12-310001048477us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001048477us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001048477us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001048477us-gaap:AdditionalPaidInCapitalMember2020-12-310001048477us-gaap:TreasuryStockMember2019-12-310001048477us-gaap:TreasuryStockMember2018-12-310001048477us-gaap:TreasuryStockMember2017-12-310001048477us-gaap:TreasuryStockMember2020-01-012020-12-310001048477us-gaap:TreasuryStockMember2019-01-012019-12-310001048477us-gaap:TreasuryStockMember2018-01-012018-12-310001048477us-gaap:TreasuryStockMember2020-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2018-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2017-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-01-012020-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-01-012019-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2018-01-012018-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001048477us-gaap:RetainedEarningsMember2019-12-310001048477us-gaap:RetainedEarningsMember2018-12-310001048477us-gaap:RetainedEarningsMember2017-12-310001048477us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001048477us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001048477us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310001048477us-gaap:RetainedEarningsMember2020-01-012020-12-310001048477us-gaap:RetainedEarningsMember2019-01-012019-12-310001048477us-gaap:RetainedEarningsMember2018-01-012018-12-310001048477us-gaap:RetainedEarningsMember2020-12-310001048477us-gaap:LeaseholdImprovementsMember2020-01-012020-12-310001048477srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2020-01-012020-12-310001048477us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2020-01-012020-12-310001048477srt:MinimumMemberus-gaap:EquipmentMember2020-01-012020-12-310001048477us-gaap:EquipmentMembersrt:MaximumMember2020-01-012020-12-310001048477us-gaap:ComputerEquipmentMembersrt:MinimumMember2020-01-012020-12-310001048477us-gaap:ComputerEquipmentMembersrt:MaximumMember2020-01-012020-12-310001048477us-gaap:OfficeEquipmentMember2020-01-012020-12-310001048477us-gaap:VehiclesMember2020-01-012020-12-310001048477srt:MinimumMemberus-gaap:LandImprovementsMember2020-01-012020-12-310001048477us-gaap:LandImprovementsMembersrt:MaximumMember2020-01-012020-12-31xbrli:pure0001048477srt:MinimumMemberbmrn:ProductOneMember2020-12-310001048477bmrn:ProductOneMembersrt:MaximumMember2020-12-31bmrn:tranchebmrn:Segment0001048477us-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2020-12-310001048477us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477bmrn:ForeignGovernmentAndOtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2019-12-310001048477us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477bmrn:ForeignGovernmentAndOtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:FairValueInputsLevel2Member2019-12-310001048477srt:MaximumMember2019-01-012019-12-310001048477srt:MaximumMember2020-01-012020-12-310001048477srt:MinimumMember2020-01-012020-12-310001048477srt:MinimumMember2019-01-012019-12-310001048477bmrn:StrategicInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:StrategicInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberbmrn:FirdapseMember2020-01-310001048477us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberbmrn:FirdapseMember2020-01-012020-03-310001048477us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberbmrn:FirdapseMember2020-03-310001048477bmrn:AcquiredIntellectualPropertyMember2020-12-310001048477bmrn:AcquiredIntellectualPropertyMember2020-01-012020-12-310001048477bmrn:RepurchasedRoyaltyRightsMember2020-12-310001048477bmrn:RepurchasedRoyaltyRightsMember2020-01-012020-12-310001048477bmrn:TechnologyTransferMember2020-12-310001048477us-gaap:OtherIntangibleAssetsMember2020-12-310001048477us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2020-01-012020-12-310001048477us-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2020-01-012020-12-310001048477bmrn:MedivationMember2019-01-012019-12-310001048477bmrn:MedivationMember2018-01-012018-12-310001048477us-gaap:BuildingAndBuildingImprovementsMember2020-12-310001048477us-gaap:BuildingAndBuildingImprovementsMember2019-12-310001048477us-gaap:EquipmentMember2020-12-310001048477us-gaap:EquipmentMember2019-12-310001048477us-gaap:ComputerEquipmentMember2020-12-310001048477us-gaap:ComputerEquipmentMember2019-12-310001048477us-gaap:LandMember2020-12-310001048477us-gaap:LandMember2019-12-310001048477us-gaap:LeaseholdImprovementsMember2020-12-310001048477us-gaap:LeaseholdImprovementsMember2019-12-310001048477us-gaap:FurnitureAndFixturesMember2020-12-310001048477us-gaap:FurnitureAndFixturesMember2019-12-310001048477us-gaap:LandImprovementsMember2020-12-310001048477us-gaap:LandImprovementsMember2019-12-310001048477us-gaap:ConstructionInProgressMember2020-12-310001048477us-gaap:ConstructionInProgressMember2019-12-310001048477bmrn:PreLaunchValoctocogeneRoxaparvovecMember2019-12-310001048477bmrn:PreLaunchValoctocogeneRoxaparvovecMember2020-12-310001048477bmrn:AccruedRebatesMember2019-12-310001048477bmrn:AccruedRebatesMember2020-01-012020-12-310001048477bmrn:AccruedRebatesMember2020-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2019-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2020-01-012020-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2020-12-310001048477bmrn:AccruedRebatesMember2018-12-310001048477bmrn:AccruedRebatesMember2019-01-012019-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2018-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2019-01-012019-12-310001048477bmrn:AccruedRebatesMember2017-12-310001048477bmrn:AccruedRebatesMember2018-01-012018-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2017-12-310001048477bmrn:AllowancesForReserveForCashDiscountsMember2018-01-012018-12-310001048477us-gaap:FairValueInputsLevel1Member2019-12-310001048477us-gaap:FairValueInputsLevel1Member2020-12-310001048477us-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel3Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel3Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001048477us-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477bmrn:ContingentPaymentMember2019-12-310001048477bmrn:ContingentPaymentMember2020-01-012020-12-310001048477bmrn:ContingentPaymentMember2020-12-310001048477us-gaap:NondesignatedMember2020-01-012020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberus-gaap:ForeignExchangeContractMember2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberus-gaap:ForeignExchangeContractMember2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMemberus-gaap:ForeignExchangeContractMember2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMemberus-gaap:ForeignExchangeContractMember2019-12-310001048477us-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001048477us-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2019-12-310001048477us-gaap:LongMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001048477us-gaap:LongMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001048477us-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMember2020-01-012020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMember2019-01-012019-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-12-310001048477us-gaap:NondesignatedMember2019-01-012019-12-310001048477us-gaap:ForeignExchangeContractMember2020-01-012020-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310001048477us-gaap:OperatingExpenseMember2020-01-012020-12-310001048477us-gaap:OperatingExpenseMember2019-01-012019-12-310001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member2020-12-310001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member2019-12-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2020-12-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2019-12-310001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2020-12-310001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2019-12-310001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2020-10-152020-10-150001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2018-10-15utr:D0001048477us-gaap:ConvertibleDebtMember2020-01-012020-12-310001048477us-gaap:ConvertibleDebtMember2019-01-012019-12-310001048477us-gaap:ConvertibleDebtMember2018-01-012018-12-310001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Memberus-gaap:SeniorSubordinatedNotesMember2020-05-310001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Memberus-gaap:SeniorSubordinatedNotesMember2020-05-012020-05-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2017-08-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2017-08-012017-08-310001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2017-08-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2020-01-012020-12-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-310001048477srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477us-gaap:BaseRateMembersrt:MinimumMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477us-gaap:BaseRateMembersrt:MaximumMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477srt:MinimumMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477srt:MaximumMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2020-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001048477us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-01-012018-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001048477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2017-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2017-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2017-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310001048477bmrn:AccumulatedGainLossFromOtherMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2017-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310001048477bmrn:AccumulatedGainLossFromOtherMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2017-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2017-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-01-012018-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2018-01-012018-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2018-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2019-01-012019-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2019-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2020-01-012020-12-310001048477us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2020-12-310001048477srt:MinimumMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001048477country:US2020-01-012020-12-310001048477country:US2019-01-012019-12-310001048477country:US2018-01-012018-12-310001048477srt:EuropeMember2020-01-012020-12-310001048477srt:EuropeMember2019-01-012019-12-310001048477srt:EuropeMember2018-01-012018-12-310001048477srt:LatinAmericaMember2020-01-012020-12-310001048477srt:LatinAmericaMember2019-01-012019-12-310001048477srt:LatinAmericaMember2018-01-012018-12-310001048477bmrn:RestOfWorldMember2020-01-012020-12-310001048477bmrn:RestOfWorldMember2019-01-012019-12-310001048477bmrn:RestOfWorldMember2018-01-012018-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductFourMember2020-01-012020-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductFourMember2019-01-012019-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductFourMember2018-01-012018-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2020-01-012020-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2019-01-012019-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2018-01-012018-12-310001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-12-310001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-12-310001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2018-01-012018-12-310001048477bmrn:ProductSevenMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-12-310001048477bmrn:ProductSevenMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-12-310001048477bmrn:ProductSevenMemberus-gaap:SalesChannelDirectlyToConsumerMember2018-01-012018-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSixMember2020-01-012020-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSixMember2019-01-012019-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSixMember2018-01-012018-12-310001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-12-310001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-12-310001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2018-01-012018-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2018-01-012018-12-310001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ProductOneMember2020-01-012020-12-310001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ProductOneMember2019-01-012019-12-310001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ProductOneMember2018-01-012018-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMembercountry:US2020-01-012020-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMembercountry:US2019-01-012019-12-310001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMembercountry:US2018-01-012018-12-310001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-12-310001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-12-310001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2018-01-012018-12-310001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-12-310001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-12-310001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2018-01-012018-12-310001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-12-310001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-12-310001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2018-01-012018-12-310001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerOneMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerOneMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001048477bmrn:CustomersMember2020-12-310001048477bmrn:CustomersMember2019-12-310001048477country:US2020-12-310001048477country:US2019-12-310001048477country:IE2020-12-310001048477country:IE2019-12-310001048477bmrn:RestOfWorldMember2020-12-310001048477bmrn:RestOfWorldMember2019-12-310001048477us-gaap:EmployeeStockOptionMemberbmrn:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMemberbmrn:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-12-310001048477bmrn:TwoThousandSeventeenEquityIncentivePlanMember2020-12-310001048477us-gaap:EmployeeStockMember2020-01-012020-12-310001048477us-gaap:EmployeeStockMember2020-12-310001048477bmrn:IndependentDirectorMemberus-gaap:CommonStockMemberus-gaap:RestrictedStockMember2019-09-192019-09-190001048477bmrn:IndependentDirectorMemberus-gaap:CommonStockMemberus-gaap:RestrictedStockMember2019-09-182019-09-180001048477us-gaap:CostOfSalesMember2020-01-012020-12-310001048477us-gaap:CostOfSalesMember2019-01-012019-12-310001048477us-gaap:CostOfSalesMember2018-01-012018-12-310001048477us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001048477us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001048477us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMember2019-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMember2020-01-012020-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMember2020-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMember2019-01-012019-12-310001048477bmrn:RestrictedStockWithServiceBasedVestingConditionsMember2018-01-012018-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2020-01-012020-12-310001048477srt:MinimumMemberbmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2020-01-012020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMembersrt:MaximumMember2020-01-012020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2019-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2019-01-012019-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember2018-01-012018-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember2019-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember2020-01-012020-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember2020-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember2019-01-012019-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMembersrt:MinimumMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMembersrt:MaximumMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsProbableOfVestingMember2020-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsNotProbableOfVestingMember2020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-01-012020-12-310001048477srt:MinimumMemberbmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-01-012020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMembersrt:MaximumMember2020-01-012020-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember2019-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember2020-01-012020-12-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember2020-12-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-012020-03-310001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-06-300001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-06-012020-06-300001048477bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-12-310001048477us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001048477us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001048477us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-01-012020-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-01-012020-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MinimumMember2019-01-012019-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MaximumMember2019-01-012019-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MinimumMember2018-01-012018-12-310001048477us-gaap:EmployeeStockOptionMembersrt:MaximumMember2018-01-012018-12-310001048477us-gaap:EmployeeStockOptionMember2020-12-310001048477us-gaap:EmployeeStockMember2019-01-012019-12-310001048477us-gaap:EmployeeStockMember2018-01-012018-12-310001048477us-gaap:EmployeeStockMembersrt:MinimumMember2020-01-012020-12-310001048477us-gaap:EmployeeStockMembersrt:MaximumMember2020-01-012020-12-310001048477us-gaap:EmployeeStockMembersrt:MinimumMember2019-01-012019-12-310001048477us-gaap:EmployeeStockMembersrt:MaximumMember2019-01-012019-12-310001048477us-gaap:EmployeeStockMembersrt:MinimumMember2018-01-012018-12-310001048477us-gaap:EmployeeStockMembersrt:MaximumMember2018-01-012018-12-310001048477bmrn:BiomarinRetirementSavingsPlanMember2020-01-012020-12-310001048477bmrn:BiomarinRetirementSavingsPlanMember2019-01-012019-12-310001048477bmrn:BiomarinRetirementSavingsPlanMember2018-01-012018-12-310001048477country:IE2020-09-300001048477country:NL2020-12-310001048477us-gaap:DomesticCountryMember2020-12-310001048477us-gaap:StateAndLocalJurisdictionMember2020-12-310001048477country:NLus-gaap:ForeignCountryMember2020-12-310001048477us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001048477us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001048477us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2020-01-012020-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2019-01-012019-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2018-01-012018-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-01-012020-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2019-01-012019-12-310001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2018-01-012018-12-310001048477us-gaap:RestrictedStockMember2020-01-012020-12-310001048477us-gaap:RestrictedStockMember2019-01-012019-12-310001048477us-gaap:RestrictedStockMember2018-01-012018-12-310001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2020-01-012020-12-310001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2019-01-012019-12-310001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2018-01-012018-12-310001048477us-gaap:StockCompensationPlanMember2020-01-012020-12-310001048477us-gaap:StockCompensationPlanMember2019-01-012019-12-310001048477us-gaap:StockCompensationPlanMember2018-01-012018-12-310001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2020-01-012020-12-310001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2019-01-012019-12-310001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2018-01-012018-12-310001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2019-12-310001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2018-12-310001048477bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember2019-10-012019-10-310001048477us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberbmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember2019-10-012019-10-310001048477bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember2020-12-310001048477bmrn:LicenseAgreementAndSettlementAgreementMemberbmrn:SareptaTherapeuticsMembercountry:US2017-07-012017-07-310001048477bmrn:LicenseAgreementAndSettlementAgreementMemberus-gaap:NonUsMemberbmrn:SareptaTherapeuticsMember2017-07-012017-07-31iso4217:EUR0001048477bmrn:MerckSeronoMemberbmrn:AAndRKuvanAgreementMembersrt:MaximumMember2020-12-310001048477bmrn:MerckSeronoMember2020-01-012020-12-310001048477bmrn:MerckSeronoMemberbmrn:PegvaliaseAgreementMember2020-01-012020-12-310001048477us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberbmrn:FirdapseMember2019-03-310001048477bmrn:EarlyStageDevelopmentProgramMemberbmrn:ThirdPartyMember2020-04-012020-06-300001048477bmrn:MerckSeronoMemberbmrn:CompletedProjectMember2020-01-012020-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________
Form 10-K
____________
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
Or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                    .
Commission file number: 000-26727
____________
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
____________
Delaware68-0397820
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
770 Lindaro StreetSan RafaelCalifornia94901
(Address of principal executive offices)(Zip Code)
(415) 506-6700
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $.001BMRNThe Nasdaq Global Select Market
Securities registered under Section 12(g) of the Act:
None
____________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging Growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.)    Yes  ☐    No   ☒
The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2020 was $13.9 billion, based on the closing price reported for such date on the Nasdaq Global Select Market.
As of February 12, 2021, the registrant had 181,829,680 shares of common stock, par value $0.001, outstanding.  
Documents Incorporated by Reference: Specified portions of the registrant's definitive proxy statement for the registrant's 2021 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December 31, 2020, are incorporated by reference under Part III of this Annual Report on Form 10-K.

1

BIOMARIN PHARMACEUTICAL INC.
2020 FORM 10-K ANNUAL REPORT
TABLE OF CONTENTS

2

Unless the context suggests otherwise, references in this Annual Report on Form 10-K to “BioMarin,” the “Company,” “we,” “us,” and “our” refer to BioMarin Pharmaceutical Inc. and, where appropriate, its wholly owned subsidiaries.
BioMarin®, Brineura®, Kuvan®, Naglazyme®, Palynziq® and Vimizim® are our registered trademarks. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this report are the property of their respective owners.
Forward-Looking Statements
This Annual Report on Form 10-K contains “forward-looking statements” as defined under securities laws. Many of these statements can be identified by the use of terminology such as “believes,” “expects,” “intends,” “anticipates,” “plans,” “may,” “will,” “could,” “would,” “projects,” “continues,” “estimates,” “potential,” “opportunity” or the negative versions of these terms and other similar expressions. You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of our management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that we may issue in the future as well as other cautionary statements we have made and may make. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in the section titled “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K as well as information provided elsewhere in this Annual Report on Form 10-K. You should carefully consider that information before you make an investment decision. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
Except as required by law, we do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Annual Report on Form 10-K to reflect later events or circumstances or the occurrence of unanticipated events.
Risk Factors Summary
The following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash flows or stock price. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.
Business and Operational Risks
•The COVID-19 pandemic could materially adversely affect our business, results of operations, and financial condition.
•Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve profitability.
•If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.
•If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected.
•Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.
•If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.
•The sale of generic versions of Kuvan by generic manufacturers has adversely affected and may continue to adversely affect our revenue and results of operations.
3

•If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
Regulatory Risks
•If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.
•Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.
•To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.
•Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenue and results of operations.
•Government healthcare reform could increase our costs and adversely affect our revenue and results of operations.
Risks Related to Valoctocogene Roxaparvovec
•Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional development and treatment risks in relation to our other, more traditional drug development programs.
•As compared to our other, more traditional products, our gene therapy product candidate valoctocogene roxaparvovec, if approved, may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product candidate.
Financial and Financing Risks
•If we continue to incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.
Manufacturing Risks
•If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.
•If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs,
4

we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.
•Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.
Risks Related to International Operations
•We conduct a significant amount of our sales and operations outside of the United States (U.S.), which subjects us to additional business risks that could adversely affect our revenue and results of operations.
•A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenue in these countries.
Intellectual Property Risks
•If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.
•Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.
5
Part I
Item 1. Business
Overview
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products.
Our portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. We continue to invest in our clinical and preclinical product pipeline by committing significant resources to research and development programs and business development opportunities within our areas of scientific, manufacturing and technical expertise.
A summary of our commercial products is provided below:
Commercial ProductsIndication
United States
Orphan
Drug
Exclusivity
Expiration (1)
United
States
Biologic
Exclusivity
Expiration (2)
European
Union
Orphan Drug
Exclusivity
Expiration (1)
Aldurazyme (laronidase)
MPS I (3)
ExpiredExpiredExpired
Brineura (cerliponase alfa)
CLN2 (4)
202420292027
Kuvan (sapropterin dihydrochloride)
PKU (5)
ExpiredNot ApplicableExpired
Naglazyme (galsulfase)
MPS VI (6)
ExpiredExpiredExpired
Palynziq (pegvaliase-pqpz) (7)
PKU 
202520302029
Vimizim (elosulfase alpha)
MPS IVA (8)
202120262024
(1)    See “Government Regulation—Orphan Drug Designation” in this Annual Report on Form 10-K for further discussion
(2)    See “Government Regulation—Healthcare Reform” in this Annual Report on Form 10-K for further discussion
(3)    For the treatment of Mucopolysaccharidosis I (MPS I)
(4)    For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
(5)    For the treatment of phenylketonuria (PKU)
(6)    For the treatment of Mucopolysaccharidosis VI (MPS VI)
(7)    For adult patients with PKU
(8)    For the treatment of Mucopolysaccharidosis IV Type A (MPS IVA)
A summary of our ongoing major development programs is provided below:
Major Product Candidates
in Development
Target
Indication
U.S. Orphan
Designation
EU Orphan
Designation
Stage
Valoctocogene roxaparvovecSevere Hemophilia AYesYesClinical Phase 3
VosoritideAchondroplasiaYesYesClinical Phase 3
BMN 307PKUYesYes
Clinical Phase 1/2
See “Patents and Proprietary Rights” in this Annual Report on Form 10-K for additional information on our market protection.
Recent Developments
Regulatory Review of Vosoritide for the Treatment of Achondroplasia
On February 25, 2021, we announced that the FDA granted priority review designation for our New Drug Application (NDA) for vosoritide for the treatment of children with achondroplasia. On November 2, 2020, we announced that the U.S. Food
6
and Drug Administration (FDA) accepted our vosoritide NDA and the FDA Prescription Drug User Fee Act (PDUFA) target action date is August 20, 2021. See “Major Product Candidates in Development — Vosoritide” in this Annual Report on Form 10-K for more information regarding vosoritide.
Product Candidate BMN 307 for the Treatment of PKU
On February 25, 2021, we announced that we plan to dose escalate in the PHEarless Phase 1/2 study of BMN 307, a gene therapy for the treatment of PKU, based on encouraging Phe lowering and safety signals observed in study participants who were treated with the lowest dose.
Product Candidate BMN 255 for the Treatment of a Subset of Chronic Renal Disease
On January 11, 2021, we announced that we filed an Investigational New Drug application (IND) for BMN 255, a small molecule for the treatment of a subset of chronic renal disease.
Updated Phase 3 Data for Product Candidate Valoctocogene Roxaparvovec for the Treatment of Severe Hemophilia A
On January 10, 2021, we announced topline results from our ongoing global Phase 3 study of valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. All 134 study participants received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Data from the study in the pre-specified primary analysis for Annualized Bleeding Rate (ABR) showed that a single dose of valoctocogene roxaparvovec significantly reduced ABR by 84% compared with prior treatment with prophylactic Factor VIII infusions from 4.8 (median 2.8) bleeding episodes per year at baseline to 0.8 (median 0.0). These results were from a pre-specified group of 112 participants in a non-interventional prospective baseline observational study with a median follow-up of 60.1 weeks after dosing with valoctocogene roxaparvovec. Of the 112 rollover study participants, 80% were bleed-free starting at week five after treatment. Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII usage in the rollover population by 99%, from 135.9 (median 128.6) to 2.0 (median 0.0) infusions per year. At the end of the first year post-infusion with valoctocogene roxaparvovec, 132 participants in the modified intent-to-treat (mITT) population had a mean endogenous Factor VIII expression level of 42.9 (SD 45.5, median 23.9) IU/dL, as measured by the chromogenic substrate assay, supporting the clinical benefits observed with significant reduction of bleeding episodes and Factor VIII infusion rate. Factor VIII expression declined at a slower rate compared to the Phase 1/2 study, and remained in a range to provide hemostatic efficacy. In the 17 participants who comprise a subset of the mITT population and had been dosed at least two years prior to the data cut date, Factor VIII expression declined from a mean of 42.2 (SD 50.9, median 23.9) IU/dL at the end of year one to a mean of 24.4 (SD 29.2, median 14.7) IU/dL at the end of year two with continued hemostatic efficacy demonstrated by a mean ABR of 0.9 (median 0.0) bleeding episodes per year. See “Major Product Candidates in Development — Valoctocogene Roxaparvovec” in this Annual Report on Form 10-K for more information regarding valoctocogene roxaparvovec.
Two-Year Phase 3 Data for Product Candidate Vosoritide for the Treatment of Achondroplasia

On December 21, 2020, we announced results from our pivotal global Phase 3 randomized, double-blind, placebo-controlled study of vosoritide in approximately 121 children with achondroplasia ages 5-14 for two years. The data demonstrated that children in the open-label long-term extension of the Phase 3 study maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment. An analysis comparing 52 children who were randomized and treated with vosoritide for two years to 38 children from the run-in study who were randomized to receive placebo with an untreated observation period of two years showed improvement in one-year height change in the treated group relative to the untreated group. The one-year height change improvement in the second year of treatment, 1.79 cm, was similar to the one-year height change improvement in the first year of treatment, 1.73 cm. The cumulative height gain over the two-year period for treated children was 3.52 cm more than untreated children. See “Major Product Candidates in Development — Vosoritide” in this Annual Report on Form 10-K for more information regarding vosoritide.
7
Summary of Commercial Products and Development Programs
Commercial Products
Net Product Revenues related to our commercial products consisted of the following (in millions):
Years Ended December 31,
Commercial Products202020192018
Vimizim$544.4 $544.3 $482.0 
Kuvan$457.7 $463.4 $433.6 
Naglazyme$391.3 $374.3 $345.9 
Palynziq$171.0 $86.9 $12.2 
Aldurazyme$130.1 $97.8 $135.1 
Brineura$110.2 $72.0 $39.9 
Vimizim
Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. MPS IVA is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of glycosaminoglycans such as keratan sulfate and chondroitin sulfate. This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the chest impairs respiratory function, and looseness of joints in the neck cause spinal instability and potentially spinal cord compression. Other symptoms may include hearing loss, corneal clouding, and heart disease. Initial symptoms often become evident in the first five years of life. The disease substantially limits both the quality and length of life of those affected. We have identified over 2,000 patients worldwide suffering from MPS IVA and estimate that the total number of patients suffering from MPS IV A worldwide could be as many as 3,000.
Vimizim is approved for marketing in the U.S., the EU and other international markets.
Kuvan
Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase (PAH), indicated for patients with PKU. Kuvan is the first drug for the treatment of PKU, which is an inherited metabolic disease that affects at least 50,000 diagnosed patients under the age of 40 in the developed world. We believe that approximately 30% to 50% of those with PKU could benefit from treatment with Kuvan. PKU is caused by a deficiency of activity of an enzyme, PAH, which is required for the metabolism of Phe. Phe is an essential amino acid found in all protein-containing foods. Without sufficient quantity or activity of PAH, Phe accumulates to abnormally high levels in the blood, resulting in a variety of serious neurological complications, including severe mental retardation and brain damage, mental illness, seizures and other cognitive problems. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially manufactured foods; however, it is difficult for most patients to adhere to the strict diet to the extent needed for achieving adequate control of blood Phe levels.
Kuvan tablets were granted marketing approval for the treatment of PKU in the U.S. in December 2007 and in the EU in December 2008. In December 2013, the FDA approved the use of Kuvan powder for oral solution that is provided in a dose sachet packet allowing faster dissolution of powder in solution compared to the current tablet form. We commenced the commercial launch of this new form of Kuvan in February 2014. We market Kuvan in the U.S., the EU and other international markets (excluding Japan). In certain international markets, Kuvan is also approved for, or is only approved for, the treatment of primary BH4 deficiency, a different disorder than PKU.
Two companies previously filed paragraph IV certifications and submitted abbreviated new drug applications (ANDAs) to produce sapropterin dihydrochloride tablets and powder and we subsequently entered into settlement agreements regarding Kuvan with both companies. Generic versions of Kuvan first became available in the U.S. in the fourth quarter of 2020. Please see “Risk Factors” included in Part I, Item 1A of this Annual Report on Form 10-K for more information regarding the settlement agreements and for a discussion of the risks posed by generic versions of Kuvan. Please see “Government Regulation – The Hatch-Waxman Act” in this Annual Report on Form 10-K for additional information regarding ANDAs.
8
Naglazyme
Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with MPS VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Patients with MPS VI typically become progressively worse and experience multiple severe and debilitating symptoms resulting from the build-up of carbohydrate residues in tissues in the body. These symptoms include: inhibited growth, spinal cord compression, enlarged liver and spleen, joint deformities and reduced range of motion, skeletal deformities, impaired cardiovascular function, upper airway obstruction, reduced pulmonary function, frequent ear and lung infections, impaired hearing and vision, sleep apnea, malaise and reduced endurance.
Naglazyme is approved for marketing in the U.S., the EU and other international markets.
Palynziq
Palynziq is a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations. On May 24, 2018, the FDA approved the use of Palynziq in adult patients with PKU who have uncontrolled blood Phe concentrations greater than 600 micromol/L (10mg/dL) on existing management. In October 2020, we announced that the FDA approved our supplemental Biologics License Application (BLA) to increase the maximum allowable dose of Palynziq Injection for treatment of adults with PKU to 60 mg daily. Previously, the maximum dose was 40 mg daily. Palynziq is our second approved treatment for PKU. Palynziq is only available in the U.S. through the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:
•prescribers must be certified by enrolling in the REMS program and completing training;
•prescribers must prescribe auto-injectable epinephrine with Palynziq;
•pharmacies must be certified with the REMS program and must dispense Palynziq only to patients who are authorized to receive it;
•patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq; and
•patients must have auto-injectable epinephrine available at all times while taking Palynziq.
Please see “Risk Factors” included in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of the risks posed by the REMS program.
On May 6, 2019, we announced that the European Commission (EC) granted marketing authorization for Palynziq in the EU, at doses of up to 60 mg once daily, to reduce Phe concentrations in patients with PKU aged 16 and older who have inadequate blood Phe control (blood Phe levels greater than 600 micromol/L) despite prior management with available treatment options.
Aldurazyme
Aldurazyme is a highly purified protein that is designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of glycosaminoglycans (GAGs). Aldurazyme is approved for marketing in the U.S., the EU and other international markets for patients with MPS I. MPS I is a progressive and debilitating life-threatening genetic disease, for which no other drug treatment currently exists, that is caused by the deficiency of alpha-L-iduronidase. Patients with MPS I typically become progressively worse and experience multiple severe and debilitating symptoms resulting from the build-up of carbohydrate residues in all tissues in the body. These symptoms include: inhibited growth, delayed and regressed mental development (in the severe form of the disease), enlarged liver and spleen, joint deformities and reduced range of motion, impaired cardiovascular function, upper airway obstruction, reduced pulmonary function, frequent ear and lung infections, impaired hearing and vision, sleep apnea, malaise and reduced endurance.
We developed Aldurazyme through collaboration with Sanofi Genzyme (Genzyme), now a wholly owned subsidiary of Sanofi. Under our collaboration agreement with Genzyme, we are responsible for manufacturing Aldurazyme and supplying it to Genzyme. We receive payments ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume. Genzyme and we are members of BioMarin/Genzyme LLC, a 50/50 limited liability company (the BioMarin/Genzyme LLC) that: (1) holds the intellectual property relating to Aldurazyme and other collaboration products and licenses all such intellectual property on a royalty-free basis to us and Genzyme to allow us to exercise our rights and perform our obligations under the agreements related to the BioMarin/Genzyme LLC, and (2) engages in research and development activities that are mutually selected and funded by Genzyme and us.
9
Brineura
Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) and is approved for the treatment of patients with CLN2, a form of Batten disease, in the U.S., the EU and other international markets. CLN2 is an incurable, rapidly progressive disease that typically ends in patient death by 10-12 years of age. Patients are initially healthy but begin to decline at approximately the age of three. We estimate that up to 1,200 to 1,600 cases exist worldwide. On April 27, 2017, Brineura was approved in the U.S. to slow the progression of loss of ambulation in symptomatic pediatric patients three years of age and older with CLN2. Brineura is the first treatment approved to slow the progression of loss of ambulation in children with CLN2 disease.
On June 1, 2017, we announced that the EC granted marketing authorization for Brineura in the EU to treat children with CLN2. Brineura is the first treatment approved in the EU for the treatment of CLN2. On April 21, 2017, the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) adopted a positive opinion for our Marketing Authorisation Application (MAA) for Brineura following an accelerated review procedure, reserved for medicinal products expected to be a major public health interest. Brineura was one of the first therapies to go through this process.
Brineura is administered via intracerebroventricular (ICV) infusion and intended to be used in combination with a delivery device, such as an injector or other delivery system. Please see “Government Regulation – Combination Products” in this Annual Report on Form 10-K for additional information on combination products.
Major Product Candidates in Development
Valoctocogene Roxaparvovec
Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Hemophilia A, also called factor VIII deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. According to the World Federation of Hemophilia rankings of severity of hemophilia A, the normal range of factor VIII activity levels is between 50% and 150%, expressed as a percentage of normal factor activity in blood, the mild hemophilia A range of factor VIII activity levels is between 5% and 40%, the moderate hemophilia A range of factor VIII activity levels is between 1% and 5%, and the severe hemophilia range of factor VIII activity levels is less than 1%. People living with hemophilia A are not able to form blood clots efficiently and are at risk for excessive bleeding from modest injuries, potentially endangering their lives. People with severe hemophilia often bleed spontaneously into their muscles or joints.
On May 21, 2020, we announced an update to our previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. The four-year update for the 6e13 vg/kg and three-year update for the 4e13 vg/kg cohorts demonstrated that all subjects in both cohorts had remained off prophylactic Factor VIII treatment since receiving their single dose of valoctocogene roxaparvovec. In addition, cumulative mean annualized bleed rates (ABR) remain less than one in both cohorts and below pre-treatment baseline levels.
On January 10, 2021, we announced topline results from our ongoing global Phase 3 study of valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. All 134 study participants received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Data from the study in the pre-specified primary analysis for ABR showed that a single dose of valoctocogene roxaparvovec significantly reduced ABR by 84% compared with prior treatment with prophylactic Factor VIII infusions from 4.8 (median 2.8) bleeding episodes per year at baseline to 0.8 (median 0.0). These results were from a pre-specified group of 112 participants in a non-interventional prospective baseline observational study with a median follow-up of 60.1 weeks after dosing with valoctocogene roxaparvovec. Of the 112 rollover study participants, 80% were bleed-free starting at week five after treatment. Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII usage in the rollover population by 99%, from 135.9 (median 128.6) to 2.0 (median 0.0) infusions per year. At the end of the first year post-infusion with valoctocogene roxaparvovec, 132 participants in the modified intent-to-treat (mITT) population had a mean endogenous Factor VIII expression level of 42.9 (SD 45.5, median 23.9) IU/dL, as measured by the chromogenic substrate assay, supporting the clinical benefits observed with significant reduction of bleeding episodes and Factor VIII infusion rate. Factor VIII expression declined at a slower rate compared to the Phase 1/2 study, and remained in a range to provide hemostatic efficacy. In the 17 participants who comprise a subset of the mITT population and had been dosed at least two years prior to the data cut date, Factor VIII expression declined from a mean of 42.2 (SD 50.9, median 23.9) IU/dL at the end of year one to a mean of 24.4 (SD 29.2, median 14.7) IU/dL at the end of year two with continued hemostatic efficacy demonstrated by a mean ABR of 0.9 (median 0.0) bleeding episodes per year.
In addition to the ongoing Phase 1/2 and Phase 3 studies of valoctocogene roxaparvovec described above, we have multiple other clinical studies of valoctocogene roxaparvovec underway. We recently began enrolling participants in a Phase 3b, single arm, open-label study to evaluate the efficacy and safety of valoctocogene roxaparvovec at a dose of 6e13 vg/kg with prophylactic corticosteroids in people with severe hemophilia A. We are conducting a Phase 1/2 study with the 6e13kg/vg dose of valoctocogene roxaparvovec in approximately 10 participants with pre-existing AAV5 antibodies, as well as another Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with severe hemophilia A with active or prior FVIII inhibitors.
10
Overall, valoctocogene roxaparvovec continues to have a favorable safety profile and has been generally well tolerated by participants across all doses in the Phase 1/2 and Phase 3 studies. None of the study participants developed inhibitors to Factor VIII or thromboembolic events. One participant in the Phase 3 study was lost to follow-up. The most common adverse events associated with valoctocogene roxaparvovec across studies occurred early and included transient infusion-associated reactions and transient, asymptomatic, and mild to moderate rises in the levels of certain proteins and enzymes measured in liver function tests. Common, steroid-related side effects can occur with temporary use of corticosteroid (or alternative immunosuppressants) to manage elevated levels of certain proteins and enzymes in the liver. These side effects have generally been mild to moderate, manageable and reversible.
On February 20, 2020, we announced that the FDA accepted for priority review our BLA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. On August 18, 2020, the FDA issued a Complete Response Letter (CRL) to our BLA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for two-year follow-up safety and efficacy data on all study participants from our ongoing Phase 3 study of valoctocogene roxaparvovec. The Phase 3 study was fully enrolled in November 2019, and the last patient in the study will complete two years of follow-up in November 2021. We plan to meet with the FDA to review the two-year follow-up data request and share the one-year top-line Phase 3 data described above.
On December 23, 2019, we announced that the EMA validated our MAA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A, which had been in review under accelerated assessment since January 2020. The EMA recently requested the 52-week results from the full Phase 3 study cohort of 134 subjects to inform their benefit-risk assessment. To facilitate this submission within the EMA regulatory framework, we recently withdrew our MAA and we are targeting resubmission of the MAA with these data in the second quarter of 2021 pending confirmation in presubmission meetings.
Valoctocogene roxaparvovec has Orphan Drug designation from the FDA and the EMA. Valoctocogene roxaparvovec has also been accepted for Priority Medicines (PRIME) scheme from the EMA. Additionally, the FDA has granted valoctocogene roxaparvovec Breakthrough Therapy designation.
Vosoritide
Vosoritide is an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) in development for the treatment of achondroplasia, the most common form of disproportionate short stature in humans. Vosoritide has been and is being tested only in children in the age range when their growth plates are still open, which is approximately 25% of people with achondroplasia. In June 2019, the New England Journal of Medicine published results from our Phase 2 open-label, dose-finding and extension study for vosoritide in children aged 5 to 14 years with achondroplasia receiving a continuous dose of 15 µg/kg/day. AGV increased from baseline in all cohorts during each 12-month interval by 1.10 to 2.34 cm/year through 42 months. In cohort 3, which received 15 μg/kg continuous dosing from baseline, the mean AGV derived between 30 and 42 months was 5.51 cm/year, representing a 1.46 cm/year change from baseline. On November 14, 2019, we announced that children in cohort 3 over 54 months achieved a statistically significant cumulative additional mean height gain of 9.0 cm compared to children, matched for age and gender, in a natural history achondroplasia dataset. In the global Phase 2 study of children with achondroplasia ages 0-5, enrollment of the first cohort (24-60 months) and the second cohort (6-24 months) is complete. Cohort 3 (0-6 months) is actively enrolling and close to completely enrolled.
On December 21, 2020, we announced results from our pivotal global Phase 3 randomized, double-blind, placebo-controlled study of vosoritide in approximately 121 children with achondroplasia ages 5-14 for two years. The data demonstrated that children in the open-label long-term extension of the Phase 3 study maintained an increase in AGV through the second year of continuous treatment. An analysis comparing 52 children who were randomized and treated with vosoritide for two years to 38 children from the run-in study who were randomized to receive placebo with an untreated observation period of two years showed improvement in one-year height change in the treated group relative to the untreated group. The one-year height change improvement in the second year of treatment, 1.79 cm, was similar to the one-year height change improvement in the first year of treatment, 1.73 cm. The cumulative height gain over the 2-year period for treated children was 3.52 cm more than untreated children.
On November 9, 2020, we announced an expansion of our clinical program for vosoritide with two new Phase 2 studies. The first study is sponsored by BioMarin to investigate the safety of vosoritide in infants with achondroplasia at risk of life-threatening foramen magnum compression. The second study, an investigator-initiated study sponsored by Children's National Hospital in Washington, D.C., will investigate vosoritide in children with selected genetic forms of short stature. Together, these two studies represent addressable patient populations of approximately 275,000.
Overall, vosoritide continues to have a favorable safety profile and has been generally well tolerated by participants across the Phase 2 and Phase 3 studies with no clinically significant blood pressure changes and a mild side effect profile.
On February 25, 2021, we announced that the FDA granted priority review designation for our NDA for vosoritide for the treatment of children with achondroplasia. On November 2, 2020, we announced that the FDA accepted our NDA for vosoritide for the treatment of children with achondroplasia and the FDA PDUFA target action date is August 20, 2021. When the FDA accepted
11
our NDA for vosoritide, the agency reiterated its position raised during the vosoritide Pediatric Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee held in May 2018, recommending two, two-year placebo-controlled trials in different age groups. Although our vosoritide clinical program does not meet every element of the FDA’s recommendation, we designed our studies of vosoritide in a manner that we believe can demonstrate efficacy and safety of the product candidate for the target patient population. However, the FDA may ultimately disagree with our position that our vosoritide trials support regulatory approval.
On August 13, 2020, we announced that the EMA validated our MAA for vosoritide for the treatment of children with achondroplasia. We anticipate an opinion from the CHMP on our MAA for vosoritide in June 2021.
Vosoritide has Orphan Drug designation from the FDA and the EMA.
BMN 307
BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with PKU. We tested a broad range of vector constructs and combinations to optimize the vector and increase potency, resulting in a 10-fold increase in potency for the selected vector. Treatment of mice in a validated PKU mouse model with BMN 307 showed a lifetime normalization of Phe and normalized neurotransmitter levels. BMN 307 will be evaluated to determine safety and whether a single dose of treatment can restore natural Phe metabolism, normalize plasma Phe levels, and enable a normal diet in patients with PKU. On January 13, 2020, we announced that both the FDA and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) granted IND status and approved our Clinical Trial Application (CTA), respectively, for BMN 307 for the treatment of PKU. On September 24, 2020, we announced that we had dosed the first participant in the global PHEarless Phase 1/2 study of BMN 307. On February 25, 2021, we announced that we plan to dose escalate in the PHEarless Phase 1/2 study of BMN 307 based on encouraging Phe lowering and safety signals observed in study participants who were treated with the lowest dose.
BMN 307 has Orphan Drug designation from the FDA and the EMA and Fast Track designation from the FDA.
Manufacturing
We manufacture the active pharmaceutical ingredients (API) for Aldurazyme, Naglazyme, Palynziq, Vimizim and vosoritide in our production facilities located in Novato, California. We currently also manufacture the API for Brineura and Vimizim in our manufacturing facility in Shanbally, Cork, Ireland. These facilities have demonstrated compliance with current Good Manufacturing Practices (cGMPs) to the satisfaction of the FDA, the EC and health agencies in other countries for the commercial production of Naglazyme, Palynziq, and Vimizim. We believe that with our Novato, California facility and our Shanbally facility, we have ample manufacturing capacity to support anticipated commercial demand for Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim for at least the next five years.
We contract with third parties to manufacture Kuvan API and drug substance. All our drug product manufacturing (which includes vials, syringes, tablets, and powder) and most packaging operations are performed by contract manufacturers. We expect to continue to contract with outside service providers for certain manufacturing services, including drug substance, drug product, and packaging operations for our products. All of our facilities and those of any third-party manufacturers will be subject to periodic inspections confirming compliance with applicable law and must pass inspection before we can manufacture our drugs for commercial sales. Third-party manufacturers’ facilities are subject to periodic inspections to confirm compliance with applicable law and must be cGMP certified. We believe that our current agreements with third-party manufacturers and suppliers provide for ample operating capacity to support the anticipated clinical and commercial demand for these products. In certain instances, there is only one approved contract manufacturer for certain aspects of the manufacturing process. In such cases, we attempt to prevent disruption of supplies through supply agreements, maintaining safety stock and other appropriate strategies.
In July 2017, we commissioned our commercial-scale gene therapy manufacturing facility, located in Novato, California, where we conduct cGMP production of valoctocogene roxaparvovec and BMN 307 to support clinical development activities and anticipated commercial demand. This facility has the potential to support the commercial production of multiple gene therapy products to meet global commercial demand, depending on dose and production mix. The facility’s production processes have been developed in accordance with International Conference on Harmonisation Technical Requirements for Registration of Pharmaceuticals for Human Use facilitating worldwide registration with health authorities.
12
Raw Materials
Raw materials and supplies required for the production of our products and product candidates are available in some instances from one supplier and in other instances from multiple suppliers. In those cases where raw materials are only available through one supplier, such supplier may be either a sole source (the only recognized supply source available to us) or a single source (the only approved supply source for us among other sources). We have adopted policies to attempt, to the extent feasible, to minimize our raw material supply risks, including maintenance of greater levels of raw materials inventory and implementation of multiple raw materials sourcing strategies, especially for critical raw materials. Although to date we have not experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future.
Sales and Marketing
We have established a commercial organization, including a sales force, to support our product lines directly in the U.S., Europe, South America and certain other significant markets. For other selected markets, we have signed agreements with other companies to act as distributors of Brineura, Kuvan, Naglazyme and Vimizim. Most of these agreements generally grant the distributor the right to market the product in the territory and the obligation to secure all necessary regulatory approvals for commercial or named patient sales. Additional markets are being assessed at this time and additional agreements may be signed in the future.
Genzyme has the exclusive right to distribute, market and sell Aldurazyme globally and is required to purchase its requirements exclusively from us.
In the U.S., our products (other than Aldurazyme) are marketed through our commercial teams, including sales representatives and supporting staff members, who promote our products, directly to physicians in specialties appropriate for each product. Outside of the U.S., our sales representatives and supporting staff members market our products (other than Aldurazyme). We believe that with moderate changes in 2021, the size of our sales force will be appropriate to effectively reach our target customers in markets where our products are directly marketed. The launch of any future products, if approved, will likely require expansion of our commercial organization, including our sales force, in the U.S. and international markets.
We utilize third-party logistics companies to store and distribute our products. Moreover, we use third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities.
Customers
Our Brineura, Kuvan, Naglazyme, Palynziq and Vimizim customers include a limited number of specialty pharmacies and end-users, such as hospitals and non-U.S. government agencies. We also sell Brineura, Kuvan, Naglazyme, Palynziq and Vimizim to our authorized distributors and to certain larger pharmaceutical wholesalers globally, which act as intermediaries between us and end-users and generally do not stock significant quantities of our products. However, in certain countries, such as those in Latin America, governments place large periodic orders for Naglazyme and Vimizim. The timing of these orders can be inconsistent and can create significant quarter to quarter variation in our revenue. Palynziq is currently distributed in the U.S. pursuant to the REMS program through a limited number of certified specialty pharmacies. During 2020, 45% of our net product revenues, excluding Aldurazyme, was generated by three customers. Genzyme is our sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
Competition
The biopharmaceutical industry is rapidly evolving and highly competitive. Within the industry, there are many public and private companies, including pharmaceutical companies and biotechnology companies that have or may soon initiate programs for the same indications that our products and product candidates are intended to treat. Furthermore, universities and non-profit research organizations may have research programs, both early-stage and clinical, in the same disease areas. Our competitors may have advantages over us due to greater financial or scientific resources, lower labor and other costs, or due to higher headcount and more robust organizational structures. Our competitors have considerable experience in drug manufacturing, preclinical and clinical research and development, regulatory affairs, marketing, sales, and distribution. They pursue broad patent portfolios and other intellectual property to protect the products they are developing. Their products may outcompete ours due to one or more factors, including faster progress through preclinical and clinical development, lower manufacturing costs, superior safety and efficacy, lower pricing, stronger patent protection, and better marketing, sales, and distribution capabilities. In this event, our products and product candidates, if approved, could fail to gain significant market share, and as a result, our business, financial condition and results of operations could be adversely affected.
Other than Kuvan (which faces generic competition, as described below), our products have no direct approved competition currently on the market in the U.S. or the EU; however, other companies are in the development phase with new and
13
generic products. Our products and product candidates have potential competition from products under development either using similar technology to our programs or different treatment strategies. The following is a summary of some of the primary possible future competitors for our products and product candidates, but the information below may not include all potential competition.
Commercial Products
Aldurazyme, Naglazyme, and Vimizim
In the mucopolysaccharidosis field, several companies are researching treatments using small molecules, gene therapy, and other novel technologies. Aldurazyme, for the treatment of MPS I, has potential competition from clinical stage product candidates from ArmaGen, Inc., JCR Pharmaceuticals Co., Ltd., Orchard Therapeutics Plc, RegenxBio Inc. and earlier stage product candidates, including a product candidate from Immusoft Corporation. Naglazyme, for the treatment of MPS VI, has potential competition from a clinical stage product candidate from Inventiva S.A. and other potential candidates in earlier stages. Vimizim, for the treatment of MPS IVA, has potential competition from a preclinical product candidate from Esteve Pharmaceuticals, S.A. and other potential candidates in earlier stages.
Brineura
Brineura, for the treatment of CLN2, has potential competition from preclinical product candidates from RegenxBio Inc. and the Roche Group.
Kuvan and Palynziq
There are currently no other approved, non-generic drugs on the market in the U.S. or the EU for the treatment of PKU. However, two companies previously filed paragraph IV certifications and submitted ANDAs to produce sapropterin dihydrochloride tablets and powder. We entered into settlement agreements regarding Kuvan with both companies, which allowed these companies to market generic versions of sapropterin dihydrochloride. Generic versions of Kuvan first became available in the U.S. in October 2020. Please see “Risk Factors” included in Part I, Item 1A of this Annual Report on Form 10-K for more information regarding the settlement agreements and for a discussion of the risks posed by generic versions of Kuvan in the U.S. and international markets. Please see “Government Regulation – The Hatch-Waxman Act” in this Annual Report on Form 10-K for additional information regarding ANDAs. Kuvan and Palynziq also have potential competition from clinical stage product candidates from Homology Medicines, Inc., Nestle Health Science, S.A., PTC Therapeutics, Inc. and Synlogic, Inc. and earlier stage product candidates, including product candidates from Generation Bio Co., LogicBio Therapeutics, Inc., Moderna Therapeutics, Inc., Sangamo Therapeutics, Inc. and SOM Innovation Biotech, S.A. BMN 307 is our clinical gene therapy program for PKU, and other companies are also developing gene therapy product candidates for PKU, as described in “Competition—Product Candidates—BMN 307” in this Annual Report on Form 10-K.
Major Product Candidates in Development
Valoctocogene roxaparvovec
Valoctocogene roxaparvovec, a gene therapy product candidate for severe hemophilia A, could have competition from marketed recombinant factor VIII replacement therapies, a novel bispecific antibody marketed by the Roche Group, and clinical stage programs, including gene therapy product candidates under development by Bayer AG, Pfizer, Inc., the Roche Group, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Ltd. and preclinical product candidates from other companies, including Freeline Therapeutics Ltd. and Uniqure N.V. In addition, Novo Nordisk A/S, Pfizer, Inc. and Sanofi S.A. are developing novel non-factor replacement product candidates in the clinic for the treatment of hemophilia A.
Vosoritide
Vosoritide, for the treatment of achondroplasia, could have competition from clinical stage products under development by Ascendis Pharma A/S and Pfizer, Inc., and preclinical product candidates from other companies, including QED Therapeutics, Inc.
BMN 307
BMN 307, a gene therapy product candidate for the treatment of PKU, has potential competition from clinical stage product candidates from PTC Therapeutics, Inc., Homology Medicines, Inc., Nestle Health Science, S.A., Synlogic, Inc. and earlier
14
stage product candidates, including product candidates from Generation Bio Co., LogicBio Therapeutics, Inc., Moderna Therapeutics, Inc., Sangamo Therapeutics, Inc. and SOM Innovation Biotech, S.A.
BMN 331
BMN 331, a gene therapy product candidate for the treatment of hereditary angioedema, has potential competition from marketed therapies by BioCryst Pharmaceuticals, Inc., CSL Limited and Takeda Pharmaceutical Company Ltd., clinical stage product candidates from CSL Limited, Ionis Pharmaceuticals, Inc., Kalvista Pharmaceuticals, Inc. and Pharvaris GmbH and earlier stage product candidates from Intellia Therapeutics, Inc. and Regenxbio Inc.
Patents and Proprietary Rights
Our success depends on an intellectual property portfolio that supports our future revenue streams and also erects barriers to our competitors. We are maintaining and building our patent portfolio through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent applications. Furthermore we seek to protect our ownership of know-how, trade secrets and trademarks through an active program of legal mechanisms including registrations, assignments, confidentiality agreements, material transfer agreements, research collaborations and licenses.
The table below lists our outstanding patents and patent applications of primary importance for our products other than Aldurazyme by territory, general subject matter (including composition, methods of treatment and approved use, methods of production and purification, pharmaceutical compositions and clinical formulations) and latest expiry date. With respect to Aldurazyme, the last of our patents expired in November 2020. One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately in the table below. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend patent exclusivity beyond the expiration dates listed in the table below. In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the EU. For more information regarding regulatory exclusivity for our products, see the summary of our commercial products under “Overview” in Part I, Item 1 of this Annual Report on Form 10-K.
ProductTerritory
Patent No(s).
General Subject Matter
Patent Expiration
BrineuraU.S.8,029,781Method of treatment
July 3, 2023(1)
9,044,473Method of treatment by administration into the cerebrospinal fluidFebruary 18, 2032
10,279,015Formulation; kitMay 5, 2036
EU1,673,104Pharmaceutical compositionAugust 30, 2024
16793229.2(2)
Formulation
May 5, 2036
KuvanEU
3138566(2)
Use for treating with once daily dosing regimenNovember 7, 2024
2545939; 3461503(2)
Use for treating once daily after a mealApril 11, 2028
NaglazymeU.S.6,866,844Compositions; methods of treatment; production; purificationNovember 7, 2022
7,713,709Antibody assaysJuly 20, 2028
EU1565209; 2327414Compositions; pharmaceutical compositions; use to treat an enzyme deficiencyNovember 7, 2023
PalynziqU.S.7,534,595Composition; method of treating
August 16, 2027 / May 24, 2032(3)
10,221,408PurificationFebruary 3, 2031
9,557,340Antibody detection assayJuly 30, 2029
EU2152868Composition; pharmaceutical composition
May 23, 2028 / May 23, 2033(4)
2531209; 3025728Formulation; purificationFebruary 03, 2031
VimizimU.S.8,128,925Compositions; methods of treatmentApril 10, 2030
8,765,437Purification; formulation; methods of treatmentJanuary 10, 2032
EU2245145Composition; use for treatingApril 30, 2029
2595650Purification; composition; use for treating; formulationJuly 22, 2031
15
(1)    Under a patent term extension (PTE) that has been granted.
(2)    Patent application.
(3)    We filed for a PTE for this patent, and if granted, the patent expiration will extend to May 24, 2032.
(4)     We applied for Supplementary Protection Certificate (SPC) for this patent, and we have received SPC to extend the patent expiration to May 23, 2033 in certain European countries, including Austria, Cyprus, Estonia, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Spain, Slovenia, and Sweden.
With respect to our clinical product candidates, we believe we have the necessary intellectual property rights to allowing us to undertake the development of these candidates. Certain of our product candidates are in therapeutic areas that have been the subject of many years of extensive research and development by academic organizations and third parties who may control patents or other intellectual property that they might assert against us, should one or more of our product candidates in these therapeutic areas succeed in obtaining regulatory approval and thereafter be commercialized. We continually evaluate the intellectual property rights of others in these areas in order to determine whether a claim of infringement may be made by others against us. Should we determine that a third party has intellectual property rights that could impact our ability to freely market a compound we consider a number of factors in determining how best to prepare for the commercialization of any such product candidate. In making this determination we consider, among other things, the stage of development of our product candidate and whether we and our outside counsel believe the intellectual property rights of others are valid, whether we infringe the intellectual property rights of others, whether a license is available upon commercially reasonable terms, whether we will seek to challenge the intellectual property rights of others, and the likelihood of and liability resulting from an adverse outcome should we be found to infringe the intellectual property rights of others.
Government Regulation
Regulation by governmental authorities in the U.S. and other countries is a significant factor in the development, manufacture, commercialization, pricing and reimbursement of our products. Our industry is subject to significant federal, state, local and non-U.S. regulation. Our present and future business has been, and will continue to be, subject to a variety of laws in the U.S. and other jurisdictions. In the U.S., failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.
Our products require approval from the FDA, the EMA and corresponding agencies in other countries before they can be marketed.
Approval Process in the U.S. and EU
Pharmaceutical product development in the U.S. and the EU typically involves preclinical laboratory and animal tests, the submission to the applicable regulatory agency of an application (e.g., an IND or a CTA), which must become effective before clinical testing may commence, and adequate and well-controlled human clinical trials to establish the safety and effectiveness of the drug for each indication for which marketing approval is sought. Currently, European clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new European Regulation on Clinical Trials, which is expected to take effect in 2021, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Satisfaction of FDA and European pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.
Preclinical tests include laboratory evaluation, as well as animal studies, to assess the characteristics and potential pharmacology, pharmacokinetics and toxicity of the product. The conduct of the preclinical tests must comply with FDA and/or EMA regulations and requirements, including good laboratory practices. The results of preclinical testing, along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol are submitted to the applicable regulatory agency as part of an IND or CTA. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND or CTA is submitted. Until the CTA or IND is approved, or becomes effective following a waiting period, we may not start the clinical trial in the relevant jurisdiction.
Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with applicable regulations, good clinical practices (GCP), as well as under protocols detailing the objectives of the trial and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on patients and subsequent protocol amendments must be submitted to the FDA as part of the IND and to the relevant regulatory agency in the EU as part of a new CTA.
The regulatory agencies may order the temporary halt or permanent discontinuation of a clinical trial at any time or impose other sanctions if they believe that the clinical trial is not being conducted in accordance with applicable requirements or presents
16
an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (IRB) or ethics committee, for approval. An IRB/ethics committee may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB/ethics committee’s requirements, or may impose other conditions.
Clinical trials to support NDAs, BLAs or MAAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population, to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites. After completion of the required clinical testing, an application is prepared and submitted to the regulatory agency. Approval of the application by the applicable regulatory agency is required before marketing of the product may begin. In the European Economic Area (i.e., the EU as well as Iceland, Liechtenstein and Norway) (the EEA), an MAA is prepared and, for all orphan designated products, is submitted to the EMA under the centralized application procedure. EC approval of the MAA under the centralized application procedure results in a single marketing authorization that is valid across the EEA. The NDA, BLA or MAA must include the results of all preclinical, clinical and other testing, a compilation of data relating to the product’s pharmacology, chemistry, manufacture and controls and proposed labeling, among other things. In the U.S., each NDA or BLA is subject to a significant user fee at the time of submission, unless a waiver is granted by the FDA.
The FDA and the EMA initially review the applications for a threshold determination that it is sufficiently complete to permit substantive review, typically within 30-60 days. The regulatory agency may request additional information rather than accepting an application for filing or validation. Once the submission is accepted, the applicable agency begins an in-depth review. For the FDA, the review period for standard review applications is typically an additional ten months and, for priority review of drugs, that is, drugs that the FDA determines address a significant unmet need and represent a significant improvement over existing therapy, the review period is typically an additional six months in duration. The review process may be extended by the FDA for three additional months to consider new information submitted during the review or clarification regarding information already provided in the submission. The FDA may also refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. After the FDA evaluates the information provided in the NDA/BLA, it issues an approval letter, or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed and the NDA/BLA has been resubmitted, the FDA will re-initiate review. If it is satisfied that the deficiencies have been addressed, the FDA will issue an approval letter.
Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. At the end of the review period, the CHMP provides an opinion to the EC. If the opinion is favorable, the EC may then adopt a decision to grant marketing authorization. In the event of a negative opinion, the company may request a re-examination of the application within 15 days of receipt of the negative opinion. The company then has 60 days to provide the CHMP with detailed grounds for requesting the re-examination. Within 60 days of providing this information, the CHMP shall re-examine its opinion. The EC follows the recommendation of the CHMP in almost all cases. In exceptional cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days. This is usually when the product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation.
During the review period, the FDA and/or the EMA will typically inspect one or more clinical sites and/or the sponsor to assure compliance with GCP regulations and will inspect the facility or the facilities at which the drug is manufactured to ensure compliance with cGMPs regulations. Neither the FDA nor the EMA will approve the product unless compliance is satisfactory and the application contains data that provide substantial evidence that the drug is safe and effective in the indication studied.
A marketing approval authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA or BLA approval, the FDA may require a REMS, to help ensure that the benefits of the drug outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, such as special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug’s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.
17
Combination Products
A combination product is a product comprising (i) two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (ii) two or more separate products packaged together in a single package or as a unit and comprising drug and device products, device and biological products, or biological and drug products; (iii) a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (iv) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.
The FDA is divided into various branches, or Centers, by product type. Different Centers typically review drug, biologic, or device applications. In order to review an application for a combination product, the FDA must decide which Center should be responsible for the review. FDA regulations require that the FDA determine the combination product’s primary mode of action, which is the single mode of a combination product that provides the most important therapeutic action of the combination product. The Center that regulates that portion of the product becomes the lead evaluator. When evaluating an application, a lead Center may consult other Centers but still retain complete reviewing authority, or it may collaborate with another Center, by which the Center assigns review of a specific section of the application to another Center, delegating its review authority for that section. Typically, the FDA requires a single marketing application submitted to the Center selected to be the lead evaluator, although the agency has the discretion to require separate applications to more than one Center. One reason to submit multiple applications is if the applicant wishes to receive some benefit that accrues only from approval under a particular type of application, like new drug product exclusivity. If multiple applications are submitted, each may be evaluated by a different lead Center.
Disclosure of Clinical Trial Information
Sponsors of clinical trials of FDA-regulated products, including drugs and biologics, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial are then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. In certain circumstances, disclosure of the results of these trials can be delayed for up to two years after the date of completion of the trial. Competitors may use this publicly-available information to gain knowledge regarding the progress of development programs. Moreover, there is an increasing trend in the EU requiring public disclosure of development data, in particular clinical trial data. These data were traditionally regarded as confidential commercial information; however, under policies recently adopted in the EU, clinical study data submitted to the EMA in MAAs, including preclinical data, and patient level data, may be subject to public disclosure.
The Hatch-Waxman Act
Upon approval of a drug through an NDA, applicants are required to submit to the FDA each patent that covers the applicant’s product or FDA approved method of using this product. Those patents are then published in the FDA’s Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA. Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strength(s), route of administration, and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.
The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product’s listed patents or that such patents are invalid is called a paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. Alternatively, for a patent covering an approved method of use, an ANDA applicant may submit a statement to the FDA that the company is not seeking approval for the covered use.
If the ANDA applicant has submitted a paragraph IV certification to the FDA, the applicant must also send notice of the paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.
18
The ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active moiety, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a paragraph IV challenge to a listed patent, in which case the submission may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new condition of use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which the FDA cannot grant effective approval of an ANDA based on that listed drug. Both of the five-year and three-year exclusivity periods, as well as any unexpired patents listed in the Orange Book for the listed drug, can be extended by six months if the FDA grants the NDA sponsor a period of pediatric exclusivity based on studies submitted by the sponsor in response to a written request.
Exclusivity for Biologics
The Biologics Price Competition and Innovation Act of 2009 (BPCIA), which was enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (as amended, the PPACA), created an abbreviated approval pathway for biological products that are demonstrated to be “biosimilar” or “interchangeable” with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-licensed product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical studies, animal studies, and at least one clinical study, absent a waiver from the Secretary of the U.S. Department of Health and Human Services. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The first biosimilar product was approved under the BPCIA in 2015, though no interchangeable products have been approved to date. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) eighteen months after the first interchangeable biosimilar is approved if there is not patent challenge, (iii) eighteen months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar’s application has been approved if a patent lawsuit is ongoing within the 42-month period.
Orphan Drug Designation
Orphan drug designation is granted by the FDA and EMA to drugs intended to treat a rare disease or condition, which in the U.S. is defined as having a prevalence of less than 200,000 individuals in the U.S. In the EU, orphan drug designation is available if a sponsor can establish: that the medicine is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, which is equivalent to around 250,000 people or fewer, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the medicinal product in the EU would generate sufficient return to justify the necessary investment. For either of these criteria, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. Orphan drug designation must be requested before submitting a marketing application.
Orphan drug designation does not shorten the regulatory review and approval process. However, if an orphan drug later receives approval for the indication for which it has designation, the relevant regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years in the U.S. and ten years in the EU (extendable to twelve years for medicines that have complied with an agreed pediatric investigation plan pursuant to Regulation 1901/2006) and, in addition, a range of other benefits during the development and regulatory review process are available in the EU, including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. Among the benefits of orphan drug designation in the U.S. are tax credits for certain research and a waiver of the NDA/BLA application user fee. Orphan drug exclusive marketing rights may be lost under certain conditions, such as if the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In the EU, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the regulatory exclusivity period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this medicinal product is safer, more effective or otherwise clinically superior to
19
the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity.
Breakthrough Therapy Designation
The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor’s request.
PRIME Designation
The EMA launched its PRIME regulatory initiative to enhance support for the development of therapies that target an unmet medical need. The initiative focuses on drugs that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options. These therapies are considered priority medicines within the EU. Through PRIME, the EMA offers early, proactive and enhanced support to drug developers to optimize the generation of robust data on a therapy’s benefits and risks and enable accelerated assessment of drug applications.
Pediatric Information
Under the Pediatric Research Equity Act of 2007 (PREA), NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the drug for the claimed indication(s) in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by statute or regulation, PREA does not apply to any drug for an indication for which orphan drug designation has been granted. The Best Pharmaceuticals for Children Act (BPCA) provides sponsors of NDAs with an additional six-month period of market exclusivity for all unexpired patent or non-patent exclusivity on all forms of the drug containing the active moiety if the sponsor submits results of pediatric studies specifically requested by the FDA under BPCA within required timeframes. The BPCIA provides sponsors of BLAs an additional six-month extension for all unexpired non-patent market exclusivity on all forms of the biological containing the active moiety pursuant to the BPCA if the conditions under the BPCA are met.
In the EU, companies developing a new medicinal product must agree to a Paediatric Investigation Plan (PIP) with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The MAA for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.
Fast Track Designation and Accelerated Approval
The FDA is required to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and that demonstrate the potential to address unmet medical needs for the condition. Under the FDA’s fast track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor’s request.
In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with the FDA, the FDA may initiate review of sections of a fast track drug’s NDA or BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA’s time period goal for reviewing an application does not begin until the last section of the NDA or BLA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.
Under the fast track program and the FDA’s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate
20
endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of a Phase 4 or post-approval clinical trial to confirm the effect on the clinical endpoint. Failure to conduct a required post-approval study or confirm a clinical benefit through a post-marketing study will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.
Post-Approval Regulatory Requirements
Following approval, the FDA and the EMA will impose certain post-approval requirements related to a product. For instance, the FDA closely regulates the post-approval marketing and promotion of approved products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Moreover, if a company obtains original FDA approval for a product via the accelerated approval pathway, the company will be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of the FDA’s marketing approval for a product.
Approved products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, may require a submission to and approval by the FDA or the EMA, as applicable, before the change can be implemented. An NDA/BLA or MAA supplement for a new indication typically requires clinical data similar to that in the original application, and similar procedures and actions in reviewing NDA/ BLA or MAA supplements as in reviewing NDAs/BLAs and MAAs.
Adverse event reporting and submission of periodic reports is required following marketing approval. Either the FDA or EMA may also require post-marketing testing, known as Phase 4 testing, a risk evaluation and mitigation strategy, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as the manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug and biological product manufacturers and certain of their subcontractors are subject to periodic unannounced inspections by the FDA or the EMA during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, prescription drug manufacturers in the U.S. must comply with applicable provisions of the Drug Supply Chain Security Act and provide and receive product tracing information, maintain appropriate licenses, ensure they only work with other properly licensed entities and have procedures in place to identify and properly handle suspect and illegitimate products.
Healthcare Reform
The U.S. and some non-U.S. jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. For example, in the U.S., the PPACA is a sweeping measure intended to improve quality of care, constrain healthcare spending, and expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program.
The PPACA also imposed a fee on certain manufacturers and importers of branded prescription drugs (excluding orphan drugs under certain conditions). The annual fee is apportioned among the participating companies based on each company’s sales of qualifying products to, or use by, certain U.S. government programs during the preceding year. Other provisions of the law have also affected us and have increased certain of our costs. For example, the Medicaid rebate rate was increased and the volume of rebated drugs has been expanded to include beneficiaries in Medicaid managed care organizations. Among other things, the PPACA also expanded the 340B drug discount program (excluding orphan drugs), including the creation of new penalties for non-compliance, and now includes a 70% discount on brand name drugs for Medicare Part D participants in the coverage gap, or “donut hole.” The law also revised the definition of “average manufacturer price” for reporting purposes. In addition, drug manufacturers are required to collect and report annually information on payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as investment interests held by physicians and their immediate family members during the preceding calendar year. Effective January 1, 2022, covered manufacturers will also be required to report on payments or transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives. The
21
reported data are posted in searchable form on a public web site. Failure to submit required information may result in civil monetary penalties. It is still unclear the full impact that the PPACA will have on our business.
There have been executive, judicial and congressional challenges to certain aspects of the PPACA. For example, former U.S. President Trump signed several Executive Orders designed to delay the implementation of any certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed legislation repealing the PPACA in its entirety, it has enacted laws that modify certain provisions of the PPACA such as removing penalties for not complying with the PPACA’s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the individual mandate was repealed by Congress as part of the Tax Cuts and Jobs Act. This case was ultimately appealed to the United States Supreme Court, and on November 10, 2020, the U.S. Supreme Court heard oral arguments in this case. It is unclear when a decision will be made. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA and our business.
Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes included the Budget Control Act of 2011, which caused aggregate reductions to Medicare payments to providers of up to 2% per fiscal year effective April 1, 2013 which, following passage of the Bipartisan Budget Act of 2015, will stay in effect through 2030 unless additional congressional action is taken. However, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. The Consolidated Appropriations Act, 2021 extended the suspension of the 2% Medicare sequester through March 31, 2021. Further, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers.
Additionally, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, at the federal level, the former Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. However, it is expected that the Biden administration will also focus on controlling drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.
Moreover, former U.S. President Trump and President Biden both issued Executive Orders intended to favor government procurement from domestic manufacturers. Former President Trump issued an Executive Order specifically aimed at the procurement of pharmaceutical products, which instructed the federal government to develop a list of “essential” medicines and then buy those and other medical supplies that are manufactured, including the manufacture of the API, in the U.S. It is unclear whether this Executive Order or something similar will be implemented by the Biden Administration.
Brexit and the Regulatory Framework in the U.K.
Following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the U.K. and the EU, the U.K. was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The Trade and Cooperation Agreement which outlines the future trading relationship between the U.K. and the EU was agreed to in December 2020. While the Trade and Cooperation Agreement provides for the tariff-free trade of medicinal products between the U.K. and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period. Further, should the U.K. diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future.
Since a significant proportion of the regulatory framework in the U.K. applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and will continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our products and product candidates in the U.K. or the EU. Great Britain is no longer covered by the EU’s procedures for obtaining the grant of marketing authorizations (Northern Ireland will be covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures. A separate marketing authorization will be required to market drugs in Great
22
Britain. However, for two years from January 1, 2021, the U.K.’s regulator, the MHRA, may adopt decisions taken by the EC on the approval of new marketing authorizations through the centralized procedure, and the MHRA will have regard to marketing authorizations approved in a country in the EEA (although in both cases a marketing authorization will only be granted if any Great Britain-specific requirements are met). Various national procedures are now available to place a drug on the market in the U.K., Great Britain, or Northern Ireland, with the main national procedure having a maximum timeframe of 150 days (excluding time taken to provide any further information or data required). The data exclusivity periods in the U.K. are currently in line with those in the EU, but the Trade and Cooperation Agreement provides that the periods for both data and market exclusivity are to be determined by domestic law, and so there could be divergence in the future. It is currently unclear whether the MHRA in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, would delay or prevent us from commercializing our product candidates in the U.K. or the EU and restrict our ability to generate revenue and achieve and sustain profitability.
Orphan designation in Great Britain following Brexit is essentially identical to the position in the EU, but is based on the prevalence of the condition in Great Britain. It is therefore possible that conditions that are currently designated as orphan conditions in Great Britain will no longer be and that conditions that are not currently designated as orphan conditions in the EU will be designated as such in Great Britain.
Other U.S. Regulatory Requirements
In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback, false claims, patient data privacy and security, and transparency statutes and regulations.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. The PPACA amended the intent requirement of the federal Anti-Kickback and certain other criminal healthcare fraud statutes such that a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.
Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. The PPACA amended the statute so that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn are used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.
The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to the CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members. Effective January 1, 2022, covered manufacturers will also be required to report on payments or transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives during the previous year.
The majority of states also have statutes or regulations similar to the federal Anti-Kickback Statute and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to individual physicians in these states while other states prohibit various
23
other marketing-related activities. Other states require submission or disclosure of certain pricing information. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, states including California, Connecticut, Nevada and Massachusetts require pharmaceutical companies to implement compliance programs or marketing codes. Currently, several additional states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Sanctions under these federal and state laws may include significant penalties, including administrative and criminal sanctions, civil monetary penalties, damages, monetary fines, disgorgement, exclusion of a company from federal healthcare programs, integrity oversight and reporting obligations, criminal fines, contractual damages, reputational harm, diminished profits and future earnings, curtailment of operations and imprisonment.
Approval Outside of the U.S./EU
For marketing outside the U.S. and the EU, we are subject to non-U.S. regulatory requirements governing human clinical testing and marketing approval for our products. These requirements vary by jurisdiction, can differ from those in the U.S. and the EU and may require us to perform additional preclinical or clinical testing. The amount of time required to obtain necessary approvals may be longer or shorter than that required for FDA or EMA approval. In many countries outside of the U.S., approvals for pricing, coverage and reimbursement offered by third-party payers, including government payers and private insurance plans, are also required.
Anti-Corruption Legislation
The U.S. Foreign Corrupt Practices Act (FCPA), to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any non-U.S. government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Similar laws exist in other countries, such as the U.K., that restrict improper payments to public and private parties. Many countries have laws prohibiting these types of payments within the respective country. Historically, pharmaceutical companies have been the target of FCPA and other anti-corruption investigations and penalties.
Pricing and Reimbursement
Because the course of treatment for patients using our products is expensive, sales of our products depend, in significant part, on the availability and extent of coverage and reimbursement offered by third-party payers, including government payers and private insurance plans. Governments may regulate access to, prices of or reimbursement levels for our products to control costs or to affect levels of use of our products, and private insurers may be influenced by government reimbursement methodologies.
Third-party payers carefully review and increasingly challenge the prices charged for drugs, examine their medical necessity, and review their cost effectiveness. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. One payer’s determination to provide coverage for a product does not assure that other payers will also provide coverage for the product. Moreover, the process for determining whether a third-party payer will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payer will pay for the product. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. A payer’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain high enough price levels to realize sufficient revenues from our investment in product development. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Outside of the U.S. our products are paid for by a variety of payers, with governments being the primary source of payment. Reimbursement in the EU and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. In many countries the government closely regulates drug pricing and reimbursement and often has a significant discretion in determining whether a product will be reimbursed at all and, if it is, how much will be paid. Negotiating prices with governmental authorities can delay patient access to and commercialization of our products. Payers in many countries use a variety of cost-containment measures that can include referencing prices in other countries and using those reference prices to set their own price, mandatory price cuts and rebates. This international patchwork of price regulation has led to different prices across countries and some cross-border trade in our products from markets with lower prices. Even after a price is negotiated, countries frequently request or require adjustments to the price and other concessions over time.
Government Programs for Marketed Drugs in the U.S.
Medicaid, the 340B Drug Pricing Program, and Medicare
24
Federal law requires that a pharmaceutical manufacturer, as a condition of having its products receive federal reimbursement under Medicaid and Medicare Part B, must pay rebates to state Medicaid programs for all units of its covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program under either a fee-for-service arrangement or through a managed care organization. This federal requirement is effectuated through a Medicaid drug rebate agreement between the manufacturer and the Secretary of Health and Human Services. CMS administers the Medicaid drug rebate agreements, which provide, among other things, that the drug manufacturer will pay rebates to each state Medicaid agency on a quarterly basis and report certain price information on a monthly and quarterly basis. The rebates are based on prices reported to CMS by manufacturers for their covered outpatient drugs. For non-innovator products, generally generic drugs marketed under ANDAs, the rebate amount is 13% of the average manufacturer price (AMP) for the quarter. The AMP is the weighted average of prices paid to the manufacturer (1) directly by retail community pharmacies and (2) by wholesalers for drugs distributed to retail community pharmacies. For innovator products (i.e., drugs that are marketed under NDAs or BLAs), the rebate amount is the greater of 23.1% of the AMP for the quarter or the difference between such AMP and the best price for that same quarter. The best price is essentially the lowest price available to non-governmental entities. Innovator products may also be subject to an additional rebate that is based on the amount, if any, by which the product’s AMP for a given quarter exceeds the inflation-adjusted baseline AMP, which for most drugs is the AMP for the first full quarter after launch. Since 2017, non-innovator products are also subject to an additional rebate.
The terms of participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in additional or lesser rebate liability, depending on the direction of the correction. In addition to retroactive rebates, if a manufacturer were found to have knowingly submitted false information to the government, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information.
A manufacturer must also participate in a federal program known as the 340B drug pricing program in order for federal funds to be available to pay for the manufacturer’s drugs under Medicaid and Medicare Part B. Under this program, the participating manufacturer agrees to charge certain safety net healthcare providers no more than an established discounted price for its covered outpatient drugs. The formula for determining the discounted price is defined by statute and is based on the AMP and the unit rebate amount as calculated under the Medicaid drug rebate program, discussed above. Manufacturers are required to report pricing information to the Health Resources and Services Administration (HRSA) on a quarterly basis. HRSA has also issued regulations relating to the calculation of the ceiling price as well as imposition of civil monetary penalties for each instance of knowingly and intentionally overcharging a 340B covered entity.
Federal law also requires that manufacturers report data on a quarterly basis to CMS regarding the pricing of drugs that are separately reimbursable under Medicare Part B. These are generally drugs, such as injectable products, that are administered “incident to” a physician service and are not generally self-administered. The pricing information submitted by manufacturers is the basis for reimbursement to physicians and suppliers for drugs covered under Medicare Part B. As with the Medicaid drug rebate program, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information. The U.S. Department of Health and Human Services, (HHS), recently published an interim final rule that establishes a Most Favored Nation(MFN), Model for Medicare Part B drug payment. This regulation would substantially change the drug reimbursement landscape as it bases Medicare Part B payment for 50 selected drugs on prices in non-U.S. countries instead of average sales price (ASP), and establishes a fixed add-on payment in place of the current 6 percent (4.3 percent after sequestration) of ASP. The MFN drug payment amount is expected to be lower than the current ASP-based payment limit because U.S. drug prices are generally the highest in the world. Although the MFN Model interim final rule with comment period was effective as of November 27, 2020, and the model payment methodology was scheduled to begin on January 1, 2021, it faces uncertain prospects for implementation. To date, three federal courts have granted orders preventing implementation of the rule. In addition to these lawsuits, the Biden administration, which has implemented a regulatory freeze, or additional litigation challenging the regulation could delay or halt the implementation of the rule.
Medicare Part D provides prescription drug benefits for seniors and people with disabilities. Medicare Part D beneficiaries have a gap in their coverage (between the initial coverage limit and the point at which catastrophic coverage begins) where Medicare does not cover their prescription drug costs, known as the coverage gap. However, starting in 2020, Medicare Part D beneficiaries pay 25% of drug costs after they reach the initial coverage limit - the same percentage they were responsible for before they reached that limit - thereby closing the coverage gap. The cost of closing the coverage gap is being borne by innovator companies and the government through subsidies. Each manufacturer of drugs approved under NDAs or BLAs is required to enter into a Medicare Part D coverage gap discount agreement and provide a 70% discount on those drugs dispensed to Medicare beneficiaries in the coverage gap, in order for its drugs to be reimbursed by Medicare Part D.
Federal Contracting/Pricing Requirements
Manufacturers are also required to make their covered drugs, which are generally drugs approved under NDAs or BLAs, available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration. The law also requires manufacturers to offer deeply discounted FSS contract pricing for purchases of their covered drugs by the Department of Veterans Affairs, the Department of Defense, the Coast Guard, and the Public Health Service (including the Indian Health Service) in order for federal funding to be available for reimbursement or purchase of the manufacturer’s drugs under certain federal programs. FSS
25
pricing to those four federal agencies for covered drugs must be no more than the Federal Ceiling Price (FCP), which is at least 24% below the Non-Federal Average Manufacturer Price (Non-FAMP) for the prior year. The Non-FAMP is the average price for covered drugs sold to wholesalers or other middlemen, net of any price reductions.
The accuracy of a manufacturer’s reported Non-FAMPs, FCPs, or FSS contract prices may be audited by the government. Among the remedies available to the government for inaccuracies is recoupment of any overcharges to the four specified federal agencies based on those inaccuracies. If a manufacturer were found to have knowingly reported false prices, in addition to other penalties available to the government, the law provides for significant civil monetary penalties per incorrect item. Finally, manufacturers are required to disclose in FSS contract proposals all commercial pricing that is equal to or less than the proposed FSS pricing, and subsequent to award of an FSS contract, manufacturers are required to monitor certain commercial price reductions and extend commensurate price reductions to the government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is recoupment of any FSS overcharges that may result from such omissions.
Human Capital
As of December 31, 2020, we had 3,059 full-time employees worldwide, 1,343 of whom were in operations, 664 of whom were in research and development, 550 of whom were in sales and marketing and 502 of whom were in administration. Of the 3,059 full-time employees as of December 31, 2020, 2,162 employees were in the U.S. and Canada, and 897 employees were in other non-U.S. countries, including 718 in Europe and the Middle East, 117 in Latin America and 62 in Asia Pacific. We also leverage temporary workers to fill short-term positions for our business and manufacturing needs. As a result of the COVID-19 pandemic, a majority of our global workforce is currently working remotely. However, a portion of our employee base in the U.S. and Ireland continues to work onsite supporting manufacturing and laboratory operations.
Diversity, Equity and Inclusion
At BioMarin, prejudice, racism and intolerance are unacceptable. We are committed to diversity, equity and inclusion (DEI) across all aspects of our organization, including hiring, promotion and development practices. As of December 31, 2020, racial and ethnic minorities represented 46% of our employees in the U.S. Globally, 50% of our workforce were women and 46% of our positions at director-level and above were held by women. We are committed to continuing our ongoing efforts to ensure diversity in all positions, including leadership.
We remain steadfast in our commitment to fostering a community that reflects equality and inclusiveness and working towards making BioMarin a place where every employee feels heard, respected and valued. This commitment is a cultural value, and we believe incorporating and encouraging different perspectives from employees of varied backgrounds and experiences helps us better achieve our business goals and objectives. In 2020, we formed a DEI Employee Advisory Committee to help us define our DEI roadmap and ensure that perspectives from employees of different age, tenure, gender, sexual orientation, race, ethnicity, level and location are considered in how we build the most inclusive environment. We also continue to support and increase the number of our employee resource groups that build community for employees from underrepresented groups.
We are honored to be recognized as a company of choice. In January 2021, we were recognized as a Best Place to Work for lesbian, gay, bisexual, transgender and queer (LGBTQ) Equality by the Human Rights Campaign, scoring 100% on their Corporate Equality Index, one of the foremost benchmarking surveys and reports in the U.S. measuring corporate policies and practices related to LGBTQ workplace equality.
Compensation, Benefits and Well-being
We offer competitive compensation and benefits in order to attract and retain excellent people and support our employees’ overall well-being. Our total rewards compensation package includes market-competitive salary, the potential to earn bonuses or sales commissions, equity, healthcare benefits, retirement savings plans, paid time off and family leave, fitness and wellness programs, free flu vaccinations and an Employee Assistance Program and other mental health services.
In 2020, in response to the COVID-19 pandemic, we developed a comprehensive global plan that established clear and standardized COVID-19 policies, safety protocols and updates to all employees. We implemented significant changes that we determined were in the best interest of our employees as well as the communities in which we operate. These include having the majority of our employees work from home, while implementing additional safety measures for employees continuing critical onsite work. We also instituted a policy prohibiting all domestic and international non-essential travel for all employees. As part of our response to the changes implemented due to the COVID-19 pandemic, we established additional employee support programs to support the transition to remote working and to provide financial support and time-off for working parents. In addition, policies and programs were established to help support our onsite manufacturing and laboratory staff, including safety screening, onsite COVID-19 testing and financial support for employees who incurred additional expenses related to higher commuting costs, fitness facility closures, personal purchase of supplies and equipment, and increased childcare demands.
26
We believe people should be paid for the value of their work, regardless of race, ethnicity, gender or other protected characteristics. To this end, we benchmark and tie compensation to market data as well as to an employee’s experience, function, and performance. We regularly review our workforce compensation practices and strive for equity. Specifically, we partner with independent, third-party experts to conduct a regular and detailed pay equity assessment to determine whether gender and race/ethnicity have a significant impact on pay levels across the organization. This pay equity analysis is conducted on an employee’s total compensation, including base pay, bonus, and equity. If we identify any pay gap across the organization, we typically make adjustments to mitigate such gaps. Our managers also receive training in how to recognize and prevent discrimination in hiring, performance management and compensation decisions.
Professional Growth and Development
We help our employees develop the skills and capabilities to support BioMarin’s growth and innovation. We continually invest in our employees’ career growth and provide them with a wide range of development opportunities, including face-to-face, virtual and self-directed learning, mentoring, mobile coaching and external development. We offer our employees career-specific training and resources and support development opportunities through company sponsored programs in addition to our tuition reimbursement program. We also provide our high-potential employees with a variety of leadership coaching and management programs.
Patient and Community Connections
We are striving to support our local communities around the world by developing programs that inspire and enrich both our patient populations and the areas where we live and work. We actively engage with underrepresented populations through a variety of outreach and programs. We have collaborated with Biotech Partners, a non-profit organization in the San Francisco Bay Area focused on helping students underrepresented in the biotechnology field to gain experience through classroom instruction and paid internships. In addition, we have a partnership with Health Career Connection, a national non-profit that prepares the next generation of diverse, transformational health, equity, and racial justice leaders, by providing promising undergraduate college students from underrepresented backgrounds and under resourced communities with paid internship programs, health equity scholars programs and alumni professional development initiatives. Through our Rare Scholars program, we award annual scholarships to students living with rare disease.
Other Information
We were incorporated in Delaware in October 1996. Our principal executive offices are located at 770 Lindaro Street, San Rafael, California 94901 and our telephone number is (415) 506-6700. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) are available free of charge at www.bmrn.com as soon as reasonably practicable after electronically filing such reports with the Security and Exchange Commission (the SEC). Such reports and other information may be accessed through the SEC’s website at www.sec.gov. Information contained in our website is not part of this or any other report that we file with or furnish to the SEC.
27
Item 1A. Risk Factors
An investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.
28
Business and Operational Risks
The COVID-19 pandemic could materially adversely affect our business, results of operations, and financial condition.
On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic has resulted in travel restrictions, quarantines, “work-from-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world, including in many countries in which we operate. We experienced an impact on our product revenues and development programs in 2020 from the COVID-19 pandemic, and we expect that the outbreak will continue to adversely impact our financial results and our business generally. Ongoing and future effects of the COVID-19 pandemic (or any future pandemic) on all aspects of our business and operations, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, and the duration of such effects, are highly uncertain and difficult to predict. We anticipate that the COVID-19 pandemic will likely continue to have an adverse impact on our business, results of operations, and financial condition.
The continued spread of COVID-19 has adversely affected and will likely continue to adversely impact our product development programs, including preclinical study and clinical trial operations. We have been, and will likely continue to be, unable to initiate or continue conducting clinical trials as originally planned due to the prioritization of hospital resources toward the outbreak, difficulty in recruiting and retaining healthcare providers and staff due to their diversion toward treating COVID-19 patients or their heightened exposure to COVID-19, potential unwillingness of patients to enroll or continue in trials for fear of exposure to COVID-19 at sites, or the inability of patients to comply with clinical trial protocols as quarantines or travel restrictions impede patient movement or otherwise interrupt healthcare services. For example, we experienced delays in certain clinical trials and have had to reevaluate expected timelines for those trials. In addition, we rely on independent clinical investigators, contract research organizations (CROs) and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. Additionally, the COVID-19 pandemic has delayed, and may continue to postpone, necessary regulatory inspections and other interactions with regulators regarding our products in development, which could delay review or approval of our regulatory submissions.
COVID-19 could adversely affect our ability to source materials and supplies and successfully manufacture and distribute our product candidates and products. The outbreak could result in reduced operations of third-party suppliers of raw materials and supplies upon whom we rely or otherwise limit our ability to obtain sufficient materials and supplies necessary for production of our therapies. Our manufacturing facilities and those of our contract manufacturers are located in areas impacted by the COVID-19 pandemic, which may result in delays or disruptions in our ability to produce product candidates and products. If we or any third party in our supply or distribution chain are adversely impacted by the COVID-19 pandemic, including as a result of required closures, staffing shortages, production slowdowns and disruptions in delivery systems, our operations may be disrupted, limiting our ability to manufacture and distribute our product candidates for clinical trials and research and development operations and our products for commercial sales.
Our commercial operations have also been, and will likely continue to be, adversely impacted by the COVID-19 pandemic. Many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Treating COVID-19 patients has become the priority for many healthcare facilities and workers, so it has become, and may continue to be, difficult for some of our patients to receive our therapies that are administered by infusion. Although we are working with our patient community and healthcare providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from doses of our products that are missed by patients and the lost revenue from delayed treatment starts for new patients will never be recouped. Moreover, some patients may choose to skip infusions because they do not want to risk exposure to COVID-19 by having a healthcare provider administer the therapy at a healthcare facility or at home. The pandemic has also hindered our ability to find new patients and start treating newly found patients, and it has limited our sales force’s ability to promote our products to distributors, hospitals, clinics, doctors and pharmacies, which could adversely affect our revenues and results of operations. In addition, the COVID-19 pandemic could adversely affect our workforce and the employees of companies with which we do business, thereby disrupting our business operations. We have implemented work-from-home policies for employees whose jobs do not require them to be onsite. Increased reliance by us and the companies with which we do business on personnel working from home may negatively impact productivity, increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations. For our employees whose jobs require them to be onsite, we have taken precautions to avoid the spread of COVID-19 among our employees, but we cannot guarantee our workforce will not face an outbreak that could adversely impact our operations.
While the long-term economic impact and the duration of the COVID-19 pandemic may be difficult to predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and convertible notes. In addition, a recession, further market correction or depression resulting from the COVID-19 pandemic could materially adversely affect our business and the value of our common stock and convertible notes.
29
To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this Risk Factors section, such as those relating to our conducting a significant amount of our sales and operations outside of the U.S., exposure to changes in foreign exchange rates, our substantial indebtedness, our need to generate sufficient cash flows to service our indebtedness and finance our operations, our ability to comply with the covenants contained in the agreements that govern our indebtedness and the volatility of our stock price.
Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve profitability.
All of our products target diseases with small patient populations. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve profitability. For Brineura, Naglazyme and Vimizim in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.
If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.
The course of treatment for patients using our products is expensive. We expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenue and gross margins will be adversely affected.
Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.
Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.
Reimbursement in the European Union (EU) and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.
For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margins may be adversely affected.
If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected.
30
Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely) or commercialize their products before we do. With respect to valoctocogene roxaparvovec, if the product candidate is approved, we will face a highly developed and competitive market for hemophilia A treatments. As we commercialize valoctocogene roxaparvovec, if approved, we may face intense competition from large pharmaceutical companies with extensive resources and established relationships in the hemophilia A community. If we do not compete successfully, our revenue would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.
Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.
Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as Aldurazyme, Naglazyme, and Vimizim in MPS diseases, could be greatly reduced. Moreover, if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will still depend, in part, on the acceptance of physicians, patients and healthcare payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost effective and safe. Changes in treatment method can be caused by the introduction of other companies’ products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.
If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.
Our future growth and development depend in part on our ability to successfully develop new products from our research and development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals, are inherently uncertain and may not result in the commercialization of any products.
Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as Aldurazyme, Kuvan and Naglazyme. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which may target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.
Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.
The sale of generic versions of Kuvan by generic manufacturers has adversely affected and may continue to adversely affect our revenue and results of operations.
The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, permits the Food and Drug Administration (FDA) to approve abbreviated new drug applications (ANDAs) for generic versions of branded drugs. We refer to this process as the ANDA process. The ANDA process permits competitor companies to obtain marketing approval for a drug with the same active ingredient as a branded drug, but does not generally require the conduct and submission of clinical efficacy studies for the generic product. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product is bioequivalent to the branded product.
Pursuant to the Hatch-Waxman Act, companies were permitted to file ANDA applications for proposed generic versions of Kuvan at any time after December 2011. We own several patents that cover Kuvan, and we have listed those patents in conjunction with that product in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book).
31
The Hatch-Waxman Act requires an ANDA applicant seeking FDA approval of its proposed generic product prior to the expiration of our Orange Book-listed patents to certify that the applicant believes that our patents are invalid or will not be infringed by the manufacture, use or sale of the drug for which the application has been submitted (a paragraph IV certification) and notify us of such certification (a paragraph IV notice). Upon receipt of a paragraph IV notice, the Hatch-Waxman Act allows us, with proper basis, to bring an action for patent infringement against the ANDA filer, asking that the proposed generic product not be approved until after our patents expire. If we commence a lawsuit within 45 days from receipt of the paragraph IV notice, the Hatch-Waxman Act provides a 30-month stay, during which time the FDA cannot finally approve the generic’s application. If the litigation is resolved in favor of the ANDA applicant during the 30-month stay period, the stay is lifted and the FDA may approve the ANDA if it is otherwise ready for approval. The discovery, trial and appeals process in such a lawsuit is costly, time consuming, and may result in generic competition if the ANDA applicant prevails.
Between 2014 and 2016 we received paragraph IV notice letters from two pharmaceutical companies notifying us that each had filed ANDAs seeking approval of proposed generic versions of Kuvan. We filed lawsuits alleging patent infringement against each company, and between 2015 and 2017 we entered into settlement agreements with the companies that resolved the patent litigation in the U.S. The settlement agreements granted the companies non-exclusive licenses to our Kuvan-related patents to allow them to market generic versions of sapropterin dihydrochloride in the U.S. for the indications approved for Kuvan beginning on October 1, 2020, or earlier under certain circumstances. Generic versions of Kuvan first became available in the U.S. in October 2020, and as expected, our U.S. sales of Kuvan in the fourth quarter of 2020 significantly declined as compared to prior periods. We expect that the continued availability of generic versions of sapropterin dihydrochloride in the U.S. will continue to adversely affect our U.S. sales of Kuvan.
Any future ANDA or related legal proceeding could have an adverse impact on our stock price, and litigation to enforce our patents has, and is likely to continue to, cost a substantial amount and require significant management attention. If the patents covering Kuvan and its use are not upheld in litigation, or if any ANDA filer we bring suit against is found to not infringe our asserted patents, the resulting generic competition following the expiration of regulatory exclusivity would have a material adverse effect on our revenue and results of operations. Moreover, generic competition following the settlements described above could have a material adverse effect on our revenue and results of operations.
We also face generic competition for Kuvan in certain non-U.S. countries, and there is a process equivalent to the ANDA process under Article 10 of Directive 2001/83/EC in the EU. Our ability to successfully market and sell Kuvan in many countries in which we operate is based upon patent rights or certain regulatory forms of exclusivity, or both. The scope of our patent rights and regulatory exclusivity for Kuvan vary from country to country and are dependent on the availability of meaningful legal remedies in each country. If our patent rights and regulatory exclusivity for Kuvan are successfully challenged, expire, or otherwise terminate in a particular country, the resulting generic competition could have a material adverse effect on our revenue and results of operations.
If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
Regulatory Risks
If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.
We must obtain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain FDA approval for each product candidate that we intend to commercialize, and in Europe we must obtain approval from the European Medicines Agency (EMA). The FDA and EMA approval processes are typically lengthy and expensive, and approval is never certain. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory agency will mean that other agencies will also approve the same product candidate. Similarly, regulatory authorities may approve a product candidate for
32
fewer or more limited indications than requested. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.
We have had fewer interactions with regulatory authorities outside the U.S. and the EU as compared to our interactions with the FDA and EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EMA approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EMA does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by regulatory authorities in other non-U.S. countries or by the FDA or EMA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA or EMA approval. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.
Because of the risks and uncertainties in pharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. We also rely on independent third-party CROs to file some of our non-U.S. marketing applications and important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.
Although the FDA and the EMA have programs to facilitate expedited development and accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. In addition, the FDA, the EMA and other international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy to grant approval and may require additional data. If we fail to obtain regulatory approval for our product candidates, we will be unable to market and sell those product candidates, which would have a negative effect on our business and financial condition.
With respect to valoctocogene roxaparvovec, we may experience challenges specific to gene therapy that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials, the FDA has only approved a very small number of vector-based gene therapy products thus far. Moreover, there are very few approved gene therapy products outside the U.S. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for valoctocogene roxaparvovec in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. For example, in October 2020, it was reported that the Director of the Center for Biologics Evaluation and Research, the center of the FDA responsible for reviewing marketing applications for gene therapies, stated that the FDA will assess the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Regulatory review agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our treatment candidate or lead to significant post-approval studies, limitations or restrictions. For example, on August 18, 2020 the FDA issued a Complete Response Letter (CRL) to our BLA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for two-year follow-up safety and efficacy data on all study participants from our ongoing Phase 3 study of valoctocogene roxaparvovec. The trial will not complete two years of follow-up until November 2021. Continued delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring valoctocogene roxaparvovec to market could have a negative effect on our business and financial condition. Even if we do obtain regulatory approval, ethical, social and legal concerns about gene therapy arising in the future could result in additional regulations restricting or prohibiting sale of our product.
In addition, some of our product candidates are intended to be used in combination with a delivery device, such as an injector or other delivery system. Medical products containing a combination of new drugs, biological products or medical devices may be regulated as “combination products” in the U.S. A combination product generally is defined as a product consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). Each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Our product candidates intended for use with such devices, or expanded indications that we may seek for our products used with such devices, may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug or biologic product and device is sought under a single application, the increased complexity of the review process may delay approval. The FDA review process and criteria are not well-established areas, which could also lead to delays in the approval process. In addition, because these delivery devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to
33
maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.
From time to time during the development and regulatory approval process for our products and product candidates, we engage in discussions with the FDA and comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory agencies globally, but we do not always follow such guidance. This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. For example, when the FDA accepted our new drug application for vosoritide in late 2020, the agency reiterated its position raised during the vosoritide Pediatric Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee held in May 2018, recommending two, two-year placebo-controlled trials in different age groups. Although our vosoritide clinical program does not meet every element of the FDA’s recommendation, we designed our studies of vosoritide in a manner that we believe can demonstrate efficacy and safety of the product candidate for the target patient population. However, the FDA may ultimately disagree with our position that our vosoritide trials support regulatory approval. Moreover, sometimes different regulatory agencies provide different or conflicting advice. While we attempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other non-U.S. regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.
Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.
Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim have received regulatory approval to be commercially marketed and sold in the U.S., the EU and certain other countries, and Palynziq has received regulatory approval to be commercially marketed in the U.S. and the EU. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.
An example of the ongoing regulatory requirements our products are subject to is the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., Palynziq is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:
•prescribers must be certified by enrolling in the REMS program and completing training;
•prescribers must prescribe auto-injectable epinephrine with Palynziq;
•pharmacies must be certified with the REMS program and must dispense Palynziq only to patients who are authorized to receive it;
•patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq; and
•patients must have auto-injectable epinephrine available at all times while taking Palynziq.
Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of Palynziq. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the Palynziq REMS program, or whether the FDA will permit modifications to the Palynziq REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute Palynziq in the U.S., impair the safety profile of Palynziq, disrupt continuity of care for Palynziq patients and/or negatively affect sales of Palynziq.
Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product's approved labeling. In particular, a
34
product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.
Moreover, if original FDA approval for one of our product candidates is granted via the accelerated approval pathway, we will be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of the FDA’s marketing approval for a product candidate. In addition, the FDA often requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient.
Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:
•restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
•restrictions on product manufacturing processes;
•restrictions on the marketing of a product;
•restrictions on product distribution;
•requirements to conduct post-marketing clinical trials;
•untitled or warning letters or other adverse publicity;
•withdrawal of the products from the market;
•refusal to approve pending applications or supplements to approved applications that we submit;
•recall of products;
•refusal to permit the import or export of our products;
•product seizure;
•fines, restitution or disgorgement of profits or revenue;
•injunctions; or
•imposition of civil or criminal penalties.
If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory agency withdraws its approval of a product, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.
To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.
As part of the drug development process we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early stage product candidates, we may need to perform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial
35
will be favorable. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials, such as the data we have announced from the GENEr-8-1 study for valoctocogene roxaparvovec. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.
Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.
Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:
•slow or insufficient patient enrollment;
•slow recruitment of, and completion of necessary institutional approvals at, clinical sites;
•budgetary constraints or prohibitively high clinical trial costs;
•longer treatment time required to demonstrate efficacy;
•lack of sufficient supplies of the product candidate;
•adverse medical events or side effects in treated patients, including immune reactions;
•lack of effectiveness of the product candidate being tested;
•availability of competitive therapies to treat the same indication as our product candidates;
•regulatory requests for additional clinical trials or preclinical studies;
•deviations in standards for Good Clinical Practice (GCP); and
•disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services reportable to the FDA or other regulatory authority. If the FDA or other regulatory authority concludes that a financial relationship between us and a principal investigator has created a conflict of interest, the FDA or other regulatory authority may question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.
Similar rules governing clinical trials to those in place in the United States apply in the EU and the U.K. Following the U.K.’s exit from the EU, commonly referred to as Brexit, and the end of the transition period that was in place until the end of 2020, clinical trials that take place in the U.K. are seen as trials that have taken place in a “third country” and will only be considered during the course of a marketing authorization application if they are carried out on a basis that is in line with the regulations governing clinical trials in the EU. Clinical trials in the EU must be conducted in accordance with the requirements of the EU Clinical Trials Directive, as implemented in national law by individual member states, and applicable good clinical practice standards. The EU Clinical Trials Directive is due to be replaced with the new EU Clinical Trials Regulation (EU CTR) at the end of 2021. Should the U.K. not seek to align its regulations governing clinical trials with the EU CTR then trials that take place in the U.K. may carry less weight than they currently do when applying for a marketing authorization in the EU.
Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenue and results of operations.
We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has recently come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug
36
treatments, have been made in the U.S. Specifically, there have been several recent U.S. congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.
International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected.
We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenue and results of operations.
Government healthcare reform could increase our costs and adversely affect our revenue and results of operations.
Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. Since its enactment, there have been executive, judicial and congressional challenges to certain aspects of the PPACA. For example, the U.S. Supreme Court is currently reviewing the U.S. Court of Appeals for the 5th Circuit ruling that that the individual mandate was unconstitutional and to determine the constitutionality of the PPACA in its entirety, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.
We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Recently there has been heightened governmental scrutiny in countries worldwide over the manner in which manufacturers set prices for their marketed products.
In the U.S., there have been several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. For example, at the federal level, during the former Trump administration there were multiple executive orders issued, initiatives implemented and calls for legislation form Congress to reduce drug prices, increase competition and reduce out of pocket costs of drugs for patients. The likelihood of implementation of any of the former Trump administration healthcare reform initiatives is uncertain, particularly in light of the new Biden administration and its implementation of a regulatory freeze. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition, individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.
Likewise, in many EU countries, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU countries and other non-U.S. countries use prices for medicinal products established in other
37
countries as “reference prices” to help determine the price of the product in their own territory. If the price of one of our products decreases substantially in a reference price country, it could impact the price for that product in other countries. Consequently, a downward trend in prices of our products in some countries could contribute to similar downward trends elsewhere, which would have a material adverse effect on our revenue and results of operations. Moreover, in order to obtain reimbursement for our products in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our products to other available therapies.
Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
For more information regarding government healthcare reform, see “Government Regulation - Health Reform” in Part I, Item 1 of this Annual Report on Form 10-K for the year ended December 31, 2020.
If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.
As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. In the EU, orphan drug designation is available if a sponsor can establish: that the medicine is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, which is equivalent to around 250,000 people or fewer or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the medicinal product in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity (extendable to twelve years for medicines that have complied with an agreed pediatric investigation plan pursuant to Regulation 1901/2006) is available. Orphan drug marketing exclusivity may be lost in the EU if a manufacturer is unable to supply sufficient quantities and marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this medicinal product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug exclusivity for our products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.
Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor product’s orphan drug exclusivity period expires. Moreover, with respect to certain biologics and gene therapies, it is uncertain how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidates’ orphan drug exclusivities. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.
We may face competition from biosimilars approved through an abbreviated regulatory pathway.
Our Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act (the FDC Act) and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation
38
Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated approval of biological products that are demonstrated to be “biosimilar” or “interchangeable” with an FDA-approved biological product. A similar abridged marketing authorization process is available to biosimilar products in the EU. In order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of exclusivity for reference products. In Europe, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or Marketing Authorization Applications (MAAs) in Europe, as well as products in development that may be approved under those regimes in the future, could be reference products for biosimilar marketing applications.
Changes in funding for the FDA, the EMA and other government agencies or government shutdowns could hinder the ability of such agencies to hire and retain key leadership and other personnel or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
Changes in funding levels of government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA to timely review and approve INDs or marketing authorizations for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.
Government shutdowns could also impact the ability of government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory agencies, such as the FDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Risks Related to Valoctocogene Roxaparvovec
Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional development and treatment risks in relation to our other, more traditional drug development programs.
In addition to the risks set forth in this Risk Factors section associated with developing more traditional pharmaceutical drugs, there are additional, unique development and treatment risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. The goal of gene therapy is to be able to correct an inborn genetic defect through one-time administration of therapeutic genetic material containing non-defective gene copies. The gene copies are designed to reside permanently in a patient, allowing the patient to produce an essential protein or ribonucleic acid (RNA) molecule that a healthy person would normally produce. There is a risk, however, that the new gene copies will produce too little or too much of the desired protein or RNA. Although a one-time administration of a gene therapy product like our product candidate valoctocogene roxaparvovec is intended to correct an inborn genetic defect for the entire lifetime of a patient, there is a risk that the therapeutic effect will not be durable and production of the desired protein or RNA will decrease over time or cease entirely. Because the treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential overproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Furthermore, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed.
As compared to our other, more traditional products, our gene therapy product candidate valoctocogene roxaparvovec, if approved, may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product candidate.
In addition to the risks set forth in this Risk Factors section associated with commercializing more traditional pharmaceutical drugs, there are additional, unique commercial risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we face uncertainty with respect to the pricing, coverage and reimbursement of valoctocogene roxaparvovec, if approved. In order to recover our research and development costs and commercialize this one-time treatment on a profitable basis, we expect the cost of a single administration of valoctocogene roxaparvovec to be substantial. Therefore, we expect that coverage and reimbursement by governments and other third-party payers will be essential for the vast majority of patients to be able to afford valoctocogene roxaparvovec. Accordingly, sales of valoctocogene roxaparvovec, if
39
approved, will depend substantially, both domestically and internationally, on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of valoctocogene roxaparvovec.
We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. Even if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product candidate in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of valoctocogene roxaparvovec until the product candidate has been on the market for a certain amount of time. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, valoctocogene roxaparvovec
We have implemented a data access plan for valoctocogene roxaparvovec, which restricts our management’s review of emerging data from these trials. Without access to ongoing data, management does not have the ability to adjust the trials based on such emerging data, which could adversely impact the ultimate outcome of these trials.
In order to preserve the scientific integrity of the valoctocogene roxaparvovec trials and to allow us to only report on data at intervals that we believe will be meaningful to investors, we have implemented a data access plan related to the ongoing open label trials, which is designed to significantly mirror blinded trials. Pursuant to this plan, the ongoing emerging data are generally not collected by us, with the exception that certain specific data points are collected and reviewed by a small group of medical personnel monitoring and managing the trial, and then, only to the extent necessary to allow them to perform their monitoring responsibilities. As we disclose and publicly discuss prior data from these trials, such discussions do not incorporate any of the currently emerging data that are being collected and reviewed by personnel monitoring the trial and, accordingly, this prior data may differ significantly from more recent data that are only available to such personnel. Further, because our management does not have access to any of the ongoing data and does not have the ability to adjust the trials based on such emerging data, the data access plan could adversely impact the ultimate outcome of the trials.
Financial and Financing Risks
If we continue to incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.
Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for each year since our inception, with the exception of 2008, 2010 and 2020. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we fail to become profitable or are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.
If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.
As of December 31, 2020, we had cash, cash equivalents and investments totaling $1.4 billion and debt obligations of $1.1 billion (undiscounted), which consisted of our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes) and our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes). The 2024 Notes and the 2027 Notes (collectively, the Notes), if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.
In January 2016, we terminated our License and Commercialization Agreement with Ares Trading, S.A. (Merck Serono). Pursuant to the Termination and Transition Agreement related to Kuvan and the Termination Agreement related to Palynziq, we are obligated to make certain payments to Merck Serono if sales and development milestones are achieved. The remaining milestone payments that may become payable include up to a maximum of €60 million, in cash, if future sales milestones are met with respect to Kuvan and Palynziq.
We may require additional financing to fund the repayment of the Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If
40
we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.
We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:
•our ability to successfully market and sell our products;
•the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);
•the timing, number, size and scope of our preclinical studies and clinical trials;
•the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;
•the progress of research programs carried out by us;
•our possible achievement of development and commercial milestones under agreements with third parties, such as the Kuvan and Palynziq milestones under the termination agreements with Merck Serono;
•any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;
•Sanofi Genzyme’s (Genzyme) ability to continue to successfully commercialize Aldurazyme; and
•whether our convertible debt is converted to common stock in the future.
Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:
•additional licenses and collaborative agreements;
•additional contracts for product manufacturing; and
•additional financing facilities or arrangements.
We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.
We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.
As of December 31, 2020, we had $1.1 billion (undiscounted) principal amount of indebtedness, including $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes and $600.0 million (undiscounted) principal amount of indebtedness under the 2027 Notes. In October 2018, we also entered into an unsecured credit agreement (the 2018 Credit Facility) with Bank of America, N.A., as the administrative agent, swingline lender and a lender, Citibank N.A. as letter of credit issuer and each of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citibank, N.A. and Wells Fargo Securities, LLC as joint lead arrangers and joint bookrunners, providing up to $200.0 million in revolving loan commitments. Our indebtedness may:
•limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;
•limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;
•require us to use a substantial portion of our cash flow from operations to make debt service payments;
•limit our flexibility to plan for, or react to, changes in our business and industry;
•place us at a competitive disadvantage compared to our less leveraged competitors; and
41
•increase our vulnerability to the impact of adverse economic and industry conditions.
In addition, the 2018 Credit Facility contains, and any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full. If we default under the 2018 Credit Facility, the outstanding borrowings thereunder could become immediately due and payable, the 2018 Credit Facility lenders could refuse to permit additional borrowings under the facility, or it could lead to defaults under agreements governing our current or future indebtedness, including the indentures governing the Notes. If we default under any of the Notes, such Notes could become immediately due and payable and it could lead to defaults under the other Notes and/or the 2018 Credit Facility.
In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.
Our outstanding indebtedness consists primarily of the 2024 Notes and 2027 Notes, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon maturity of the Notes, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.
In addition, we also may borrow up to $200.0 million in revolving loans under the 2018 Credit Facility, which would be required to be repaid in cash at maturity on October 19, 2021.
Manufacturing Risks
If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.
Before we can begin commercial manufacture of our products, regulatory authorities must approve marketing applications that identify manufacturing facilities operated by us or our contract manufacturers that have passed regulatory inspection and manufacturing processes that are acceptable to the regulatory authorities. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced inspection by the FDA and international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facility in the U.S. has been approved by the FDA and the European Commission (EC) for the manufacture of Palynziq, and it has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Aldurazyme, Brineura, Naglazyme and Vimizim. Our manufacturing facility in Shanbally, Cork, Ireland has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Vimizim, and it has been approved by the FDA and the EMA as a formulated bulk drug substance manufacturing and quality control facility for Brineura. In addition, our third-party manufacturers’ facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.
Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal or international regulatory inspection.
If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.
If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.
Due to the complexity of manufacturing our product candidates and products, we may not be able to manufacture sufficient quantities. Our inability to produce enough of our product candidate at acceptable costs may result in the delay or termination of development programs. With respect to our commercial portfolio, we may not be able to manufacture our products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins.
42
The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.
With respect to valoctocogene roxaparvovec, gene therapy products are relatively novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the valoctocogene roxaparvovec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all, or commercializing valoctocogene roxaparvovec on a profitable basis, if at all.
Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.
Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs, including Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim, have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.
We currently rely on third parties for portions of the manufacture of each of our commercial products. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.
In addition, our manufacturing processes subject us to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.
Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.
We depend on single-source suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:
•timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;
•labor interruptions;
•changes in our sources for manufacturing;
•the timing and delivery of shipments;
43
•our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; and
•conditions affecting the cost and availability of raw materials.
If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.
Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.
With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.
If our Manufacturing, Marketing and Sales Agreement with Genzyme were terminated, we could be prevented from continuing to commercialize Aldurazyme or our ability to successfully commercialize Aldurazyme would be delayed or diminished.
Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Genzyme and us related to Aldurazyme for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.
If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to Aldurazyme and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to Aldurazyme will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to Aldurazyme is to be sold to the highest bidder, with the proceeds to be split between Genzyme and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.
If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to Aldurazyme exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offeree’s interest in Aldurazyme and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating party’s interest in Aldurazyme and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to Aldurazyme. The Amended and Restated Collaboration Agreement between us and Genzyme will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.
If we were obligated or given the option to buy out Genzyme’s interest in Aldurazyme and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to Aldurazyme, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Genzyme’s interest, we may be held in breach of the agreement and may lose any claim to the rights to Aldurazyme and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing Aldurazyme. If this happened, not only would our product revenues decrease, but our share price would also decline.
Risks Related to International Operations
We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenue and results of operations.
A significant portion of the sales of Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim are generated from countries other than the U.S. Similarly, we expect a significant portion of the sales of Palynziq to be generated from countries other than the U.S. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that
44
we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:
•the increased complexity and costs inherent in managing international operations;
•diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;
•political and economic instability;
•diminished protection of intellectual property in some countries outside of the U.S.;
•trade protection measures and import or export licensing requirements;
•difficulty in staffing and managing international operations;
•differing labor regulations and business practices;
•potentially negative consequences from changes in or interpretations of tax laws;
•changes in international medical reimbursement policies and programs;
•financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by non-U.S. governments;
•regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ and service providers’ activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); and
•rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.
Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations.
As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenue and profitability.
A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenue in these countries.
We make a significant portion of our international sales of Naglazyme and Vimizim through special access or “named patient” programs, which do not require full product approval, and we expect a significant portion of our international sales of Brineura will also be through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained for each patient. The approval normally requires an application or a lawsuit accompanied by evidence of medical need. Generally, the approvals for each patient must be renewed from time to time.
These programs are not well defined in some countries and are subject to changes in requirements and funding levels. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.
Without the special access programs, we would need to seek full product approval to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek and maintain a full product approval, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.
45
U.S. export control and economic sanctions may adversely affect our business, financial condition and operating results. Moreover, compliance with such regulatory requirements may increase our costs and negatively impact our ability to sell our products and collect cash from customers.
Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or hinder our ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. If we fail to comply with these laws and regulations, we could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges and fines.
We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, be renewed in the future or that we will remain in compliance. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
Moreover, U.S. export control and economic sanctions may make operating in certain countries more difficult and expensive. For example, we may be unable to find distributors or financial institutions willing to facilitate the sale of our products and collection of cash from such sales in a cost-effective manner, if at all.
Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.
We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the U.S., the United Kingdom (U.K.) Bribery Act and other similar laws in other countries in which we do business. We operate in a number of countries that are recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered non-U.S. officials for purposes of applicable anti-corruption laws.
Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.
Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.
Our international operations pose currency risks, which may adversely affect our operating results and net income.
A significant and growing portion of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the Great British Pound, the Canadian Dollar and several other currencies, changes in those currencies relative to the U.S. Dollar (USD) will impact our revenues and expenses. If the USD were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase,
46
having a negative impact on earnings. Conversely, if the USD were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. In addition, because our financial statements are reported in USD, changes in currency exchange rates between the USD and other currencies have had, and will continue to have, an impact on our results of operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.
We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.
We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.
Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.
Intellectual Property Risks
If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.
Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.
The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of Aldurazyme, Naglazyme and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in Kuvan) has also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.
We own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:
•With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.
•Patents have limited duration and expire.
•Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs.
•Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.
•The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a “first-to-invent” system to a “first-to-file” system, and the implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.
47
It is also unclear whether our trade secrets are adequately protected. Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.
Under policies recently adopted in the EU, clinical trial data submitted to the EMA in MAAs that were traditionally regarded as confidential commercial information are now subject to public disclosure. Subject to our ability to review and redact a narrow sub-set of confidential commercial information, the new EU policies will result in the EMA’s public disclosure of certain of our clinical study reports, clinical trial data summaries and clinical overviews for recently completed and future MAA submissions. The move toward public disclosure of development data could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, and enabling competitors to use our data to gain approvals for their own products.
Competitors may interfere with our patent process in a variety of ways. Competitors may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, a competitor could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent. Moreover, generic manufacturers may use litigation and regulatory means to obtain approval for generic versions of our products notwithstanding our filed patents or patent applications.
If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenue and financial results generally.
Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.
Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, such as valoctocogene roxaparvovec, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. If someone else claims we infringe its intellectual property, we would face a number of issues, including the following:
•Defending a lawsuit takes significant executive resources and can be very expensive.
•If a court decides that our product infringes a competitor’s intellectual property, we may have to pay substantial damages.
•With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.
•We may need to redesign our product so it does not infringe the intellectual property rights of others.
•Redesigning our product so it does not infringe the intellectual property rights of competitors may not be possible or could require substantial funds and time.
We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations.
If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed
48
in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.
Risks Related to Ownership of Our Securities
Our stock price may be volatile, and an investment in our stock could suffer a decline in value.
Our valuation and stock price may have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock will fluctuate due to factors including:
•product sales and profitability of our products;
•manufacturing, supply or distribution of our product candidates and commercial products;
•progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;
•results of clinical trials, announcements of technological innovations or new products by us or our competitors;
•generic competition to Kuvan tablets and powder relating to our settlements with the two pharmaceutical companies described above in this Risk Factors section or potential generic competition from future competitors;
•government regulatory action affecting our product candidates, our products or our competitors’ product candidates and products in both the U.S. and non-U.S. countries;
•developments or disputes concerning patent or proprietary rights;
•general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;
•economic conditions in the U.S. or abroad;
•negative publicity about us or the pharmaceutical industry;
•changes in the structure of healthcare payment systems;
•cybersecurity incidents experienced by us or others in our industry;
•broad market fluctuations in the U.S., the EU or in other parts of the world;
•actual or anticipated fluctuations in our operating results, including due to timing of large orders for our products, in particular in Latin America, where governments place large periodic orders for Naglazyme and Vimizim;
•changes in company assessments or financial estimates by securities analysts;
•acquisitions of products, businesses, or other assets; and
•sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.
Furthermore, the stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In some cases, these fluctuations have been unrelated or disproportionate to the operating performance of those companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. For example, in September 2020, after a substantial drop in our stock price that followed an announcement providing a regulatory update regarding valoctocogene roxaparvovec, we and certain of our officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false and misleading statements. We may be the target of additional litigation of this type in the future as well. Securities litigation against us could result in substantial costs and divert our management’s time and attention from other business concerns, which could harm our business.
In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.
49
Conversion of the Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress the price of our common stock.
The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.
Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.
We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholders’ meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.
The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take us over.
The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of us would trigger options by the respective holders of the applicable Notes to require us to repurchase such Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the Notes.
Our amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the U.S. as the exclusive forums for the adjudication of certain disputes, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:
•any derivative claim or cause of action brought on our behalf;
•any claim or cause of action for breach of a fiduciary duty owed by any director, officer or other employee of BioMarin to us or our stockholders;
•any claim or cause of action against us or any of our directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate of incorporation or our amended and restated bylaws;
•any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction to the Court of Chancery of the State of Delaware; and
•any claim or cause of action against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.
This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. In addition, our amended and restated bylaws provide that the federal district courts of the U.S. of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.
50
While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.
These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either of our exclusive forum provisions to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. Our amended and restated bylaws further provide that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provisions.
General Risk Factors
We depend upon our key personnel and our ability to attract and retain employees.
Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of any member of our senior management or the inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results.
Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officers’ ability to compete with us after their employment is terminated. The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. Due to this intense competition, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. If we are unsuccessful in our recruitment and retention efforts, our business may be harmed.
Our success depends on our ability to manage our growth.
Product candidates that we are currently developing or may license or acquire in the future may be intended for patient populations that are significantly larger than any of the patient populations we currently target. In order to continue development and marketing of these products, if approved, we will need to significantly expand our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory and corruption risks and our management may be unable to manage successfully future market opportunities or our relationships with customers and other third parties.
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business and financial condition.
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (TCJA), enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, the application of certain tax credits (including a reduction of tax credits under the Orphan Drug Act), the deductibility of expenses, the utilization of net operating losses (NOLs) and other deferred tax assets, and the taxation of non-U.S. earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, enacted on March 27, 2020, modified certain provisions of the TCJA, including provisions relating to NOL utilization. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the CARES Act, or any newly enacted federal tax legislation. The impact of changes under the TCJA, the CARES Act, or future reform legislation could increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.
Moreover, changes in the tax laws of non-U.S. jurisdictions could arise, including as a result of the base erosion and profit shifting (BEPS) project that was undertaken by the Organization for Economic Co-operation and Development (OECD), or other initiatives led by the European Commission. The OECD, which represents a coalition of member countries including the U.S. and other countries in which we have operations, made several recommendations with the aim of addressing tax avoidance and ensuring that profits are taxed where economic activities generating the profits are performed and where value is created. These
51
changes, as adopted by countries, may increase tax uncertainty and may adversely affect our provision for income taxes, results of operations and cash flows. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm's length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities successfully challenge our transfer prices as not reflecting arm's length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, resulting in a higher tax liability. In addition, if a country from which income is reallocated does not agree with the reallocation, both that country and the other country to which the income was allocated could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our business, financial condition, results of operations and cash flows.
If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.
We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase, order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers.
Federal and state false claims laws, including the civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
In addition, recent healthcare reform legislation has strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and non-U.S. laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices outside of the European Economic Area (EEA) are likely to remain uncertain for the foreseeable future. In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California consumers expanded rights to access and delete their personal information, opt out of certain personal information sales, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA will be expanded substantially on January 1, 2023 when the California Privacy Rights Act of 2020 (CPRA), becomes fully operative. The CPRA will, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, expand an individual’s private right of action and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. Aspects of the CCPA and CPRA and their interpretation and enforcement remain uncertain. The potential effects of the CCPA and CPRA are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.
The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EU Member State implementing legislations, apply to the processing of personal data of individuals located in the EEA, including health-related
52
information, by companies located in the EEA, or in certain circumstances, by companies located outside of the EEA. These laws impose strict obligations on the ability to collect, record, store, disclose, use and transmit personal data, including health-related information. These include several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Potential pecuniary fines for noncompliant companies may be up to the greater of €20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process and has increased our compliance costs.
The GDPR and other European data protection laws generally restrict the transfer of personal information from Europe, including the EEA and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from Europe has been the European Commission’s Standard Contractual Clauses (SCCs). However, the Court of Justice of the EU issued a decision that called into question whether the SCCs can lawfully be used for transfers of personal information from Europe to the United States or most other countries. At present, there are few, if any, viable alternatives to the SCCs, on which we have relied for personal information transfers from Europe to the United States and other “third countries.” The Court of Justice of the EU ruled that subject to their containing “effective mechanisms” to ensure compliance with the protections offered by EU law, namely implementation of transfer impact assessments regarding country surveillance laws, the SCCs were generally upheld. New SCCs will be published in the coming months and will require implementation within 12 months from publication. Compliance with the regulations covering the transfer of personal information from Europe to the U.S. has increased our compliance costs.
Following the U.K.’s withdrawal from the EU on January 31, 2020 and the end of the transitional arrangements agreed to between the U.K. and EU, the GDPR no longer has effect in law in the U.K. However, the data protection obligations of the GDPR continue to apply to U.K.-related processing of personal data in substantially unvaried form under the so-called “UK GDPR” (i.e., the GDPR as it continues to form part of law in the U.K. However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the U.K. and EEA. Furthermore, the relationship between the U.K. and the EEA in relation to certain aspects of data protection law remains unclear, which could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. Also in the event of a violation of the GDPR affecting data subjects across the U.K. and the EEA, we could potentially be investigated by, and ultimately fined by the U.K. Information Commissioner’s Office and the supervisory authority in each and every EEA Member State where data subjects have been affected by such violation.
Substantial new laws and regulations affecting compliance have also been adopted in the U.S. and certain non-U.S. countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as investment and ownership interests held by such physicians and their immediate family members during the preceding calendar year. Effective January 1, 2022, manufacturers will also be required to report on payments or transfers of value, and ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many non-U.S. countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted non-U.S. legislation creates reporting obligations on payments, gifts and benefits made to these professionals; however, implementing regulations enacting such laws are still pending and subject to varying interpretations by courts and government agencies. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.
Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement agencies in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to significant criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-
53
compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.
If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.
We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercialization of our product programs.
We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively and have a material adverse effect on our business, reputation, financial condition, and results of operations.
We rely significantly on our information technology systems to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively. Our ability to manage and maintain our operations, inventory and internal reports, to manufacture and ship our products to customers and timely invoice them depends significantly on our enterprise resource planning, production management and other information systems. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, cyberattack and other disruptions. Potential problems and interruptions associated with the implementation of new or upgraded technology systems or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations and expose us to greater risk of security breaches. Cybersecurity incidents, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems are becoming increasingly frequent and more sophisticated. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access or unavailability of these systems, have occurred in the past and may affect our ability in the future to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations.
As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties for which we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation. Data security breaches may be the result of unauthorized or unintended activity (or lack of activity) by our employees or contractors or malware, hacking, business email compromise, phishing or other cyberattacks directed by third parties. These third parties for which we depend on to operate our business have experienced and may continue to experience cybersecurity incidents. While we have implemented measures to protect our information and data stored in our technology systems and those of the third parties that we rely on, our efforts may not be successful.
We have experienced and may continue to experience cybersecurity incidents. Although to our knowledge we have not experienced any material incident or interruption to date, if such an event were to occur it could result in a material disruption of our development programs and commercial operations, including due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information. Further, these cybersecurity incidents can lead to the public disclosure of personal information (including sensitive personal information) of our employees, clinical trial patients and others and result in demands for ransom or other forms of blackmail. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, “hacktivists”, nation states and others. Moreover, the costs to us to investigate and mitigate cybersecurity incidents could be significant. For example, the loss of clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security breach that results in the unauthorized access, use or disclosure of personal data may require us to notify individuals, governmental authorities, credit reporting agencies, or other parties pursuant to privacy and security laws and regulations or other obligations. Such a security compromise could harm our reputation, erode confidence in our information security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, proprietary or personal information, we could be exposed to a risk of loss, enforcement measures,
54
penalties, fines, indemnification claims, litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.
If a natural disaster, terrorist or criminal activity or other unforeseen event caused significant damage to our facilities or those of our third-party manufacturers and suppliers or significantly disrupted our operations or those of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.
The occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair the ability for us or our third-party manufacturers to manufacture our products and product candidates. Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for Aldurazyme, Naglazyme and Palynziq and is one of two manufacturing facilities for Brineura and Vimizim. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support valoctocogene roxaparvovec clinical development activities and the anticipated commercial demand for valoctocogene roxaparvovec, if approved. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely, impaired, and our commercialization efforts and revenue could be seriously impaired.
Moreover, other unforeseen events, such as power outages, could significantly disrupt our operations or those of our third-party manufacturers and suppliers, which could result in significant delays in the manufacture of our products and adversely impact our commercial operations and revenues. Pacific Gas and Electric Company, the electric utility in the San Francisco Bay Area where many of our facilities are located, commenced widespread blackouts during the fall of 2019 to avoid and contain wildfires sparked during strong wind events by downed power lines or equipment failures. While we have not experienced damage to our facilities or material disruption to our operations as a result of these power outages, ongoing blackouts, particularly if prolonged or frequent, could impact our business going forward. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.
Our business is affected by macroeconomic conditions.
Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counter parties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.
We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenue would be adversely affected.
Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.

55

Item 1B. Unresolved Staff Comments
None.

Item 2. Properties
The following table contains information about our significant owned and leased properties as of December 31, 2020:
Location
Approximate
Square Feet
Use
Lease
Expiration
Date
San Rafael facility, San Rafael, California407,300 Corporate headquarters, laboratory and officeOwned 
property
Several facilities in Novato, California293,300 Clinical and commercial manufacturing, laboratory and officeOwned 
property
Several leased facilities in Novato, California203,700 Office and warehouse2023
Shanbally facility, Cork, Ireland203,500 Manufacturing, laboratory and officeOwned 
property
We expect that these properties, together with our other smaller leased office facilities in various countries, will be adequate for our operations for the foreseeable future.

Item 3. Legal Proceedings
On September 25, 2020, a purported shareholder class action lawsuit was filed against us, our Chief Executive Officer, our President of Worldwide Research and Development and our Executive Vice President and Chief Financial Officer in the United States District Court in the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made materially false or misleading statements regarding the clinical trials and Biologics License Application (BLA) for valoctocogene roxaparvovec by purportedly failing to disclose that differences between the Company’s Phase 1/2 and Phase 3 clinical studies limited the ability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect and, as a result, that it was foreseeable that the FDA would not approve the BLA without additional data. The complaint seeks an unspecified amount of damages, pre-judgment and post-judgment interest, attorneys’ fees, expert fees, and other costs. In December 2020, the court hearing the case appointed Arbejdsmarkedets Tillægspension as lead plaintiff. The lead plaintiff filed an amended complaint in February 2021, dropping our Chief Financial Officer as a defendant, and asserting that the Company misled investors about the progress of the FDA's review of our BLA for valoctocogene roxaparvovec. Our motion to dismiss the complaint is due on April 22, 2021. We believe that the claims have no merit and we intend to vigorously defend this action.

Item 4. Mine Safety Disclosures
Not applicable.
56
Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is listed under the symbol “BMRN” on the Nasdaq Global Select Market.
We have never paid any cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future.
Recent Sales of Unregistered Securities
We did not sell any unregistered securities during the year ended December 31, 2020 that were not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.
Issuer Purchases of Equity Securities
None.
Holders
As of February 12, 2021, there were 39 holders of record of 181,829,680 outstanding shares of our common stock.
Performance Graph
The following is not deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing we make under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation by reference language in such filing.
The following graph shows the value of an investment in BioMarin common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, assuming the investment of $100.00 at the beginning of the period and the reinvestment of dividends, if any. Our common stock is traded on the Nasdaq Global Select Market and is a component of both the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The comparisons shown in the graph are based upon historical data and
57
we caution that the stock price performance shown in the graph is not indicative of, nor intended to forecast, the potential future performance of our stock.
bmrn-20201231_g1.jpg

* $100 invested on December 31, 2015 in stock or index, including reinvestment of dividends.
201520162017201820192020
BioMarin Pharmaceutical Inc.$100.00 $79.08 $85.12 $81.28 $80.71 $83.71 
Nasdaq Composite Index$100.00 $108.87 $141.13 $137.12 $187.44 $271.64 
Nasdaq Biotechnology Index$100.00 $78.65 $95.67 $87.19 $109.08 $137.90 

58
Item 6. Selected Consolidated Financial Data
We derived the selected consolidated statements of operations data for the years ended December 31, 2020, 2019 and 2018 and the selected consolidated balance sheet data as of December 31, 2020 and 2019 from the audited Consolidated Financial Statements appearing elsewhere in this Annual Report on Form 10-K. We derived the selected consolidated statements of operations data for the years ended December 31, 2017 and 2016 and the selected consolidated balance sheet data as of December 31, 2018, 2017 and 2016 from audited Consolidated Financial Statements not included in this Annual Report on Form 10-K. The information set forth below is not necessarily indicative of results of future operations, and should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the Consolidated Financial Statements and related notes thereto included in Item 15 of this Annual Report on Form 10-K to fully understand factors that may affect the comparability of the information presented below:

Years Ended December 31,
(In millions, except for per share data)
2020 (1)
2019 (1)
2018 (1)
20172016
Consolidated Statements of Operations data:
Total revenues$1,860.5 $1,704.0 $1,491.2 $1,313.6 $1,116.9 
Total costs and expenses$1,897.2 $1,804.5 $1,614.7 $1,328.3 $1,920.3 
Loss from operations$(36.8)$(100.5)$(123.5)$(14.7)$(803.4)
Provision for (benefit from) income taxes$(901.4)$(71.0)$(65.5)$81.2 $(200.8)
Net Income (loss)$859.1 $(23.8)$(77.2)$(117.0)$(630.2)
Net income (loss) per share, basic$4.75 $(0.13)$(0.44)$(0.67)$(3.80)
Net income (loss) per share, diluted$4.53 $(0.13)$(0.44)$(0.67)$(3.81)
Weighted average common shares
outstanding, basic		180.8 179.0 177.1 174.4 166.0 
Weighted average common shares
outstanding, diluted		191.7 179.0 177.3 174.4 166.2 

December 31,
(In millions)
20202019201820172016
Consolidated Balance Sheets data:
Cash, cash equivalents and investments$1,350.9 $1,165.8 $1,320.2 $1,781.7 $1,362.4 
Total assets$5,848.0 $4,690.0 $4,427.1 $4,633.1 $4,023.7 
Convertible senior notes, net$1,075.1 $848.1 $830.4 $1,174.5 $683.2 
Other long-term obligations$174.3 $148.9 $105.5 $194.4 $157.3 
Total stockholders' equity$4,106.0 $3,122.4 $2,967.9 $2,808.7 $2,766.3 
(1)Refer to “Management's Discussion and Analysis of Financial Condition and Results of Operations — Results of Operations” in Part II, Item 7 of this Annual Report on Form 10-K for additional discussion of our operating results and changes in our financial position.
59

Quarterly Financial Data (unaudited)
You should read the following tables presenting our unaudited quarterly results of operations in conjunction with the Consolidated Financial Statements and related notes contained elsewhere in this Annual Report on Form 10-K. We have prepared this unaudited information on the same basis as our audited Consolidated Financial Statements. Our quarterly operating results have fluctuated in the past and may continue to do so in the future as a result of a number of factors, including, but not limited to, the timing and nature of research and development activities.
Three Months Ended
(In millions, except per share data, unaudited)
March 31,June 30,September 30,December 31,
2020:
Total revenues$502.1 $429.5 $476.8 $452.1 
Net income (loss)$81.4 $(29.2)$784.8 $22.1 
Net income (loss) per share, basic$0.45 $(0.16)$4.33 $0.12 
Net income (loss) per share, diluted$0.44 $(0.16)$4.01 $0.12 
2019:
Total revenues$400.7 $387.8 $461.1 $454.4 
Net income (loss)$(56.5)$(37.4)$55.0 $15.0 
Net income (loss) per share, basic$(0.32)$(0.21)$0.31 $0.08 
Net income (loss) per share, diluted$(0.32)$(0.21)$0.30 $0.08 
Refer to “Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations” in Part II, Item 7 of this Annual Report on Form 10-K for discussion of our operating results.
60

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to help the reader understand our results of operations and financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited Consolidated Financial Statements and the accompanying notes to the Consolidated Financial Statements and other disclosures included in this Annual Report on Form 10-K, including the disclosures under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. In particular, we encourage you to review the risk factor related to the impact of the coronavirus pandemic, “The COVID-19 pandemic could materially adversely affect our business, results of operations and financial condition.” These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled “Forward-Looking Statements” that appears at the beginning of this Annual Report on Form 10-K. These statements, like all statements in this report, speak only as of the date of this Annual Report on Form 10-K (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) and are presented in U.S. Dollars (USD).
Overview
We are a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products.
Our portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. A summary of our commercial products, as of December 31, 2020, is provided below:
Commercial ProductsIndication
United States
Orphan
Drug
Exclusivity
Expiration (1)
United
States
Biologic
Exclusivity
Expiration (2)
European
Union
Orphan Drug
Exclusivity
Expiration (1)
Aldurazyme (laronidase)
MPS I (3)
ExpiredExpiredExpired
Brineura (cerliponase alfa)
CLN2 (4)
202420292027
Kuvan (sapropterin dihydrochloride)
PKU (5)
ExpiredNot ApplicableExpired
Naglazyme (galsulfase)
MPS VI (6)
ExpiredExpiredExpired
Palynziq (pegvaliase-pqpz) (7)
PKU 
202520302029
Vimizim (elosulfase alpha)
MPS IVA (8)
202120262024
(1)See “Government Regulation—Orphan Drug Designation” in Part I, Item 1 of this Annual Report on Form 10-K for further discussion
(2)See “Government Regulation— Healthcare Reform” in Part I, Item 1 of this Annual Report on Form 10-K for further discussion
(3)For the treatment of Mucopolysaccharidosis I (MPS I)
(4)For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
(5)For the treatment of phenylketonuria (PKU)
(6)For the treatment of Mucopolysaccharidosis VI (MPS VI)
(7)For adult patients with PKU
(8)For the treatment of Mucopolysaccharidosis IV Type A (MPS IVA)
61

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
A summary of our on-going major development programs as of December 31, 2020, is provided below:
Major Product Candidates
in Development
Target
Indication
U.S. Orphan
Designation
EU Orphan
Designation
Stage
Valoctocogene roxaparvovecSevere Hemophilia A Yes  Yes  Clinical Phase 3
Vosoritide Achondroplasia  Yes  Yes  Clinical Phase 3
BMN 307PKU YesYesClinical Phase 1/2

Uncertainty Relating to the COVID-19 Pandemic
The outbreak of novel coronavirus disease (COVID-19) continues to affect economies and business around the world. Our global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and our overall business operations were impacted by COVID-19 during the year ended December 31, 2020 and we anticipate a continued impact on our financial results in fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor related to the impact of the coronavirus pandemic, “The COVID-19 pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.
Business Developments
We continued to grow our commercial business and advance our product candidate pipeline during 2020. We believe that the combination of our internal research programs, acquisitions and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Below is a summary of key business developments:
Continued Emphasis on Research and Development
•Vosoritide - In February 2021, we announced that the FDA granted priority review designation for our New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans.
In December 2020, we announced results from our pivotal global Phase 3 randomized, double-blind, placebo-controlled study of vosoritide in approximately 121 children with achondroplasia ages 5-14 for two years. The data demonstrated that children in the open-label long-term extension of the Phase 3 study maintained an increase in Annual Growth Velocity through the second year of continuous treatment. An analysis comparing 52 children who were randomized and treated with vosoritide for two years to 38 children from the run-in study who were randomized to receive placebo with an untreated observation period of two years showed improvement in one-year height change in the treated group relative to the untreated group. The one-year height change improvement in the second year of treatment, 1.79 cm, was similar to the one-year height change improvement in the first year of treatment, 1.73 cm. The cumulative height gain over the 2-year period for treated children was 3.52 cm more than untreated children.
In 2020, marketing applications for vosoritide were validated and accepted by the EMA and FDA, respectively. The Committee for Medicinal Products for Human Use (CHMP) opinion is expected in Europe in June 2021. The U.S. NDA for vosoritide is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) Target Action Date of August 20, 2021. Vosoritide has Orphan Drug designation from the FDA and EMA.
•BMN 307 - In February 2021, we announced that we plan to dose escalate participants in PHEarless, the Phase 1/2 study of BMN 307 our gene therapy candidate for PKU based on encouraging Phe lowering and safety signals observed in study participants who were treated with the lowest dose. Both the FDA and EMA have granted BMN 307 Orphan Drug Status. Additionally, the FDA has granted fast track designation to BMN 307. All subjects participating in the PHEarless study are receiving product made at commercial scale from our gene therapy manufacturing facility.
•Valoctocogene roxaparvovec – In January 2021, we announced topline results from our ongoing global Phase 3 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. All 134 study participants received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Data from the study in the pre-specified primary analysis for Annualized Bleeding Rate (ABR) showed that a single dose of valoctocogene roxaparvovec significantly reduced ABR by 84% compared
62

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
with prior treatment with prophylactic Factor VIII infusions from 4.8 (median 2.8) bleeding episodes per year at baseline to 0.8 (median 0.0). These results were from a pre-specified group of 112 participants in a non-interventional prospective baseline observational study with a median follow-up of 60.1 weeks after dosing with valoctocogene roxaparvovec. Of the 112 rollover study participants, 80% were bleed-free starting at week five after treatment.
Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII usage in the rollover population by 99%, from 135.9 (median 128.6) to 2.0 (median 0.0) infusions per year. At the end of the first year post-infusion with valoctocogene roxaparvovec, 132 participants in the modified intent-to-treat (mITT) population had a mean endogenous Factor VIII expression level of 42.9 (SD 45.5, median 23.9) IU/dL, as measured by the chromogenic substrate assay, supporting the clinical benefits observed with significant reduction of bleeding episodes and Factor VIII infusion rate. Factor VIII expression declined at a slower rate compared to the Phase 1/2 study, and remained in a range to provide hemostatic efficacy. In the 17 participants who comprise a subset of the mITT population and had been dosed at least two years prior to the data cut date, Factor VIII expression declined from a mean of 42.2 (SD 50.9, median 23.9) IU/dL at the end of year one to a mean of 24.4 (SD 29.2, median 14.7) IU/dL at the end of year two with continued hemostatic efficacy demonstrated by a mean ABR of 0.9 (median 0.0) bleeding episodes per year
In the United States, the Food and Drug Administration (FDA) recommended that we complete the Phase 3 study and submit two-year follow-up safety and efficacy data on all study participants. We plan to meet with FDA to review the two-year data request and share the Phase 3 results announced in January 2021. We are targeting resubmission of the Marketing Authorization Application (MAA) with these results to the European Medicines Agency (EMA) in the second quarter of 2021 pending confirmation in presubmission meetings.
•BMN 255 - In January 2021, we announced that we filed an Investigational New Drug application (IND) for BMN 255, a small molecule for the treatment of a subset of chronic renal disease. BMN 255 was driven by genetic discoveries for both mechanism and for identifying individuals for treatment.
•Palynziq - In October 2020 we announced that the FDA approved our supplemental BLA to increase the maximum allowable dose of Palynziq Injection for treatment of adults with PKU to 60 mg daily. Previously, the maximum dose was 40 mg daily. In the Phase 3 PRISM studies, 19% of study participants required a 60 mg dose to achieve adequate response to Palynziq.
Palynziq is indicated to reduce blood Phe concentrations in adults with PKU, who have uncontrolled blood Phe concentrations greater than 600 μmol/L on existing management. Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, is the first and only approved enzyme substitution therapy to target the underlying cause of PKU by helping the body to break down Phe.
•BMN 331 - In July 2020, we began IND-enabling studies for our third gene therapy product candidate, BMN 331, for the treatment of hereditary angioedema.
•BMN 351 - IND-enabling studies are underway for BMN 351, an oligonucleotide therapy that has demonstrated a high-level of protein expression in pre-clinical models for the treatment of Duchenne Muscular Dystrophy. We intend to determine the timing of a potential IND filing at the end of the year based on the results of these studies.
•Gene therapy manufacturing facility - In January 2020, we announced significant improvements in productivity at our gene therapy facility which has the potential to support the commercial production of multiple gene therapy products to meet global commercial demand, depending on dose and production mix.
2021 Outlook
In 2021, we will continue to focus on our key operating objectives which include continued progression of our product pipeline and continued uptake of our commercial products. From a research and development (R&D) perspective, we expect to continue to invest in our various ongoing clinical studies which support both our commercial products and research and early development pipeline. We expect to move forward on a number of late-stage clinical studies for new product candidates and plan to file marketing applications for various therapeutic areas.
From a commercial perspective, we expect to continue to build-out our commercial organization to support the commercialization of Palynziq and incur pre-commercialization expenses related to vosoritide.
While the continued impact of the COVID-19 pandemic on the global business environment remains uncertain, we expect the conditions and effects of the pandemic on our business will persist. We expect significant declines in Kuvan revenues in the U.S. due to the October 2020 loss of market exclusivity and plan to implement strategies to retain market share aimed to mitigate a complete loss of market share. We expect to experience continued growth in our base business for the other commercial products.
63

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
We continue to monitor conditions in the macroeconomic environment that could affect our ability to achieve our goals, such as the continuing impact of the COVID-19 pandemic on all aspects of our business, changes in the reimbursement and payer landscape, changes in economic conditions in certain key markets, particularly in Europe and Latin America, patent expiration of competitive products and the launch of generic competitors, government pricing pressures internationally and the potential volatility in foreign currency exchange rates. We will adjust our business processes, as appropriate, to attempt to mitigate these risks to our business.
We expect that our product pipeline investments and expanding commercial infrastructure will enable us to execute on our 2021 operating objectives.
2020 Financial Highlights
Key components of our results of operations include the following:
Years Ended December 31,
202020192018
Total revenues$1,860.5 $1,704.0 $1,491.2 
Cost of sales$524.3 $359.5 $315.3 
R&D expense $628.1 $715.0 $696.3 
Selling, general and administrative (SG&A) expense$737.7 $680.9 $604.4 
Gain on sale of nonfinancial assets$(59.5)$(25.0)$(50.0)
Benefit from income taxes$(901.4)$(71.0)$(65.5)
Net income (loss)$859.1 $(23.8)$(77.2)
The increase in Net Income for the year ended December 31, 2020 as compared to 2019 was primarily attributed to:
•an increase in the benefit from income taxes primarily due to the completion of an intra-entity transfer of certain intellectual property rights to an Irish subsidiary, to better align ownership of the intellectual property rights with how our business operates, resulting in a tax benefit of $835.1 million based on the fair value of the transferred intellectual property rights;
•decreased R&D expense primarily due to lower clinical activity spend for valoctocogene roxaparvovec and for tralesinidase alfa which was licensed to a third-party in the fourth quarter of 2019; and
•an increase in the gain of nonfinancial assets due primarily to the divestiture and sale of Firdapse in 2020; partially offset by
•decreased gross profits due primarily to $87.2 million of inventory charges recorded in 2020 related to pre-launch valoctocogene roxaparvovec inventory reserves due to regulatory responses received in the third quarter of 2020 requesting additional data extending anticipated regulatory approval timelines; and
•higher SG&A expense primarily due to an increase in pre-commercial activities related to valoctocogene roxaparvovec and vosoritide.
See “Results of Operations” below for additional information related to the Net Income (Loss) fluctuations presented above.
Our cash, cash equivalents and investments totaled $1.4 billion as of December 31, 2020, compared to $1.2 billion as of December 31, 2019. We have historically financed our operations primarily through our cash flows from operating activities and the issuance of common stock and convertible debt. We will be highly dependent on our net product revenues to supplement our current liquidity and fund our operations for the foreseeable future. We may in the future elect to supplement this with further debt or equity offerings or commercial borrowing. Further, depending on market conditions, our financial position and performance and other factors, we may in the future choose to use a portion of our cash, cash equivalents or investments to repurchase our convertible debt or other securities. See “Financial Position, Liquidity and Capital Resources” below for a further discussion of our liquidity and capital resources.
Critical Accounting Policies, Estimates and Judgments
In preparing our Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates
64

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions.
The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs will depend on future developments that continue to remain highly uncertain at this time. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.
While our significant accounting policies are more fully described in Note 3 to our accompanying Consolidated Financial Statements included in this Annual Report on Form 10-K, we believe the critical accounting policies below reflect the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.
•Revenue Recognition and Related Allowances
•Inventory Produced Prior to Regulatory Approval
•Valuation of Goodwill and Acquired Intangible Assets
•Valuation of Contingent Consideration
•Income Taxes
Historically, our assumptions, judgments and estimates relative to our critical accounting policies have not differed materially from actual results.
Revenue Recognition and Related Allowances
Net Product Revenues – We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. For Aldurazyme revenues, we receive a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Sanofi Genzyme (Genzyme) depending on sales volume, which is included in Net Product Revenues in our Consolidated Statements of Operations. We recognize our best estimate of the entire revenue that we expect to receive when the product is released and control is transferred to Genzyme. We record Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from our estimates. Differences between the estimated variable consideration to be received from Genzyme and actual payments received are not expected to be material. If actual results vary from our estimates, we will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known.
Gross-to-Net Sales Adjustments – We record product sales net of estimated mandatory and supplemental discounts to government payers, in addition to discounts to private payers, and other related charges. Rebates, cash discounts and distributor fees represent the majority of our gross-to-net deductions and are recorded in the same period the related sales occur. Rebates include amounts paid to Medicaid, other government programs, certain managed care providers, as well as foreign government rebates. Rebates, cash discounts and distributor fees are estimates based on contractual arrangements or statutory obligations, which may vary by product and payer. Estimation requires evaluation of our historical experience, customer mix, current contractual and statutory obligations, specific known market events and trends and industry data. We evaluate our customer mix to estimate which sales will be subject to these revenue dilutive items and consider changes to government program guidelines that would impact the actual rebates and/or our estimates of which sales qualify for such rebates.
We update our estimates and assumptions each quarter based on actual historical experience, current contractual and statutory requirements, specific known market events and trends and forecasted customer buying and payment patterns and record any necessary adjustments to our reserves to reflect current information. We believe the methodologies that we use to estimate allowances are reasonable and appropriate given the facts and circumstances. However, actual results may differ significantly from our estimates.
65

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
The following table summarizes the consolidated activities and ending balances of all our gross-to-net sales adjustments:
Balance at Beginning of YearProvision for Current Period
Sales		PaymentsBalance at End of Year
Year ended December 31, 2020$114.4 $239.9 $(249.9)$104.4 
Year ended December 31, 201980.7 198.1 (164.4)114.4 
Year ended December 31, 2018$63.3 $151.6 $(134.2)$80.7 
Inventory Produced Prior to Regulatory Approval
When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and we expect to realize economic benefit in the future, we capitalize pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, management considers a number of factors based on the information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends.
In applying the lower of cost or net realizable value to pre-launch inventory, we estimate a range of likely commercial prices based on our comparable commercial products and consider the product candidate’s stability data for all of the pre-approval production to date to determine whether there is adequate expected shelf life for the capitalized pre-launch production costs. If the criteria for capitalizing inventory produced prior to regulatory approval are not met, we recognize such costs as R&D expense in the period incurred. As of December 31, 2020, there were no pre-launch inventory costs on our Consolidated Balance Sheets.
Valuation of Goodwill and Acquired Intangible Assets
We have recorded goodwill and acquired intangible assets primarily related to in-process research and development (IPR&D) projects through acquisitions accounted for as business combinations. When identifiable intangible assets, including IPR&D, are acquired, we determine the fair value of these assets as of the acquisition date. Discounted cash flow models are typically used in these valuations if quoted market prices are not available, and the models require significant estimates and assumptions including but not limited to:
•estimating the time and resources needed to complete the development and approval of product candidate;
•estimating future cash flows from product sales;
•developing appropriate probability of success rates for unapproved product candidates considering their stages of development;
•projecting timing of regulatory approval; and
•risks related to the viability of and potential alternative treatments in any future target markets.
Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing. We review our goodwill and indefinite lived intangible assets for impairment annually in the fourth quarter, or more frequently if warranted by events or changes in circumstances indicate that the carrying amount may not be recoverable.
We assess goodwill impairment by comparing the fair value of our single reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference will be recorded.
We assess impairment of indefinite-lived intangible assets first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of our indefinite-lived intangible assets is less than its carrying amount, then we will perform a quantitative assessment and record an impairment loss. We assess definite-lived intangible assets for recoverability when there is an indication of impairment by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. As of December 31, 2020, we had no indefinite-lived intangible assets on our Consolidated Balance Sheets.
66

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
Valuation of Contingent Consideration
Significant estimates and judgments are required in determining the acquisition fair value of any contingent obligations incurred in connection with an acquisition. We estimate the fair value of contingent consideration utilizing a probability-based income approach inclusive of an estimated discount rate. Each period we reassess the fair value of the contingent consideration associated with certain acquisitions and record increases in the fair value as contingent consideration expense and record decreases in the fair value as a reduction of contingent consideration expense. Changes in the fair value of the contingent consideration can result from changes to one or multiple inputs including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Accordingly, subsequent changes in the underlying facts and circumstances could result in changes to our estimates and assumptions, which could have a material impact on the estimated future fair values of contingent consideration.
We believe the fair value used to record contingent consideration incurred in connection with business combinations is based on reasonable estimates and assumptions given the facts and circumstances as of the related valuation date.
Income Taxes
We calculate and provide for income taxes in each of the tax jurisdictions in which we operate. Our Consolidated Balance Sheets reflect net deferred tax assets and liabilities, which are measured using enacted tax rates. The net deferred tax assets primarily represent the tax benefit of tax credits and timing differences between book and tax recognition of certain revenue and expense items, net of a valuation allowance. When it is more likely than not that all or some portion of deferred tax assets may not be realized, we establish a valuation allowance for the amount that may not be realized. We utilize financial projections to support our net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our deferred tax assets. Changes in our valuation allowance will result in a change to tax expense.
We establish liabilities or reduce assets for certain tax positions when we believe those certain tax positions are not more likely than not to be sustained if challenged. Each quarter, we evaluate these uncertain tax positions and adjust the related tax assets and liabilities in light of changing facts and circumstances.
We are subject to income taxes in the U.S. and various foreign jurisdictions, including Ireland. Due to economic and political conditions, various countries are actively considering changes to existing tax laws. We cannot predict the form or timing of potential legislative changes that could have a material adverse impact on our results of operations. In addition, significant judgment is required in determining our worldwide provision for income taxes. For example, the 2020 income tax benefit included a $835.1 million deferred tax benefit related to an intra-entity transfer of certain intellectual property rights to an Irish subsidiary. The transaction resulted in a step-up of the Irish tax-deductible basis, and the Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. We expect to be able to realize the deferred tax asset resulting from this transaction and have not recorded a valuation allowance as of December 31, 2020. Management is not aware of any potential changes that would have a material effect on our Consolidated Financial Statements.
Recent Accounting Pronouncements
See Note 4 to our accompanying Consolidated Financial Statements for a full description of recent accounting pronouncements and our expectation of their impact, if any, on our results of operations and financial condition.
67

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
Results of Operations
Net Income (Loss)
Net Income (Loss) consisted of the following:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Total revenues
$1,860.5 $1,704.0 $1,491.2 $156.5 $212.8 
Cost of sales
524.3 359.5 315.3 164.8 44.2 
R&D expense
628.1 715.0 696.3 (86.9)18.7 
SG&A expense
737.7 680.9 604.4 56.8 76.5 
Intangible asset amortization and contingent consideration
66.7 74.1 48.8 (7.4)25.3 
Gain on sale of nonfinancial assets
(59.5)(25.0)(50.0)(34.5)25.0 
Other income (expense), net(5.5)5.7 (19.1)(11.2)24.8 
Benefit from income taxes(901.4)(71.0)(65.5)(830.4)(5.5)
Net income (loss)
$859.1 $(23.8)$(77.2)$882.9 $53.4 
Our Net Income for the year ended December 31, 2020 was $859.1 million, compared to Net Loss of $23.8 million and $77.2 million for the years ended December 31, 2019 and 2018, respectively. The changes in Net Income (Loss) were primarily a result of the following:
Net Product Revenues
Net Product Revenues consisted of the following:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Net product revenues by product:
Vimizim$544.4 $544.3 $482.0 $0.1 $62.3 
Kuvan457.7 463.4 433.6 (5.7)29.8 
Naglazyme391.3 374.3 345.9 17.0 28.4 
Palynziq171.0 86.9 12.2 84.1 74.7 
Brineura110.2 72.0 39.9 38.2 32.1 
Firdapse1.2 $22.3 $21.7 $(21.1)$0.6 
Total net product revenues marketed by the Company$1,675.8 $1,563.2 $1,335.3 $112.6 $227.9 
Aldurazyme net product revenues marketed by Sanofi Genzyme130.1 97.8 135.1 32.3 (37.3)
Total net product revenues$1,805.9 $1,661.0 $1,470.4 $144.9 $190.6 
 2020 compared to 2019
The increase in Net Product Revenues for the year ended December 31, 2020 as compared to 2019 was primarily attributed to the following:
•Palynziq: the increase was attributed to a combination of revenue from more patients achieving maintenance dosing and new patients initiating therapy in the U.S.;
•Brineura: the increase was primarily attributed to growth in the number of patients in all regions;
•Aldurazyme: the increase was attributed to timing of product fulfillment to Genzyme;
68

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
•Naglazyme: the increase was primarily attributed to increased orders from the Middle East and growth in North America; partially offset by
•Firdapse: the decrease was primarily attributed to the divestiture and sale of the Firdapse business in January 2020; and
•Kuvan: the decrease was primarily attributed to the U.S. loss of market exclusivity in October 2020 resulting in generic competition.
2019 compared to 2018
The increase in Net Product Revenues for the year ended December 31, 2019 as compared to 2018 was primarily attributed to the following:
•Palynziq: the increase was attributed to a combination of revenue from more patients achieving maintenance dosing and new patients initiating therapy in the U.S. as the product launched in the third quarter of 2018;
•Vimizim: the increase was primarily attributed to increased sales volume due to patient growth in the U.S. and orders from Latin America;
•Brineura: the increase was primarily attributed to growth in the number of patients in all regions;
•Kuvan: the increase was primarily attributed to increased sales volume due to patient growth in North America and in European markets;
•Naglazyme: the increase was primarily attributed to increased sales volume driven by orders from Latin America; partially offset by
•Aldurazyme: the decrease was primarily attributed to timing of product fulfillment to Genzyme.
In certain countries, such as in Latin America, governments place large periodic orders for Naglazyme and Vimizim. The timing of these large government orders can be inconsistent and can create significant period to period variation in our revenues.
We anticipate the COVID-19 pandemic will have a continued impact on future Net Product Revenues in 2021 as many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Although we are working with our patient community and health care providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from the doses of our products that are missed by patients and the lost revenue from delayed treatment starts for new patients will never be recouped. See the risk factor “The COVID-19 pandemic could materially adversely affect our business, results of operations and financial condition” in “Risk Factors” included in Part I, Item 1A of this Annual Report on Form 10-K for additional information.
In October 2020, we lost U.S. market exclusivity for Kuvan which adversely affected revenues in the fourth quarter of 2020. We have been preparing for this loss of exclusivity which will continue to result in a reduction in market share and adversely affect our revenue and results of operations in 2021. See the risk factor “The sale of generic versions of Kuvan by generic manufacturers may adversely affect our revenues and results of operations” in “Risk Factors” included in Part I, Item 1A of this Annual Report on Form 10-K for additional information. Additionally, the responses received from the FDA and EMA requesting additional safety and efficacy data from our valoctocogene roxaparvovec Phase 3 studies have extended our anticipated regulatory approval timelines which will have a negative impact on net product revenue growth for 2021.
We face exposure to movements in foreign currency exchange rates, primarily the Euro. We use foreign currency exchange contracts to hedge a percentage of our foreign currency exposure. The following table shows our Net Product Revenues denominated in USD and foreign currencies:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Sales denominated in USD$1,063.2 $932.6 $891.7 $130.6 $40.9 
Sales denominated in foreign currencies742.7 728.4 578.7 14.3 149.7 
Total net product revenues$1,805.9 $1,661.0 $1,470.4 $144.9 $190.6 
The net impact of foreign currency exchange rates on product sales denominated in currencies other than USD during 2020 and 2019 was unfavorable by $23.3 million and $24.8 million respectively, which was primarily driven by a weakening, relative to the USD, of currencies in Latin American markets such as Brazil, Colombia and Argentina.
69

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
See “Quantitative and Qualitative Disclosures about Market Risk” in Part II, Item 7A of this Annual Report on Form 10-K for information on currency exchange rate risk related to our revenues.
Royalty and Other Revenues
Royalty revenues include royalties earned on net sales of products sold and milestones achieved by licensees or sublicensees. Other revenues include revenues earned from the sale of licenses of our intellectual property and rental income associated with the tenants in our facilities.
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Royalty revenues$38.6 $39.7 $19.3 $(1.1)$20.4 
Other revenues16.0 3.3 1.6 12.7 1.7 
Total Royalty and Other revenues$54.6 $43.0 $20.9 $11.6 $22.1 
The 2020 increase in Royalty and Other Revenues compared to 2019 was primarily due to license revenues earned from the third-party that licensed tralesinidase alfa from us.
The 2019 increase in Royalty and Other Revenues compared to 2018 was primarily due to a one time license payment from a third party due to their achievement of a regulatory milestone and royalty revenues earned from Catalyst Pharmaceutical Partners, Inc. (Catalyst) on net product sales of Firdapse in North America, which was approved for sale in November 2018. See Note 20 to our accompanying Consolidated Financial Statements for additional information regarding our license and collaboration agreements.
We expect to continue to earn royalties from third parties in the future.
Cost of Sales and Product Gross Margin
Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and internal and external final formulation and packaging costs. Cost of Sales also includes royalties payable to third parties based on sales of our products and charges for inventory valuation reserves.
The following table summarizes our Cost of Sales and product gross margin:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Total net product revenues$1,805.9 $1,661.0 $1,470.4 $144.9 $190.6 
Cost of sales$524.3 $359.5 $315.3 $164.8 $44.2 
Product gross margin71.0 %78.4 %78.6 %(7.4)%(0.2)%
Cost of Sales increased for 2020 compared to 2019 primarily due to $87.2 million of inventory charges recorded in 2020 related to pre-launch valoctocogene roxaparvovec inventory as a result of anticipated regulatory approval delays. Product gross margin for 2020 compared to 2019 decreased primarily due to higher costs of sales and product mix as there were higher sales of lower margin products.
The 2019 increase in Cost of Sales compared to 2018 was primarily attributable to increased sales volumes. Product gross margin was relatively flat in 2019 compared to 2018.
We expect total product gross margin to remain near 75% over the next twelve months.
Research and Development
R&D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our approved products. R&D expense primarily includes preclinical and clinical studies, personnel
70

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs.
We manage our R&D expense by identifying the R&D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.
We continuously evaluate the recoverability of costs associated with pre-launch or pre-qualification manufacturing activities, and capitalize the costs incurred related to those activities if it is determined that recoverability is highly likely and therefore future revenues are expected. When regulatory approval and the likelihood of future revenues for a product candidate are less certain, the related manufacturing costs are expensed as R&D expenses. We did not have any pre-launch or pre-qualification manufacturing activities capitalized as of December 31, 2020. See Note 8 to our accompanying Consolidated Financial Statements for additional information regarding our inventory.
R&D expense consisted of the following:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Research and early development$164.9 $79.4 $68.2 $85.5 $11.2 
Vosoritide130.8 120.9 89.3 9.9 31.6 
Valoctocogene roxaparvovec116.2 192.8 161.7 $(76.6)$31.1 
Other approved products83.2 104.1 117.5 (20.9)(13.4)
BMN 30772.6 89.2 18.1 (16.6)71.1 
Palynziq50.5 71.7 94.8 (21.2)(23.1)
Tralesinidase alfa1.4 27.4 82.2 (26.0)(54.8)
Other8.5 29.5 64.5 (21.0)(35.0)
Total R&D expense$628.1 $715.0 $696.3 $(86.9)$18.7 
2020 compared to 2019
The decrease in R&D expense primarily comprised the following:
•a decrease in costs related to valoctocogene roxaparvovec, due primarily to lower clinical activity spend;
•a decrease in tralesinidase alfa costs as the program was licensed to a third-party in the fourth quarter of 2019;
•a decrease in clinical study costs related to Palynziq due to the 2019 completion of the studies supporting European regulatory approval;
•a decrease in expenses related to approved products primarily due to completion of Brineura extension studies;
•a decrease in clinical manufacturing costs related to BMN 307; partially offset by
•an increase in early stage research program spending due primarily to the $26.3 million payment made for preclinical programs licensed from a third party and costs related to BMN 331 for the treatment of hereditary angioedema.
We expect R&D expense to increase in future periods compared to 2020, primarily due to increased spending on preclinical activities for our research and early development programs while we continue to develop our later stage programs.
2019 compared to 2018
The increase in R&D expense primarily comprised the following:
•an increase in preclinical and manufacturing activities related to our BMN 307 development program, including clinical manufacturing costs; and
•an increase in clinical activity related to our late-stage product candidates valoctocogene roxaparvovec and vosoritide; partially offset by
•a decrease in tralesinidase alfa clinical manufacturing costs; and
71

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
•a decrease in costs related to Palynziq, for which capitalization of manufacturing costs began in the second quarter of 2018 following FDA approval.
Selling, General and Administrative
Sales and marketing (S&M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and administrative (G&A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.
SG&A expenses consisted of the following:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
S&M expense$403.4 $382.2 $324.2 $21.2 $58.0 
G&A expense334.3 298.7 280.2 35.6 18.5 
Total SG&A expense$737.7 $680.9 $604.4 $56.8 $76.5 
S&M expenses by product were as follows:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
PKU Products (Kuvan and Palynziq)$127.5 $137.2 $118.6 $(9.7)$18.6 
MPS Products (Aldurazyme, Naglazyme and Vimizim)108.1 119.2 115.8 (11.1)3.4 
Valoctocogene roxaparvovec87.3 50.3 17.0 37.0 33.3 
Brineura37.8 45.4 44.2 (7.6)1.2 
Vosoritide34.5 13.3 7.3 21.2 6.0 
Other8.2 16.8 21.3 (8.6)(4.5)
Total S&M expense$403.4 $382.2 $324.2 $21.2 $58.0 
2020 compared to 2019
The increase in S&M expense was primarily a result of an increase in pre-commercial activities related to valoctocogene roxaparvovec and vosoritide, partially offset by decreases in MPS Products, PKU Products and Brineura.
The increase in G&A expense was primarily due to employee-related expenses due to a higher headcount and the unfavorable impact of foreign exchange revaluation of non-USD denominated assets and liabilities.
We expect SG&A expense to increase in future periods as a result of preparing to launch new products and support of our global business as it grows.
2019 compared to 2018
The increase in S&M expense was primarily a result of an increase in pre-commercialization activities related to valoctocogene roxaparvovec and commercialization activities in support of the continued U.S. expansion and EU commercial launches of Palynziq.
The increase in G&A expense was primarily due to consulting fees and higher employee related expenses to support our growth.
72

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets
Changes during the periods presented for Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets were as follows:
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Changes in the fair value of contingent consideration (gain) / loss
$4.5 $20.6 $18.5 $(16.1)$2.1 
Amortization of intangible assets
62.2 53.5 30.3 8.7 23.2 
Total intangible asset amortization and contingent consideration
$66.7 $74.1 $48.8 $(7.4)$25.3 
Gain on sale of nonfinancial assets
$59.5 $25.0 $50.0 $34.5 $(25.0)
2020 compared to 2019
Fair value of contingent consideration: the 2020 increase in the fair value of contingent consideration is lower than the increase in 2019 due primarily to the achievement in 2019 of the Palynziq EU regulatory approval milestone.
Amortization of intangible assets: the increase in 2020 was due to the Palynziq intangible assets that were in service for the entire year compared to seven months in 2019.
Gain on Sale of Nonfinancial Assets: we recognized a gain of $59.5 million in 2020 due to the divestiture and sale of Firdapse compared to $25.0 million in 2019 due to the achievement of milestones by third parties, related to previously sold intangible assets. See Note 6 to the accompanying Consolidated Financial Statements for additional information.
2019 compared to 2018
Fair value of contingent consideration: the increase in the fair value of the contingent consideration in 2019 was primarily attributable to changes in the estimated probability of achieving development milestones, related to our Palynziq program which received EU marketing approval in May 2019.
Amortization of intangible assets: the increase in 2019 was due to the Palynziq IPR&D assets that were placed into service following EU marketing approval in May 2019.
Gain on Sale of Nonfinancial Assets: we recognized a gain of $25.0 million in 2019 compared to $50.0 million in 2018 due to the achievement of milestones by third parties, related to previously sold intangible assets.
Interest Income
We invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk.
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Interest income $16.6 $22.7 $22.8 $(6.1)$(0.1)
The decrease in Interest Income during 2020 compared to 2019 was primarily due to lower interest rates. Interest Income during 2019 was flat compared to 2018.
We expect Interest Income to be lower over the next 12 months due to lower interest rates and yields on our cash equivalents and investments.
73

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
Interest Expense
We incur Interest Expense primarily on our convertible debt.
Years Ended December 31,
2020201920182020 vs. 20192019 vs. 2018
Total interest expense$29.3 $23.5 $43.7 $5.8 $(20.2)
The increase in Interest Expense in 2020 compared to 2019 was primarily due to the issuance of the 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes) in the second quarter of 2020 partially offset by the maturity of our 1.50% senior subordinated convertible notes which matured in October 2020 (the 2020 Notes).
The decrease in Interest Expense in 2019 compared to 2018 was primarily due to the maturity of our 0.75% senior subordinated convertible notes, which matured in October 2018.
We expect Interest Expense to be lower over the next 12 months due to the maturity of the 2020 Notes. See Note 13 to our accompanying Consolidated Financial Statements for additional information regarding our debt.
Benefit from Income Taxes

We recognized an income tax benefit of $901.4 million, $71.0 million and $65.5 million in 2020, 2019 and 2018, respectively. Benefit from Income Taxes for 2020, 2019 and 2018 consisted of state, federal and foreign current tax expense which was offset by tax benefits related to stock option exercises and deferred tax benefits from federal orphan drug credits, federal R&D credits and California R&D credits. The Benefit from Income Taxes for the years ended December 31, 2020 and 2019 were further impacted by the following items:
•In the third quarter of 2020, we completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where our ex-U.S. regional headquarters are located and we have significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, our Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, we recognized a deferred tax asset of $835.1 million and related tax benefit in the third quarter based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. We expect to be able to realize the deferred tax asset resulting from this transaction and have not recorded a valuation allowance as of December 31, 2020.
•2019 included a tax benefit of $29.6 million for the release of the valuation allowance against the net deferred tax asset of our Dutch subsidiary. In the second quarter of 2019, we determined that it is more likely than not that the deferred tax assets, including net operating losses and tax credit carryforwards of our Dutch subsidiary, will be realized. In making this determination, we analyzed our recent history of earnings, forecasts of future earnings and cumulative earnings for the last three years of our Dutch subsidiary and we reached the conclusion that it was appropriate to release the valuation allowance reserve.
•On March 27, 2020, The Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law lifting certain limitations originally imposed by the Tax Cuts and Jobs Act of 2017, including the calculation of certain deductions and treatment of net operating losses. On June 29, 2020, California enacted legislative changes (California AB 85) which suspended California net operating loss utilization for years 2020 through 2022. The enactment of both the CARES Act and California AB 85 did not result in any material adjustments to our income tax provision for the year ended December 31, 2020, or to our net deferred tax assets as of December 31, 2020.

Financial Position, Liquidity and Capital Resources
As of December 31, 2020, we had $1.4 billion in cash, cash equivalents, and investments which includes net proceeds of $535.8 million from our May 2020 convertible debt offering, net of the repurchase of our common stock. We believe our net product revenues from our commercial products, cash, cash equivalents and investments, potentially supplemented by proceeds from equity or debt financings and loans, or collaborative agreements with corporate partners will be sufficient to satisfy our liquidity requirements for the next 12 months. We may require additional financing to fund the repayment of our convertible debt, future milestone payments and our future operations, including the commercialization of our products and product candidates currently
74

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The timing and mix of our funding options could change depending on many factors, including how much we elect to spend on our development programs, potential licenses and acquisitions of complementary technologies, products and companies or if we elect to settle all or a portion of our convertible debt in cash. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the ongoing COVID-19 pandemic.
In managing our liquidity needs in the U.S., we do not rely on unrepatriated earnings as a source of funds. As of December 31, 2020, $248.2 million of our $1.4 billion balance of cash, cash equivalents and investments was held in non-U.S. subsidiaries, a significant portion of which is required to fund the liquidity needs of these non-U.S. subsidiaries. See Note 18 to our accompanying Consolidated Financial Statements for additional discussion regarding income taxes.
We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to be unable to pay for our products. We will continue to monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.
Our liquidity and capital resources as of December 31, 2020, 2019 and 2018 were as follows:
2020201920182020 vs. 20192019 vs. 2018
Cash and cash equivalents$649.2 $437.4 $494.0 $211.7 $(56.6)
Short-term investments416.2 316.4 590.3 99.9 (273.9)
Long-term investments285.5 412.0 235.9 (126.5)176.1 
Cash, cash equivalents and investments$1,350.9 $1,165.8 $1,320.2 $185.1 $(154.4)
Total convertible debt, net$1,075.1 $848.1 $830.4 $227.0 $17.7 
Our cash flows for each of the years ended December 31, 2020, 2019 and 2018 are summarized as follows:
2020201920182020 vs. 20192019 vs. 2018
Cash & cash equivalents at the beginning of the period
$437.4 $494.0 $598.0 $(56.6)$(104.0)
Net cash provided by operating activities85.4 48.3 20.2 37.1 28.1 
Net cash provided by (used in) investing activities(53.6)(31.0)264.4 (22.6)(295.4)
Net cash provided by (used in) financing activities181.1 (74.7)(388.0)255.8 313.3 
Foreign exchange impact(1.1)0.8 (0.6)(1.9)1.4 
Cash & cash equivalents at the end of the period
$649.2 $437.4 $494.0 $211.8 $(56.6)
Short-term and long-term investments701.7 728.4 826.2 (26.7)(97.8)
Cash, cash equivalents and investments$1,350.9 $1,165.8 $1,320.2 $185.1 $(154.4)
Cash Provided by Operating Activities
Net cash provided by operating activities during 2020 was $85.4 million, compared to net cash provided by operating activities of $48.3 million during 2019. The change in net cash provided by operating activities in 2020 compared to 2019 was due
75

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
to increased cash receipts from our customers, licensees and sublicensees, due in part to higher sales. The increase was partially offset by timing of payments made to vendors and due to increased payments for inventory purchases.
Net cash provided by operating activities during 2019 was $48.3 million, compared to net cash provided by operating activities of $20.2 million during 2018. The change in net cash provided by operating activities in 2019 compared to 2018 was primarily attributed to the timing of payments to vendors and cash receipts from customers.
Cash Provided by (Used in) Investing Activities
Net cash used in investing activities during 2020 was $53.6 million, compared to net cash used in investing activities of $31.0 million during 2019. The change in net cash used in investing activities in 2020 compared to 2019 was primarily attributable to a decrease of $82.0 million in proceeds from net maturities and sales of investments partially offset by an increase in proceeds from the sale of nonfinancial assets and lower purchases of property, plant and equipment.
Net cash used in investing activities during 2019 was $31.0 million, compared to net cash provided by investing activities of $264.4 million during 2018. The change in net cash used in investing activities in 2019 compared to 2018 was primarily due to a decrease of $250.8 million in proceeds from net maturities and sales of investments, lower cash receipts from milestone payments related to previously sold intangible assets and an increase in cash used in the purchase of intangible assets.
Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities during 2020 was $181.1 million, compared to net cash used in financing activities of $74.7 million during 2019. The increase in net cash provided by financing activities in 2020 compared to 2019 was primarily attributed to the net proceeds from the issuance of the 2027 Notes and exercises of awards under our equity incentive plans, partially offset by the cash settlement of the 2020 Notes and the repurchase of our common stock.
Net cash used in financing activities during 2019 was $74.7 million, compared to net cash used in financing activities of $388.0 million during 2018. The decrease in net cash used in financing activities in 2019 compared to 2018 was primarily due to the settlement, in 2018, of the 2018 Notes which did not recur in 2019 .
Other Information
Our $1.1 billion (undiscounted) of total convertible debt as of December 31, 2020 will impact our liquidity due to the semi-annual cash interest payments. As of December 31, 2020, our indebtedness consisted of the 2027 Notes and our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes and together with the 2027 Notes, the Notes), which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principle amount of the Notes if not converted.
Our 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes. See Note 13 to our accompanying Consolidated Financial Statements for additional discussion on our outstanding debt.
In October 2018, we entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is also intended to finance ongoing working capital needs and for other general corporate purposes. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable. The 2018 Credit Facility contains financial covenants requiring us to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of December 31, 2020, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility and we were in compliance with all covenants. See Note 13 to our accompanying Consolidated Financial Statements for additional discussion.
Funding Commitments
We cannot estimate with certainty the cost to complete any of our product development programs. Additionally, except as disclosed under “Overview” above, we cannot precisely estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see “Risk Factors” included in
76

Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions of U.S. Dollars, except as otherwise disclosed)
Part I, Item 1A of this Annual Report on Form 10-K, for a discussion of the reasons we are unable to estimate such information, and in particular the following risk factors:
Business and Operational Risks:
•    The COVID-19 pandemic could materially affect our business, results of operations, and financial condition;
•    If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected.
•    If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
Regulatory Risks:
•    If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase;
Manufacturing Risks:
•    If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program;
Our investment in our product development programs and continued development of our existing commercial products has a major impact on our operating performance. Our R&D expenses for the period since inception as of December 31, 2020 for certain of our key programs were as follows:
Since Program
Inception
Palynziq$739.9 
Valoctocogene roxaparvovec$710.0 
Vosoritide$570.7 
BMN 307$179.9 
Other approved products$1,524.8 
We may need or elect to increase our spending above our current long-term plans to be able to achieve our long-term goals. This may increase our capital requirements, including: costs associated with the commercialization of our products; additional clinical trials; investments in the manufacturing of our commercial products; preclinical studies and clinical trials for our product candidates; potential licenses and other acquisitions of complementary technologies, products and companies; and general corporate purposes.
Our future capital requirements will depend on many factors, including, but not limited to:
•our ability to successfully market and sell our products;
•the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities;
•the progress and success of our preclinical studies and clinical trials (including the manufacture of materials for use in such studies and trials);
•the timing, number, size and scope of our preclinical studies and clinical trials;
•the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities; and
•the progress of research programs carried out by us.

77

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our consolidated financial position or results of operations.

Contractual and Commercial Obligations
We have contractual and commercial obligations under our convertible debt, operating leases and other obligations related to R&D activities, purchase commitments, licenses and sales royalties with annual minimums. Our contractual obligations as of December 31, 2020 are presented in the table below.
Payments Due within
1 Year
or Less
>1 -3
Years
> 3 - 5
Years
More
Than 5
Years
Total
2024 Notes and related interest$3.0 $5.9 $498.0 $— $506.9 
2027 Notes and related interest7.5 15.0 15.0 611.3 648.8 
Leases14.4 22.9 12.2 16.8 66.3 
R&D and purchase commitments139.6 2.2 1.0 — 142.8 
Total$164.5 $46.0 $526.2 $628.1 $1,364.8 
As of December 31, 2020, we were also subject to contingent payments totaling approximately $662.8 million upon achievement of certain development and regulatory activities and commercial sales milestones if they occur before certain dates in the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $73.6 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from Merck Serono and $237.7 million related to programs that are no longer being developed.
As of December 31, 2020, we have recorded $60.1 million of contingent consideration on our Consolidated Balance Sheet, all of which was long-term. See Note 21 to our accompanying Consolidated Financial Statements for additional discussion on our commitments.
In addition, our liability for unrecognized tax benefits has been excluded from the above contractual and commercial obligations table as the nature and timing of future payments, if any, cannot be reasonably estimated. As of December 31, 2020, our liability for unrecognized tax benefits was $182.6 million. See Note 18 to our accompanying Consolidated Financial Statements for additional discussion on our income taxes.
78
Item 7A. Quantitative and Qualitative Disclosure About Market Risk
We are exposed to market risks that may result from changes in foreign currency exchange rates, interest rates and credit risks. To reduce certain of these risks, we enter into foreign currency derivative hedging transactions, follow investment guidelines and monitor outstanding trade receivables as part of our risk management program.
Foreign Currency Exchange Rate Risk
Our operations include manufacturing activities in the U.S. and Ireland and sales activities in the U.S. as well as in regions outside the U.S, including Europe, Latin America and Asia Pacific. As a result, our financial results may be significantly affected by factors such as the impact of the COVID-19 pandemic in these regions, changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we sell our products. Our operating results are exposed to changes in foreign currency exchange rates between the U.S. Dollar (USD) and various foreign currencies, primarily the Euro. When the USD strengthens against these currencies, the relative value of the sales made in the respective foreign currency decreases. Conversely, when the USD weakens against these currencies, the relative value of such sales increases. Overall, we are a net receiver of foreign currencies and, therefore, benefit from a weaker USD and are adversely affected by a stronger USD relative to those foreign currencies in which we transact significant business.
During 2020, approximately 41% of our net product sales were denominated in foreign currencies and 21% of our operating expenses, excluding Cost of Sales, were denominated in foreign currencies. To partially mitigate the impact of changes in currency exchange rates on net cash flows from our foreign currency denominated sales and operating expenses, we may enter into forward foreign currency exchange contracts (forward contracts). We also hedge certain monetary assets and liabilities, primarily those denominated in Euros, using forward contracts, which reduces but does not eliminate our exposure to currency fluctuations between the date the transaction is recorded and the date the cash is collected or paid. Generally, the market risks of these contracts are offset by the corresponding gains and losses on the transactions being hedged.
We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the effects of changes in foreign currency exchange rates. The counterparties to these forward contracts are creditworthy multinational commercial banks, which minimizes the risk of counterparty nonperformance. We regularly review our hedging program and may, as part of this review, make changes to the program.
As of December 31, 2020, we had open forward contracts with net notional amounts of $678.9 million. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the USD relative to exchange rates as of December 31, 2020 would have resulted in a reduction in the value received over the remaining life of these contracts by approximately $70.9 million on this date and, if realized, would negatively affect earnings during the remaining life of the contracts. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. This analysis does not consider the impact of the hypothetical changes in foreign currency rates would have on the forecasted transactions that these foreign currency sensitive instruments were designated to offset. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different.
Based on our overall foreign currency denominated exposures as of December 31, 2020, we believe that a near-term 10% fluctuation of the USD exchange rate could result in a potential change in the fair value of our net foreign currency denominated assets and liabilities, excluding our investments and open forward contracts, by approximately $9.1 million. We expect to continue to enter into transactions based in foreign currencies that could be impacted by changes in exchange rates.
Interest Rate Market Risk
Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio, which includes our cash equivalents and marketable debt securities. By policy, we place our investments with highly rated credit issuers and limit the amount of credit exposure to any one issuer. As stated in our investment policy, we seek to improve the safety and likelihood of preservation of our invested funds by limiting default risk and market risk.
We mitigate default risk by investing in high credit quality securities and by positioning our portfolio to respond appropriately to a significant reduction in a credit rating of any investment issuer or guarantor. The portfolio includes only marketable securities with active secondary or resale markets to ensure portfolio liquidity.
We have outstanding $495.0 million (undiscounted) of the 2024 Notes and $600.0 million (undiscounted) of the 2027 Notes. The interest rates on these notes are fixed and therefore they do not expose us to risk related to rising interest rates. As of December 31, 2020, the fair value of our convertible debt was $1.2 billion.
As of December 31, 2020, our investment portfolio did not include any investments with significant exposure to countries that face economic volatility and weakness. Although not predictive in nature, we believe a hypothetical 100 basis point threshold reflects a reasonably possible near-term change in interest rates. Based on our investment portfolio and interest rates at December 31, 2020, period ending, we believe that a 100 basis point increase in interest rates could result in a potential loss in fair
79
value of our investment portfolio of approximately $5.9 million. Changes in interest rates may affect the fair value of our investment portfolio. However, we will not recognize such gains or losses in our Consolidated Statements of Operations unless the investments are sold or we determine that the declines in the investment’s fair values below the cost basis are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses.
The table below summarizes the expected maturities and average interest rates of our interest-generating investments as of December 31, 2020 (in millions):
Expected Maturity
20212022202320242025ThereafterTotal
Available-for-sale debt securities$430.3 $169.5 $105.8 $9.9 $— $0.2 $715.7 
Average interest rate0.3 %0.3 %0.3 %0.4 %— %5.4 %0.3 %
Counterparty credit risks
Our financial instruments, including derivatives, are subject to counterparty credit risk that we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by requiring transactions to be with institutions with minimum credit ratings of A or equivalent by Standards & Poor’s, Moody's or Fitch. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

Item 8. Financial Statements and Supplementary Data
The information required to be filed in this item appears under “Exhibits, Financial Statement Schedules” in Part IV, Item 15 of this Annual Report on Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.

Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2020.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining an adequate internal control structure and procedures for financial reporting. Under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, our management has assessed the effectiveness of our internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act as of December 31, 2020. Our management’s assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), Internal Control-Integrated Framework (2013).
Based on the COSO criteria, our management has concluded that our internal control over financial reporting as of December 31, 2020 was effective at the reasonable assurance level.
80
Our independent registered public accounting firm, KPMG LLP, has audited the financial statements included in this Annual Report on Form 10-K and has issued a report on the effectiveness of our internal control over financial reporting. The report of KPMG LLP is incorporated by reference to Item 8 of this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We continue to utilize the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control. We believe that our ability to maintain an effective internal control environment has not been impacted by the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.
Scope of the Effectiveness of Controls
Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:
•pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;
•provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our board of directors; and
•provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Item 9B. Other Information
None.
81
Part III
Item 10. Directors, Executive Officers and Corporate Governance
The information required by this Item regarding our directors, executive officers and corporate governance is incorporated into this section by reference to the sections captioned “Election of Directors” and “Executive Officers” in the proxy statement for our 2021 annual meeting of stockholders.
Item 11. Executive Compensation
The information required by this Item regarding executive compensation is incorporated into this section by reference to the section captioned “Executive Compensation” in the proxy statement for our 2021 annual meeting of stockholders.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item regarding security ownership of our beneficial owners, management and related stockholder matters is incorporated into this section by reference to the section captioned “Security Ownership of Certain Beneficial Owners and Management” in the proxy statement for our 2021 annual meeting of stockholders.
The information required by this Item regarding the securities authorized for issuance under our equity compensation plans is incorporated into this section by reference to the section captioned “Equity Compensation Plan Information” in the proxy statement for our 2021 annual meeting of stockholders.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item regarding certain relationships, related transactions and director independence is incorporated into this section by reference to the sections captioned “Other Board Governance Information — Transactions with Related Persons, Promoters and Certain Control Persons,” “Other Board Governance Information — Review, Approval and Ratification of Transactions with Related Parties” and “Director Independence” in the proxy statement for our 2021 annual meeting of stockholders.
Item 14. Principal Accountant Fees and Services
The information required by this Item regarding our principal accountant fees and services is incorporated into this section by reference to the section captioned “Independent Registered Public Accounting Firm” in the proxy statement for our 2021 annual meeting of stockholders.

82
Part IV
Item 15. Exhibits, Financial Statement Schedules

83
Exhibit Index
Exhibit NumberDescription
2.1
2.2
2.3
2.4
3.1
3.2
4.1
4.2
4.3
4.4
10.1†
10.2†
10.3†
10.4†
10.5†
84
10.6†
10.7†
10.8
10.9
10.10
10.11
10.12
10.13†
10.14†
10.15†
10.16
10.17†
10.18†
10.19†
10.20†
10.21
85
10.22
10.23†
10.24†
10.25†
10.26†
10.27†
10.28†
10.29†
10.30
10.31
10.32*†
21.1*
23.1*
24.1*
31.1*
31.2*
32.1*
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase
86
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Link Document
104
XBRL tags for the cover page from the Company’s Quarterly Report on Form 10-K for the year ended December 31, 2020, are embedded within the Inline XBRL document.
*    Filed herewith
†    Management contract or compensatory plan or arrangement

Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2020 and December 31, 2019, (ii) Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018, (iii) Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2020, 2019 and 2018, (iv) Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020, 2019 and 2018, (v) Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018, and (vi) Notes to Consolidated Financial Statements.

Item 16. Form 10-K Summary
None.
87
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOMARIN PHARMACEUTICAL INC.
Dated: February 26, 2021By:/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President, Chief Financial Officer

88
Exhibit 24.1
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jean-Jacques Bienaimé and Brian R. Mueller, his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to the Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
SignatureTitleDate
/S/ JEAN-JACQUES BIENAIMÉ
Chairman and Chief Executive Officer
(Principal Executive Officer)
February 26, 2021
Jean-Jacques Bienaimé
/S/ BRIAN R. MUELLERExecutive Vice President, Chief Financial Officer
(Principal Financial Officer)		February 26, 2021
Brian R. Mueller
/S/ ANDREA L. ACOSTAGroup Vice President, Chief Accounting Officer
(Principal Accounting Officer)		February 26, 2021
Andrea L. Acosta
/S/ ELIZABETH MCKEE ANDERSONDirectorFebruary 26, 2021
Elizabeth McKee Anderson
/S/ WILLARD H. DERE, M.D.DirectorFebruary 26, 2021
Willard H. Dere, M.D.
/S/ MICHAEL G. GREYDirectorFebruary 26, 2021
Michael G. Grey
/S/ ELAINE J. HERONDirectorFebruary 26, 2021
Elaine J. Heron
/S/ ROBERT J. HOMBACHDirectorFebruary 26, 2021
Robert J. Hombach
/S/ V. BRYAN LAWLISDirectorFebruary 26, 2021
V. Bryan Lawlis
/S/ RICHARD A. MEIERLead Independent DirectorFebruary 26, 2021
Richard A. Meier
/S/ DAVID PYOTTDirectorFebruary 26, 2021
David Pyott
/S/ DENNIS J. SLAMONDirectorFebruary 26, 2021
Dennis J. Slamon

89
BIOMARIN PHARMACEUTICAL INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

90
Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors
BioMarin Pharmaceutical Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries (the Company) as of December 31, 2020 and December 31, 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and December 31, 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 26, 2021 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
Change in Accounting Principle
As discussed in Note 3 to the consolidated financial statements, the Company has changed its method of accounting for Leases as of January 1, 2019 due to the adoption of Accounting Standards Codification 842 (ASC 842), Leases.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Evaluation of variable consideration relating to Aldurazyme product sales
As described in Notes 3 and 15 to the consolidated financial statements, during the year ended December 31, 2020 the Company recognized $130 million in Aldurazyme net product revenue. Under its arrangement with Genzyme Corporation (Genzyme), a wholly owned subsidiary of Sanofi, the Company receives payments ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme, depending on Genzyme’s sales volume. The Company estimates this variable consideration based on the amount that it expects to be entitled to from Genzyme’s sales of Aldurazyme. The Company recognizes this revenue upon satisfying the product performance obligation, which is when the product is shipped to Genzyme and all required quality control certificates are complete.
We identified the evaluation of variable consideration relating to Aldurazyme net product revenue as a critical audit matter. Evaluating the key assumptions of forecasted Genzyme sales volume and average price per vial involved a high degree of
91
Report of Independent Registered Public Accounting Firm
subjective auditor judgment due to the nature of available supporting evidence being limited to historical sales and price data related to these assumptions. Changes in these key assumptions could have had a significant impact on Aldurazyme net product revenue.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s process for recognizing Aldurazyme net product revenue. This included controls over forecasting Genzyme’s sales volume and average price per vial used to estimate variable consideration. We evaluated the Company’s ability to estimate the variable consideration by comparing historical estimates of sales volume and price per vial to actual sales volume and price per vial of product sold by Genzyme. We also compared the Company’s current-period forecasts of future Genzyme sales volume and average price per vial to Genzyme’s historical sales volume and price per vial. We performed a sensitivity analysis to assess the impact of changes in these key assumptions on the Company’s estimate of variable consideration.
Evaluation of the fair value of the underlying intangible assets utilized to recognize a deferred tax asset
As discussed in Note 18 to the consolidated financial statements, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary during the year ended December 31, 2020, resulting in the recognition of a deferred tax asset and a related income tax benefit of $835.1 million.
We identified the evaluation of the fair value of the underlying intangible assets utilized to recognize a deferred tax asset as a critical audit matter. A high degree of auditor judgment was required to evaluate certain assumptions utilized by the Company in estimating the fair value of the underlying intangible assets. These assumptions included product-specific projected revenues and the inclusion or exclusion of a terminal value for each product.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company’s process to estimate the fair value of the underlying intangible assets. This included controls over the development of product-specific projected revenues and the inclusion or exclusion of terminal value for each product. We compared the product-specific projected revenue data to historical revenue data and compared the estimated fair value of each intangible asset to industry reports. We involved professionals with specialized skills and knowledge who assisted in evaluating the Company’s inclusion or exclusion of terminal value for each product by assessing the likelihood and potential magnitude of future competitor products.

/s/ KPMG LLP
We have served as the Company’s auditor since 2002.
San Francisco, California
February 26, 2021

92
Report of Independent Registered Public Accounting Firm


To the Stockholders and Board of Directors
BioMarin Pharmaceutical Inc.:
Opinion on Internal Control Over Financial Reporting
We have audited BioMarin Pharmaceutical Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and December 31, 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements), and our report dated February 26, 2021 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ KPMG LLP
San Francisco, California
February 26, 2021
93

BIOMARIN PHARMACEUTICAL INC.
CONSOLIDATED BALANCE SHEETS
December 31, 2020 and 2019
(In thousands of U.S. Dollars, except share and per share amounts)

December 31,
2020		December 31,
2019
ASSETS
Current assets:
Cash and cash equivalents$649,158 $437,446 
Short-term investments416,228 316,361 
Accounts receivable, net448,351 377,404 
Inventory698,548 680,275 
Other current assets129,934 130,657 
Total current assets2,342,219 1,942,143 
Noncurrent assets:
Long-term investments285,473 411,978 
Property, plant and equipment, net1,032,471 1,010,868 
Intangible assets, net417,271 456,580 
Goodwill196,199 197,039 
Deferred tax assets1,432,150 549,422 
Other assets142,237 122,009 
Total assets$5,848,020 $4,690,039 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities$492,548 $570,621 
Short-term convertible debt, net— 361,882 
Total current liabilities492,548 932,503 
Noncurrent liabilities:
Long-term convertible debt, net1,075,145 486,238 
Long-term contingent consideration60,130 50,793 
Other long-term liabilities114,195 98,124 
Total liabilities1,742,018 1,567,658 
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized;
   181,740,999 and 179,838,114 shares issued and outstanding, respectively
182 180 
Additional paid-in capital4,993,407 4,832,707 
Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)(9,839)(9,961)
Accumulated other comprehensive income (loss)(16,139)20,164 
Accumulated deficit(861,609)(1,720,709)
Total stockholders’ equity4,106,002 3,122,381 
Total liabilities and stockholders’ equity$5,848,020 $4,690,039 
The accompanying notes are an integral part of these Consolidated Financial Statements.
94
BIOMARIN PHARMACEUTICAL INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Years Ended December 31, 2020, 2019 and 2018
(In thousands of U.S. Dollars, except per share amounts)

202020192018
REVENUES:
Net product revenues$1,805,861 $1,661,043 $1,470,356 
Royalty and other revenues54,594 43,005 20,856 
Total revenues1,860,455 1,704,048 1,491,212 
OPERATING EXPENSES:
Cost of sales524,272 359,466 315,264 
Research and development628,116 715,007 696,328 
Selling, general and administrative737,669 680,924 604,353 
Intangible asset amortization and contingent consideration66,658 74,108 48,791 
Gain on sale of nonfinancial assets(59,495)(25,000)(50,000)
Total operating expenses1,897,220 1,804,505 1,614,736 
LOSS FROM OPERATIONS(36,765)(100,457)(123,524)
Equity in the loss of BioMarin/Genzyme LLC(6)(587)(553)
Interest income16,610 22,748 22,831 
Interest expense(29,309)(23,460)(43,664)
Other income, net7,148 6,945 2,205 
LOSS BEFORE INCOME TAXES(42,322)(94,811)(142,705)
Benefit from income taxes(901,422)(70,963)(65,494)
NET INCOME (LOSS)$859,100 $(23,848)$(77,211)
NET INCOME (LOSS) PER SHARE, BASIC$4.75 $(0.13)$(0.44)
NET INCOME (LOSS) PER SHARE, DILUTED$4.53 $(0.13)$(0.44)
Weighted average common shares outstanding, basic180,804 179,039 177,061 
Weighted average common shares outstanding, diluted191,678 179,039 177,268 
The accompanying notes are an integral part of these Consolidated Financial Statements.
95
BIOMARIN PHARMACEUTICAL INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Years Ended December 31, 2020, 2019 and 2018
(In thousands of U.S. Dollars)

202020192018
NET INCOME (LOSS)$859,100 $(23,848)$(77,211)
OTHER COMPREHENSIVE INCOME (LOSS):
Available-for-sale debt securities:
Unrealized holding gain (loss) arising during the period, net
   of tax impact of $(227), $(1,640) and $(413), respectively.
749 5,482 1,391 
Less: reclassifications to net income (loss), net of tax impact of
   $(127), $0 and $0, respectively.
425 — — 
Net change in unrealized holding gain (loss), net of tax324 5,482 1,391 
Cash flow hedges:
Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented.
(23,462)25,266 25,386 
Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented.
13,180 15,853 (2,047)
Net change in unrealized holding gain (loss), net of tax(36,642)9,413 27,433 
Other15 (2)(6)
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX(36,303)14,893 28,818 
COMPREHENSIVE INCOME (LOSS)$822,797 $(8,955)$(48,393)
The accompanying notes are an integral part of these Consolidated Financial Statements.


96
BIOMARIN PHARMACEUTICAL INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Years Ended December 31, 2020, 2019 and 2018
(In thousands of U.S. Dollars and share amounts in thousands)
202020192018
Shares of Common Stock, beginning balances179,838 178,253 175,844 
Issuances under equity incentive plans2,421 1,585 2,314 
Repurchase of common stock(518)— — 
Conversion of convertible notes, net— — 95 
Shares of Common Stock, ending balances181,741 179,838 178,253 
Total stockholders' equity, beginning balances$3,122,381 $2,967,940 $2,808,663 
Common stock:
Beginning balances180 178 176 
Issuances under equity incentive plans, net of tax2 2 2 
Ending balances182 180 178 
Additional paid-in capital:
Beginning balances4,832,707 4,669,926 4,483,220 
Issuances under equity incentive plans, net of tax27,275 (11,071)31,583 
Stock-based compensation183,547 163,891 155,139 
Repurchase of common stock(50,000)— — 
Conversion of convertible notes, net— — (16)
Common stock held by the NQDC(122)(692)— 
Accounting impact of NQDC Plan change (See Note 17)— 10,653 — 
Ending balances4,993,407 4,832,707 4,669,926 
Treasury stock:
Beginning balances— — — 
Purchase of treasury stock(50,000)— — 
Retirement of treasury stock50,000 — — 
Ending balance— — — 
Company common stock held by the NQDC:
Beginning balances(9,961)(13,301)(14,224)
Common stock held by the NQDC122 692 923 
Accounting impact of NQDC Plan change (See Note 17)— 2,648 — 
Ending balances(9,839)(9,961)(13,301)
Accumulated other comprehensive income (loss):
Beginning balances20,164 5,271 (22,961)
Impact of change in accounting principle— — (586)
Other comprehensive income (loss)(36,303)14,893 28,818 
Ending balances(16,139)20,164 5,271 
Accumulated Deficit:
Beginning balances(1,720,709)(1,694,134)(1,637,548)
Impact of changes in accounting principles— (2,727)20,625 
Net income (loss)859,100 (23,848)(77,211)
Ending balances(861,609)(1,720,709)(1,694,134)
Total stockholders' equity, ending balances$4,106,002 $3,122,381 $2,967,940 
The accompanying notes are an integral part of these Consolidated Financial Statements.
97
BIOMARIN PHARMACEUTICAL INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended December 31, 2020, 2019 and 2018
(In thousands of U.S. dollars)
202020192018
CASH FLOWS FROM OPERATING ACTIVITIES:
NET INCOME (LOSS)$859,100 $(23,848)$(77,211)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization105,172 105,300 95,671 
Non-cash interest expense16,511 13,960 31,186 
Amortization of premium on investments (accretion of discount)567 (2,000)358 
Stock-based compensation expense189,711 159,865 148,819 
Gain on sale of nonfinancial assets(59,495)(25,000)(50,000)
Inventory reserves, net of stock-based compensation75,609 — — 
Deferred income taxes(888,907)(82,760)(68,378)
Unrealized foreign exchange loss (gain)8,011 1,025 (17,766)
Non-cash changes in the fair value of contingent consideration4,500 5,205 9,296 
Other(997)(2,393)(2,347)
Changes in operating assets and liabilities:
Accounts receivable, net(59,035)(37,852)(54,274)
Inventory(61,151)(107,554)(23,747)
Other current assets18,312 (27,008)(17,767)
Other assets(28,647)(8,895)(935)
Accounts payable and accrued liabilities(87,025)77,089 38,389 
Other long-term liabilities(6,871)3,128 8,914 
Net cash provided by operating activities85,365 48,262 20,208 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment(114,312)(145,026)(144,620)
Maturities and sales of investments555,834 740,211 993,734 
Purchase of available-for-sale debt securities(529,663)(632,023)(634,753)
Proceeds from sale of nonfinancial assets67,159 25,000 50,000 
Purchase of intangible assets(23,207)(18,380)— 
Investment in convertible note(8,709)— — 
Other(723)(808)(10)
Net cash provided by (used in) investing activities(53,621)(31,026)264,351 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of awards under equity incentive plans71,913 31,611 67,488 
Taxes paid related to net share settlement of equity awards(44,638)(42,680)(35,919)
Repurchase of common stock(50,000)— — 
Proceeds from convertible senior subordinated note offering, net585,752 — — 
Repayments of convertible debt(374,991)— (374,953)
Payment of contingent consideration— (58,518)(44,623)
Principal repayments of financing leases(6,918)(5,087)— 
Net cash provided by (used in) financing activities181,118 (74,674)(388,007)
Effect of exchange rate changes on cash(1,150)902 (598)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS211,712 (56,536)(104,046)
Cash and cash equivalents:
Beginning of period437,446 493,982 598,028 
End of period$649,158 $437,446 $493,982 
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest, net of interest capitalized into fixed assets$12,178 $8,552 $11,623 
Cash paid for income taxes$8,977 $9,726 $16,676 
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Increase (decrease) in accounts payable and accrued liabilities related to fixed assets
$(5,184)$7,589 $(1,206)
Increase (decrease) in accounts payable and accrued liabilities related to intangible assets(292)4,247 — 
The accompanying notes are an integral part of these Consolidated Financial Statements.
98
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)


(1) NATURE OF OPERATIONS AND BUSINESS RISKS
BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.
The Company is subject to a number of risks, including: the continuing impact of the novel coronavirus disease (referred to as COVID-19) pandemic on the Company's business; the financial performance of its commercial products; the potential need for additional financing; the Company’s ability to successfully commercialize its approved products; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.

(2) BASIS OF PRESENTATION
Basis of Presentation
These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.
On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements. See Note 4 to these Consolidated Financial Statements for additional discussion of the adoption of ASU 2016-13 and required disclosures.

Use of Estimates
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly
99

BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents
The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.
Marketable and Non-Marketable Securities
Marketable Securities
The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations.
All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.
Non-Marketable Equity Securities
The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income, Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.
Inventory
Commercial Inventory
The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.
Inventory Produced Prior to Regulatory Approval
When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing
100
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&D).
Property, Plant and Equipment
Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&D and Selling, General and Administrative (SG&A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&D projects with no alternative future uses are expensed as incurred and recorded to R&D in the Consolidated Statements of Operations.
Leasehold improvementsShorter of life of asset or lease term
Building and improvements
20 to 50 years
Manufacturing and laboratory equipment
5 to 15 years
Computer hardware and software
3 to 7 years
Office furniture and equipment5 years
Vehicles5 years
Land improvements
10 to 20 years
LandNot applicable
Construction-in-progressNot applicable
Leases
Effective January 1, 2019, the Company adopted Accounting Standards Codification (ASC) Topic 842, Leases. The amended guidance required balance sheet recognition of lease right-of-use (ROU) assets and liabilities by lessees for leases classified as operating leases. The Company adopted ASC Topic 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption through a cumulative adjustment to Accumulated Deficit.
The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.
Goodwill and Intangible Assets
The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
101
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Impairment
The Company assesses its goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable.
Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.
Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Impairment charges that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Long-lived Asset Impairment
The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&A in the Consolidated Statements of Operations. Impairment charges related to finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC Topic 606, the Company performs the following five steps:
(i)identification of the promised goods or services in the contract;
(ii)determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii)measurement of the transaction price, including the constraint on variable consideration;
(iv)allocation of the transaction price to the performance obligations based on estimated selling prices; and
(v)recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.
Net Product Revenues
In the U.S., the Company’s commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues.
For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Genzyme
102
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known.
Revenue Reserves
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.
Government Rebates: The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.
Sales Returns: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.
Other Incentives: Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on Brineura, Kuvan or Palynziq therapy. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.
Royalty and Other Revenues
Royalties: For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone payments: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal
103
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Research and Development
R&D costs are generally expensed as incurred. These expenses include contract R&D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs and R&D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.
Convertible Debt
For non-conventional convertible debt that may be settled entirely or partially in cash, the Company separately accounts for the liability and equity components by allocating the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. The liability component is presented net of any discounts and issuance costs. For conventional convertible debt that may only be settled with common shares, the Company reports debt, net of any discounts or issuance costs, on the Consolidated Balance Sheets.
The Company recognizes discount accretion and debt issuance cost amortization using the effective interest method and is reported in Interest Expense on the Consolidated Statements of Operations.
Net Income (Loss) Per Common Share
Basic net income (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.
Stock-Based Compensation
The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&D or SG&A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur.
Restricted Stock Units
The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed.
Stock Options and Purchase Rights
The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock
104
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period.
The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.
Income Taxes
The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.
The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.
Foreign Currency
For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in SG&A in the Consolidated Statements of Operations.
Derivatives and Hedging Activities
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&A in the Consolidated Statements of Operations.
Fair Value of Financial Instruments
The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the
105
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:
•Income approach, which is based on the present value of a future stream of net cash flows
•Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
The Company’s fair value methodologies depend on the following types of inputs:
•Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)
•Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)
•Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)
The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.
The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of long-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of the contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations.
See Notes 5, 10, 11, 13, 19 and 20 to these Consolidated Financial Statements for further information on the nature of these financial instruments.
Segment Information
The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.

(4) RECENT ACCOUNTING PRONOUNCEMENTS
Effective January 1, 2020, the Company adopted FASB ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount
106
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
under the previous other-than-temporary impairment model. The adoption of this standard had no impact on the Company’s Financial Statements.

(5) FINANCIAL INSTRUMENTS
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2020 and 2019, respectively:
December 31, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$370,325 $— $— $370,325 $370,325 $— $— 
Level 2:
Money market instruments
264,833 — — 264,833 264,833 — — 
Corporate debt securities
413,137 3,261 (8)416,390 — 220,551 195,839 
U.S. government agency securities
265,298 1,555 (1)266,852 14,000 192,488 60,364 
Asset-backed securities31,659 85 (2)31,742 — 3,189 28,553 
Foreign and other
549 168 — 717 — — 717 
Subtotal
975,476 5,069 (11)980,534 278,833 416,228 285,473 
Total
$1,345,801 $5,069 $(11)$1,350,859 $649,158 $416,228 $285,473 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments
173,100 — — 173,100 173,100 — — 
Corporate debt securities
518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities
209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other
549 145 (1)693 — — 693 
Subtotal
901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total
$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company’s long-term marketable securities mature between one and five years.
As of December 31, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.
107
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December 31, 2020 and 2019, the fair value of the Company’s strategic investments was $10.5 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Consolidated Balance Sheets.
See Note 3 to these Consolidated Financial Statements for additional discussion regarding the Company’s fair value measurements.
(6) GOODWILL AND INTANGIBLE ASSETS
The change in the carrying value of Goodwill was as follows:
December 31,
20202019
Beginning balance $197,039 $197,039 
Less: disposition(840)— 
Ending carrying value$196,199 $197,039 
In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. As a result of the sale of Firdapse, in the first quarter of 2020 the Company recognized a $0.8 million reduction to Goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million.
The Company performed its annual assessment for goodwill impairment for the year ended December 31, 2020 and no goodwill impairment charges were recorded.
Intangible Assets, Net consisted of the following:
December 31,
20202019
Finite-lived intangible assets$644,087 $652,734 
Less: Accumulated amortization(226,816)(196,154)
Net carrying value$417,271 $456,580 
The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2020:
Net BalanceAverage Remaining Life
Acquired intellectual property$350,275 6.9 years
Repurchased royalty rights19,687 2.9 years
Technology transfer46,657 Not applicable (1)
Other652 
0.5 - 3.4 years
Total$417,271 
(1)The technology transfer intangible asset has not yet been placed into service.
As of December 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:
108
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Fiscal YearAmount
2021$61,963 
202261,939 
202361,311 
202455,036 
202535,759 
Thereafter94,606 
$370,614 
In 2019 and 2018, the Company received $25.0 million and $50.0 million, respectively, due to the achievement by a third party of development and regulatory milestones and commercial sales milestones related to a previously sold intangible asset, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Operations.

(7) PROPERTY, PLANT AND EQUIPMENT
Property, Plant and Equipment, Net, consisted of the following:
December 31,
20202019
Building and improvements$761,560 $725,906 
Manufacturing and laboratory equipment414,439 366,951 
Computer hardware and software189,740 167,554 
Land90,418 90,418 
Leasehold improvements55,134 51,324 
Furniture and equipment40,223 38,569 
Land improvements7,412 7,349 
Construction-in-progress109,140 111,897 
1,668,066 1,559,968 
Accumulated depreciation(635,595)(549,100)
Total property, plant and equipment, net$1,032,471 $1,010,868 
The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.
Years Ended December 31,
202020192018
Depreciation expense$88,169 $89,285 $90,375 
Depreciation capitalized into inventory$44,492 $37,481 $25,227 

109

(8) INVENTORY
Inventory consisted of the following:
December 31,
20202019
Raw materials$76,673 $74,442 
Work-in-process308,286 349,978 
Finished goods313,589 255,855 
Total inventory$698,548 $680,275 

Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. The Company had $29.2 million of valoctocogene roxaparvovec pre-launch inventory as of December 31, 2019.
In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requesting additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $87.2 million to Cost of Sales during the year ended December 31, 2020. The Company had no pre-launch inventory balance as of December 31, 2020.
110
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(9) SUPPLEMENTAL BALANCE SHEET INFORMATION
Accounts Payable and Accrued Liabilities consisted of the following:
December 31,
20202019
Accounts payable and accrued operating expenses$191,429 $240,981 
Accrued compensation expense165,023 192,467 
Accrued rebates payable$65,526 57,163 
Forward foreign currency exchange contracts17,798 10,448 
Accrued royalties payable17,155 30,797 
Lease liability11,754 10,700 
Accrued income taxes9,661 3,195 
Value added taxes payable9,562 8,395 
Deferred revenue152 13,037 
Other4,488 3,438 
Total accounts payable and accrued liabilities$492,548 $570,621 
The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2020, 2019 and 2018, were as follows:
Balance at
Beginning
of Period
Provision for Current Period SalesPayments
Balance at
End of
Period
Year ended December 31, 2020:
Accrued rebates$57,163 $113,165 $(104,802)$65,526 
Reserve for cash discounts$1,889 $17,191 $(17,364)$1,716 
Year ended December 31, 2019:
Accrued rebates$43,116 $91,748 $(77,701)$57,163 
Reserve for cash discounts$1,197 $15,335 $(14,643)$1,889 
Year ended December 31, 2018:
Accrued rebates$36,472 $67,843 $(61,199)$43,116 
Reserve for cash discounts$1,055 $12,474 $(12,332)$1,197 

111
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(10) FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies to these Consolidated Financial Statements.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2020 and 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 13 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2020 and 2019.

Fair Value Measurements as of December 31, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$2,415 $— $2,415 
Other assets:
NQDC Plan assets19,962 — 19,962 
Restricted investments (1)
4,487 — 4,487 
Total other assets24,449 — 24,449 
Total assets$26,864 $— $26,864 
Liabilities:
Current liabilities:
NQDC Plan liability$2,415 $— $2,415 
Other long-term liabilities:
NQDC Plan liability19,962 — 19,962 
Contingent consideration— 60,130 60,130 
Total other long-term liabilities19,962 60,130 80,092 
Total liabilities$22,377 $60,130 $82,507 

112
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Fair Value Measurements as of December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current Liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)The restricted investments as of December 31, 2020 and 2019 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.
There were no transfers between levels during the periods presented.
Liabilities measured at fair value using Level 3 inputs primarily consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.
Contingent consideration as of December 31, 2019$50,793 
Changes in the fair value of contingent consideration4,500 
Foreign exchange remeasurement of Euro denominated contingent consideration4,837 
Contingent consideration as of December 31, 2020$60,130 

(11) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company's forward foreign currency exchange contracts (forward contracts) designated as hedging instruments have maturities up to two years and three months. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to three months.
The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.
113
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Foreign Exchange ContractsDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Sell$782,327 $820,546 
Purchase$189,540 $212,348 
Derivatives not designated as hedging instruments:
Sell$98,343 $77,335 
Purchase$12,277 $30,818 
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$6,268 $19,584 
Other assets3,148 13,539 
Subtotal$9,416 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$17,551 $8,184 
Other long-term liabilities11,020 5,493 
Subtotal$28,571 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$84 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$247 $2,264 
Total Derivatives Assets$9,500 $33,592 
Total Derivatives Liabilities$28,818 $15,941 
(1)    See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.
114
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Years Ended December 31,
20202019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,805,861 $18,122 $1,661,043 $17,672 
Operating expenses as reported$1,897,220 $(4,942)$1,804,505 $(3,453)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$115 $(5,259)
As of December 31, 2020, the Company expects to reclassify unrealized losses of $12.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 14 to these Consolidated Financial Statements.

(12) LEASES
The following table presents the Company’s ROU assets and lease liabilities for the periods presented.
December 31,
Lease ClassificationClassification20202019
Assets:
OperatingOther assets$46,014 $49,045 
FinancingOther assets11,095 10,389 
Total ROU assets$57,109 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$8,889 $7,451 
FinancingAccounts payable and accrued liabilities2,865 3,249 
Noncurrent:
OperatingOther long-term liabilities40,483 44,092 
FinancingOther long-term liabilities4,006 6,708 
Total lease liabilities$56,243 $61,500 
115
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
2021$11,295 $3,095 $14,390 
202210,127 2,383 12,510 
20238,605 1,800 10,405 
20246,570 50 6,620 
20255,561 21 5,582 
Thereafter16,758 — 16,758 
Total lease payments58,916 7,349 66,265 
Less: Interest(9,544)(478)(10,022)
Present value of lease liabilities$49,372 $6,871 $56,243 

Lease costs associated with payments under the Company’s leases for the periods presented were as follows:
Years Ended December 31,
Lease CostClassification20202019
Operating (1)
Operating expenses$12,841 $13,026 
Financing:
AmortizationOperating expenses3,271 2,615 
Interest expenseOperating expenses448606
Total lease costs$16,560 $16,247 
(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Years Ended December 31,
Other Information20202019
Weighted average remaining lease term (in years):
Operating leases6.87.9
Financing leases2.63.3
Weighted average discount rate:
Operating leases4.9 %5.2 %
Financing leases5.2 %5.4 %
As of December 31, 2020, no leases were expected to commence that would create significant rights and obligations for the Company.
116
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Years Ended December 31,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$10,536 $8,183 
Financing leases$450 $628 
Cash used in financing activities:
Financing leases$6,918 $5,087 
ROU assets obtained in exchange for lease obligations:
Operating leases$4,779 $9,772 
Financing leases$3,941 $3,267 

(13) DEBT
Convertible Notes
As of December 31, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
20202019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,312)— 
Unamortized deferred offering costs(683)— 
2027 Notes, net587,005 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,116)(6,533)
Unamortized deferred offering costs(1,744)(2,229)
2024 Notes, net488,140 486,238 
1.50% senior subordinated convertible notes matured in October 2020 (the 2020 Notes)
— 374,993 
Unamortized discount— (12,078)
Unamortized deferred offering costs— (1,033)
2020 Notes, net (1)
— 361,882 
Total convertible debt, net$1,075,145 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$627,090 $— 
2024 Notes
530,714 521,839 
2020 Notes
— 405,679 
Total fair value of fixed rate convertible debt$1,157,804 $927,518 
(1)The 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. There were no shares issued in connection with the settlement as the Company’s share price did not exceed the conversion price of
117
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
$94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
(2)The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
Interest expense on the Company’s convertible debt consisted of the following:
Years Ended December 31,
202020192018
Coupon interest$12,350 $4,907 $12,452 
Amortization of debt issuance costs1,829 2,031 3,610 
Accretion of discount on convertible notes14,682 15,917 27,602 
Total interest expense on convertible debt$28,861 $22,855 $43,664 
2027 Notes
In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense.
The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.
The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act.
2024 Notes
In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common
118
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
stock. A holder may convert fewer than all of such holder’s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million.
The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company’s existing and future senior debt, (ii) equal in right of payment to any of the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.
In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9 million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes. In connection with the issuance of the 2024 Notes, the Company incurred $3.4 million of issuance costs.
See Note 19 to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on net income (loss) per common share.
Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the 2018 Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of December 31, 2020, there were no outstanding amounts due under the 2018 Credit Facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.

(14) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018.

119
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Years Ended December 31,
Details about AOCI ComponentsConsolidated Statements of
Operations Classification		202020192018
Gains (losses) on cash flow hedges:
Forward contractsNet product revenues$18,122 $17,672 $(6,005)
Forward contractsOperating expenses(4,942)(1,819)3,958 
Total gain (loss) on cash flow hedges
13,180 15,853 (2,047)
Gain on sale of available-for-sale debt securities
Other income, net552 — — 
Income tax effect of the above
Benefit from income taxes(127)— — 
Total gain on available-for-sale debt securities
425 — — 
$13,605 $15,853 $(2,047)

The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.
Unrealized Gains (Losses) on Cash Flow HedgesUnrealized Gains (Losses) on Available-for-Sale Debt SecuritiesOtherTotal
AOCI balance at December 31, 2017(20,232)(2,722)(7)(22,961)
Impact of change in accounting principle (1)
— (586)— (586)
AOCI balance as of January 1, 2018(20,232)(3,308)(7)(23,547)
Other comprehensive income (loss) before
reclassifications		25,386 1,804 (6)27,184 
Less: gain (loss) reclassified from AOCI(2,047)— — (2,047)
Tax effect— (413)— (413)
Net current-period other comprehensive income (loss)27,433 1,391 (6)28,818 
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
reclassifications		25,266 7,122 (2)32,386 
Less: gain (loss) reclassified from AOCI15,853 — — 15,853 
Tax effect— (1,640)— (1,640)
Net current-period other comprehensive income (loss)9,413 5,482 (2)14,893 
AOCI balance at December 31, 201916,614 3,565 (15)20,164 
Other comprehensive income (loss) before
reclassifications		(23,462)976 15 (22,471)
Less: gain (loss) reclassified from AOCI13,180 552 — 13,732 
Tax effect— (100)— (100)
Net current-period other comprehensive income (loss)(36,642)324 15 (36,303)
AOCI balance at December 31, 2020(20,028)3,889 — (16,139)
(1)The amount represents the reclassification from AOCI to Accumulated Deficit due to the adoption of ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02) in the first quarter of 2018.
(15) REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers
120
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.
Years Ended December 31,
202020192018
Total revenues by geographic region:
United States$912,375 $778,440 $696,793 
Europe518,465 509,188 436,434 
Latin America205,862 218,792 185,046 
Rest of world223,753 197,628 172,939 
Total revenues$1,860,455 $1,704,048 $1,491,212 
The following table disaggregates total Net Product Revenues by product.
Years Ended December 31,
202020192018
Net product revenues by product:
Vimizim544,257 544,345 481,977 
Kuvan457,736 463,353 433,582 
Naglazyme391,298 374,334 345,851 
Palynziq170,983 86,857 12,173 
Brineura110,192 71,997 39,889 
Firdapse1,288 22,348 21,787 
Total net product revenues marketed by the Company1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme130,107 97,809 135,097 
Total net product revenues$1,805,861 $1,661,043 $1,470,356 
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.
Years Ended December 31,
202020192018
United States$756,863 $669,171 $560,030 
Europe498,725 485,596 424,357 
Latin America205,862 218,792 184,984 
Rest of world214,304 189,675 165,888 
Total net product revenues marketed by the Company
1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme
130,107 97,809 135,097 
Total net product revenue$1,805,861 $1,661,043 $1,470,356 
121
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Years Ended December 31,
202020192018
Customer A16 %17 %18 %
Customer B15 %13 %12 %
Customer C12 %11 %10 %
Total43 %41 %40 %
On a consolidated basis, two customers accounted for 24% and 22% of the Company’s December 31, 2020 accounts receivable balance, respectively, compared to December 31, 2019 when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of December 31, 2020 and 2019, the accounts receivable balance for Genzyme included $72.1 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Genzyme. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The outbreak of COVID-19 continues to affect economies and business around the world. The Company's global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and its business operations were impacted by COVID-19 during the year ended December 31, 2020 and the Company anticipates a continued impact due to COVID-19 on its financial results in fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.
The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.
Long-lived assets, which consist of property, plant and equipment and ROU assets are summarized by geographic region in the following table.
December 31,
20202019
Long-lived assets by geography:
United States$771,286 $773,991 
Ireland300,555 278,082 
Rest of world17,739 18,229 
Total long-lived assets$1,089,580 $1,070,302 


(16) EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION
Equity Compensation Plans
Shares Available Under Equity Compensation Plans
As of December 31, 2020, an aggregate of approximately 36.7 million unissued shares was authorized for future issuance under the Company’s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan and the ESPP.
122
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Under the 2017 Equity Incentive Plan, shares issued under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. Shares formerly reserved for future issuance under the 2006 Share Incentive Plan were transferred to the 2017 Equity Incentive Plan and became available for issuance thereunder upon the effectiveness of the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company’s stock-based compensation plans are administered by the Company’s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note 3 to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.
2017 Equity Incentive Plan
The 2017 Equity Incentive Plan provides for awards of RSUs and stock options as well as other forms of equity compensation. Stock option awards granted to employees generally vest over a four-year period on a cliff basis twelve months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally ten years from the grant date. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. As of December 31, 2020, approximately 20.5 million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.
Employee Stock Purchase Plan
The ESPP was initially approved in June 2006, replacing the Company’s previous plan, and was most recently amended in June 2019. Under BioMarin’s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. During the year ended December 31, 2020, the Company issued 0.3 million shares under the ESPP. As of December 31, 2020, approximately 7.0 million shares were authorized and 3.4 million shares reserved for future issuance under the ESPP.
Board of Director Grants
On September 19, 2019, the Board of BioMarin approved revised compensation for the Independent Directors of the Company. On the date of the Company’s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000 ($375,000 prior to September 19, 2019), with the number of RSUs to be granted calculated based on the three-month trailing average closing price of the Company’s common stock on the Nasdaq Global Select Market. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company’s next annual meeting of stockholders.
Stock-based Compensation
Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:
Years Ended December 31,
202020192018
Cost of sales$26,246 $16,146 $13,558 
Research and development61,942 56,649 57,557 
Selling, general and administrative101,523 87,070 77,704 
Total stock-based compensation expense$189,711 $159,865 $148,819 
Stock-based compensation of $20.1 million, $20.3 million and $20.0 million was capitalized into inventory for the years ended December 31, 2020, 2019 and 2018, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.
123
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Restricted Stock Units
Restricted Stock Unit Awards with Service-Based Vesting Conditions
Below is a summary of activity related to RSUs with service-based vesting conditions under the plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 20193,585,384 $88.54 
Granted2,190,380 $77.13 
Vested(1,308,962)$87.57 
Forfeited(293,678)$85.17 
Non-vested units as of December 31, 20204,173,124 $83.41 
The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2020, 2019 and 2018, was $77.13, $91.28 and $84.63, respectively. The total intrinsic value of restricted stock that vested and was released in the years ended December 31, 2020, 2019 and 2018, was $109.9 million, $101.0 million and $84.5 million respectively.
As of December 31, 2020, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $245.3 million was expected to be recognized over a weighted average period of 2.6 years.
Restricted Stock Unit Awards with Performance-based Vesting Conditions
The Compensation Committee of the Board (with respect to awards to certain executive officers other than the Chief Executive Officer) and the Board (with respect to awards to the Chief Executive Officer) may grant RSUs with performance-based vesting conditions (PRSUs) to certain executive officers.
Revenue PRSUs: Although no PRSUs with vesting conditions based on revenue performance were granted during the year ended December 31, 2020, awards granted during prior periods presented were contingent upon the achievement of an annual revenue target and the earned RSUs vest over a three-year service period. The number of shares that may be earned ranged between 50% and 200% of the base RSUs, depending on the percentage of the respective annual year's Net Product Revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates achieved against the target, with a threshold achievement level of 75% of target and a ceiling achievement level of 125% of target.
Below is a summary of activity related to Revenue PRSUs under the Company's equity plan for the year ended December 31, 2020:
SharesWeighted Average Grant Date Fair Value
Non-vested units as of December 31, 2019226,884 $89.09 
Adjustment for shares earned2,272 $73.82 
Vested(126,608)$88.09 
Forfeited(3,197)$94.53 
Non-vested units as of December 31, 202099,351 $90.31 
The weighted-average grant date fair value of Revenue PRSUs was $94.53 and $83.57 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2020, total unrecognized compensation expense of $3.5 million related to Revenue PRSUs was expected to be recognized over a weighted average period of approximately 1.0 year.
124
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Other PRSUs: Below is a summary of activity related to RSUs with vesting conditions based on other performance targets under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201944,260 $81.00 
Granted184,460 $84.17 
Vested(4,495)$73.82 
Forfeited(3,560)$78.72 
Non-vested units as of December 31, 2020220,665 $83.83 
The weighted-average grant date fair value of Other PRSUs was $84.17 and $81.00 for the years ended December 31, 2020 and 2019, respectively.
Non-vested Other PRSUs include a grant with vesting contingent upon the achievement of a three-year Non-GAAP income target and a grant with vesting contingent upon achievement of a three-year strategic goal target. The awarded PRSUs, if any, vest ratably over a three-year service period. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.
Also included in non-vested Other PRSUs are grants that vest contingent upon achievement of certain regulatory milestones that, for accounting purposes, were deemed not yet probable of vesting as of December 31, 2020. Therefore, as of December 31, 2020, total unrecognized compensation expense of $8.1 million related to awards deemed probable of vesting and $7.9 million related to awards not yet deemed probable of vesting. The expected weighted average period over which expense is to be recognized for the awards that are considered probable of vesting as of December 31, 2020 was 2.2 years.
Restricted Stock Unit Awards with Market-based Vesting Conditions
The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s TSR is above the 50th percentile but negative on an absolute basis.
Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201999,010 $143.92 
Granted131,350 $115.85 
Vested— $— 
Forfeited(9,370)$143.92 
Non-vested units as of December 31, 2020220,990 $127.23 
The Company utilized a Monte Carlo simulation model to determine the grant date fair value per base TSR-RSU of $112.12 using the following assumptions for the grant in March 2020: an expected term of 2.8 years, discount rate of 0.4%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. In June 2020, the Compensation Committee of the Board approved an additional grant of RSUs with market-based vesting conditions with identical terms as those granted in March 2020. The third-party valuation per base TSR-RSU of $217.65 used the following assumptions: an expected term of 2.5 years, discount rate of 0.2%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. As of
125
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

December 31, 2020, total unrecognized compensation expense of $14.1 million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.8 years.
Stock Options and Purchase Rights
Stock Options
The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2020. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Years
Aggregate
Intrinsic
Value (1)
Options outstanding as of December 31, 20197,264,235 $67.99 $146,700 
Granted891,610 $76.02 
Exercised(1,240,511)$43.87 
Expired and forfeited(85,897)$86.07 
Options outstanding as of December 31, 20206,829,437 $73.19 4.8$119,607 
Options unvested as of December 31, 20201,438,573 $81.56 8.6$11,635 
Exercisable at December 31, 20205,390,864 $70.95 3.8$107,972 
(1)The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $87.69, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 31, 2020.
The weighted-average fair value per stock option granted in the years ended December 31, 2020, 2019 and 2018, were $27.47, $36.84 and $33.40, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018, was $71.9 million, $32.5 million and $79.9 million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.
The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:
Years Ended December 31,
202020192018
Expected volatility
36.5 – 42.2%
37.1 – 37.4%
36.8 – 38.4%
Dividend yield0.00%0.00%0.00%
Expected term
4.6 – 5.9 years
4.6 – 5.8 years
4.6 – 5.7 years
Risk-free interest rate
0.3 – 1.7%
2.2 – 3.0%
2.3 – 2.8%
As of December 31, 2020, total unrecognized compensation cost related to unvested stock options of $35.3 million was expected to be recognized over a weighted average period of 2.5 years. The net tax benefit from stock options exercised during the year ended December 31, 2020 was $4.5 million.
126
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Stock Purchase Rights
The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:
Years Ended December 31,
202020192018
Expected volatility
30.6 – 69.2%
27.7 – 35.0%
29.7% – 35.0%
Dividend yield0.00%0.00%0.00%
Expected term
0.5 – 2.0 years
0.5 – 2.0 years
0.5 – 2.0 years
Risk-free interest rate
0.1 – 2.8%
1.2 – 2.8%
1.2 – 2.8%
As of December 31, 2020, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $18.3 million was expected to be recognized over a weighted average period of 1.4 years.

(17) OTHER EMPLOYEE BENEFITS
Employment Agreements
The Company has entered into employment agreements with certain officers. Generally, these agreements can be terminated without cause by the Company upon prior written notice and payment of specified severance, or by the officer upon four weeks’ prior written notice to the Company.
401(k) Plan
The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan). Eligible employees may contribute to the 401(k) Plan up to the lesser of 60% of their current compensation or an amount up to a statutorily prescribed annual limit. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee’s eligible contributions, up to a maximum of the lesser of 6% of the employee’s annual compensation or the annual statutory contribution limit. The Company’s matching contribution vests immediately and was approximately $26.4 million, $28.5 million and $23.0 million for the years ended December 31, 2020, 2019 and 2018, respectively.
Deferred Compensation Plan
The Company amended the NQDC in the second quarter of 2019 to prohibit the diversification of deferrals of Company stock, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity and, subsequent to the 2019 amendment, changes in the fair value of Company stock held in the NQDC are no longer recognized in earnings. Other contributions held in the NQDC are classified as trading securities and recorded at fair value with the corresponding deferred compensation obligation classified as a liability. Changes in the fair value of non-BioMarin investments are recognized in earnings in the period they occur.
See Note 10 to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities.

(18) INCOME TAXES
The benefit from income taxes was based on loss before income taxes as follows:
127
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Years Ended December 31
202020192018
U.S. Source$(162,939)$(182,112)$(128,700)
Non-U.S. Source120,617 87,301 (14,005)
Loss before income taxes$(42,322)$(94,811)$(142,705)
The U.S. and foreign components of the benefit from income taxes were as follows:
Years Ended December 31,
202020192018
Provision for (benefit from) current income tax expense:
Federal$(14,758)$5,127 $(2,660)
State and local1,201 1,331 588 
Foreign1,042 5,339 4,956 
(12,515)11,797 2,884 
Provision for (benefit from) deferred income taxes:
Federal(45,038)(58,311)(72,074)
State and local(5,321)(5,394)(994)
Foreign(838,548)(19,055)4,690 
(888,907)(82,760)(68,378)
Benefit from income taxes$(901,422)$(70,963)$(65,494)
In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2020.

128
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The following is a reconciliation of the statutory federal income tax (benefit) expense to the Company’s effective tax rate:
December 31,
202020192018
Federal statutory income tax benefit$(8,888)$(19,911)$(29,968)
State and local taxes(3,264)(2,784)(276)
Orphan Drug & General Business Credit(44,114)(43,124)(66,451)
Stock compensation expense(1,101)239 (5,647)
Changes in the fair value of contingent consideration— (1,804)(2,361)
Foreign Source Income Subject to U.S. Tax6,266 (52)6,543 
Foreign tax rate differential (1)
(16,238)(30,639)12,583 
Section 162(m) limitation9,571 8,294 7,440 
Tax Reserves2,166 12,123 8,545 
Intra-entity transfer of assets(852,338)— — 
CARES Act carryback claim(2,201)— — 
Other1,843 (1,132)(423)
Valuation allowance/deferred benefit6,876 7,827 4,521 
Effective income tax (benefit) expense$(901,422)$(70,963)$(65,494)
(1)     For the year ended December 31, 2019, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the benefit of the valuation allowance release against the deferred tax assets of the Company’s Dutch subsidiary of $29.6 million.
The significant components of the Company’s net deferred tax assets were as follows:
December 31,
20202019
Net deferred tax assets:
Net operating loss carryforwards$30,718 $32,181 
Tax credit carryforwards532,394 508,560 
Accrued expenses, reserves, and prepaids66,889 61,807 
Intangible assets873,575 29,413 
Stock-based compensation47,011 42,873 
Lease liabilities8,991 11,470 
Inventory32,012 6,290 
Other454 575 
Valuation allowance(93,075)(86,197)
Total deferred tax assets1,498,969 606,972 
Joint venture basis difference(1,164)(993)
Acquired intangibles(1,364)(1,647)
Deferred revenue(1,517)(3,003)
Convertible notes discount— (2,364)
ROU assets(8,280)(10,258)
Property, plant and equipment(54,682)(46,642)
Total deferred tax liabilities(67,007)(64,907)
Net deferred tax assets$1,431,962 $542,065 
Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. The valuation allowance increased in 2020 due primarily to the Company’s expectation that state R&D credits will not be utilized.
129
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
As of December 31, 2020, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:
TypeAmountYear
Federal net operating loss carryforwards$4,753  2030 – 2033
Federal R&D and orphan drug credit carryforwards$566,887  2024 – 2040
State net operating loss carryforwards$182,961  2021 – 2040
Dutch net operating loss carryforwards$75,718  2022 – 2025
Not included in the table above are $124.3 million of state research credit carryovers that will carry forward indefinitely.
The Company’s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by IRC Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits.
The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.
A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2020 and 2019, is as follows:
December 31,
20202019
Balance at beginning of period$168,748 $147,445 
Additions based on tax positions related to the current year
16,481 19,287 
(Deletions) Additions for tax positions of prior years(2,527)2,016 
Lapse of statute of limitations(138)— 
Balance at end of period$182,564 $168,748 
Included in the balance of unrecognized tax benefits as of December 31, 2020 were potential benefits of $175.1 million that, if recognized, would affect the effective tax rate. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December 31, 2020. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.
The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from three to five years. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.
U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. This excess totaled approximately $15.2 million as of December 31, 2020, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.

(19) NET INCOME (LOSS) PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt.
130
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The following table sets forth the computation of basic and diluted income (loss) per common share (common shares in thousands):
Years Ended December 31,
202020192018
Numerator:
Net income (loss), basic$859,100 $(23,848)$(77,211)
Add: Interest on convertible notes8,313 — — 
Less: gain on the Company's common stock held by the NQDC— — (710)
Net income (loss), diluted$867,413 $(23,848)$(77,921)
Denominator:
Weighted-average common shares outstanding, basic180,804 179,039 177,061 
Effect of dilutive securities:
Options to purchase common stock1,543 — — 
Common stock issuable under the 2027 notes2,874 — — 
Common stock issuable under the 2024 notes3,970 — — 
Unvested RSUs1,938 — — 
Common stock potentially issuable for ESPP purchases353 — — 
The Company's common stock held by the NQDC196 — 207 
Weighted-average common shares outstanding, diluted191,678 179,039 177,268 
Net income (loss) per common share, basic$4.75 $(0.13)$(0.44)
Net income (loss) per common share, diluted$4.53 $(0.13)$(0.44)

In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income (loss) per common share as they were anti-dilutive (in thousands):
Years Ended December 31,
202020192018
Options to purchase common stock5,287 7,264 7,364 
Common stock issuable under the 2020 Notes— 3,983 3,983 
Common stock issuable under the 2024 Notes— 3,970 3,970 
Unvested RSUs2,235 3,956 3,404 
Common stock potentially issuable for ESPP purchases314 587 435 
The Company's common stock held by the NQDC— 205 — 
Total number of potentially issuable shares7,836 19,965 19,156 
The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as the Company’s closing stock price on December 31, 2019 and 2018 did not exceed the conversion price of $94.15 per share for the 2020 Notes. There is no similar capped call transaction associated with the 2024 Notes or 2027 Notes. See Note 13 to these Consolidated Financial Statements for information on the Company’s convertible debt.

(20) LICENSE AND COLLABORATION AGREEMENTS
In October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0 million, a minority 15% equity ownership interest in the licensee,
131
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and sales milestones are met by the licensee.
The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee’s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December 31, 2020. As a result, the Company's loss exposure is limited to the value of the equity investment of $8.1 million which is included in Other Assets on the Company’s Consolidated Balance Sheets as of December 31, 2020.
In July 2017, the Company executed a license agreement and a settlement agreement with Sarepta Therapeutics (Sarepta) that provide Sarepta with global exclusive rights to the Company’s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under these agreements, Sarepta may pay certain additional regulatory and commercial milestone fees for exons 51, 45, 53 and possibly on future exon-skipping products to the Company if certain development and sales milestones are achieved. Additionally, the Company receives from Sarepta royalties based on 5% of net sales in the U.S. through the end of 2023 and 8% of net sales in the EU and in other countries, where certain of the Company’s patents exist, through September 30, 2024. The Company retained the right to convert the license to a co-exclusive right in the event it decides to proceed with an exon-skipping therapy for DMD.
On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to Kuvan and Palynziq from Merck Serono, with the exception of Kuvan in Japan. Previously, the Company had exclusive rights to Kuvan in the U.S. and Canada and Palynziq in the U.S. and Japan. Pursuant to the A&R Kuvan Agreement, if future sales milestones are met, the Company is obligated to pay Merck Serono up to a maximum of €60.0 million, in cash, which was an estimated fair value of $73.6 million as of December 31, 2020. Pursuant to the Pegvaliase Agreement, the Company paid Merck Serono €125.0 million in cash when the Palynziq development milestones were achieved.
In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to Firdapse, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of Firdapse in North America. In January 2020, the Company completed the sale of worldwide rights to Firdapse to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note 6 to these Consolidated Financial Statements for further information about the Firdapse sale.
In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the Kuvan new drug application. The Company receives royalties on net sales of the product in Japan.
The Company is engaged in R&D collaborations with various other entities. These provide for sponsorship of R&D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.

(21) COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.
Contingent Payments
As of December 31, 2020, the Company was subject to contingent payments totaling approximately $662.8 million upon achievement of certain development and regulatory activities and commercial sales milestones if they occur before certain dates in
132
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $73.6 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from Merck Serono and $237.7 million related to programs that are no longer being developed.
As of December 31, 2020, the Company recorded $60.1 million of contingent liabilities on its Consolidated Balance Sheet, all of which was long-term. See Note 3 and Note 10 to these Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
The Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are included as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients, certain inventory related items and certain third-party R&D services. As of December 31, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $142.8 million. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.
Under certain of the Company’s lease agreements, the Company is contractually obligated to return leased space to its original condition upon termination of the applicable lease agreement. The Company records interest expense to accrete the asset retirement obligation liability to full value and depreciates each retirement obligation asset, both over the term of the associated lease agreement. As of December 31, 2020 and 2019, the balance of the asset retirement obligation liability was $3.7 million and $3.0 million, respectively. See Note 3 to these Consolidated Financial Statements for further information on the Company's fair value measurements.
133
 EX-10.32 2 exhibit1032.htm EX-10.32 Document
Exhibit 10.32
PART-TIME EMPLOYMENT AGREEMENT
THIS PART-TIME EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of January 1, 2021 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Robert A Baffi, Ph.D. (“Employee”).
WHEREAS, Employee currently serves as Senior Advisor to the Company, a full-time position, pursuant to the Amended and Restated Employment Agreement by and between the Company and Employee, dated June 10, 2015 (the “2015 Employment Agreement”);
WHEREAS, Employee desires to retire from his full-time position with the Company and terminate the 2015 Employment Agreement; and
WHEREAS, the Company desires to continue to employ Employee on a part-time basis as set forth below, and Employee desires to accept such part-time employment with the Company.
NOW THEREFORE, for good and valuable consideration (the receipt and adequacy of which are hereby acknowledged and agreed) the parties hereby covenant and agree as follows:
1.Termination of the 2015 Employment Agreement. As of the Effective Date, the 2015 Employment Agreement shall terminate pursuant to Employee’s election under Section 6(a) of the 2015 Employment Agreement (At-Will Employment). Employee shall not be entitled to the Severance Benefits (as such term is defined in the 2015 Employment Agreement) or any other compensation or benefits under the 2015 Employment Agreement.
2.Title; Duties. The Company hereby employs the Employee on a part-time basis as Senior Advisor (“Title”) to perform such duties consistent with his Title and position as may be determined and assigned to Employee by the Company’s Chief Executive Officer (“CEO”), including, without limitation, the following duties:
(a)consult the Company’s senior executives, including without limitation, the Company’s CEO; Executive Vice President, Chief Technical Officer (“CTO”); President, Worldwide Research & Development (“President, WWRD”); and others on matters that you may be asked to provide strategic input;
(b)assist with specific internal projects at the request of the Company’s CEO CTO, or President, WWRD;
(c)advise the Company regarding business development opportunities and transactions as directed by the CEO or Group Vice President, Business Development;
(d)at the request of the Company’s CEO, CTO or the President, WWRD, participate in industry and regulatory groups and advisory committees; and
(e)prepare a written history of the Company’s Technical Operations (TOPS) department and gene therapy manufacturing efforts for future publication by the Company.
The Employee may generally perform his duties remotely from his home office in Florida, provided that Employee acknowledges that his job duties may require occasional travel depending on the tasks involved.
3.Time and Effort. The Employee agrees to devote a reasonably appropriate amount of his professional employment time and effort to the performance of his duties as Title and to perform such other duties consistent with his Title and position as are reasonably assigned Employee from time to time by the CEO.
4.Term. The Company agrees to employ the Employee in accordance with the terms of this Agreement, which terms shall be effective commencing on the Effective Date and continuing thereafter until December 31, 2021 or earlier if terminated pursuant to Section 6 hereof (the “Term”).
5.Compensation; Benefits.
1


(a)Base Salary. For all the services to be rendered by the Employee in any capacity hereunder, the Company agrees to pay the Employee a base salary (“Base Salary”) of two hundred thousand dollars ($200,000.00) per annum. Base Salary shall be payable in approximately equal installments in accordance with the Company’s customary payroll practices. The foregoing annual compensation amount may be, from time to time, adjusted above the Base Salary specified above by action of the CEO. In the event the Base Salary is adjusted upward by the CEO, such adjusted amount will be deemed to be the new Base Salary.
(b)Annual Bonus. The Employee shall not be entitled to participate in the Company’s generally applicable employee bonus program.
(c)ESPP; Stock Options and Restricted Stock Units. Employee can continue to participate in the Company’s Employee Stock Purchase Plan (ESPP) in accordance with the Company’s customary practices. Employee was previously granted options to purchase certain shares of the Company’s common stock and certain restricted stock units (“RSUs”). Nothing herein shall affect any stock options or RSUs previously granted to the Employee which shall continue to be governed by the applicable agreements and governing equity plans.
(d)Benefits Plans. During the Term, the Employee and his spouse shall continue to participate fully in all insurance benefit plans and programs (including, without limitation, medical, dental and vision insurance) pursuant to the terms of such plans or programs. The Company shall pay the premiums for such insurance benefit plans and programs on behalf of the Employee and his spouse. The Employee shall be responsible for any taxes on such insurance premium payments.
(e)Vacation. The Employee shall not be entitled to annual paid vacation time.
(f)Expenses. The Company shall reimburse the Employee for all reasonable and customary travel, business and entertainment expenses incurred in connection with the Employee’s performance of his services hereunder in accordance with the policies and procedures established by the Company and paid promptly after the Employee makes a request therefore and no later than the end of the calendar year following the calendar year in which the expenses were incurred by the Employee.
(g)Withholding. The amounts payable pursuant to this Agreement (including insurance premium payments) shall be subject to withholding for appropriate taxes, assessments or withholdings as required by applicable law.
6.At-Will Employment; Termination of Employment.
(a)At-Will Employment.     Employee’s employment with the Company under this Agreement is employment “at will.” The Employee may terminate Employee’s employment with Company at any time and for any reason whatsoever (or no reason) simply by notifying the Company. Likewise, the Company may terminate Employee’s employment at any time, with or without Cause (as such term is defined in the 2015 Employment Agreement), and with or without advance notice.
(b)Employment Termination. In the event of a termination of Employee’s employment at any time by the Employee for any reason whatsoever (or no reason) or by the Company for Cause, the Company shall be obligated only to pay the Employee the compensation due Employee up to the date of termination, all accrued, vested or earned benefits under any applicable benefit plan, and any other compensation to which the Employee is entitled under Section 5 up to and ending on the date of the Employee’s termination. If the Company terminates Employee’s employment without Cause (including in connection with a Change in Control (as such term is defined in the 2015 Employment Agreement)), then the Company shall be obligated to pay the Employee any unpaid Base Salary and the amount of unpaid insurance premium payments that would have been paid had the Employee’s employment not been terminated by the Company.
(c)Employee’s Disability. The Company shall be entitled, by providing written notice to the Employee, to terminate the Employee’s employment under this Agreement if the Employee shall become Disabled (as defined herein). Any delay or forbearance by the Company in exercising any such right to terminate this Agreement shall not constitute a waiver thereof. “Disabled” means such that Employee is unable to carry out his duties hereunder for four (4) consecutive calendar months or for a period aggregating one hundred twenty (120) days in any period of twelve (12) consecutive calendar months because of a physical or mental impairment.
2


(d)Employee’s Death. The Employee’s employment will immediately terminate upon the death of the Employee. The Employee’s surviving designated beneficiary, or, if none, the Employee’s estate, shall be entitled to receive the compensation due the Employee up to the date of the Employee’s death, all accrued, vested or earned benefits under any applicable benefit plan and any other compensation to which the Employee is entitled under this Agreement up to and ending on the date of the Employee’s death.
7.Compliance with Code Section 409A. If any amounts or benefits payable under this Agreement on account of Employee’s termination of employment constitute deferred compensation subject to Section 409A of the Code, no payments or benefits shall be paid or provided until Employee incurs a separation from service within the meaning of Treas. Reg. § 1.409A-1(h) from the Company and any entity that would be considered a single employer with the Company under Code Sections 414(b) or 414(c) (“Separation from Service”). If, at the time of Employee’s Separation from Service, the Employee is a “specified employee” (within the meaning of Code Section 409A and Treas. Reg. §1.409A-3(i)(2)), the Company will not pay or provide any “Specified Benefits” (as defined herein) during the six-month period (the “409A Suspension Period”) beginning immediately after the Employee’s Separation from Service. For purposes of this Agreement, “Specified Benefits” are any amounts or benefits that would be subject to Code Section 409A penalties if the Company were to pay them, pursuant to this Agreement, on account of the Employee’s Separation from Service.
This Agreement is intended to comply with (or be exempt from) Code Section 409A, and the Company shall have complete discretion to interpret and construe this Agreement and any associated documents in any manner that establishes an exemption from (or otherwise conforms them to) the requirements of Code Section 409A. If, for any reason including imprecision in drafting, the Agreement does not accurately reflect its intended establishment of an exemption from (or compliance with) Code Section 409A, as demonstrated by consistent interpretations or other evidence of intent, the provision shall be considered ambiguous and shall be interpreted by the Company in a fashion consistent herewith, as determined in the sole and absolute discretion of the Company. The Company reserves the right to unilaterally amend this Agreement without the consent of the Employee in order to accurately reflect its correct interpretation and operation, as well as to maintain an exemption from or compliance with Code Section 409A. Nevertheless, and notwithstanding any other provision of this Agreement, neither the Company nor any of its employees, directors, or their agents shall have any obligation to mitigate, nor to hold the Employee harmless from, any or all taxes (including any imposed under Code Section 409A) arising under this Agreement.
8.Choice of Law; Venue. This Agreement shall be construed and performed in accordance to the laws (but not the conflicts of laws) of the State of California. Venue of any proceeding shall be exclusively in the County of Marin in the foregoing state, and both parties consent and agree to such exclusive venue.
9.Arbitration.     To ensure rapid and economical resolution of any disputes which may arise under this Agreement, Employee and the Company agree that any and all claims, disputes or controversies of any nature whatsoever arising from or regarding the interpretation, performance, negotiation, execution, enforcement or breach of this Agreement, Employee’s employment with the Company, or the termination of Employee’s employment from the Company, including but not limited to statutory claims, shall be resolved by confidential, final and binding arbitration conducted before a single arbitrator with JAMS, Inc. (“JAMS”) in San Francisco, California, in accordance with JAMS’ then-applicable arbitration rules, which can be found at http://www.jamsadr.com/rules-clauses/, and which will be provided to Employee upon request. The parties acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute through a trial by jury, judge or administrative proceeding. Employee will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. Nothing in this Agreement shall prevent either Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.
10.Notices. All notices provided for or permitted to be given pursuant to this Agreement must be in writing. All notices shall be given to the other party by personal delivery, overnight courier (with receipt signature), or facsimile transmission (with “answerback” confirmation of transmission), to the Company or the Employee at the Company’s principal executive offices if to the Company or to the residential address of the Employee as contained in
3


Employee’s personnel file if to Employee. Each such notice shall be deemed effective upon the date of actual receipt in the case of personal delivery, receipt signature in the case of overnight courier, or confirmation of transmission in the case of facsimile.
11.Entire Agreement; Amendment. This Agreement contains the sole and entire agreement of the parties and supersedes all prior agreements and understandings between the Employee and the Company and cannot be modified or changed by any oral or verbal promise or statement by whomsoever made; nor shall any written modification of it be binding upon the Company until such written modification shall have been approved in writing by the CEO.
12.Waiver; Consent. In the event any term or condition contained in this Agreement should be breached by any party and thereafter waived or consented to by the other party, which waiver or consent must be effectuated by a written instrument signed by the party against whom any waiver or consent is sought (and, in the case of the Company, approved by the CEO), such waiver or consent shall be limited to the particular breach so waived or consented to and shall not be deemed to waive or consent to any other breach occurring prior or subsequent to the breach so waived or consented to.
13.Severability. If any provisions of this Agreement or the application thereof to any person or circumstances shall be invalid or unenforceable to any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the extent permitted by law.
14.Survival. The provisions hereof which are to be performed or observed after the termination of this Agreement, and the representations, covenants and agreements of the parties contained herein with respect thereto shall survive the termination of this Agreement and be effective according to their terms.
15.Successors. All of the terms and provisions of this Agreement shall be binding upon and shall inure to the benefit of and be enforceable by and against the parties to this Agreement and the respective heirs, executors, and successors in interest; provided, however, that the duties of the Employee hereunder are personal in nature and may not be delegated without a written consent of the Company.
16.Assignment. This Agreement and the rights and benefits contained herein may not be assigned by either party hereto, except by the Company in connection with a merger, consolidation, share exchange, business combination or other reorganization of the Company or a sale of all or substantially all of the Company’s business or assets.
17.Certain Representations, Covenants and Acknowledgements.
(a)The Employee represents that Employee is not subject to any employment, confidentiality, or other agreement or restriction that would prevent Employee from fully satisfying his duties under this Agreement or that would be violated if Employee did so.
(b)Without the Company’s prior written approval, the Employee agrees not to: (i) disclose proprietary information belonging to a former employer or other entity without its written permission; (ii) contact any former employer’s customers or employees to solicit their business or employment on behalf of the Company; or (iii) distribute announcements about or otherwise publicize his employment with the Company.
(c)The Employee acknowledges that Employee is free to seek advice from independent counsel with respect to this Agreement. The Employee is not relying on any representation or advice from the Company or any of its officers, directors, attorneys or other representatives regarding this Agreement, its content or effect.
18.Construction. The masculine pronoun, wherever used herein, shall be construed to include the feminine and the neuter, where appropriate. The singular form, wherever used herein, shall be construed to include the plural, where appropriate.
19.Drafting. The parties represent and acknowledge that they both have participated in the preparation and drafting of this Agreement and have each given their approval to all of the language contained in this
4


Agreement, and it is expressly agreed and acknowledged that if either party later claims that there is an ambiguity in the language of this Agreement, there shall be no presumption that such ambiguity be construed for or against either party hereto.
20.Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement as of the date indicated above.
5


BIOMARIN PHARMACEUTICAL INC.
By:    /s/ Jean-Jacques Bienaimé
Name: Jean-Jacques Bienaimé
Its: Chief Executive Officer

EMPLOYEE
By:    /s/ Robert A. Baffi, Ph.D.
Robert A. Baffi, Ph.D.



6

 EX-21.1 3 bmrn-20201231xexx211.htm EX-21.1 Document

Exhibit 21.1
Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2020

NameDirect ParentOwnershipJurisdiction of Incorporation
BioMarin Commercial LtdBioMarin Pharmaceutical Inc.100%Ireland
BioMarin International Holdings IncBioMarin Pharmaceutical Inc.100%Delaware
BioMarin International LtdBioMarin Commercial Ltd.100%Ireland


 EX-23.1 4 bmrn-20201231xexx231.htm EX-23.1 Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

The Board of Directors
BioMarin Pharmaceutical Inc.:

We consent to the incorporation by reference in the registration statements (Nos. 333‑136963, 333-168552, 333-181697, 333-188620, 333-197759, 333-201504, 333-206094, 333-218695, and 333-234231) on Forms S-8 and in the registration statement (No. 333-212974) on Form S-3 of BioMarin Pharmaceutical Inc. of our reports dated February 26, 2021, with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020,and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2020, which reports appear in the December 31, 2020 annual report on Form 10‑K of BioMarin Pharmaceutical Inc.
Our report refers to a change in accounting for leases as of January 1, 2019 due to the adoption of Financial Accounting Standards Board Accounting Standards Codification Topic 842, Leases.

/s/ KPMG LLP
San Francisco, California
February 26, 2021

 EX-31.1 5 bmrn-20201231xexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Jean-Jacques Bienaimé, certify that:
1.I have reviewed this Annual Report on Form 10-K of BioMarin Pharmaceutical Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 26, 2021
/S/ JEAN-JACQUES BIENAIMÉ 
Jean-Jacques Bienaimé
Chief Executive Officer


 EX-31.2 6 bmrn-20201231xexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Brian R. Mueller certify that:
1.I have reviewed this Annual Report on Form 10-K of BioMarin Pharmaceutical Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 26, 2021
/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President, Chief Financial Officer


 EX-32.1 7 bmrn-20201231xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of BioMarin Pharmaceutical Inc. (the Company) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Jean-Jacques Bienaimé, and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/ JEAN-JACQUES BIENAIMÉ 
Jean-Jacques Bienaimé
Chief Executive Officer
February 26, 2021

/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President, Chief Financial Officer
February 26, 2021
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 EX-101.SCH 8 bmrn-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - NATURE OF OPERATIONS AND BUSINESS RISKS link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2109105 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2113106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2120107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 2426412 - Disclosure - INVENTORY - Schedule of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 2427413 - Disclosure - INVENTORY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2430414 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2431415 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail) link:presentationLink link:calculationLink link:definitionLink 2132110 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2333307 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) link:presentationLink link:calculationLink link:definitionLink 2136111 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2438418 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2439419 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2142112 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2343309 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2444422 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2445423 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - LEASES - Schedule of Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 2447425 - Disclosure - LEASES - Schedule of Other Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2448426 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2149113 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2451427 - Disclosure - DEBT - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2452428 - Disclosure - DEBT - Summary of Senior Subordinated Convertible Obligations (Detail) link:presentationLink link:calculationLink link:definitionLink 2453429 - Disclosure - DEBT - Summary of Interest Expense on Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2154114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 2355311 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 2456430 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) link:presentationLink link:calculationLink link:definitionLink 2457431 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) link:presentationLink link:calculationLink link:definitionLink 2158115 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 2359312 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2460432 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2461433 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) link:presentationLink link:calculationLink link:definitionLink 2462434 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 2463435 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) link:presentationLink link:calculationLink link:definitionLink 2464436 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) link:presentationLink link:calculationLink link:definitionLink 2465437 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail) link:presentationLink link:calculationLink link:definitionLink 2166116 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2367313 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2468438 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2469439 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2470440 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2471441 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2472442 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 2473443 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 2174117 - Disclosure - OTHER EMPLOYEE BENEFITS link:presentationLink link:calculationLink link:definitionLink 2475444 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2176118 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2377314 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2478445 - Disclosure - INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2479446 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2480447 - Disclosure - INCOME TAXES - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2481448 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2482449 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2483450 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail) link:presentationLink link:calculationLink link:definitionLink 2484451 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail) link:presentationLink link:calculationLink link:definitionLink 2185119 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2386315 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2487452 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2488453 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2489454 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2190120 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 2491455 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2192121 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2493456 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bmrn-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 bmrn-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 bmrn-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Shares, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Thereafter Operating And Finance Lease Liability Payments Due After Year Five Operating And Finance Lease Liability Payments Due After Year Five Acquired intangibles Deferred Tax Liabilities, Intangible Assets Lease liability Operating And Finance Lease Liability, Current Operating And Finance Lease Liability, Current Aggregate Intrinsic Value, Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse Products Excluding Product One [Member] Products excluding product one. Total gain on available-for-sale debt securities Debt Securities, Available-for-sale, Unrealized Gain (Loss) Accretion of discount on convertible notes Amortization of Debt Discount (Premium) Early Stage Development Program Early Stage Development Program [Member] Early Stage Development Program Debt issuance costs Debt Issuance Costs, Gross Range Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Amortization Finance Lease, Right-of-Use Asset, Amortization Security Exchange Name Security Exchange Name Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Summary of Non-Monetary Long-Lived Assets by Geographic Region Long-lived Assets by Geographic Areas [Table Text Block] Total current liabilities Liabilities, Current Amount Reclassified from AOCI (Gain) Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share) Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate Variable Rate [Domain] Increase (decrease) in accounts payable and accrued liabilities related to intangible assets Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets Total lease payments Finance Lease, Liability, Payment, Due ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Initial time period vesting requirements Share Based Compensation Arrangement By Share Based Payment Award Initial Time Period Vesting Requirement Share based compensation arrangement by share based payment award initial time period vesting requirement. Operating leases Operating Lease, Payments ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Firdapse Product Five [Member] Product 5 [Member] 2021 Operating And Finance Lease Liability Payments Due Next Twelve Months Operating And Finance Lease Liability Payments Due Next Twelve Months Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Concentration Risk And Segment Reporting Disclosure [Text Block] Concentration risk and segment reporting disclosure. Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Shares, Options outstanding beginning balance (in shares) Shares, Options outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Unrecognized compensation cost related to unvested awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] State and local Current State and Local Tax Expense (Benefit) Beginning Balance (in shares) Ending Balance (in shares) Shares, Outstanding Aggregate Intrinsic Value, Options unvested at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value Share based compensation arrangement by share based payment award options nonvested aggregate intrinsic value. Operating expenses Operating Expenses OTHER COMPREHENSIVE INCOME (LOSS): Other Comprehensive Income (Loss), Net of Tax [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Principal amount on conversion rate Principal Amount On Conversion Rate Principal amount per note used in conversion rate. Other long-term liabilities Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Weighted Average Exercise Price, Expired and forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Financing leases Finance Lease, Principal Payments Work-in-process Inventory, Work in Process, Net of Reserves Inventory Total inventory Inventory, Net Fair Value, Measurement Frequency Measurement Frequency [Domain] Concentration risk, percentage Concentration Risk, Percentage Contractual term of stock option awards, years Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Percentage of threshold achievement Fair Value Inputs Revenue Multiple Threshold Achievement Percentage Fair value inputs revenue multiple threshold achievement percentage. Customer Customers [Member] Customers. Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Payment received as percentage of net product sales Payment Received As Percentage Of Net Product Sales Payment received from sale of a product as percentage of worldwide net product sales. Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Other Accounts Payable and Accrued Liabilities Computer hardware and software Computer Equipment [Member] Purchase Long [Member] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Statement [Table] Statement [Table] Proceeds from sale of nonfinancial assets Proceeds From Sale Of Nonfinancial Assets Proceeds From Sale Of Nonfinancial Assets Range Statistical Measurement [Axis] Ireland IRELAND Long-term convertible debt, net Convertible Notes, net of unamortized discount and deferred offering costs Convertible Debt, Noncurrent Cash Flow Hedging Gains (Losses) Reclassified into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Marketable Securities Marketable Securities, Policy [Policy Text Block] Fair value of other current liabilities Other Liabilities Current Fair Value Disclosure Other liabilities current fair value disclosure. Entity Small Business Entity Small Business Latin America Latin America [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Cost of sales Cost of Revenue Amendment Flag Amendment Flag Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Liabilities remeasured Contingent consideration, beginning balance Contingent consideration, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Share based awards, authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Deferred Tax Assets, Gross [Abstract] Deferred Tax Assets, Gross [Abstract] Shares reserved for future issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Supplemental Balance Sheet Information [Table] Supplemental Balance Sheet Information [Table] Supplemental balance sheet information. Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts Schedule Of Estimated Accrued Rebates And Reserve For Cash Discounts Table [Text Block] Schedule of estimated accrued rebates and reserve for cash discounts. Measurement Frequency Measurement Frequency [Axis] Repurchase of note principal amount Senior Subordinated Notes Repurchased Percentage Of Principal Amount Senior subordinated notes repurchased percentage of principal amount. Fair Value of Financial Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Gains (Losses) Recognized in Earnings Derivative, Gain (Loss) on Derivative, Net Common stock issuable under the 2027 Notes Convertible Senior Notes Due Two Thousand Twenty Seven [Member] Convertible Senior Notes Due Two Thousand Twenty Seven Derivatives and Hedging Activities Derivatives, Policy [Policy Text Block] Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Domain] Total lease payments Operating And Finance Lease Liability Payments Due Operating And Finance Lease Liability Payments Due Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] Employee Stock Purchase Plan Employee Stock [Member] Disaggregates of Total Net Product Revenues from External Customers by Product Revenue from External Customers by Products and Services [Table Text Block] Balance at Beginning of Period Balance at End of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Span of offering period Span of offering period, in years Span Of Offering Period Span of offering period. Income Statement Location Income Statement Location [Domain] Orphan Drug & General Business Credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Gains (losses) on Cash Flow Hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two State State and Local Jurisdiction [Member] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Not Probable Of Vesting Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Not Probable Of Vesting [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Not Probable Of Vesting Selling, general and administrative Selling, General and Administrative Expense CARES Act carryback claim Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim Foreign Currency Derivatives Foreign exchange contracts Foreign Exchange Contract [Member] Schedule of Lease Cost Lease, Cost [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other assets Other Assets, Noncurrent Plan Name Plan Name [Axis] Cash aggregate fair value Cash and Cash Equivalents, Fair Value Disclosure Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Shares, Non-vested units beginning balance (in shares) Shares, Non-vested units ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Maximum payroll deductions Maximum Payroll Deductions Maximum payroll deductions. Common stock, shares, issued to converting holders (in shares) Debt Conversion, Converted Instrument, Shares Issued Financing Finance Lease, Liability, Payment, Due [Abstract] Antidilutive Securities Antidilutive Securities [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Cost of sales Cost of Sales [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Axis] Stock compensation expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Other Other Intangible Assets [Member] Total liabilities Liabilities Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Reserve for cash discounts Allowances For Reserve For Cash Discounts [Member] Shares earned range Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Price in Active Markets For Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Inventory Increase (Decrease) in Inventories Tax Reserves Income Tax Rate Reconciliation Tax Reserves Income tax rate reconciliation tax reserves. Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Marketed by Company Sales Channel, Directly to Consumer [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Rest of world Rest Of World [Member] Rest of world. Asset Class Asset Class [Axis] Interest expense Finance Lease, Interest Expense Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] LOSS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Joint venture basis difference Deferred Tax Liabilities Related To Joint Venture Basis Difference Deferred tax liabilities related to joint venture basis difference. 0.599% Senior Subordinated Convertible Notes Due in August 2024 Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member] Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four. Weighted Average Exercise Price, Outstanding beginning balance (in dollars per share) Weighted Average Exercise Price, Outstanding ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares authorized (in shares) Common Stock, Shares Authorized Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Property, plant and equipment, gross Property, Plant and Equipment, Gross Federal Deferred Federal Income Tax Expense (Benefit) Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) Common Stock Issued, Employee Stock Trust Operating expenses Operating Expense [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Total ROU assets Operating And Finance Lease Right Of Use Asset Operating And Finance Lease Right Of Use Asset Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Contingent Payment Contingent Payment [Member] Contingent Payment Accrued royalties payable Accrued Royalties, Current Use of Estimates Use of Estimates, Policy [Policy Text Block] Income Tax Authority Income Tax Authority [Domain] Consolidated Entities [Axis] Consolidated Entities [Axis] Business acquisition contingent consideration potential cash payments upon achievement of sales milestone Business Acquisition Contingent Consideration Potential Cash Payments Upon Achievement Of Sales Milestone Business acquisition contingent consideration potential cash payments upon achievement of sales milestone. Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Compensation Related Costs [Table] Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Counterparty Name Counterparty Name [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Dutch NETHERLANDS Intra-entity transfer of assets Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount DEBT Long-term Debt [Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Accounting impact of NQDC Plan Change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Equity in the loss of BioMarin/Genzyme LLC Income (Loss) from Equity Method Investments Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Hedging Designation Hedging Designation [Axis] Schedule Of Interest Expenses [Table] Schedule Of Interest Expenses [Table] Schedule of interest expenses table. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Domain] Schedule Of Inventory Schedule of Inventory, Current [Table Text Block] Entity Entity [Domain] Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Derivatives Designated As Hedging Instruments Designated as Hedging Instrument [Member] Company Stock Held By NQDC Deferred Compensation, Share-based Payments [Member] GOODWILL AND INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] Property, plant and equipment, useful life, (in years) Property, Plant and Equipment, Useful Life Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Investment in convertible note Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block] Summary of operating loss and tax credit carryforwards. Other current assets Increase (Decrease) in Other Current Assets Net deferred tax assets Deferred Tax Assets, Net Aggregate Fair Value Debt Securities, Available-for-sale Unvested RSUs Restricted Stock [Member] Finished goods Inventory, Finished Goods, Net of Reserves Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Land Land [Member] Less: gain on the Company's common stock held by the NQDC Employee Stock Ownership Plan (ESOP), Gain (Loss) on Transactions in Deferred Shares Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Operating, Current Operating Lease, Liability, Current Customer Two Customer B Customer Two [Member] Customer 2 Financing leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Effect of Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Stock Option Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Company's contribution to match employees contribution Defined Contribution Plan, Employer Matching Contribution, Percent of Match 2025 Operating And Finance Lease Liability Payments Due Year Five Operating And Finance Lease Liability Payments Due Year Five Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Fair Value Carrying Amount of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Weighted Average Exercise Price, Options unvested (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price Share based compensation arrangement by share based payment award options nonvested weighted average exercise price. Accounts Receivable Balance Accounts Receivable [Member] Fair value of other current assets Other Assets Current Fair Value Disclosure Other assets current fair value disclosure. Average Remaining Life (in years) Finite-Lived Intangible Assets, Remaining Amortization Period Minority equity ownership Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Customer Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Land improvements Land Improvements [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Vimizim Product Four [Member] Product 4 [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. Debt issuance costs Debt Issuance Costs, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] March 2019 Base Restricted Stock Unit Awards With Market Conditions Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions [Member] Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Weighted Average Remaining Years, Options unvested at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term Share based compensation arrangement by share based payment award options nonvested weighted average remaining contractual term. Vehicles Vehicles [Member] Conversion of convertible notes, net Stock Issued During Period, Value, Conversion of Convertible Securities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-Marketable Equity Securities Securities Owned Not Readily Marketable, Policy [Policy Text Block] Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Sale of Stock Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Options to purchase shares of common stock, percentage Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Net change in unrealized holding gain (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 2023 Operating And Finance Lease Liability Payments Due Year Three Operating And Finance Lease Liability Payments Due Year Three Foreign Source Income Subject to U.S. Tax Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Section 162(m) limitation Income Tax Rate Reconciliation Section162 Limitation Income tax rate reconciliation section 162 limitation. Arrangements and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Retirement of treasury stock Stock Repurchased and Retired During Period, Value Debt instrument, aggregate principal amount Debt Instrument, Face Amount Building and improvements Building and Building Improvements [Member] Other current assets Other Assets, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Asset Class Asset Class [Domain] Equity: Equity [Abstract] Fair value of financial assets, Total Assets, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Deferred revenue Contract with Customer, Liability, Current Restricted Stock With Service Based Vesting Conditions Restricted Stock With Service Based Vesting Conditions [Member] Restricted stock with service based vesting conditions. Supplemental Balance Sheet Information [Line Items] Supplemental Balance Sheet Information [Line Items] Supplemental balance sheet information Weighted Average Exercise Price, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Customer Concentration Risk Customer Concentration Risk [Member] Derivative Contract Derivative Contract [Domain] Schedule of Future Amortization Expense of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Palynziq Product Seven [Member] Product 7 [Member] Number of operating segments Number of operating business segment Number of Operating Segments Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Shares, Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Inventory, Current [Table] Inventory, Current [Table] Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Accrued expenses, reserves, and prepaids Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Kuvan Product Three [Member] Product 3 [Member] Other Information Other Information Lease Liability [Abstract] Other Information Lease Liability Balance at beginning of period Balance at end of period Unrecognized Tax Benefits Counterparty Name Counterparty Name [Axis] Common stock, $0.001 par value: 500,000,000 shares authorized;    181,740,999 and 179,838,114 shares issued and outstanding, respectively Common Stock, Value, Issued Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Proceeds from Issuance of Secured Debt Proceeds from Issuance of Secured Debt 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Issuances under equity incentive plans, net of tax Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Stock issued during period value new issues net excess tax benefit tax deficiency. Noncurrent assets: Assets, Noncurrent [Abstract] Entity Current Reporting Status Entity Current Reporting Status Changes in the fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Intangible asset amortization and contingent consideration Intangible Asset Amortization And Contingent Consideration The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period. Concentration Risk And Geographic Information [Table] Concentration Risk And Geographic Information [Table] Concentration risk and geographic information. Accrued rebates payable Accrued Government And Other Rebates Accrued Government And Other Rebates Purchase of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale Net Income (Loss) Per Common Share Earnings Per Share, Policy [Policy Text Block] Number of tranches in offering period Number Of Tranches In Offering Period Number Of Tranches In Offering Period Accumulated Gain Loss from Other Accumulated Gain Loss From Other [Member] Accumulated gain (loss) from other. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] LICENSE AND COLLABORATION AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Present value of lease liabilities Operating Lease, Liability Total deferred tax liabilities Deferred Tax Liabilities, Net Firdapse Firdapse [Member] Firdapse Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent NATURE OF OPERATIONS AND BUSINESS RISKS Nature of Operations [Text Block] Foreign tax rate differential (1) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount The 2018 Credit Facility Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member] Senior unsecured revolving two thousand eighteen credit facility. Entity Address, City or Town Entity Address, City or Town Cash Flow, Financing Activities, Lessee [Abstract] Cash Flow, Financing Activities, Lessee [Abstract] Accrued compensation expense Employee-related Liabilities, Current Independent Director Independent Director [Member] Independent director. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Purchase of intangible assets Payments to Acquire Intangible Assets Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Maximum percentage of qualified compensation to be used for purchase Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Sarepta Therapeutics Sarepta Therapeutics [Member] Sarepta Therapeutics. BioMarin Retirement Savings Plan Biomarin Retirement Savings Plan [Member] BioMarin retirement savings plan. Product Product [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Other assets Increase (Decrease) in Other Noncurrent Assets Construction-in-progress Construction in Progress [Member] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Finance, Noncurrent Finance Lease, Liability, Noncurrent Brineura Product Six [Member] Product six. OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Leases [Abstract] Reclassification, tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Long-term Debt, Type Long-term Debt, Type [Axis] Total current assets Assets, Current Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Components of Net Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrealized foreign exchange loss (gain) Foreign Currency Transaction Gain (Loss), Unrealized Ceiling achievement level Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Disposal Group Name [Domain] Disposal Group Name [Domain] Maturity of derivatives Derivative, Remaining Maturity Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Goodwill and intangible assets. Net income (loss), diluted Net Income (Loss) Available to Common Stockholders, Diluted Entity Filer Category Entity Filer Category Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Product and Service Product and Service [Domain] Net change in unrealized holding gain (loss), net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Amounts Reclassified out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Company's contribution from employment commencement Defined Contribution Plan, Cost Geographic Concentration Risk Geographic Concentration Risk [Member] Financing leases Finance Lease, Weighted Average Discount Rate, Percent Income tax statute of limitations period Income Tax Statute Of Limitations Period Income tax statute of limitation period. Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Probable Of Vesting Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Probable Of Vesting [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Probable Of Vesting Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings per share line Items. Leasehold improvements Leasehold Improvements [Member] Net Product Revenue Revenue Benchmark [Member] Foreign exchange remeasurement of Euro denominated contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement. Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Debt instrument, interest rate, stated percentage, per annum Debt Instrument, Interest Rate, Stated Percentage Royalties on net product sales Royalty Rate Upper Limit Royalty rate upper limit. The Company's common stock held by the NQDC Share-based Payment Arrangement [Member] Research credit carry forward Federal R&D and orphan drug credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Shares, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Stock Option Share-based Payment Arrangement, Option [Member] Fair value of other non-current liabilities Other Liabilities Noncurrent Fair Value Disclosure Other liabilities noncurrent fair value disclosure. OPERATING EXPENSES: Costs and Expenses [Abstract] Sale of Stock Sale of Stock [Domain] State and local Deferred State and Local Income Tax Expense (Benefit) U.S. Source Income (Loss) from Continuing Operations before Income Taxes, Domestic Cash paid for interest, net of interest capitalized into fixed assets Interest Paid, Excluding Capitalized Interest, Operating Activities Common stock held by the NQDC Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Strategic investments fair value Equity Securities without Readily Determinable Fair Value, Amount 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Summary of Restricted Stock Unit Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Unrealized holding gain (loss) arising during the period, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 1.25% Senior Subordinated Convertible Notes Due in May 2027 1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member] 1.25% Senior Subordinated Convertible Notes Due in May 2027 Fair value of financial liabilities, Total Financial and Nonfinancial Liabilities, Fair Value Disclosure NET INCOME (LOSS) PER SHARE, DILUTED (in usd per share) Net loss per common share, diluted (in usd per share) Earnings Per Share, Diluted Schedule of Reconciliation of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Type of Arrangement and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Depreciation expense Depreciation 2024 Operating And Finance Lease Liability Payments Due Year Four Operating And Finance Lease Liability Payments Due Year Four Entity Address, Address Line One Entity Address, Address Line One Entity Emerging Growth Company Entity Emerging Growth Company Deferred income taxes Deferred income tax expense (benefit), total Deferred Income Tax Expense (Benefit) Derivative liability, fair value Derivative Liability, Fair Value, Gross Liability Repurchased royalty rights Repurchased Royalty Rights [Member] Repurchased royalty rights. Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Goodwill and intangible assets. Accumulated amortization Less: Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Maximum Maximum [Member] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Summary of Interest Expense on Debt Interest Income and Interest Expense Disclosure [Table Text Block] Short-term marketable securities maturity period Short Term Marketable Securities Maturity Period Short-term marketable securities maturity period. Aldurazyme Product One [Member] Product 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investments Investments [Domain] Accounts payable and accrued operating expenses Accounts Payable and Other Accrued Liabilities, Current Trading Symbol Trading Symbol Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Proceeds from exercises of awards under equity incentive plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Percentage of ceiling achievement Fair Value Inputs Revenue Multiple Ceiling Achievement Percentage Fair value inputs revenue multiple ceiling achievement percentage. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Manufacturing and laboratory equipment Equipment [Member] Non-U.S. Source Income (Loss) from Continuing Operations before Income Taxes, Foreign Acquired intellectual property Acquired Intellectual Property [Member] Acquired intellectual property. Entity Shell Company Entity Shell Company Fair Value, Measurements, Recurring Fair Value, Recurring [Member] 2022 Finance Lease, Liability, to be Paid, Year Two Segment Information Segment Reporting, Policy [Policy Text Block] Entity Public Float Entity Public Float Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Stock Treasury Stock [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Weighted Average Grant Date Fair Value, Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Inventory reserves, net of stock-based compensation Inventory Write-down Supplemental Cash Flow Information Supplemental Cash Flow Lease Information [Abstract] Supplemental Cash Flow Lease Information Leases Lessee, Leases [Policy Text Block] Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Other Current Assets Other Current Assets [Member] Short-term convertible debt, net Short-term convertible debt, net Convertible Debt, Current Third Party Third Party [Member] Third party. DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Schedule of Available-for-sale Securities [Line Items] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items] Schedule of cash, cash equivalents and available-for-sale securities. Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Proceeds from convertible senior subordinated note offering, net Proceeds from Convertible Debt Weighted average remaining lease term (in years): Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Available-for-sale debt securities: OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract] LOSS FROM OPERATIONS Operating Income (Loss) Impairment Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Medivation Medivation [Member] Medivation. Variable Rate Variable Rate [Axis] Employer contribution of maximum percentage over employee's annual compensation Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Long-term investments Long-term Marketable Securities Debt Securities, Available-for-sale, Noncurrent Merck Serono Merck Serono [Member] Merck Serono. Repurchase of common stock Payments for Repurchase of Common Stock Vesting period, years Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Furniture and equipment Furniture and Fixtures [Member] Depreciation capitalized into inventory Depreciation Expense Capitalized Into Inventory Depreciation expense capitalized into inventory during the reporting period. Entity Address, State or Province Entity Address, State or Province Shares, Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Federal statutory income tax benefit Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Accumulated deficit Retained Earnings (Accumulated Deficit) Operating Operating Lease, Right-of-Use Asset Changes in the fair value of contingent consideration Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration Income tax rate reconciliation changes in fair value of contingent consideration. Debt Instrument, unamortized discount Unamortized discount Debt Instrument, Unamortized Discount Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Summary of Senior Subordinated Convertible Obligations Convertible Debt [Table Text Block] Cash paid for income taxes Income Taxes Paid 2021 Finance Lease, Liability, to be Paid, Year One Contingent consideration Contingent Consideration [Member] Contingent consideration. Customer Customer [Axis] Credit Concentration Risk Credit Concentration Risk [Member] Fair Value by Liability Class Fair Value by Liability Class [Domain] Annual shareholder return multiplier Annual Shareholder Return Multiplier On Absolute Basis, Percentage Annual Shareholder Return Multiplier On Absolute Basis, Percentage Income Taxes Income Tax, Policy [Policy Text Block] Hedging Designation Hedging Designation [Domain] Total lease costs Lease, Cost Shares, Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Other Payments for (Proceeds from) Other Investing Activities Liability Class Liability Class [Axis] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Asset retirement obligation Asset Retirement Obligation Marketed by Genzyme Sales Channel, Through Intermediary [Member] Shares, Expired and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Total revenues Net product revenues Revenue from Contract with Customer, Excluding Assessed Tax Total Operating And Finance Lease Liabilities Payments Due [Abstract] Operating And Finance Lease Liabilities Payments Due Inventory [Line Items] Inventory [Line Items] Closing price of common stock (in dollars per share) Share Price Strategic Investment Strategic Investment [Member] Strategic investment. Business Acquisition Business Acquisition [Axis] Geographical Geographical [Domain] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In Measurement Of Lease Liabilities Conversion rate of shares Debt Instrument, Convertible, Conversion Ratio Long-term marketable securities maturity period Long Term Marketable Securities Maturity Period Long-term marketable securities maturity period. Foreign Deferred Foreign Income Tax Expense (Benefit) Schedule Of Interest Expenses [Line Items] Schedule Of Interest Expenses [Line Items] Schedule of interest expenses. Entity Voluntary Filers Entity Voluntary Filers Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Other Other Comprehensive Income Loss Other Net Of Tax Other comprehensive income loss other net of tax U.S. Government Agency Securities US Government Agencies Debt Securities [Member] Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Foreign Foreign Tax Authority [Member] Restricted Investments Restricted Investments [Member] Restricted investments. Other income, net Other income Other Operating Income (Expense), Net Operating Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Weighted Average Remaining Years, Exercisable at December 31, 2020 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Selling, general and administrative Selling, General and Administrative Expenses [Member] Increase (decrease) in goodwill Goodwill, Period Increase (Decrease) Summary of Forward Foreign Currency Exchange Contracts Outstanding Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Earnings Per Share [Table] Earnings Per Share [Table] Earnings per share. Computation of Basic and Diluted Earnings per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Contingent Consideration Type Contingent Consideration Type [Domain] Research and Development Research and Development Expense, Policy [Policy Text Block] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Outstanding amount Long-term Line of Credit SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Effect of dilutive securities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Royalty and Other Revenues Royalty And Other [Member] Royalty and other. Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Short-term investments Short-term Marketable Securities Debt Securities, Available-for-sale, Current 1.50% Senior Subordinated Convertible Notes Due in October 2020 One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member] One point five zero percent senior subordinated convertible notes due in October twenty twenty. Derivative Instrument Derivative Instrument [Axis] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Other Long-Term Liabilities Other Noncurrent Liabilities [Member] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Geographical Geographical [Axis] Valuation allowance/deferred benefit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Total lease payments Operating And Finance Lease Liability Undiscounted Excess Amount Operating And Finance Lease Liability Undiscounted Excess Amount Lease Classification Assets and Liabilities, Lessee [Abstract] Cash flow hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Foreign and Other Foreign Government And Other Debt Securities [Member] Foreign government and other debt securities. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Customer One Customer A Customer One [Member] Customer 1 Net proceeds from offering debt Proceeds from Debt, Net of Issuance Costs Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash Cash [Member] Federal Current Federal Tax Expense (Benefit) Maturity of Lease Liabilities Maturity Of Lease Liabilities [Abstract] Maturity Of Lease Liabilities Notional amount Derivative, Notional Amount Deferred revenue Deferred Tax Liabilities, Tax Deferred Income Average closing price of common stock, trailing period Average Closing Price Trailing Period Average closing price trailing period. (Deletions) Additions for tax positions of prior years Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions Unrecognized tax benefits increases (decreases) resulting from prior period tax positions. Financing leases Finance Lease, Interest Payment on Liability Forward foreign currency exchange contracts Derivative Liability, Current Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Net Balance Finite-Lived Intangible Assets, Net Weighted-average fair value per option granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Total long-lived assets Long-Lived Assets Unrealized holding gain (loss) arising during the period, net    of tax impact of $(227), $(1,640) and $(413), respectively. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized holding gain (loss) arising during the period, tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Schedule of Maturities of Finance Lease Liabilities Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Interest expense Total interest expense on convertible debt Interest Expense Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Depreciation and amortization Depreciation, Depletion and Amortization Schedule of Components of Provision for (Benefit From) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Product and Service Product and Service [Axis] Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract] Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract] Right Of Use Assets Obtained In Exchange For Lease Obligations Investment Type Investment Type [Axis] Other Assets Other Noncurrent Assets [Member] Unrecognized compensation cost expected to recognized over weighted average period, in years Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2025 Finance Lease, Liability, to be Paid, Year Five Initial equity grant value Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture EU and Other Countries Non-US [Member] Position Position [Domain] Net income (loss), basic Net Income (Loss) Available to Common Stockholders, Basic Unamortized deferred offering costs Deferred Offering Costs Completed Programs Completed Project [Member] Completed Project. Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Raw materials Inventory, Raw Materials, Net of Reserves Debt Instrument Debt Instrument [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Common stock issuable under the 2020 Notes Convertible Senior Notes Due 2020 Convertible Senior Notes Due Twenty Twenty [Member] Convertible senior notes due twenty twenty. Contingent Consideration by Type Contingent Consideration by Type [Axis] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block] Schedule of cash, cash equivalents and available-for-sale securities. License Agreement And Settlement Agreement License Agreement And Settlement Agreement [Member] License agreement and settlement agreement. Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Fair value of other non-current assets Other Assets Noncurrent Fair Value Disclosure Other assets noncurrent fair value disclosure. 2022 Operating And Finance Lease Liability Payments Due Year Two Operating And Finance Lease Liability Payments Due Year Two Inventory Deferred Tax Assets, Inventory Total fair value of fixed rate convertible debt Convertible Debt, Fair Value Disclosures State and local taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Research and development Research and Development Expense Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Federal Domestic Tax Authority [Member] Concentration Risk Type Concentration Risk Type [Axis] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Royalties on net product sales Royalty Rate Lower Limit Royalty rate lower limit. Add: Interest on convertible notes Interest on Convertible Debt, Net of Tax Coupon interest Interest Expense, Debt, Excluding Amortization Technology Transfer Technology Transfer [Member] Technology Transfer Award vesting service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Restricted Stock Unit Awards with non-Revenue based Performance Conditions Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions Gain on sale of nonfinancial assets Gain (Loss) on Disposition of Assets Concentration Risk And Geographic Information [Line Items] Concentration Risk And Geographic Information [Line Items] Concentration risk and geographic information. Operating, Noncurrent Operating Lease, Liability, Noncurrent 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Issuances under equity incentive plans, net of tax (in shares) Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares Stock issued during period value new issues net excess tax benefit tax deficiency, shares. Current assets: Assets, Current [Abstract] Interest income Investment Income, Interest Operating And Finance Lease Liability Operating And Finance Lease Liability Operating And Finance Lease Liability Operating And Finance Lease Liability COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2023 Finance Lease, Liability, to be Paid, Year Three Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule Of Property, Plant And Equipment Estimated Useful Lives Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block] Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Payments SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Legal Entity Legal Entity [Axis] City Area Code City Area Code Cash used in operating activities: Cash Flow, Operating Activities, Lessee [Abstract] Increase (decrease) in accounts payable and accrued liabilities related to fixed assets Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Fixed Assets Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period. Income Tax Authority Income Tax Authority [Axis] Document Period End Date Document Period End Date Value added taxes payable Sales and Excise Tax Payable, Current Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Disaggregates of Total Net Product Revenues Based on Patient Location Disaggregation of Revenue [Table Text Block] Milestone payments received Milestone Payments Received Milestone payments received. Convertible notes discount Deferred Tax Liability Related To Convertible Notes Deferred tax liability related to convertible notes. Stock-based compensation expense capitalized to inventory Share-based Payment Arrangement, Amount Capitalized Long-term Debt, Type Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Repurchase of common stock Stock Repurchased During Period, Value Principal repayments of financing leases Proceeds from (Payments for) Other Financing Activities Cover [Abstract] Base Rate Base Rate [Member] NQDC Plan assets Nonqualified Deferred Compensation Plan Assets [Member] Nonqualified deferred compensation plan assets. Investment in equity Collaborative Arrangement, Minority Equity Investment in License Collaborative Arrangement, Minority Equity Investment in License Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of Benefit from Income Taxes Based on Loss Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Axis] Discount rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Discount Rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Discount Rate Amortization of premium on investments (accretion of discount) Accretion (Amortization) of Discounts and Premiums, Investments A&R Kuvan Agreement A And R Kuvan Agreement [Member] A&R Kuvan agreement. Financial assets remeasured Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Lease Cost Lease, Cost [Abstract] Less: reclassifications to net income (loss), net of tax impact of    $(127), $0 and $0, respectively. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Total operating expenses Operating expenses as reported Costs and Expenses Equity Components Equity Components [Axis] Debt Instrument, Name Debt Instrument, Name [Domain] Minimum Minimum [Member] Balance Sheet Location Balance Sheet Location [Domain] Europe Europe [Member] Asset-backed Securities Asset-backed Securities [Member] ROU assets Deferred Tax Liabilities, Right-Of-Use Assets Deferred Tax Liabilities, Right-Of-Use Assets Accrued income taxes Accrued Income Taxes Gain on sale of nonfinancial assets Gain (loss) on disposition of other assets Gain (Loss) on Disposition of Other Assets Entity Interactive Data Current Entity Interactive Data Current United States UNITED STATES Weighted Average Exercise Price, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price REVENUES: Revenues [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Purchase commitment for the next five years Purchase Obligation Employee contribution of their current compensation Employee Contribution Of Their Current Compensation Employee contribution of their current compensation Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Assets: Lease Right Of Use Assets [Abstract] Lease Right Of Use Assets Common stock potentially issuable for ESPP purchases Common Stock Issuable To Employee Stock Purchase Plan [Member] Common stock issuable for employee Stock Purchase Plan [Member] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Foreign Current Foreign Tax Expense (Benefit) Shares, Options unvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones. Number of reportable segment Number of Reportable Segments Non-cash changes in the fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Finite-Lived Intangible Asset Finite-Lived Intangible Assets, Amortization Not Commenced, Net Finite-Lived Intangible Assets, Amortization Not Commenced, Net Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Provision for Current Period Sales SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Research and development Research and Development Expense [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Goodwill impairment charge Goodwill, Impairment Loss Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Other Deferred Tax Assets, Other LEASES Lessee Operating And Finance Leases Other Information Table [Text Block] Lessee Operating And Finance Leases Other Information Table Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Restricted Stock Unit Awards with Market Conditions Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Cash Cash Document Transition Report Document Transition Report Title of Individual Title of Individual [Axis] Employee Stock Purchase Plan Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Provision for (benefit from) deferred income taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Net tax benefit from stock options exercised Share-based Payment Arrangement, Exercise of Option, Tax Benefit Naglazyme Product Two [Member] Product 2 [Member] Derivative asset, fair value Derivative Asset, Fair Value, Gross Asset Level 2 Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Consideration received Disposal Group, Including Discontinued Operation, Consideration Sell Short [Member] Benefit from income taxes Current Income Tax Expense (Benefit), Continuing Operations [Abstract] BASIS OF PRESENTATION Basis of Accounting [Text Block] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Line Items] Schedule of share based compensation arrangements by share based payment award equity instruments other than options restricted stock units. Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Debt instrument percentage of face value Debt Instrument Percentage Of Face Value Debt instrument percentage of face value. RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Debt instrument, convertible, conversion price, per share (in dollars per share) Debt Instrument, Convertible, Conversion Price 2017 Equity Incentive Plan Two Thousand Seventeen Equity Incentive Plan [Member] Two thousand seventeen equity incentive plan. NET INCOME (LOSS) PER SHARE, BASIC (in usd per share) Net loss per common share, basic (in usd per share) Earnings Per Share, Basic Unrecognized tax benefits that would affect the effective tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Percentage of, number of shares may earned Share Based Compensation Arrangement By Share Based Payment Award Performance Percentage Share based compensation arrangement by share based payment award performance percentage. Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Operating leases Operating Lease, Weighted Average Remaining Lease Term Inventory valuation reserves Inventory Valuation Reserves Aggregate Intrinsic Value, Exercisable at December 31, 2020 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Total stock-based compensation expense Share-based Payment Arrangement, Expense Gain (Loss) on Sale of Available-for-Sale Debt Securities Unrealized Gains (Losses) on Available-for-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Balance Sheet Location Balance Sheet Location [Axis] Pegvaliase Agreement Pegvaliase Agreement [Member] Pegvaliase agreement. Disposal Group Name [Axis] Disposal Group Name [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Document Annual Report Document Annual Report Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. 2024 Finance Lease, Liability, to be Paid, Year Four OTHER EMPLOYEE BENEFITS Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block] Position Position [Axis] Shares issued under the employee stock purchase plan (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Weighted-average fair value per RSU granted (in dollars per share) Weighted Average Grant Date Fair Value, Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Property, plant and equipment, estimated useful life Property, Plant and Equipment, Estimated Useful Lives CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Forward contracts Foreign Exchange Forward [Member] Convertible Debt Debt, Policy [Policy Text Block] Common stock issuable under the 2024 Notes Convertible Senior Notes Due Two Thousand Twenty Four [Member] Pre-Launch Valoctocogene Roxaparvovec Pre-Launch Valoctocogene Roxaparvovec [Member] Pre-Launch Valoctocogene Roxaparvovec [Member] Accounts receivable, net Increase (Decrease) in Accounts Receivable Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Type Concentration Risk Type [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] Total Net Product Revenue Concentrations Attributed to Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Operating Operating Lease, Cost Deferred Tax Liabilities, Gross [Abstract] Deferred Tax Liabilities, Gross [Abstract] Undistributed earnings of foreign subsidiaries Undistributed Earnings of Foreign Subsidiaries Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Current income tax expense, total Current Income Tax Expense (Benefit) Financing leases Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other Other Noncash Income (Expense) Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Equity Component Equity Component [Domain] NQDC Plan liability Nonqualified Deferred Compensation Plan Liability [Member] Nonqualified deferred compensation plan liability. Net change in unrealized holding gain (loss), net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Accrued rebates Accrued Rebates [Member] Accrued rebates. NET INCOME (LOSS) Net Income (Loss) NET INCOME (LOSS) Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] LIBOR Rate London Interbank Offered Rate (LIBOR) [Member] INVENTORY Inventory Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Present value of lease liabilities Finance Lease, Liability Compensation Related Costs [Abstract] Compensation Related Costs [Abstract] Measurement period Debt Instrument, Convertible, Weighted Average Measurement Period Debt Instrument, Convertible, Weighted Average Measurement Period Schedule of Other Information Lessee Operating And Finance Leases Other Information Table [Table Text Block] Lessee Operating And Finance Leases Other Information Table Less: gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Restricted Stock Unit Awards with Performance-Based Vesting Conditions Two Thousand Nineteen Base Restricted Stock Unit Awards With Revenue Based Vesting Conditions [Member] Two thousand nineteen base restricted stock unit awards with revenue based vesting conditions. Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule Of Lessee Lease Assets And Liabilities Schedule Of Lessee Lease Assets And Liabilities Table [Table Text Block] Schedule Of Lessee Lease Assets And Liabilities Table Total convertible debt, net Convertible Debt Thereafter Finance Lease, Liability, to be Paid, after Year Five The total intrinsic value of restricted stock vested and released Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Shares, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures SUPPLEMENTAL CASH FLOW DISCLOSURES: Supplemental Cash Flow Information [Abstract] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Inventory [Domain] Inventory [Domain] Convertible Senior Notes Convertible Debt [Member] Schedule of Property Plant and Equipment Net Property, Plant and Equipment [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Finite-lived intangible assets Finite-Lived Intangible Assets, Gross Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Conversion of convertible notes, net (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Money Market Instruments Money Market Funds [Member] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Repayments of convertible debt Repayments of convertible debt Repayments of Convertible Debt Financing Finance Lease, Right-of-Use Asset, after Accumulated Amortization Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Debt instrument interest rate percentage Debt Instrument, Basis Spread on Variable Rate Plan Name Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Benefit from income taxes Benefit from income taxes Income Tax Expense (Benefit) Beginning of period End of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property, Plant And Equipment Property, Plant and Equipment, Policy [Policy Text Block] Relationship to Entity Title of Individual [Domain] Finance, Current Finance Lease, Liability, Current Local Phone Number Local Phone Number Business acquisition, cash paid Payments to Acquire Businesses, Gross Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Royalties receivable percentage of net sales Royalties Receivable Percentage Of Net Sales Royalties receivable percentage of net sales. Total intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Derivative [Line Items] Derivative [Line Items] Liabilities Measured at Fair Value Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Unrealized Gains (Losses) on Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Carrying value of equity component Convertible notes Long-term Debt, Gross Liabilities: Leases Liabilities [Abstract] Leases Liabilities Exclusive Licensing Agreement For Tralesinidase Alfa Exclusive Licensing Agreement For Tralesinidase Alfa [Member] Exclusive Licensing Agreement For Tralesinidase Alfa Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Reclassifications to net loss, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Senior Subordinated Notes Senior Subordinated Notes [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Amortization of debt issuance costs Amortization of Debt Issuance Costs Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Accumulated Deficit Retained Earnings [Member] Less: disposition Goodwill, Written off Related to Sale of Business Unit Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Years, Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Equity Award Award Type [Domain] Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Corporate Debt Securities Corporate Debt Securities [Member] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule of cash, cash equivalents and available-for-sale securities. Weighted Average Exercise Price, Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Percentage of commitment fees payable on undrawn amount Line of Credit Facility, Unused Capacity, Commitment Fee Percentage NET INCOME (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Office Furniture and Equipment Office Equipment [Member] FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table] Schedule of share based compensation arrangements by share based payment award, equity instruments, other than options, restricted stock units. Income Tax Contingency [Table] Income Tax Contingency [Table] Customer C Customer Three [Member] Customer 3 New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 12 bmrn-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 bmrn-20201231_g1.jpg begin 644 bmrn-20201231_g1.jpg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�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�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aG<0#W^BBB@ HHHH **** "BLCQ=INJ:UX6U:PT/63X=UFYM9(;/5 MUMDN39S,I"3>4_RR;3AMK<'PS\ _#'@#PG\(?VE[#XJZMJ&O^!O#WQ$NI M=2O_ !!J$LEQ?""&T,9N6C*FX9W5!Y1!61B%V'(% 'W[17YU?#>37/$'[(7Q M%N[;P]-X+\(_%GQ5;Z3X+\*0JL(L=-OYH+1W2-1MA21&GFVJ I^9QD2!CZG^ MU'\+?"OPM\;?#GXFV.DIH;P^,]*?6?%5G/+<:LD.TVD-C!&[ )9RB4),J2*% M0'$,K-E0#["HKXJTGP]?_#?_ (**W.K>)/&6J>*3>?#S5=7=[X)'!IUN-2B$ M=M;0H J)'%&@)Y:1P[L??$.;X:?#_P#9#\#>+?B%X+7QQ\2?&,%_=^&_ M#-X)+R2ZU+6)C=.RVIRGF(9X@9?+\Q<(BG(_&^M7D<)B0@$R$@ _2 MRBOC7XP_!KP+\5OVUO /A2'P;H%H^CV(USC S]E4 %%%% !1110 4444 %%?&G[='@W5O^%D? ?Q5/XNU1]' M3XE>&].M?"T.R*Q21[EI);F7 W32GRHE3<=L8\S:,R$CEOVA+/PIJG[6GA#P M/\*/#R7/QMN/$-EXJ\4^+ED>:XT/38502)).Y9HXY82B?9E*QE9%4K^]7(!] MZ45\T>'_ (:Z!\?/B1\=;WQ1I!UG0CJNF>&[>TN+J6&*Y33H%N&1Q&1NB^U7 M#=0U;]E+X^>#[+Q=JG@E_!^O>(+[5O#_AU4CM(8C;-> M0:98W!&Y+'7(VFVUA;D,I#!\7=T5((*E-P.1D><_ _5M#N_C%\2O$O[/WAZW\.?"3 MP/X-O-"N-8L4/D>(]83]]$^XY-RT(!_?NS/B3[VV89 /T0HK\[/V;=#OM/\ M&'PIL?!.J_\ "*ZWX^^#[ZKKVN6]O'%X]1N(W^6XG62YG&^3)/F," M2!BN3T#08_#W[-'QL\'R:]K6L7,OQR;0;5]4G^U3Z]-NL(TM[^8EZ3XZO_/\-V W:9HRRI%)'!8O MA=\!4[\^7#AWD'E(,%OIV@ HHHH **** "BBL7QGH^J>(/"NIZ=HNN2>&M5N MH&BM]7AMTN'M&/\ RT6.3Y6([!N* -JBOS[^ NA_#?PE^S?\?(?BW?7FO^!O M"_Q6UB6[FUV^EFFU%[66W$'VG:R_:W>1(R8W!61R,J>,5?AM9^(=;_8_UFQN M] ?PGX>^+/CV"U\*^$XP(TTO0[ZZA,JJ@ $:-"EY+L0!<.74?/B@#]#J*^0? MVCOAKX8^%?Q>^&/Q(L]+70I-0\<62ZSXHLIY;G5IY)H7M(+';(PV6# H)%1\ M)L7; V2R\_X;TV\^#_\ P4!\;:QXF\7:KXN/_"J)M>N;G4-B1VL2ZJP%O;1( M L421PI\HR6HK\XOBUI/P[^'?[)/PXE\:^"HO'7QE\6Z'$-3UWQ)X:^'_Q;EC\4 MR^'O@5J6L7/]H/YR'6U:""2[#D_--&N_;,,.-S,""QH _02BOSG\>6/BOQ9X M)_8P^(WB7QIK.H/J7B;PC;_V"Y5+0RRVTDLU[-@;IIY#'&59CA T@4?O":M_ M%CP?XR^#_P 5H_%%[X8DN?$>M?)]*^($-[;;I=&NC%;C1B/,^T[0A=##Y M?DD N&W*N0#]#:*** "BBB@ HHHH ***^-OVR/!VJQ?'/]G_ ,3W7BW5+K2Y M/B'I=E9^&5V1V%L?)G:2=@!NEF)0!78_(K.JCYV) /LFBO@OXN6'A;5?VQ_! MO@SX/: C?%*'Q3!XP\<^-5D>>?3M/6(1RV;W$C,ZI-$R(+96$2@H F7ROJ_A M7X7Z!\??$WQRU7Q1HL>OZ1<^*;32[/3;RZEAMKM=(@C").(_]9"+U[MC&ZNA M/)1L"@#Z=HK\Y-2\*W^N_L/?&OPY9>,]8\,KX%U+Q-%K6@Z.B1VI98VGBTZV MF.6_L]!(H "QM(A962,$I7L/@G3[;Q_XH^ N@7IE32?#?PPDUN]ECN'MVCDO M+:WL8&65"K1MY7]H8=6!&20010!]=45^<7PCURP/B;XW>-O@)X?B\(?!SP?\ M/KK0;.[L(C'%X@UFV5YHKP?Q3-&FY?.D^%8[9;6VO;*/S([R8VZ (D=T\," MNH&'P5.XCBVD/$-I:A89?L\2_PHDD MLF%' W;0 !B@#Z3HHHH **** "BBB@ HHHH **** "BBB@#R3Q9^RA\+/''A MWQ5H6M>&&O-*\4ZNNO:Q;KJ5W$+N]"JHE)24%1A%^12%X!VYK5TC]G_P9H]C MIEFL.M:C;:9J-OJUE'K/B/4M1%O,N"%(.5! M&OXJ^"_@[QIXHD\1ZQI+76M2:+<^'6NTO)XF^P7!!FB 1U +$#YP-X[,*[:B M@#R7QG^RK\,_'NJ^$M3U70[V/4?"=H+'0[K2]+OV>? WCSPYHNBZ]8ZGJ,.C"9;*^?7K]=1C66-HYD-ZLXN'21&*NCR% M7 7<#M7'I%% '%^)/@UX,\6>%?#WAG4="A;0?#]S9WFEV%O));Q6DEH1]FV" M-E^5-HPA^7 P016+JG[-/PWUCQY+XQN_#GF:U/=P7]PJW]REEZ7XIU6S%Y(IROFQQ7*QLH).$*[0"1C!Q6]JWP#\!ZYX3U MCPU>Z"L^D:MJLFN72?:IQ+]O>;SC<1S!Q)$X?!4QLNP !=H %>@T4 <-X;^" M?@WPCX'UOPCINDNFB:X]U)JJW%[<7%S?R7"[9Y)[F21II)&7"[V'P19ZUHMA;K(L6EMXEU.YL$WGG^&K"2TCO;N2_O+BZNYKRZN[A\;I9KB= MWEE<@*-SL2 J@< "NJHH **** "BBB@ HHHH *\@\6?LD_"GQOX9\3>'M:\+ M-=Z/XDUP^(]6M5U.\B%UJ!4*9BR3!E&%7Y%(3(!VYYKU^B@#SO2?@'X.TFUT MFW\K6M2BTG4XM8L5UKQ'J.I&WNHXGBC93L>&+,6&C7VEZY?Z=+8PX(VQM;3QX."06ZD<$XKUF MB@#S7QG^SMX%^(7A_1M'\0V&I:C#H\4UO9WC:[?I?K%,GESQ/>+.+B1)%P'1 MY&5]J[@=JXV/%'P=\'>,= \-Z'JFAPR:1X;OK/4=)L[>22WCM)[7_CV*B)E^ M5.R'*X&"#7944 T[]_+%Y%];DF&7Y&7=M+'Y6RISR#7$:=^R?\ #;1?'^N>-=+T_7-(\2ZY M>K?ZI=Z9XIU6U6]F5RZ^;%':#YNCWVK2:]*HO)UG74'G-PUS'.)!+%)YA)#(ZE1\JX7BK.@_!#P7X;^' MNM^";#1V7P]KGVPZK'/>7$]Q?O=!A<23W,DC322.&(\QG+ !0" J@=U10!Y[ MIGP"\":/ILMC9Z(T%M)X:@\'E5OK@LNDPK(L5NK&3&U\%V6L:3IL, MHT4 >>?#?]G_ ,!?"/6+W5/"NA-IU[=6RV6Z6]N+E;:V61Y5MK9)I'6V@#R. MWE0A$SCY?E7$,G[./PZF\-^+- D\-QR:7XIUF7Q#JL374Y:749"A:YCDW[X9 M 8HRIB*;"H*[3S7I-% '+?#OX8^&_A3HMSI?AFP>RM[N\EU"[EN+J:[N;NYD M(,DT\\SO++(<*-SLQPJKG"@#J:** "BBB@ HHHH **** /&O%G['_P (_''A M'6?"^M>%&O-"UCQ'-XLO[1=4O(A/JDH(DG+),& .X_NP1&#@A00*Z72_@7X2 MTQM%9TUK5I-&U,ZQI\FN^(M1U-[>[,$EOYBM9]F^T;"1YWE[\G=NW< MU>\8? 7P+X\\1:WKNN:(UYJNM>')/"5_<+>W$1FTIY&D>WPDBA06=CO4!^<; ML<5Z!10!Y1XX_9;^&_Q$\<:'XQUC2-0C\3Z'8_V;IFJ:3KVH:9+9V_[P%(S: MSQ[I5MI) JYXW_9S\!?$?1=*TSQ'IE_J<6FV26LJ!) MH)KI)A-/'(H&])7=7P"P)%>ET4 ?QU'X?(\13WW]JNQO[ MDVGVWR!!]J%F9/LZS^6-OFB,/RQW9))]+HH **** "BBB@ HHHH *Y?QM\,_ M#?Q$NO#=SXATW^T)O#NJ1ZUI;>?+%]GO(U94EPC#=@.WRME3GD5U%% 'C_A_ M]DWX:^$O&^L>+M#T_7-&U[6M1_M;4YM/\5:K!%?7/F-)NGA2Z$4B[G?Y&4IA MB-N"16UJG[//P_UCP.GA*ZT G18]7;7X?*O;B*Z@U%KIKHW<5TD@GBE\YW8. MC@@,5&%.VO1J* ."T_X%^!],^&.L?#ZWT3'A76([I-2M7NYWFO3<[C1]S9D9R_\ M<"HE^ /@1=+UO3UT-A:ZSH%OX6O5%[<;I-,@25(K=6\S<@" MSRY9"K-NRQ) (]"HH \Q^%O[-W@/X+V*Z?X2LM7L=(2VDM$T>Z\1:E?:?''( MV]PMI<7$D*DMD[@@/S-S\QSA3?L9_!^X\*Z]X;F\*2S:-K=O;65Y;RZQ?.1: MV\IF@MH7,^Z"!)"6$,12/_9Q7M=% 'E.G?LP?#W3?!MQX36QUF\\/2);)%8Z MEXEU.]6S^SG-NUH9KEVM6C(!5H"C#:O/RC'9> /AWX?^%_AU=#\-6!L-/$\U MT_F3R7$TTTKF2666:5FDED9F)+NS,?6NDHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BOA;4/^"//P9U*_N;N3Q-X\$D\K2L/[2M&Y8DGEK4L>O4DGU)J#_AS;\%_ M^AG\>?\ @PLO_D2OH/JN5_\ 05+_ ,%__;F7-/\ E_$^\**^#_\ AS;\%_\ MH9_'G_@PLO\ Y$H_X"_!WQ3^!-Q\-[;Q=<366EZI;^*[/6 US''YFQXH4! M5=H/SYX..",D>:?M.?LBP?!O_@GQXY^&OPQLO%'C&:\U.TU"*SD4ZA?2.;NV M\P(D,:_*JQ;L*G&&8]2:\I^'_P (O#4WQ\^$VH_ ;]GWXJ_![4]+U^.Z\0ZY MXRL[NTL9=("D7,&Z>YE#.ZG:%&"6,A;5V,F#;RD. MF!N^\*Y_X^?M9>'?A+^SKKGQ<\+-I?Q)TG39H(%32-8C\B9I+B.%@+B-95!4 MR9(P>F.,YKXLO_@?XZ;P%XLU/4OAQKWB?PWI/Q]U/Q/JO@[["ZW&MZ28X52> M"!P/M29SA!E9,D= Q&%\4O@IXL\:?!O]HWQ-X!^#GB3P!X0\4GP_;Z+X#;1F MM]0N;BVNHC<70TZ$-Y*@;ONC##+^M8C/I+XG?\%*-/\ A_\ LS_#OXJVO@:3 M6-1\774]L?#1U0P/9?9Q*+HM+Y#%O+>,*1Y:\/DXQ@_1DG[07@/0/"OA?5_& M/B[P[X(FU_3H=1M[/7-9M[9F5XU9@AE9-X4N 6 ].F:_-GXF?LN_$>Z^(7Q_ MTK_A%];U'P=X5LM;U3P4L&F3RK<76L&W:2"T8#$H2,2J53+*VX-UX]#_ &C/ M"OBOQ9:Z7X)N_@/J.N/-\/+*VT/Q5HOA*QOK]=1%LZM;7M]>JRV5NC$_(B+. M&^9)%S@@'WKXD^-OP[\&WR66O^/O#&AWCVR7JV^I:S;6\C6[OL28*[@E&;Y0 MW0G@'-?$'X;7E[HFB_!:PM%D\2Z'(;:TU:*] M5?*/G1[5N$C:0A3\P!W 8P:XZ]^ GBOQ)H::-K'P^UV^TJ^_:>FU:]M+C2)S M'+HTBHCW;@I_QZLI8&7[F,\T ?I5X)^(WA3XEZ;-J/A#Q/HWBK3X9C;RW6B: MA%>11R!0Q1GC9@&PRG!.<,#WKYO\5_MB?$U_C9\1OA]\.O@*WQ$7P.UD-0U% M?%UMIQ/VFW\Z/$,T.23B1<(S?$_ =\O MAZ31Q:Z:;339W6RV,3-:K)$]XY4INDG&X;\!GX [5Q_A# MP=XR^#_[/?[0NEZ/\%X_%6FCXKWLVE^$M:\./=VLVD&:W"W%K9'9]J14C!C" M,%RH8'"F@#[;L_CS\,]1\*ZAXGM/B)X3NO#6GRI!>:S#K=L]G;2,0%228/L1 MB64 $@G7*17:^<#:Z= D$QC51($(9QDDU];?%S]EOPM=?M6?L\Z/IOPLL)_ACIEGKKZE:VVAJ^DPS-; M)Y)N0$\O<[HN/,Y9E'4T ?4ME\9? &I:IH>F6?CGPW=:EKL'VK2;.'5[=YM0 MA^;]Y;H'S*G[M_F0$?(WH:3_ (71\/O^$U_X0[_A._#7_"7>9Y/]@?VO;_;_ M #-N[9]GW^9NV_-C;G'-?FSX*_9AU3PG\)/A#K&F_"W4=/\ &]C\;[>XN[Q- M"E%_;Z.DTQ#N2F]+0!(FYQ'D@]6)+/B5X-\:_$7XH:/JA_9_UGPCXG\/?$JU MO=2U#PYX-L[?3+C35O6*W7VU4:\O;ABP:1XG6':-YC!&X@'Z8W'Q8\$6GC:+ MP;/XQ\/P^+Y<>7X?DU2!=0?*;QBW+^8G/2G:]\4O!?A?Q1IOAK6O%V M@Z1XCU/9]AT>_P!3A@N[O>Y1/*A9@[[G!4;0,+^TN-*UKPS\.+#Q&AMS&D4:G49[B&33V MB,8C*ATX3>3L*LP!^J+?$;PI'<>)(&\3Z,L_AF%;C7(SJ$0;2HVC:17NAN_< M*45G!? *J3T%>?77[7'PKC^*6B?#ZU\8:5J'B+6-,_M2T-O?0FU9&V&"/SM^ MTR3K(&C1-Q9 6("E2WQK\1-.^(OPG\=_M2Z WPP\<^/[CXG^$=.LM*U[0M*, M]F9(=(GMKA[F4.0C[WA9OP]^$=_X&^./[._B'6_@[K6JVUQ\+ MM/T6[OK;PX)SI>M(55)[TL 8'BC5%\QOG4 *N=I /M+X;_M%:+K_P #]!^( MWCJ]\,_#VUU.6:%A)XJLK^PCD6>6-42_C80RLRQ;L*)/'_P &/$WQ"\)>&+?Q)9ZUX)CT+[7?V5S=7EPUO.^G3;3*K+L.6&% M5\YV;O8/%]I?^&OV:/!$&E?LOW5OX,U#Q-*=7T6RE64I=VUA<# M9;7+L[,(V#Q0;B&1MY6@#Z+^*7[5_A[P5I_POU+PQ_9GC[2/''C*R\(QZCI. MKQM;VS3LRM,'C6192A3!CRN?[PK9_: ^/G_"B[OX:0?V%_;?_"9^,+#PIN^V M?9_L?VDL/M'^K?S-NW[GRYS]X5^>_P /?@?X\T.U\+60^'7BO2[6W_:$TOQ" MEK=:*D;6VE&)2+F06D2VT:*N!(8@(HV!7Y< 5]B?MO\ A#7O%FJ?L^/H>B:C MK*Z7\4]$U&_;3[22<6EK&TGF3R[ =D:Y&7;"C/)H ]D\2?'GX9^#KZ_L=?\ MB)X3T.]T^6*"\M]2UNVMY+:21#)&DBNX*,Z*S*#@D*2.!6EXV^*W@KX:V]E< M>+_&&@>%8+XL+676]3@LUG*@%A&9&4-@$9QGJ*^&?'G[-H\>?$[]M[7M?^&D MVNWL_AZR_P"$-U"^T5YFFNAI,X8Z>[(=\HFC@4^5E@P5>^#Q:?#O5/ NM?#G MQ5\4_@-XI^,?ARZ^$FE^'+33-/T$:CD:<@F\I-._M)VW27*J0WE[ ;6ZO+OP MP^IB1KB&.)I(Y%G\H85RCIG8=I7D'(SZE\"_V3/"'[/WB&_UGP]J6N7EU>VO MV21-3N8GC";U?(5(T^;*CDYP,XZFO@*W_9=^(^C_ +$.F^+_ MX5UC3_B39 MV>O>&M:\-SZ9*E[JVBW]U*-GDE1(S1.R7$8 Y^8_-P*[Z,JDH7JQY7VO?\=# MTZ$ZLX_XV1^B.@?M*^!C\+_ /C#QEXF\/?#]O%^BVNL6MAKFM00$ M"6".5XT>4IYNSS54L%'4' SBNE\6?&CX?> ;72[GQ-X[\,^'+?5(C-83:MK% MO:I>1@*2\1D<"10'0Y7(^8>HK\^_B/X3\6ZMX ^%?@35O@)J>NA_A9I=AI_B M+3/"-C?ZI::PMN$-G=W-^C1Z?;(2=^4$@8EE=2"*X7QM\&+ZP^#/P:UB7X;_ M !/E^(MMX-CT1I(?AU8>*=-@BAN)7-O<6%\1);3AW4K-M7Y&.S?E\;'0?J=X MH^(WA/P1X>@U[Q'XHT;0-"G9%BU/5-0AMK:0N"R!978*2P!(P>0.*\L^%_[6 MGAGQVOQ/OM:FTGPCX<\$^(#H?]O7^LQ?8[Q2$,<_F,J)&'+J NYLY&&.:^:/ MC%X+\876D?LR>./'OP0;Q-X9\.6M]!XD^&G@S25O8K*:> ):M'IY8JR(%&5) M(C/&>1GSGP3X;\6> _AK\1Y4_9KO[KPIK7Q/%Z_A74O"B:I=Z9I+V[ 7%A9/ MB)YDW!%8%XHR2"&7- 'Z2V'Q<\"ZKX-NO%UEXT\/7GA.U++<:];ZK ]C"5(# M!YP^Q<$C.3W%2>#_ (J>"OB%/-!X6\7Z#XEFAA2XDCT?4X+MDB#@XK\M]/^ /CBW^&_C$_\*H\5WGA?3OBAI'BNY\&7NDV]K=ZOH@MGW(D% MI&EM))\\>^W@7"-E6 *5[M^PPVD7'[8GQTNM!^'-Y\*M(NM&T::W\,ZA8QV$ M\"E&&][:,E8"Y!;8/7)Y)H ]R^+7[5'B'0/BM=_#7X6_"V^^+/C'2[&+4M:B MCU>WTFSTV&4XB5[B8%6F8%6$> 2AW G:P7J_@?\ M'Z1\6O@[/X]UG3+KX>0 MZ;/<66LVWB1A;QV%Q;MLN!Y[A4DB1]R^;P,JP(5E95\1U[4O%W[*/[4WQ1\< M/\./%WQ(\"?$BVTRXAG\#Z>NH7NG7UI"8&AEM]ZMY;H6?SX#^6K;G0 M8+9RZCN*JS?'WX8V^GZI?R_$?PE%8Z5=+9:A=/KEJ(K.X8L%AF8R8CD)1\*V M"=IXX-?FQ\5/@SXF\??##]H_Q7\.?@MXD^&_@[Q#I?A_3-.\$2:&;/4-3O;? M4;:26Z33H WEK''Y@RHPP9GZ^9M]*\5?L?\ AV/X]?%6.P^$%O\ \(NGPG*: M.L.@$V9U?#*##A-C7F ,,N91DG.2<@'WAXE^*G@KP9;Z=/X@\7Z#H4&HQ27% ME)J6IP6ZW4<:"21XB[ .JH0S%<@*03Q3[#XG^#=5\&2^+[+Q;H=YX2A1Y)-> MM]2A>P14)#L9PVP!2""2>"#FOS;^)VDMX=\'_L,6'C?X*/^%23V8M+Z[TBVB>.YQ9 _*TCE"+?&&$8*Y58R0#]+=%^*W@KQ'X2O?%6 MD^,- U3PQ8B0W6M66IP365N(UW2&296*+M4@G)& ?M+>&M.^#_ (G\ M<> =7\*_$7^PS"DEO;^++&SM-\DJ)LEO78Q0':Y8;S\V HY85\8:?\#+'XG6 M_P >_$R?!/Q]\.O@[K^C:79#P1H>F6VF:[J-Y:3).UW;Z>S")?+VD!>?,W,4 M#NS*. M_ 7Q-U[]E[X_>'K#X2ZE'IM[::+M!U'Q18*S7>B6FIPRWMN MJE0QD@5BZ %E!R!@L/6OCOXW?#6XT_\ ;$^#'BW_ (5?J7B*TN_#O]DR:UIN M@+>KI>J>9&MK>7;D?N1;EE?S6^9%1BF=I ^,O M#^M^$]9EO+R_C^'&GPZ?*H>02J_B 74<]W'+&[ ;ED^_A48** /T@^*?QZ_X M5I\8OA)X$_L/^TO^$^NK^V_M#[7Y7V'[- LN[R]C>9NW8QN7&,\]*WM(^/?P MR\0:QIFDZ7\1?">I:KJ89K"QL]_:1\( MZ[KG[5G[,.KZ;HNHZAI6CZCK;ZE?6MI)+!9+)9QK&9I%!6,,P(!8C)&!7R#X M+_9;U#1?V3_A)K,/PIO[/XH6OQ.MKZ^NQH,JZO%:+>S?/*=GFK (Q&WS?N^% M;K@T ?=O[1O[5GA'X >"/%>H#4M%\0>+M!M([UO!XUJ&WOY8V>-=Q3#R*NV0 M-N\LC ]\UW&M?&3P;X-\,Z)K/C'Q1H?@V#5H4DM_[O>*KC7=$^(&GZ(+R!-/DF@DC6.\ MYD5E177R(P<[BI -=;^VI\$_B%?_%_PEXG_ + \1:QX6N/!%MHT7]A> +3Q MA-97*/NEB>SNG06Q(?<)U.[/RC^+ !^E%Q\0/"]KX@DT*;Q)I$.MQV!U5]-D MOHEN5LP=IN3$6W"('CS,;<]ZN>&_$VC^,M$M=9T#5;'7-'NU+6^H:;H-?F'\WFH>+-?MI M-($FGN&6/0RT4TL4DTJE$,(F8($7+(KR;/T5^!NM66O_ A\)7FG>$]0\"67 M]GQPQ>&M4L7LY],$8\OR&B=5("E"%. &7:PX84 =U1110 456U*QCU33[JSE M+K%<1-"[1MM8!@02#V/->7_\,U>&/^?[5O\ O]%_\;KQ KK6]"DU71_$>J&QO+V*Z,;:="H0O.(Q&YF(5B=@*D[>O-=;_P MS5X8_P"?[5O^_P!%_P#&Z\@_:9^#,^K_ !#_ &;]%LO#^H^)?"VG:]?1ZNS6 MKW4,5K+;,K?:65=J(VXK\V!SBO2P&*S*M4<<;AE2C;1JISZ]K9GK!_:&MY?VE]%^%%II45[::IX2;Q7#XAAO@R%!<&%8UB" M$,&&&$@?OT[UUO@SXT?#WXC:K<:9X3\=^&?%&I6\1FFL]%UBWNYHHPP4NR1N MQ"AF49(QD@=Z^ _AS\%?BS\&?VI/%&DCPE=>.?#'A/X_EPTC;5=2K*/=/,/TC\%_&;X?_$C M4KG3O"7CGPWXHU"UC\V>UT75[>\EB3<%W.D;L5&2!DCJ0*\U_: _; \(_!71 M[@Z9?:+XQ\36>J6>G7WANTUR&.\LUGF2(RRQJ)'0*77AD&=P&1D5\J_L0^#_ M !)X)_:(L-.\-?"SQ!I_P]CL+B*YUSXB?#G3] UC2HDCQ"D.HVQ#7[RR%1)O M7.T!L?>->+ZA\%_$FD_"72_A[??L\>*M4^+VB^-DU+5_B1!H/FP7UJ;QV,T5 MZN9;@,LD8,0&T -(2"A% 'ZM:E\:/A[HWC*+PCJ'COPS8^+)98H8]!N=8MX[ MYY) #&@@+ARSAEVC&3N&.M'B?XU?#SP3KAT7Q%X\\,Z!K*VYNSIVJ:Q;VUP( M0K,9?+=PVP*CG=C&%)[&OS8_:I\)^-/B=XH\>PI^S]K6D^*=$\5)>6FO>%?! MMHUIJFDI<0!;N743&]W(_$>JR:]X?^(ZZ='-8:=IV8V1&OF.;=HE1QY:?-(2J$ %20#](OCQ\:;?X M,_ OQ)\2K2QB\36FDV*W\-M#>")+M&90I68*X (<$,%.:\-T+]M7XCZ;XG^' M<'Q'^ 5QX$\+^-]5MM&T[7K;Q;::JWVFY1FMP;>*-7"MCYF)&T9/)&TZG[0' MAS5O%W_!.?4='T+2[W6M7N_!^GQV]AI]N\\\S;(#M2- 68X!. .U?'?A?X+^ M'KOQ3\(E^#'[.OQ;^&'Q,T_Q#IUUJ7BWQ)8WEGIB6L:,;WS'GN9$V,,_)M4N M/D&=WEN ?H]X+^-,>N:E\21K]OHWAO1_!NH-:OJG_"1VEVCP+'O:>Y5"#9$# M.8YB& &>E;FG?&;P#K7@O5?%^F>-?#^J^%M*\S[=K.GZG#.17Y_?%/X&_$#Q'I?QZN+;P5K6L:1'\5M/\27>@?99(G\2Z/!$3 M/#;;@//!)1@$SDQX7+8![OX#?"0_$3XO?%CQ?X>^#-_\*/A9K/@X>&_^$0\3 M:+#I;:OJ8<2"X^P@E%1$;R]Y^5BY()82!0#Z?^'O[5/PN^)'PL'Q#LO&.DZ9 MX56X:UFO-8OX+46L@#(O%][XM MT.S\)3(DD>O7&I0I8.KD!&$Y;80Q( (/)(Q7Y'7'P/\ 'M]^SC\%SI?PJ\5^ M&_\ A#-3U.W\663^ +?4[R_NYXT^SWR:;<%5U! F83))@QXR,[0:[[0?V>_% M7@OX8_"7Q/KG@7QE\3?A_I/C'5];UGP'?>#[6QU$1W=O#%"T>D1W,R>5'.DS MB+Y,"9B45/F(!]T_$C]JKP_X(USX41Z6=-\3>'?'FHW%DOB*TU>,6EI'#$7> M<.JNDJC:P/S*!@\\5WUG\9OA_J'AF#Q':^.O#5SX>GNUL(M6AU>W>TDN6.%A M64/L,A) " Y.>E?!EW\$[?XD:Q\$C9_L]ZMX%^'US\0]2U6[\-:HDUVBVK0I MMN;NT*F/3XY'3'V7/E@+QE6YYGXD_LY:Y'H7QI\):+\-M6A\)WWQ4T2[L-+T MW1IDMI;$H1<2P+&@'DKT+)\J^U 'Z3>"OB9X/^)4-Y+X1\5Z'XIBLY!%!O&'B?4/#>@^-/#VM^(M.$AO=(T[58+B[M MA&XCD,D*.73:[*IW 88@'DU\GZ9^S_J?A7]I3X_:9\.?"P\!:'XA^'<5GI&H MZ;IALM,75&21%:-D01^8A8,0O/4D9YKQ/X+_ @U76/$7[/GA?PU\ ?$'PM\ M<_#W5X;WQEX[U+1X[.TOK: &.ZCCO%.;TW+-A0,X#';F,,P /MKX)_M3:#\3 M?@_J/Q#\2C3OA]HUCJ]UI4TVJZM']G0PS^2KM/(L:KO8C"GN0,FO2;7XF>#[ M[P2WC*V\5Z'<>$%1Y3X@BU&%M/"(Y1V^T!O+PKJRD[N""#R*_-'3/@KXST?X M5_"W7_$WPL\0^-/!_A;Q]X@U#Q%X#726EO;V&Y<):726?$&7P-/\._A)K'Q(T'6;/X8:WY6F7=Y8VL(?A_8K9>'-2M8 M;&:UNBR/;S2VD3,ELWG1))Y8Y^4.P#2$5[3_ ,$X;WQ#\8V\;_&_QE;M!KNL M)8>%[6.1]VR'3[9$N)%[XFNFEEQ1V MFJ>'[S7YM?FOA$EHENV&5HRF",9)L&OK6REE@6YD#^7"9%4J)&R-J9R>PKQOX:_LTS>!?"_[&^MZ/\ #&ZT M;Q99ZR7\4W]OHCQWL,:<*#@8'% 'U=^T!^V!X1^"NCW!TR M^T7QCXFL]4L].OO#=IKD,=Y9K/,D1EEC42.@4NO#(,[@,C(KU.^^*7@S2_&5 MIX1O?%V@VGBR[4/;Z#/J4*7TRD$@I 6WL"%;H/X3Z5^36H?!?Q)I/PETOX>W MW[/'BK5/B]HOC9-2U?XD0:#YL%]:F\=C-%>KF6X#+)&#$!M #2$@H15CXH?L MP_$[5OVB/B#I.JZ=XSBN/$7C&35M)\2>'/AS8:S$L#S*]K+_ &U+P(J MM"KJJ!#DD.<@'ZP7OQ,\'Z;>:]9W?BO0[6[T"W6[UBWFU&%)--A9=RRW"ELQ M(5^8,^ 1S6UI.K6.O:59ZGIEY;ZCIM["ES:WEI*LL,\3J&21'4D,K*00P."" M"*_.[]O#X2>,OC1\<8M6\&_#+4-8TWP+I%O/XMFF2YLHO&5J+J&Z72+8 8N] MGDM)A=V'(4'S%C5OT%\(:O;Z_P"%=(U*STZ\TBUNK2*:+3]0LVM+BV4J"(I( M6 ,;+T*D<$8H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ KD]'^%?A;0?B)X@\=V&E^1XJU^WM[74M0^T2MY\4 VQ M+Y98HNT=U4$]\UUE% !1110 4444 *M:TO[9KWA.6XFT M:[^T2Q_97G01RG8K!7W*H'SAL8XP:ZVBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "L#Q]X#T+XG^#=6\*^)K'^TM U: M VUY:>=)%YL9QE=\;*R].JD&M^B@"EHNCV?AW1[#2M/A^SV%C!':V\.XMLC1 M0JKEB2< 9))J[110 4444 %%%% !1110 4444 %;3-9SLR?,IRK*Z$,C ]&4@CUKJZ* /&OAW^Q_\)?A)X1\0>&O!GA> M;PSINOM&=2ETW5[Z*\G"?=7[6)O/11S\JR!?F?CYVSZ%\._AWX<^$_@O2O"7 MA+2H=$\.Z7$8;2Q@+%8U+%F)9B69F9F9F8EF9B222371T4 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 944 %%%% !1110 4444 %%%% !1110!__V0$! end XML 14 bmrn-20201231_htm.xml IDEA: XBRL DOCUMENT 0001048477 2020-01-01 2020-12-31 0001048477 2020-06-30 0001048477 2021-02-12 0001048477 2020-12-31 0001048477 2019-12-31 0001048477 us-gaap:ProductMember 2020-01-01 2020-12-31 0001048477 us-gaap:ProductMember 2019-01-01 2019-12-31 0001048477 us-gaap:ProductMember 2018-01-01 2018-12-31 0001048477 bmrn:RoyaltyAndOtherMember 2020-01-01 2020-12-31 0001048477 bmrn:RoyaltyAndOtherMember 2019-01-01 2019-12-31 0001048477 bmrn:RoyaltyAndOtherMember 2018-01-01 2018-12-31 0001048477 2019-01-01 2019-12-31 0001048477 2018-01-01 2018-12-31 0001048477 us-gaap:CommonStockMember 2019-12-31 0001048477 us-gaap:CommonStockMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2017-12-31 0001048477 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001048477 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001048477 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001048477 us-gaap:CommonStockMember 2020-12-31 0001048477 2018-12-31 0001048477 2017-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001048477 us-gaap:TreasuryStockMember 2019-12-31 0001048477 us-gaap:TreasuryStockMember 2018-12-31 0001048477 us-gaap:TreasuryStockMember 2017-12-31 0001048477 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001048477 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001048477 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0001048477 us-gaap:TreasuryStockMember 2020-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-01-01 2020-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001048477 us-gaap:RetainedEarningsMember 2019-12-31 0001048477 us-gaap:RetainedEarningsMember 2018-12-31 0001048477 us-gaap:RetainedEarningsMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2017-12-31 0001048477 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001048477 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001048477 us-gaap:RetainedEarningsMember 2020-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001048477 us-gaap:OfficeEquipmentMember 2020-01-01 2020-12-31 0001048477 us-gaap:VehiclesMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:LandImprovementsMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:LandImprovementsMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductOneMember srt:MinimumMember 2020-12-31 0001048477 bmrn:ProductOneMember srt:MaximumMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001048477 srt:MaximumMember 2019-01-01 2019-12-31 0001048477 srt:MaximumMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember 2019-01-01 2019-12-31 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-01-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-01-01 2020-03-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-03-31 0001048477 bmrn:AcquiredIntellectualPropertyMember 2020-12-31 0001048477 bmrn:AcquiredIntellectualPropertyMember 2020-01-01 2020-12-31 0001048477 bmrn:RepurchasedRoyaltyRightsMember 2020-12-31 0001048477 bmrn:RepurchasedRoyaltyRightsMember 2020-01-01 2020-12-31 0001048477 bmrn:TechnologyTransferMember 2020-12-31 0001048477 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001048477 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-12-31 0001048477 bmrn:MedivationMember 2019-01-01 2019-12-31 0001048477 bmrn:MedivationMember 2018-01-01 2018-12-31 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001048477 us-gaap:EquipmentMember 2020-12-31 0001048477 us-gaap:EquipmentMember 2019-12-31 0001048477 us-gaap:ComputerEquipmentMember 2020-12-31 0001048477 us-gaap:ComputerEquipmentMember 2019-12-31 0001048477 us-gaap:LandMember 2020-12-31 0001048477 us-gaap:LandMember 2019-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001048477 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001048477 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001048477 us-gaap:LandImprovementsMember 2020-12-31 0001048477 us-gaap:LandImprovementsMember 2019-12-31 0001048477 us-gaap:ConstructionInProgressMember 2020-12-31 0001048477 us-gaap:ConstructionInProgressMember 2019-12-31 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2019-12-31 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2020-12-31 0001048477 bmrn:AccruedRebatesMember 2019-12-31 0001048477 bmrn:AccruedRebatesMember 2020-01-01 2020-12-31 0001048477 bmrn:AccruedRebatesMember 2020-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2019-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2020-01-01 2020-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2020-12-31 0001048477 bmrn:AccruedRebatesMember 2018-12-31 0001048477 bmrn:AccruedRebatesMember 2019-01-01 2019-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2018-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2019-01-01 2019-12-31 0001048477 bmrn:AccruedRebatesMember 2017-12-31 0001048477 bmrn:AccruedRebatesMember 2018-01-01 2018-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2017-12-31 0001048477 bmrn:AllowancesForReserveForCashDiscountsMember 2018-01-01 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001048477 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:ContingentPaymentMember 2019-12-31 0001048477 bmrn:ContingentPaymentMember 2020-01-01 2020-12-31 0001048477 bmrn:ContingentPaymentMember 2020-12-31 0001048477 us-gaap:NondesignatedMember 2020-01-01 2020-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2020-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2020-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-12-31 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-12-31 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-12-31 0001048477 us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-12-31 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0001048477 us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001048477 us-gaap:OperatingExpenseMember 2019-01-01 2019-12-31 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member 2020-12-31 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member 2019-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2020-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2019-12-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2020-12-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2019-12-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2020-10-15 2020-10-15 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2018-10-15 0001048477 us-gaap:ConvertibleDebtMember 2020-01-01 2020-12-31 0001048477 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001048477 us-gaap:ConvertibleDebtMember 2018-01-01 2018-12-31 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member us-gaap:SeniorSubordinatedNotesMember 2020-05-31 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member us-gaap:SeniorSubordinatedNotesMember 2020-05-01 2020-05-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2017-08-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2017-08-01 2017-08-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2017-08-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2020-01-01 2020-12-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2020-12-31 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-12-31 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-12-31 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-12-31 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-01-01 2018-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-01-01 2019-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-01-01 2020-12-31 0001048477 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-12-31 0001048477 srt:MinimumMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 country:US 2020-01-01 2020-12-31 0001048477 country:US 2019-01-01 2019-12-31 0001048477 country:US 2018-01-01 2018-12-31 0001048477 srt:EuropeMember 2020-01-01 2020-12-31 0001048477 srt:EuropeMember 2019-01-01 2019-12-31 0001048477 srt:EuropeMember 2018-01-01 2018-12-31 0001048477 srt:LatinAmericaMember 2020-01-01 2020-12-31 0001048477 srt:LatinAmericaMember 2019-01-01 2019-12-31 0001048477 srt:LatinAmericaMember 2018-01-01 2018-12-31 0001048477 bmrn:RestOfWorldMember 2020-01-01 2020-12-31 0001048477 bmrn:RestOfWorldMember 2019-01-01 2019-12-31 0001048477 bmrn:RestOfWorldMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-12-31 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-12-31 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomersMember 2020-12-31 0001048477 bmrn:CustomersMember 2019-12-31 0001048477 country:US 2020-12-31 0001048477 country:US 2019-12-31 0001048477 country:IE 2020-12-31 0001048477 country:IE 2019-12-31 0001048477 bmrn:RestOfWorldMember 2020-12-31 0001048477 bmrn:RestOfWorldMember 2019-12-31 0001048477 us-gaap:EmployeeStockOptionMember bmrn:TwoThousandSeventeenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember bmrn:TwoThousandSeventeenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001048477 bmrn:TwoThousandSeventeenEquityIncentivePlanMember 2020-12-31 0001048477 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001048477 us-gaap:EmployeeStockMember 2020-12-31 0001048477 bmrn:IndependentDirectorMember us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2019-09-19 2019-09-19 0001048477 bmrn:IndependentDirectorMember us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2019-09-18 2019-09-18 0001048477 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001048477 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001048477 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2020-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-01-01 2019-12-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2018-01-01 2018-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2019-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2020-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2019-01-01 2019-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember 2018-01-01 2018-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2019-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2020-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2019-01-01 2019-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2020-03-01 2020-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2020-03-01 2020-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember 2020-03-01 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsProbableOfVestingMember 2020-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsNotProbableOfVestingMember 2020-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-01-01 2020-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember 2019-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember 2020-01-01 2020-12-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember 2020-12-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-01 2020-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-06-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-06-01 2020-06-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2020-12-31 0001048477 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001048477 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001048477 srt:MinimumMember us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001048477 srt:MaximumMember us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001048477 bmrn:BiomarinRetirementSavingsPlanMember 2020-01-01 2020-12-31 0001048477 bmrn:BiomarinRetirementSavingsPlanMember 2019-01-01 2019-12-31 0001048477 bmrn:BiomarinRetirementSavingsPlanMember 2018-01-01 2018-12-31 0001048477 country:IE 2020-09-30 0001048477 country:NL 2020-12-31 0001048477 us-gaap:DomesticCountryMember 2020-12-31 0001048477 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001048477 country:NL us-gaap:ForeignCountryMember 2020-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2020-01-01 2020-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2019-01-01 2019-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2018-01-01 2018-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2020-01-01 2020-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2018-01-01 2018-12-31 0001048477 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001048477 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001048477 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2018-01-01 2018-12-31 0001048477 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001048477 us-gaap:StockCompensationPlanMember 2019-01-01 2019-12-31 0001048477 us-gaap:StockCompensationPlanMember 2018-01-01 2018-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2020-01-01 2020-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-01-01 2019-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-01-01 2018-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-12-31 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-12-31 0001048477 bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember 2019-10-01 2019-10-31 0001048477 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember 2019-10-01 2019-10-31 0001048477 bmrn:ExclusiveLicensingAgreementForTralesinidaseAlfaMember 2020-12-31 0001048477 bmrn:SareptaTherapeuticsMember country:US bmrn:LicenseAgreementAndSettlementAgreementMember 2017-07-01 2017-07-31 0001048477 bmrn:SareptaTherapeuticsMember us-gaap:NonUsMember bmrn:LicenseAgreementAndSettlementAgreementMember 2017-07-01 2017-07-31 0001048477 srt:MaximumMember bmrn:MerckSeronoMember bmrn:AAndRKuvanAgreementMember 2020-12-31 0001048477 bmrn:MerckSeronoMember 2020-01-01 2020-12-31 0001048477 bmrn:MerckSeronoMember bmrn:PegvaliaseAgreementMember 2020-01-01 2020-12-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2019-03-31 0001048477 bmrn:ThirdPartyMember bmrn:EarlyStageDevelopmentProgramMember 2020-04-01 2020-06-30 0001048477 bmrn:MerckSeronoMember bmrn:CompletedProjectMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure bmrn:tranche bmrn:Segment utr:D iso4217:EUR false 2020 FY 0001048477 P1Y P1Y P2Y3M us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent P3Y 10-K true 2020-12-31 --12-31 false 000-26727 BioMarin Pharmaceutical Inc DE 68-0397820 770 Lindaro Street San Rafael CA 94901 415 506-6700 Common Stock, par value $.001 BMRN NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 13900000000 181829680 Specified portions of the registrant's definitive proxy statement for the registrant's 2021 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December 31, 2020, are incorporated by reference under Part III of this Annual Report on Form 10-K. 649158000 437446000 416228000 316361000 448351000 377404000 698548000 680275000 129934000 130657000 2342219000 1942143000 285473000 411978000 1032471000 1010868000 417271000 456580000 196199000 197039000 1432150000 549422000 142237000 122009000 5848020000 4690039000 492548000 570621000 0 361882000 492548000 932503000 1075145000 486238000 60130000 50793000 114195000 98124000 1742018000 1567658000 0.001 0.001 500000000 500000000 181740999 181740999 179838114 179838114 182000 180000 4993407000 4832707000 9839000 9961000 -16139000 20164000 -861609000 -1720709000 4106002000 3122381000 5848020000 4690039000 1805861000 1661043000 1470356000 54594000 43005000 20856000 1860455000 1704048000 1491212000 524272000 359466000 315264000 628116000 715007000 696328000 737669000 680924000 604353000 66658000 74108000 48791000 59495000 25000000 50000000 1897220000 1804505000 1614736000 -36765000 -100457000 -123524000 -6000 -587000 -553000 16610000 22748000 22831000 29309000 23460000 43664000 7148000 6945000 2205000 -42322000 -94811000 -142705000 -901422000 -70963000 -65494000 859100000 -23848000 -77211000 4.75 -0.13 -0.44 4.53 -0.13 -0.44 180804000 179039000 177061000 191678000 179039000 177268000 859100000 -23848000 -77211000 227000 1640000 413000 749000 5482000 1391000 127000 0 0 425000 0 0 324000 5482000 1391000 0 0 0 -23462000 25266000 25386000 0 0 0 13180000 15853000 -2047000 -36642000 9413000 27433000 15000 -2000 -6000 -36303000 14893000 28818000 822797000 -8955000 -48393000 179838000 178253000 175844000 2421000 1585000 2314000 518000 0 0 0 0 95000 181741000 179838000 178253000 3122381000 2967940000 2808663000 180000 178000 176000 2000 2000 2000 182000 180000 178000 4832707000 4669926000 4483220000 27275000 -11071000 31583000 183547000 163891000 155139000 50000000 0 0 0 0 -16000 122000 692000 0 0 10653000 0 4993407000 4832707000 4669926000 0 0 0 50000000 0 0 -50000000 0 0 0 0 0 -9961000 -13301000 -14224000 -122000 -692000 -923000 0 2648000 0 -9839000 -9961000 -13301000 20164000 5271000 -22961000 0 0 -586000 -36303000 14893000 28818000 -16139000 20164000 5271000 -1720709000 -1694134000 -1637548000 0 -2727000 20625000 859100000 -23848000 -77211000 -861609000 -1720709000 -1694134000 4106002000 3122381000 2967940000 859100000 -23848000 -77211000 105172000 105300000 95671000 16511000 13960000 31186000 -567000 2000000 -358000 189711000 159865000 148819000 59495000 25000000 50000000 75609000 0 0 -888907000 -82760000 -68378000 -8011000 -1025000 17766000 4500000 5205000 9296000 997000 2393000 2347000 59035000 37852000 54274000 61151000 107554000 23747000 -18312000 27008000 17767000 28647000 8895000 935000 -87025000 77089000 38389000 -6871000 3128000 8914000 85365000 48262000 20208000 114312000 145026000 144620000 555834000 740211000 993734000 529663000 632023000 634753000 67159000 25000000 50000000 23207000 18380000 0 8709000 0 0 723000 808000 10000 -53621000 -31026000 264351000 71913000 31611000 67488000 44638000 42680000 35919000 50000000 0 0 585752000 0 0 374991000 0 374953000 0 58518000 44623000 -6918000 -5087000 0 181118000 -74674000 -388007000 -1150000 902000 -598000 211712000 -56536000 -104046000 437446000 493982000 598028000 649158000 437446000 493982000 12178000 8552000 11623000 8977000 9726000 16676000 -5184000 7589000 -1206000 -292000 4247000 0 NATURE OF OPERATIONS AND BUSINESS RISKS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to a number of risks, including: the continuing impact of the novel coronavirus disease (referred to as COVID-19) pandemic on the Company's business; the financial performance of its commercial products; the potential need for additional financing; the Company’s ability to successfully commercialize its approved products; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.</span></div> BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements. See Note 4 to these Consolidated Financial Statements for additional discussion of the adoption of ASU 2016-13 and required disclosures.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly </span></div>uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted FASB ASU No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount </span>under the previous other-than-temporary impairment model. The adoption of this standard had no impact on the Company’s Financial Statements. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly </span></div>uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income, Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Inventory </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;D).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;D and Selling, General and Administrative (SG&amp;A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;D in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted Accounting Standards Codification (ASC) Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amended guidance required balance sheet recognition of lease right-of-use (ROU) assets and liabilities by lessees for leases classified as operating leases. The Company adopted ASC Topic 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption through a cumulative adjustment to Accumulated Deficit. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses its goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Impairment charges that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Asset Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;A in the Consolidated Statements of Operations. Impairment charges related to finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC Topic 606, the Company performs the following five steps:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt">identification of the promised goods or services in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt">measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt">allocation of the transaction price to the performance obligations based on estimated selling prices; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Company’s commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Genzyme </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Reserves</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on Brineura, Kuvan or Palynziq therapy. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D costs are generally expensed as incurred. These expenses include contract R&amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs and R&amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debt</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For non-conventional convertible debt that may be settled entirely or partially in cash, the Company separately accounts for the liability and equity components by allocating the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. The liability component is presented net of any discounts and issuance costs. For conventional convertible debt that may only be settled with common shares, the Company reports debt, net of any discounts or issuance costs, on the Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes discount accretion and debt issuance cost amortization using the effective interest method and is reported in Interest Expense on the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Common Share</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;D or SG&amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in SG&amp;A in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;A in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Income approach, which is based on the present value of a future stream of net cash flows</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of long-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of the contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Notes 5, 10, 11, 13, 19 and 20 to these Consolidated Financial Statements for further information on the nature of these financial instruments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.</span></div> Cash and Cash EquivalentsThe Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.</span></div> Non-Marketable Equity SecuritiesThe Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income, Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Inventory </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventory Produced Prior to Regulatory Approval</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing </span></div>application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&amp;D). <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&amp;D and Selling, General and Administrative (SG&amp;A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&amp;D projects with no alternative future uses are expensed as incurred and recorded to R&amp;D in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.827%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of life of asset or lease term</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable</span></td></tr></table> Shorter of life of asset or lease term P20Y P50Y P5Y P15Y P3Y P7Y P5Y P5Y P10Y P20Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted Accounting Standards Codification (ASC) Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amended guidance required balance sheet recognition of lease right-of-use (ROU) assets and liabilities by lessees for leases classified as operating leases. The Company adopted ASC Topic 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption through a cumulative adjustment to Accumulated Deficit. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&amp;D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses its goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Impairment charges that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Asset Impairment</span></div>The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&amp;A in the Consolidated Statements of Operations. Impairment charges related to finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC Topic 606, the Company performs the following five steps:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.03pt">identification of the promised goods or services in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.04pt">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:24.05pt">measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.53pt">allocation of the transaction price to the performance obligations based on estimated selling prices; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Company’s commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Genzyme </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Reserves</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on Brineura, Kuvan or Palynziq therapy. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal </span></div>would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer. 0.395 0.50 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D costs are generally expensed as incurred. These expenses include contract R&amp;D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs and R&amp;D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debt</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For non-conventional convertible debt that may be settled entirely or partially in cash, the Company separately accounts for the liability and equity components by allocating the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. The liability component is presented net of any discounts and issuance costs. For conventional convertible debt that may only be settled with common shares, the Company reports debt, net of any discounts or issuance costs, on the Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes discount accretion and debt issuance cost amortization using the effective interest method and is reported in Interest Expense on the Consolidated Statements of Operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Common Share</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&amp;D or SG&amp;A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.</span></div> 4 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in SG&amp;A in the Consolidated Statements of Operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&amp;A in the Consolidated Statements of Operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Income approach, which is based on the present value of a future stream of net cash flows</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of long-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of the contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Notes 5, 10, 11, 13, 19 and 20 to these Consolidated Financial Statements for further information on the nature of these financial instruments.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.</span></div> 1 1 RECENT ACCOUNTING PRONOUNCEMENTS<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted FASB ASU No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount </span>under the previous other-than-temporary impairment model. The adoption of this standard had no impact on the Company’s Financial Statements. FINANCIAL INSTRUMENTS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2020 and 2019, respectively:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">980,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,833 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,345,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350,859 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649,158 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,473 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,785 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company’s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company’s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MzMyZDE1Yzg3YjRhMTdiMDM5NGE1MzgwZDQ0ZGZhL3NlYzowNzMzMmQxNWM4N2I0YTE3YjAzOTRhNTM4MGQ0NGRmYV8xNjkvZnJhZzpjNGUyMDFkMWI5NWQ0MmY5YjJmMjUxNjkyYjA0ZmE0MC90ZXh0cmVnaW9uOmM0ZTIwMWQxYjk1ZDQyZjliMmYyNTE2OTJiMDRmYTQwXzIxOTkwMjMyNjAyMTM_96fe2c84-be08-4007-bb26-8e03f797caef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MzMyZDE1Yzg3YjRhMTdiMDM5NGE1MzgwZDQ0ZGZhL3NlYzowNzMzMmQxNWM4N2I0YTE3YjAzOTRhNTM4MGQ0NGRmYV8xNjkvZnJhZzpjNGUyMDFkMWI5NWQ0MmY5YjJmMjUxNjkyYjA0ZmE0MC90ZXh0cmVnaW9uOmM0ZTIwMWQxYjk1ZDQyZjliMmYyNTE2OTJiMDRmYTQwXzIxOTkwMjMyNjAyMTM_c6aedf41-30b0-4d27-aa5e-7c6fdbfcfa77">one</span></span> and five years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December 31, 2020 and 2019, the fair value of the Company’s strategic investments was $10.5 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 3 to these Consolidated Financial Statements for additional discussion regarding the Company’s fair value measurements.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2020 and 2019, respectively:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">980,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,833 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,473 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,345,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350,859 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649,158 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,473 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,785 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company’s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company’s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MzMyZDE1Yzg3YjRhMTdiMDM5NGE1MzgwZDQ0ZGZhL3NlYzowNzMzMmQxNWM4N2I0YTE3YjAzOTRhNTM4MGQ0NGRmYV8xNjkvZnJhZzpjNGUyMDFkMWI5NWQ0MmY5YjJmMjUxNjkyYjA0ZmE0MC90ZXh0cmVnaW9uOmM0ZTIwMWQxYjk1ZDQyZjliMmYyNTE2OTJiMDRmYTQwXzIxOTkwMjMyNjAyMTM_96fe2c84-be08-4007-bb26-8e03f797caef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MzMyZDE1Yzg3YjRhMTdiMDM5NGE1MzgwZDQ0ZGZhL3NlYzowNzMzMmQxNWM4N2I0YTE3YjAzOTRhNTM4MGQ0NGRmYV8xNjkvZnJhZzpjNGUyMDFkMWI5NWQ0MmY5YjJmMjUxNjkyYjA0ZmE0MC90ZXh0cmVnaW9uOmM0ZTIwMWQxYjk1ZDQyZjliMmYyNTE2OTJiMDRmYTQwXzIxOTkwMjMyNjAyMTM_c6aedf41-30b0-4d27-aa5e-7c6fdbfcfa77">one</span></span> and five years.</span></div> 370325000 370325000 370325000 264833000 0 0 264833000 264833000 0 0 413137000 3261000 8000 416390000 0 220551000 195839000 265298000 1555000 1000 266852000 14000000 192488000 60364000 31659000 85000 2000 31742000 0 3189000 28553000 549000 168000 0 717000 0 0 717000 975476000 5069000 11000 980534000 278833000 416228000 285473000 1345801000 5069000 11000 1350859000 649158000 416228000 285473000 259347000 259347000 259347000 173100000 0 0 173100000 173100000 0 0 518523000 3575000 12000 522086000 0 233294000 288792000 209633000 993000 67000 210559000 4999000 83067000 122493000 549000 145000 1000 693000 0 0 693000 901805000 4713000 80000 906438000 178099000 316361000 411978000 1161152000 4713000 80000 1165785000 437446000 316361000 411978000 P1Y P1Y P5Y P5Y 10500000 6200000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying value of Goodwill was as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: disposition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,199 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. As a result of the sale of Firdapse, in the first quarter of 2020 the Company recognized a $0.8 million reduction to Goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company performed its annual assessment for goodwill impairment for the year ended December 31, 2020 and no goodwill impairment charges were recorded. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Remaining Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intellectual property</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchased royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology transfer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable (1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 3.4 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The technology transfer intangible asset has not yet been placed into service.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,614 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2019 and 2018, the Company received $25.0 million and $50.0 million, respectively, due to the achievement by a third party of development and regulatory milestones and commercial sales milestones related to a previously sold intangible asset, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Operations.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying value of Goodwill was as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: disposition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,199 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 197039000 197039000 840000 0 196199000 197039000 67200000 59500000 -800000 32200000 31600000 0 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 644087000 652734000 226816000 196154000 417271000 456580000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Remaining Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intellectual property</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchased royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology transfer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not applicable (1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 3.4 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The technology transfer intangible asset has not yet been placed into service.</span></div> 350275000 P6Y10M24D 19687000 P2Y10M24D 46657000 652000 P0Y6M P3Y4M24D 417271000 As of December 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,614 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 61963000 61939000 61311000 55036000 35759000 94606000 370614000 25000000.0 50000000.0 PROPERTY, PLANT AND EQUIPMENT<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725,906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,668,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,032,471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,169 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,285 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,375 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation capitalized into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725,906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,668,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,032,471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,169 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,285 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,375 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation capitalized into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 761560000 725906000 414439000 366951000 189740000 167554000 90418000 90418000 55134000 51324000 40223000 38569000 7412000 7349000 109140000 111897000 1668066000 1559968000 635595000 549100000 1032471000 1010868000 88169000 89285000 90375000 44492000 37481000 25227000 INVENTORY<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,673 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,442 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,286 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,978 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,589 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,855 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698,548 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. The Company had $29.2 million of valoctocogene roxaparvovec pre-launch inventory as of December 31, 2019.</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requesting additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $87.2 million to Cost of Sales during the year ended December 31, 2020. The Company had no pre-launch inventory balance as of December 31, 2020.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,673 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,442 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,286 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,978 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,589 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,855 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698,548 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 76673000 74442000 308286000 349978000 313589000 255855000 698548000 680275000 29200000 0 87200000 0 SUPPLEMENTAL BALANCE SHEET INFORMATION<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2020, 2019 and 2018, were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision for Current Period Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2018:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 191429000 240981000 165023000 192467000 65526000 57163000 17798000 10448000 17155000 30797000 11754000 10700000 9661000 3195000 9562000 8395000 152000 13037000 4488000 3438000 492548000 570621000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2020, 2019 and 2018, were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision for Current Period Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2018:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 57163000 113165000 104802000 65526000 1889000 17191000 17364000 1716000 43116000 91748000 77701000 57163000 1197000 15335000 14643000 1889000 36472000 67843000 61199000 43116000 1055000 12474000 12332000 1197000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Consolidated Financial Statements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2020 and 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 13 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,377 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,465 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The restricted investments as of December 31, 2020 and 2019 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities measured at fair value using Level 3 inputs primarily consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2020 and 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 13 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,377 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,465 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The restricted investments as of December 31, 2020 and 2019 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div> 0 0 0 0 2415000 0 2415000 19962000 0 19962000 4487000 0 4487000 24449000 0 24449000 26864000 0 26864000 2415000 0 2415000 19962000 0 19962000 0 60130000 60130000 19962000 60130000 80092000 22377000 60130000 82507000 1177000 0 1177000 16288000 0 16288000 3168000 0 3168000 19456000 0 19456000 20633000 0 20633000 1177000 0 1177000 16288000 0 16288000 0 50793000 50793000 16288000 50793000 67081000 17465000 50793000 68258000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities measured at fair value using Level 3 inputs primarily consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 50793000 4500000 4837000 60130000 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's forward foreign currency exchange contracts (forward contracts) designated as hedging instruments have maturities up to two years and three months. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to three months. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">782,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:67.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,416 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,818 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,941 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,897,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company expects to reclassify unrealized losses of $12.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 14 to these Consolidated Financial Statements.</span></div> P3M The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">782,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 782327000 820546000 189540000 212348000 98343000 77335000 12277000 30818000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:67.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,416 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,818 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,941 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.</span></div> 6268000 19584000 3148000 13539000 9416000 33123000 17551000 8184000 11020000 5493000 28571000 13677000 84000 469000 247000 2264000 9500000 33592000 28818000 15941000 The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,897,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1805861000 18122000 1661043000 17672000 1897220000 -4942000 1804505000 -3453000 115000 -5259000 -12200000 LEASES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company’s ROU assets and lease liabilities for the periods presented. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,243 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: </span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company’s leases for the periods presented were as follows:</span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, no </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">leases were expected to commence that would create significant rights and obligations for the Company.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company’s ROU assets and lease liabilities for the periods presented. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,243 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 46014000 49045000 11095000 10389000 57109000 59434000 8889000 7451000 2865000 3249000 40483000 44092000 4006000 6708000 56243000 61500000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: </span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: </span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:59.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11295000 3095000 14390000 10127000 2383000 12510000 8605000 1800000 10405000 6570000 50000 6620000 5561000 21000 5582000 16758000 0 16758000 58916000 7349000 66265000 9544000 478000 10022000 49372000 6871000 56243000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company’s leases for the periods presented were as follows:</span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12841000 13026000 3271000 2615000 448000 606000 16560000 16247000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P6Y9M18D P7Y10M24D P2Y7M6D P3Y3M18D 0.049 0.052 0.052 0.054 10536000 8183000 450000 628000 6918000 5087000 4779000 9772000 3941000 3267000 DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% senior subordinated convertible notes matured in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed rate convertible debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,157,804 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. There were no shares issued in connection with the settlement as the Company’s share price did not exceed the conversion price of </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company’s convertible debt consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,855 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,664 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2027 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2024 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">stock. A holder may convert fewer than all of such holder’s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company’s existing and future senior debt, (ii) equal in right of payment to any of the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9 million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes. In connection with the issuance of the 2024 Notes, the Company incurred $3.4 million of issuance costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 19 to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on net income (loss) per common share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the 2018 Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of December 31, 2020, there were no outstanding amounts due under the 2018 Credit Facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.</span></div> 1100000000 The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: <div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% senior subordinated convertible notes matured in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed rate convertible debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,157,804 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. There were no shares issued in connection with the settlement as the Company’s share price did not exceed the conversion price of </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.</span></div> 0.0125 600000000 0 12312000 0 683000 0 587005000 0 0.00599 495000000 495000000 5116000 6533000 1744000 2229000 488140000 486238000 0.0150 0 374993000 0 12078000 0 1033000 0 361882000 1075145000 848120000 627090000 0 530714000 521839000 0 405679000 1157804000 927518000 375000000.0 0 94.15 25 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company’s convertible debt consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,855 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,664 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12350000 4907000 12452000 1829000 2031000 3610000 14682000 15917000 27602000 28861000 22855000 43664000 600000000.0 0.0125 7.2743 137.47 585800000 13500000 700000 495000000.0 0.98 0.00599 8.0212 1000000 124.67 1000 481700000 1 9900000 3400000 200000000.0 0.0100 0.0195 0.0000 0.0095 0.0015 0.0035 1000000.0 0 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Details about AOCI Components</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of<br/>Operations Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,958 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain (loss) on cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of available-for-sale debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of the above</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain on available-for-sale debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of change in accounting principle </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance as of January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,308)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,547)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,386 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,184 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,917)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,413 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,482 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,893 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The amount represents the reclassification from AOCI to Accumulated Deficit due to the adoption of ASU 2018-02, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span> (ASU 2018-02) in the first quarter of 2018. The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Details about AOCI Components</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of<br/>Operations Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,958 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain (loss) on cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of available-for-sale debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of the above</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain on available-for-sale debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 18122000 17672000 -6005000 -4942000 -1819000 3958000 13180000 15853000 -2047000 552000 0 0 -127000 0 0 425000 0 0 13605000 15853000 -2047000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of change in accounting principle </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance as of January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,308)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,547)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,386 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,184 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,917)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,413 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,482 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,893 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The amount represents the reclassification from AOCI to Accumulated Deficit due to the adoption of ASU 2018-02, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span> (ASU 2018-02) in the first quarter of 2018. -20232000 -2722000 -7000 -22961000 0 -586000 0 -586000 -20232000 -3308000 -7000 -23547000 25386000 1804000 -6000 27184000 -2047000 0 0 -2047000 0 413000 0 413000 27433000 1391000 -6000 28818000 7201000 -1917000 -13000 5271000 25266000 7122000 -2000 32386000 15853000 0 0 15853000 0 1640000 0 1640000 9413000 5482000 -2000 14893000 16614000 3565000 -15000 -15000 20164000 -23462000 976000 15000 -22471000 13180000 552000 0 13732000 0 100000 0 100000 -36642000 324000 15000 -36303000 -20028000 3889000 0 -16139000 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues by geographic region:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates total Net Product Revenues by product.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Firdapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470,356 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for 24% and 22% of the Company’s December 31, 2020 accounts receivable balance, respectively, compared to December 31, 2019 when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of December 31, 2020 and 2019, the accounts receivable balance for Genzyme included $72.1 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Genzyme. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outbreak of COVID-19 continues to affect economies and business around the world. The Company's global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and its business operations were impacted by COVID-19 during the year ended December 31, 2020 and the Company anticipates a continued impact due to COVID-19 on its financial results in fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets, which consist of property, plant and equipment and ROU assets are summarized by geographic region in the following table.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-lived assets by geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,070,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 0.10 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues by geographic region:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 912375000 778440000 696793000 518465000 509188000 436434000 205862000 218792000 185046000 223753000 197628000 172939000 1860455000 1704048000 1491212000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates total Net Product Revenues by product.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Firdapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470,356 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 544257000 544345000 481977000 457736000 463353000 433582000 391298000 374334000 345851000 170983000 86857000 12173000 110192000 71997000 39889000 1288000 22348000 21787000 1675754000 1563234000 1335259000 130107000 97809000 135097000 1805861000 1661043000 1470356000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,805,861 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,661,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 756863000 669171000 560030000 498725000 485596000 424357000 205862000 218792000 184984000 214304000 189675000 165888000 1675754000 1563234000 1335259000 130107000 97809000 135097000 1805861000 1661043000 1470356000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.16 0.17 0.18 0.15 0.13 0.12 0.12 0.11 0.10 0.43 0.41 0.40 0.24 0.22 0.24 0.16 72100000 60200000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets, which consist of property, plant and equipment and ROU assets are summarized by geographic region in the following table.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-lived assets by geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,070,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 771286000 773991000 300555000 278082000 17739000 18229000 1089580000 1070302000 EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Shares Available Under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, an aggregate of approximately 36.7 million unissued shares was authorized for future issuance under the Company’s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan and the ESPP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the 2017 Equity Incentive Plan, shares issued under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. Shares formerly reserved for future issuance under the 2006 Share Incentive Plan were transferred to the 2017 Equity Incentive Plan and became available for issuance thereunder upon the effectiveness of the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company’s stock-based compensation plans are administered by the Company’s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note 3 to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2017 Equity Incentive Plan provides for awards of RSUs and stock options as well as other forms of equity compensation. Stock option awards granted to employees generally vest over a four-year period on a cliff basis twelve months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally ten years from the grant date. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. As of December 31, 2020, approximately 20.5 million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ESPP was initially approved in June 2006, replacing the Company’s previous plan, and was most recently amended in June 2019. Under BioMarin’s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. During the year ended December 31, 2020, the Company issued 0.3 million shares under the ESPP. As of December 31, 2020, approximately 7.0 million shares were authorized and 3.4 million shares reserved for future issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Board of Director Grants</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 19, 2019, the Board of BioMarin approved revised compensation for the Independent Directors of the Company. On the date of the Company’s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000 ($375,000 prior to September 19, 2019), with the number of RSUs to be granted calculated based on the three-month trailing average closing price of the Company’s common stock on the Nasdaq Global Select Market. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company’s next annual meeting of stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,819 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $20.1 million, $20.3 million and $20.0 million was capitalized into inventory for the years ended December 31, 2020, 2019 and 2018, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Service-Based Vesting Conditions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with service-based vesting conditions under the plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,585,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,190,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,308,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,173,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2020, 2019 and 2018, was $77.13, $91.28 and $84.63, respectively. The total intrinsic value of restricted stock that vested and was released in the years ended December 31, 2020, 2019 and 2018, was $109.9 million, $101.0 million and $84.5 million respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $245.3 million was expected to be recognized over a weighted average period of 2.6 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Performance-based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Compensation Committee of the Board (with respect to awards to certain executive officers other than the Chief Executive Officer) and the Board (with respect to awards to the Chief Executive Officer) may grant RSUs with performance-based vesting conditions (PRSUs) to certain executive officers. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue PRSUs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Although no PRSUs with vesting conditions based on revenue performance were granted during the year ended December 31, 2020, awards granted during prior periods presented were contingent upon the achievement of an annual revenue target and the earned RSUs vest over a three-year service period. The number of shares that may be earned ranged between 50% and 200% of the base RSUs, depending on the percentage of the respective annual year's Net Product Revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates achieved against the target, with a threshold achievement level of 75% of target and a ceiling achievement level of 125% of target. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to Revenue PRSUs under the Company's equity plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment for shares earned</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of Revenue PRSUs was $94.53 and $83.57 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2020, total unrecognized compensation expense of $3.5 million related to Revenue PRSUs was expected to be recognized over a weighted average period of approximately 1.0 year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other PRSUs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">: Below is a summary of activity related to RSUs with vesting conditions based on other performance targets under the Company's equity plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of Other PRSUs was $84.17 and $81.00 for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-vested Other PRSUs include a grant with vesting contingent upon the achievement of a three-year Non-GAAP income target and a grant with vesting contingent upon achievement of a three-year strategic goal target. The awarded PRSUs, if any, vest ratably over a three-year service period. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also included in non-vested Other PRSUs are grants that vest contingent upon achievement of certain regulatory milestones that, for accounting purposes, were deemed not yet probable of vesting as of December 31, 2020. Therefore, as of December 31, 2020, total unrecognized compensation expense of $8.1 million related to awards deemed probable of vesting and $7.9 million related to awards not yet deemed probable of vesting. The expected weighted average period over which expense is to be recognized for the awards that are considered probable of vesting as of December 31, 2020 was 2.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards with Market-based Vesting Conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s TSR is above the 50th percentile but negative on an absolute basis. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's equity plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilized a Monte Carlo simulation model to determine the grant date fair value per base TSR-RSU of $112.12 using the following assumptions for the grant in March 2020: an expected term of 2.8 years, discount rate of 0.4%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. In June 2020, the Compensation Committee of the Board approved an additional grant of RSUs with market-based vesting conditions with identical terms as those granted in March 2020. The third-party valuation per base TSR-RSU of $217.65 used the following assumptions: an expected term of 2.5 years, discount rate of 0.2%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. As of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2020, total unrecognized compensation expense of $14.1 million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.8 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Purchase Rights</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2020. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:50.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,264,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,240,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,829,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,573 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,390,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $87.69, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted-average fair value per stock option granted in the years ended December 31, 2020, 2019 and 2018, were $27.47, $36.84 and $33.40, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018, was $71.9 million, $32.5 million and $79.9 million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 – 42.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.1 – 37.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.8 – 38.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 – 1.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 – 3.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 – 2.8%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, total unrecognized compensation cost related to unvested stock options of $35.3 million was expected to be recognized over a weighted average period of 2.5 years.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net tax benefit from stock options exercised during the year ended December 31, 2020 was $4.5 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Purchase Rights</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 – 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7 – 35.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7% – 35.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 – 2.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 – 2.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 – 2.8%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $18.3 million was expected to be recognized over a weighted average period of 1.4 years.</span></div> 36700000 P4Y P12M P10Y P4Y 20500000 0.85 P2Y 0.10 25000 300000 7000000.0 3400000 400000 375000 P3M P1Y <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,711 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,819 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 26246000 16146000 13558000 61942000 56649000 57557000 101523000 87070000 77704000 189711000 159865000 148819000 20100000 20300000 20000000.0 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with service-based vesting conditions under the plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,585,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,190,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,308,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,173,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to Revenue PRSUs under the Company's equity plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment for shares earned</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Below is a summary of activity related to RSUs with vesting conditions based on other performance targets under the Company's equity plan for the year ended December 31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's equity plan for the year ended December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3585384 88.54 2190380 77.13 1308962 87.57 293678 85.17 4173124 83.41 77.13 91.28 84.63 109900000 101000000.0 84500000 245300000 P2Y7M6D P3Y 0.50 2 0.75 1.25 226884 89.09 2272 73.82 126608 88.09 3197 94.53 99351 90.31 94.53 83.57 3500000 P1Y 44260 81.00 184460 84.17 4495 73.82 3560 78.72 220665 83.83 84.17 81.00 P3Y 0.50 2 8100000 7900000 P2Y2M12D P3Y 0 2 1 0.50 99010 143.92 131350 115.85 0 0 9370 143.92 220990 127.23 112.12 P2Y9M18D 0.004 0 217.65 P2Y6M 0.002 0 14100000 P1Y9M18D <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2020. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:50.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,264,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,240,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,829,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,573 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,390,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $87.69, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 31, 2020.</span></div> 7264235 67.99 146700000 891610 76.02 1240511 43.87 85897 86.07 6829437 73.19 P4Y9M18D 119607000 1438573 81.56 P8Y7M6D 11635000 5390864 70.95 P3Y9M18D 107972000 87.69 27.47 36.84 33.40 71900000 32500000 79900000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5 – 42.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.1 – 37.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.8 – 38.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6 – 5.7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 – 1.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 – 3.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 – 2.8%</span></div></td></tr></table></div> 0.365 0.422 0.371 0.374 0.368 0.384 0.0000 0.0000 0.0000 P4Y7M6D P5Y10M24D P4Y7M6D P5Y9M18D P4Y7M6D P5Y8M12D 0.003 0.017 0.022 0.030 0.023 0.028 35300000 P2Y6M 4500000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6 – 69.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7 – 35.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7% – 35.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 – 2.0 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 – 2.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 – 2.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 – 2.8%</span></div></td></tr></table></div> 0.306 0.692 0.277 0.350 0.297 0.350 0.0000 0.0000 0.0000 P0Y6M P2Y P0Y6M P2Y P0Y6M P2Y 0.001 0.028 0.012 0.028 0.012 0.028 18300000 P1Y4M24D OTHER EMPLOYEE BENEFITS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with certain officers. Generally, these agreements can be terminated without cause by the Company upon prior written notice and payment of specified severance, or by the officer upon four weeks’ prior written notice to the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">401(k) Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan). Eligible employees may contribute to the 401(k) Plan up to the lesser of 60% of their current compensation or an amount up to a statutorily prescribed annual limit. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee’s eligible contributions, up to a maximum of the lesser of 6% of the employee’s annual compensation or the annual statutory contribution limit. The Company’s matching contribution vests immediately and was approximately $26.4 million, $28.5 million and $23.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company amended the NQDC in the second quarter of 2019 to prohibit the diversification of deferrals of Company stock, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity and, subsequent to the 2019 amendment, changes in the fair value of Company stock held in the NQDC are no longer recognized in earnings. Other contributions held in the NQDC are classified as trading securities and recorded at fair value with the corresponding deferred compensation obligation classified as a liability. Changes in the fair value of non-BioMarin investments are recognized in earnings in the period they occur. </span></div>See Note 10 to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities. 0.60 1 0.06 26400000 28500000 23000000.0 INCOME TAXESThe benefit from income taxes was based on loss before income taxes as follows:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Source</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,939)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Source</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,811)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142,705)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. and foreign components of the benefit from income taxes were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) current income tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(838,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(888,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,760)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68,378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(901,422)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,963)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,494)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a reconciliation of the statutory federal income tax (benefit) expense to the Company’s effective tax rate:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax benefit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan Drug &amp; General Business Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Source Income Subject to U.S. Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax rate differential </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfer of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(852,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CARES Act carryback claim</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance/deferred benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax (benefit) expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(901,422)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,963)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,494)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)     For the year ended December 31, 2019, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the benefit of the valuation allowance release against the deferred tax assets of the Company’s Dutch subsidiary of $29.6 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant components of the Company’s net deferred tax assets were as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, reserves, and prepaids</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joint venture basis difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,642)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,007)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,907)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,431,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542,065 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. The valuation allowance increased in 2020 due primarily to the Company’s expectation that state R&amp;D credits will not be utilized.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2030 – 2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal R&amp;D and orphan drug credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2024 – 2040 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2021 – 2040 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2022 – 2025 </span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not included in the table above are $124.3 million of state research credit carryovers that will carry forward indefinitely.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by IRC Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2020 and 2019, is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Deletions) Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,748 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December 31, 2020 were potential benefits of $175.1 million that, if recognized, would affect the effective tax rate. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December 31, 2020. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MzMyZDE1Yzg3YjRhMTdiMDM5NGE1MzgwZDQ0ZGZhL3NlYzowNzMzMmQxNWM4N2I0YTE3YjAzOTRhNTM4MGQ0NGRmYV8yMjAvZnJhZzpmYTg5ZDBiYzhhZjM0OTg4YmJjNDg4ODY5N2I2NmUxZi90ZXh0cmVnaW9uOmZhODlkMGJjOGFmMzQ5ODhiYmM0ODg4Njk3YjY2ZTFmXzQ3OTE_26ed1716-170d-4598-a523-fdf4d8b4f0e1">three</span> to five years. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. This excess totaled approximately $15.2 million as of December 31, 2020, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.</span></div> The benefit from income taxes was based on loss before income taxes as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Source</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,939)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Source</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,811)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142,705)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -162939000 -182112000 -128700000 120617000 87301000 -14005000 -42322000 -94811000 -142705000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. and foreign components of the benefit from income taxes were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) current income tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) deferred income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(838,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(888,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,760)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68,378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(901,422)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,963)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,494)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -14758000 5127000 -2660000 1201000 1331000 588000 1042000 5339000 4956000 -12515000 11797000 2884000 -45038000 -58311000 -72074000 -5321000 -5394000 -994000 -838548000 -19055000 4690000 -888907000 -82760000 -68378000 -901422000 -70963000 -65494000 835100000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a reconciliation of the statutory federal income tax (benefit) expense to the Company’s effective tax rate:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax benefit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan Drug &amp; General Business Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Source Income Subject to U.S. Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax rate differential </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfer of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(852,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CARES Act carryback claim</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance/deferred benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax (benefit) expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(901,422)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,963)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,494)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)     For the year ended December 31, 2019, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the benefit of the valuation allowance release against the deferred tax assets of the Company’s Dutch subsidiary of $29.6 million.</span></div> -8888000 -19911000 -29968000 -3264000 -2784000 -276000 44114000 43124000 66451000 -1101000 239000 -5647000 0 -1804000 -2361000 6266000 -52000 6543000 -16238000 -30639000 12583000 9571000 8294000 7440000 2166000 12123000 8545000 -852338000 0 0 2201000 0 0 1843000 -1132000 -423000 6876000 7827000 4521000 -901422000 -70963000 -65494000 29600000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant components of the Company’s net deferred tax assets were as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, reserves, and prepaids</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joint venture basis difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,642)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,007)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,907)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,431,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542,065 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30718000 32181000 532394000 508560000 66889000 61807000 873575000 29413000 47011000 42873000 8991000 11470000 32012000 6290000 454000 575000 93075000 86197000 1498969000 606972000 1164000 993000 1364000 1647000 1517000 3003000 0 2364000 8280000 10258000 54682000 46642000 67007000 64907000 1431962000 542065000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2030 – 2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal R&amp;D and orphan drug credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2024 – 2040 </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2021 – 2040 </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2022 – 2025 </span></td></tr></table></div> 4753000 566887000 182961000 75718000 124300000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2020 and 2019, is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Deletions) Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,748 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 168748000 147445000 16481000 19287000 -2527000 2016000 138000 0 182564000 168748000 175100000 P5Y 15200000 NET INCOME (LOSS) PER COMMON SHAREPotentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted income (loss) per common share (common shares in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">859,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain on the Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income (loss) per common share as they were anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as the Company’s closing stock price on December 31, 2019 and 2018 did not exceed the conversion price of $94.15 per share for the 2020 Notes. There is no similar capped call transaction associated with the 2024 Notes or 2027 Notes. See Note 13 to these Consolidated Financial Statements for information on the Company’s convertible debt.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted income (loss) per common share (common shares in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">859,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain on the Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss), diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 859100000 -23848000 -77211000 8313000 0 0 0 0 -710000 867413000 -23848000 -77921000 180804000 179039000 177061000 1543000 0 0 2874000 0 0 3970000 0 0 1938000 0 0 353000 0 0 196000 0 207000 191678000 179039000 177268000 4.75 -0.13 -0.44 4.53 -0.13 -0.44 <div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income (loss) per common share as they were anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:62.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,836 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5287000 7264000 7364000 0 3983000 3983000 0 3970000 3970000 2235000 3956000 3404000 314000 587000 435000 0 205000 0 7836000 19965000 19156000 94.15 94.15 LICENSE AND COLLABORATION AGREEMENTSIn October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0 million, a minority 15% equity ownership interest in the licensee, <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and sales milestones are met by the licensee.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee’s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December 31, 2020. As a result, the Company's loss exposure is limited to the value of the equity investment of $8.1 million which is included in Other Assets on the Company’s Consolidated Balance Sheets as of December 31, 2020. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2017, the Company executed a license agreement and a settlement agreement with Sarepta Therapeutics (Sarepta) that provide Sarepta with global exclusive rights to the Company’s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under these agreements, Sarepta may pay certain additional regulatory and commercial milestone fees for exons 51, 45, 53 and possibly on future exon-skipping products to the Company if certain development and sales milestones are achieved. Additionally, the Company receives from Sarepta royalties based on 5% of net sales in the U.S. through the end of 2023 and 8% of net sales in the EU and in other countries, where certain of the Company’s patents exist, through September 30, 2024. The Company retained the right to convert the license to a co-exclusive right in the event it decides to proceed with an exon-skipping therapy for DMD.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to Kuvan and Palynziq from Merck Serono, with the exception of Kuvan in Japan. Previously, the Company had exclusive rights to Kuvan in the U.S. and Canada and Palynziq in the U.S. and Japan. Pursuant to the A&amp;R Kuvan Agreement, if future sales milestones are met, the Company is obligated to pay Merck Serono up to a maximum of €60.0 million, in cash, which was an estimated fair value of $73.6 million as of December 31, 2020. Pursuant to the Pegvaliase Agreement, the Company paid Merck Serono €125.0 million in cash when the Palynziq development milestones were achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to Firdapse, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of Firdapse in North America. In January 2020, the Company completed the sale of worldwide rights to Firdapse to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note 6 to these Consolidated Financial Statements for further information about the Firdapse sale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the Kuvan new drug application. The Company receives royalties on net sales of the product in Japan.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is engaged in R&amp;D collaborations with various other entities. These provide for sponsorship of R&amp;D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.</span></div> 3000000.0 0.15 8100000 0.05 0.08 60000000.0 73600000 125000000.0 0.07 0.10 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company was subject to contingent payments totaling approximately $662.8 million upon achievement of certain development and regulatory activities and commercial sales milestones if they occur before certain dates in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $73.6 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from Merck Serono and $237.7 million related to programs that are no longer being developed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company recorded $60.1 million of contingent liabilities on its Consolidated Balance Sheet, all of which was long-term. See Note 3 and Note 10 to these Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;D activities. These amounts are included as R&amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients, certain inventory related items and certain third-party R&amp;D services. As of December 31, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $142.8 million. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under certain of the Company’s lease agreements, the Company is contractually obligated to return leased space to its original condition upon termination of the applicable lease agreement. The Company records interest expense to accrete the asset retirement obligation liability to full value and depreciates each retirement obligation asset, both over the term of the associated lease agreement. As of December 31, 2020 and 2019, the balance of the asset retirement obligation liability was $3.7 million and $3.0 million, respectively. See Note 3 to these Consolidated Financial Statements for further information on the Company's fair value measurements.</span></div> 662800000 235000000.0 73600000 237700000 60100000 142800000 3700000 3000000.0 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2020
Feb. 12, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-26727    
Entity Registrant Name BioMarin Pharmaceutical Inc    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 68-0397820    
Entity Address, Address Line One 770 Lindaro Street    
Entity Address, City or Town San Rafael    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94901    
City Area Code 415    
Local Phone Number 506-6700    
Title of 12(b) Security Common Stock, par value $.001    
Trading Symbol BMRN    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 13.9
Entity Common Stock, Shares Outstanding   181,829,680  
Documents Incorporated by Reference Specified portions of the registrant's definitive proxy statement for the registrant's 2021 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December 31, 2020, are incorporated by reference under Part III of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001048477    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 649,158 $ 437,446
Short-term investments 416,228 316,361
Accounts receivable, net 448,351 377,404
Inventory 698,548 680,275
Other current assets 129,934 130,657
Total current assets 2,342,219 1,942,143
Noncurrent assets:    
Long-term investments 285,473 411,978
Property, plant and equipment, net 1,032,471 1,010,868
Intangible assets, net 417,271 456,580
Goodwill 196,199 197,039
Deferred tax assets 1,432,150 549,422
Other assets 142,237 122,009
Total assets 5,848,020 4,690,039
Current liabilities:    
Accounts payable and accrued liabilities 492,548 570,621
Short-term convertible debt, net 0 361,882
Total current liabilities 492,548 932,503
Noncurrent liabilities:    
Long-term convertible debt, net 1,075,145 486,238
Long-term contingent consideration 60,130 50,793
Other long-term liabilities 114,195 98,124
Total liabilities 1,742,018 1,567,658
Stockholders’ equity:    
Common stock, $0.001 par value: 500,000,000 shares authorized;    181,740,999 and 179,838,114 shares issued and outstanding, respectively 182 180
Additional paid-in capital 4,993,407 4,832,707
Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) (9,839) (9,961)
Accumulated other comprehensive income (loss) (16,139) 20,164
Accumulated deficit (861,609) (1,720,709)
Total stockholders’ equity 4,106,002 3,122,381
Total liabilities and stockholders’ equity $ 5,848,020 $ 4,690,039
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 181,740,999 179,838,114
Common stock, shares outstanding (in shares) 181,740,999 179,838,114
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
REVENUES:      
Total revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
OPERATING EXPENSES:      
Cost of sales 524,272 359,466 315,264
Research and development 628,116 715,007 696,328
Selling, general and administrative 737,669 680,924 604,353
Intangible asset amortization and contingent consideration 66,658 74,108 48,791
Gain on sale of nonfinancial assets (59,495) (25,000) (50,000)
Total operating expenses 1,897,220 1,804,505 1,614,736
LOSS FROM OPERATIONS (36,765) (100,457) (123,524)
Equity in the loss of BioMarin/Genzyme LLC (6) (587) (553)
Interest income 16,610 22,748 22,831
Interest expense (29,309) (23,460) (43,664)
Other income, net 7,148 6,945 2,205
LOSS BEFORE INCOME TAXES (42,322) (94,811) (142,705)
Benefit from income taxes (901,422) (70,963) (65,494)
NET INCOME (LOSS) $ 859,100 $ (23,848) $ (77,211)
NET INCOME (LOSS) PER SHARE, BASIC (in usd per share) $ 4.75 $ (0.13) $ (0.44)
NET INCOME (LOSS) PER SHARE, DILUTED (in usd per share) $ 4.53 $ (0.13) $ (0.44)
Weighted average common shares outstanding, basic (in shares) 180,804 179,039 177,061
Weighted average common shares outstanding, diluted (in shares) 191,678 179,039 177,268
Product      
REVENUES:      
Total revenues $ 1,805,861 $ 1,661,043 $ 1,470,356
Royalty and Other Revenues      
REVENUES:      
Total revenues $ 54,594 $ 43,005 $ 20,856
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement of Comprehensive Income [Abstract]      
Net Income (Loss) $ 859,100 $ (23,848) $ (77,211)
Available-for-sale debt securities:      
Unrealized holding gain (loss) arising during the period, net    of tax impact of $(227), $(1,640) and $(413), respectively. 749 5,482 1,391
Less: reclassifications to net income (loss), net of tax impact of    $(127), $0 and $0, respectively. 425 0 0
Net change in unrealized holding gain (loss), net of tax 324 5,482 1,391
Cash flow hedges:      
Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented. (23,462) 25,266 25,386
Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented. 13,180 15,853 (2,047)
Net change in unrealized holding gain (loss), net of tax (36,642) 9,413 27,433
Other 15 (2) (6)
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX (36,303) 14,893 28,818
COMPREHENSIVE INCOME (LOSS) $ 822,797 $ (8,955) $ (48,393)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement of Comprehensive Income [Abstract]      
Unrealized holding gain (loss) arising during the period, tax $ (227,000) $ (1,640,000) $ (413,000)
Reclassification, tax (127,000) 0 0
Unrealized holding gain (loss) arising during the period, tax 0 0 0
Reclassifications to net loss, tax $ 0 $ 0 $ 0
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Company Stock Held By NQDC
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning Balance (in shares) at Dec. 31, 2017   175,844              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax (in shares)   2,314              
Repurchase of common stock (in shares)   0              
Conversion of convertible notes, net (in shares)   95              
Ending Balance (in shares) at Dec. 31, 2018   178,253              
Beginning Balance at Dec. 31, 2017 $ 2,808,663 $ 176 $ 4,483,220 $ 0 $ (14,224) $ (22,961) $ (586) $ (1,637,548) $ 20,625
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax   2 31,583            
Conversion of convertible notes, net     (16)            
Stock-based compensation     155,139            
Repurchase of common stock     0 0          
Common stock held by the NQDC     0   923        
Accounting impact of NQDC Plan Change     0   0        
Retirement of treasury stock       0          
Other comprehensive income (loss) 28,818                
Net Income (Loss) (77,211)             (77,211)  
Ending Balance at Dec. 31, 2018 2,967,940 $ 178 4,669,926 0 (13,301) 5,271 0 (1,694,134) (2,727)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax (in shares)   1,585              
Repurchase of common stock (in shares)   0              
Conversion of convertible notes, net (in shares)   0              
Ending Balance (in shares) at Dec. 31, 2019   179,838              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax   $ 2 (11,071)            
Conversion of convertible notes, net     0            
Stock-based compensation     163,891            
Repurchase of common stock     0 0          
Common stock held by the NQDC     (692)   692        
Accounting impact of NQDC Plan Change     10,653   2,648        
Retirement of treasury stock       0          
Other comprehensive income (loss) 14,893                
Net Income (Loss) (23,848)             (23,848)  
Ending Balance at Dec. 31, 2019 3,122,381 $ 180 4,832,707 0 (9,961) 20,164 $ 0 (1,720,709) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax (in shares)   2,421              
Repurchase of common stock (in shares)   (518)              
Conversion of convertible notes, net (in shares)   0              
Ending Balance (in shares) at Dec. 31, 2020   181,741              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuances under equity incentive plans, net of tax   $ 2 27,275            
Conversion of convertible notes, net     0            
Stock-based compensation     183,547            
Repurchase of common stock     (50,000) (50,000)          
Common stock held by the NQDC     (122)   122        
Accounting impact of NQDC Plan Change     0   0        
Retirement of treasury stock       50,000          
Other comprehensive income (loss) (36,303)                
Net Income (Loss) 859,100             859,100  
Ending Balance at Dec. 31, 2020 $ 4,106,002 $ 182 $ 4,993,407 $ 0 $ (9,839) $ (16,139)   $ (861,609)  
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:      
NET INCOME (LOSS) $ 859,100 $ (23,848) $ (77,211)
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Depreciation and amortization 105,172 105,300 95,671
Non-cash interest expense 16,511 13,960 31,186
Amortization of premium on investments (accretion of discount) 567 (2,000) 358
Stock-based compensation expense 189,711 159,865 148,819
Gain on sale of nonfinancial assets (59,495) (25,000) (50,000)
Inventory reserves, net of stock-based compensation 75,609 0 0
Deferred income taxes (888,907) (82,760) (68,378)
Unrealized foreign exchange loss (gain) 8,011 1,025 (17,766)
Non-cash changes in the fair value of contingent consideration 4,500 5,205 9,296
Other (997) (2,393) (2,347)
Changes in operating assets and liabilities:      
Accounts receivable, net (59,035) (37,852) (54,274)
Inventory (61,151) (107,554) (23,747)
Other current assets 18,312 (27,008) (17,767)
Other assets (28,647) (8,895) (935)
Accounts payable and accrued liabilities (87,025) 77,089 38,389
Other long-term liabilities (6,871) 3,128 8,914
Net cash provided by operating activities 85,365 48,262 20,208
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchases of property, plant and equipment (114,312) (145,026) (144,620)
Maturities and sales of investments 555,834 740,211 993,734
Purchase of available-for-sale debt securities (529,663) (632,023) (634,753)
Proceeds from sale of nonfinancial assets 67,159 25,000 50,000
Purchase of intangible assets (23,207) (18,380) 0
Investment in convertible note (8,709) 0 0
Other (723) (808) (10)
Net cash provided by (used in) investing activities (53,621) (31,026) 264,351
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from exercises of awards under equity incentive plans 71,913 31,611 67,488
Taxes paid related to net share settlement of equity awards (44,638) (42,680) (35,919)
Repurchase of common stock (50,000) 0 0
Proceeds from convertible senior subordinated note offering, net 585,752 0 0
Repayments of convertible debt (374,991) 0 (374,953)
Payment of contingent consideration 0 (58,518) (44,623)
Principal repayments of financing leases (6,918) (5,087) 0
Net cash provided by (used in) financing activities 181,118 (74,674) (388,007)
Effect of exchange rate changes on cash (1,150) 902 (598)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 211,712 (56,536) (104,046)
Cash and cash equivalents:      
Beginning of period 437,446 493,982 598,028
End of period 649,158 437,446 493,982
SUPPLEMENTAL CASH FLOW DISCLOSURES:      
Cash paid for interest, net of interest capitalized into fixed assets 12,178 8,552 11,623
Cash paid for income taxes 8,977 9,726 16,676
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Increase (decrease) in accounts payable and accrued liabilities related to fixed assets (5,184) 7,589 (1,206)
Increase (decrease) in accounts payable and accrued liabilities related to intangible assets $ (292) $ 4,247 $ 0
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.4
NATURE OF OPERATIONS AND BUSINESS RISKS
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
NATURE OF OPERATIONS AND BUSINESS RISKS NATURE OF OPERATIONS AND BUSINESS RISKS
BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.
The Company is subject to a number of risks, including: the continuing impact of the novel coronavirus disease (referred to as COVID-19) pandemic on the Company's business; the financial performance of its commercial products; the potential need for additional financing; the Company’s ability to successfully commercialize its approved products; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
Basis of Presentation
These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.
On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements. See Note 4 to these Consolidated Financial Statements for additional discussion of the adoption of ASU 2016-13 and required disclosures.

Use of Estimates
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly
uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents
The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.
Marketable and Non-Marketable Securities
Marketable Securities
The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations.
All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.
Non-Marketable Equity Securities
The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income, Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.
Inventory
Commercial Inventory
The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.
Inventory Produced Prior to Regulatory Approval
When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing
application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&D).
Property, Plant and Equipment
Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&D and Selling, General and Administrative (SG&A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&D projects with no alternative future uses are expensed as incurred and recorded to R&D in the Consolidated Statements of Operations.
Leasehold improvementsShorter of life of asset or lease term
Building and improvements
20 to 50 years
Manufacturing and laboratory equipment
5 to 15 years
Computer hardware and software
3 to 7 years
Office furniture and equipment5 years
Vehicles5 years
Land improvements
10 to 20 years
LandNot applicable
Construction-in-progressNot applicable
Leases
Effective January 1, 2019, the Company adopted Accounting Standards Codification (ASC) Topic 842, Leases. The amended guidance required balance sheet recognition of lease right-of-use (ROU) assets and liabilities by lessees for leases classified as operating leases. The Company adopted ASC Topic 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption through a cumulative adjustment to Accumulated Deficit.
The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.
Goodwill and Intangible Assets
The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Impairment
The Company assesses its goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable.
Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.
Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Impairment charges that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Long-lived Asset Impairment
The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&A in the Consolidated Statements of Operations. Impairment charges related to finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC Topic 606, the Company performs the following five steps:
(i)identification of the promised goods or services in the contract;
(ii)determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii)measurement of the transaction price, including the constraint on variable consideration;
(iv)allocation of the transaction price to the performance obligations based on estimated selling prices; and
(v)recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.
Net Product Revenues
In the U.S., the Company’s commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues.
For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Genzyme
and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known.
Revenue Reserves
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.
Government Rebates: The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.
Sales Returns: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.
Other Incentives: Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on Brineura, Kuvan or Palynziq therapy. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.
Royalty and Other Revenues
Royalties: For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone payments: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal
would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Research and Development
R&D costs are generally expensed as incurred. These expenses include contract R&D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs and R&D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.
Convertible Debt
For non-conventional convertible debt that may be settled entirely or partially in cash, the Company separately accounts for the liability and equity components by allocating the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. The liability component is presented net of any discounts and issuance costs. For conventional convertible debt that may only be settled with common shares, the Company reports debt, net of any discounts or issuance costs, on the Consolidated Balance Sheets.
The Company recognizes discount accretion and debt issuance cost amortization using the effective interest method and is reported in Interest Expense on the Consolidated Statements of Operations.
Net Income (Loss) Per Common Share
Basic net income (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.
Stock-Based Compensation
The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&D or SG&A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur.
Restricted Stock Units
The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed.
Stock Options and Purchase Rights
The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock
options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period.
The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.
Income Taxes
The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.
The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.
Foreign Currency
For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in SG&A in the Consolidated Statements of Operations.
Derivatives and Hedging Activities
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&A in the Consolidated Statements of Operations.
Fair Value of Financial Instruments
The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the
market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:
•Income approach, which is based on the present value of a future stream of net cash flows
•Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
The Company’s fair value methodologies depend on the following types of inputs:
•Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)
•Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)
•Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)
The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.
The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of long-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of the contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations.
See Notes 5, 10, 11, 13, 19 and 20 to these Consolidated Financial Statements for further information on the nature of these financial instruments.
Segment Information
The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.4
RECENT ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Dec. 31, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTSEffective January 1, 2020, the Company adopted FASB ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the previous other-than-temporary impairment model. The adoption of this standard had no impact on the Company’s Financial Statements.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCIAL INSTRUMENTS
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2020 and 2019, respectively:
December 31, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$370,325 $— $— $370,325 $370,325 $— $— 
Level 2:
Money market instruments
264,833 — — 264,833 264,833 — — 
Corporate debt securities
413,137 3,261 (8)416,390 — 220,551 195,839 
U.S. government agency securities
265,298 1,555 (1)266,852 14,000 192,488 60,364 
Asset-backed securities31,659 85 (2)31,742 — 3,189 28,553 
Foreign and other
549 168 — 717 — — 717 
Subtotal
975,476 5,069 (11)980,534 278,833 416,228 285,473 
Total
$1,345,801 $5,069 $(11)$1,350,859 $649,158 $416,228 $285,473 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments
173,100 — — 173,100 173,100 — — 
Corporate debt securities
518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities
209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other
549 145 (1)693 — — 693 
Subtotal
901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total
$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company’s long-term marketable securities mature between one and five years.
As of December 31, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.
The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December 31, 2020 and 2019, the fair value of the Company’s strategic investments was $10.5 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Consolidated Balance Sheets.
See Note 3 to these Consolidated Financial Statements for additional discussion regarding the Company’s fair value measurements.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
The change in the carrying value of Goodwill was as follows:
December 31,
20202019
Beginning balance $197,039 $197,039 
Less: disposition(840)— 
Ending carrying value$196,199 $197,039 
In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. As a result of the sale of Firdapse, in the first quarter of 2020 the Company recognized a $0.8 million reduction to Goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million.
The Company performed its annual assessment for goodwill impairment for the year ended December 31, 2020 and no goodwill impairment charges were recorded.
Intangible Assets, Net consisted of the following:
December 31,
20202019
Finite-lived intangible assets$644,087 $652,734 
Less: Accumulated amortization(226,816)(196,154)
Net carrying value$417,271 $456,580 
The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2020:
Net BalanceAverage Remaining Life
Acquired intellectual property$350,275 6.9 years
Repurchased royalty rights19,687 2.9 years
Technology transfer46,657 Not applicable (1)
Other652 
0.5 - 3.4 years
Total$417,271 
(1)The technology transfer intangible asset has not yet been placed into service.
As of December 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:
Fiscal YearAmount
2021$61,963 
202261,939 
202361,311 
202455,036 
202535,759 
Thereafter94,606 
$370,614 
In 2019 and 2018, the Company received $25.0 million and $50.0 million, respectively, due to the achievement by a third party of development and regulatory milestones and commercial sales milestones related to a previously sold intangible asset, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Operations.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT
 12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
Property, Plant and Equipment, Net, consisted of the following:
December 31,
20202019
Building and improvements$761,560 $725,906 
Manufacturing and laboratory equipment414,439 366,951 
Computer hardware and software189,740 167,554 
Land90,418 90,418 
Leasehold improvements55,134 51,324 
Furniture and equipment40,223 38,569 
Land improvements7,412 7,349 
Construction-in-progress109,140 111,897 
1,668,066 1,559,968 
Accumulated depreciation(635,595)(549,100)
Total property, plant and equipment, net$1,032,471 $1,010,868 
The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.
Years Ended December 31,
202020192018
Depreciation expense$88,169 $89,285 $90,375 
Depreciation capitalized into inventory$44,492 $37,481 $25,227 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY
 12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory consisted of the following:
December 31,
20202019
Raw materials$76,673 $74,442 
Work-in-process308,286 349,978 
Finished goods313,589 255,855 
Total inventory$698,548 $680,275 

Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. The Company had $29.2 million of valoctocogene roxaparvovec pre-launch inventory as of December 31, 2019.
In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requesting additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $87.2 million to Cost of Sales during the year ended December 31, 2020. The Company had no pre-launch inventory balance as of December 31, 2020.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL BALANCE SHEET INFORMATION
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION
Accounts Payable and Accrued Liabilities consisted of the following:
December 31,
20202019
Accounts payable and accrued operating expenses$191,429 $240,981 
Accrued compensation expense165,023 192,467 
Accrued rebates payable$65,526 57,163 
Forward foreign currency exchange contracts17,798 10,448 
Accrued royalties payable17,155 30,797 
Lease liability11,754 10,700 
Accrued income taxes9,661 3,195 
Value added taxes payable9,562 8,395 
Deferred revenue152 13,037 
Other4,488 3,438 
Total accounts payable and accrued liabilities$492,548 $570,621 
The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2020, 2019 and 2018, were as follows:
Balance at
Beginning
of Period
Provision for Current Period SalesPayments
Balance at
End of
Period
Year ended December 31, 2020:
Accrued rebates$57,163 $113,165 $(104,802)$65,526 
Reserve for cash discounts$1,889 $17,191 $(17,364)$1,716 
Year ended December 31, 2019:
Accrued rebates$43,116 $91,748 $(77,701)$57,163 
Reserve for cash discounts$1,197 $15,335 $(14,643)$1,889 
Year ended December 31, 2018:
Accrued rebates$36,472 $67,843 $(61,199)$43,116 
Reserve for cash discounts$1,055 $12,474 $(12,332)$1,197 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies to these Consolidated Financial Statements.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2020 and 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 13 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2020 and 2019.

Fair Value Measurements as of December 31, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$2,415 $— $2,415 
Other assets:
NQDC Plan assets19,962 — 19,962 
Restricted investments (1)
4,487 — 4,487 
Total other assets24,449 — 24,449 
Total assets$26,864 $— $26,864 
Liabilities:
Current liabilities:
NQDC Plan liability$2,415 $— $2,415 
Other long-term liabilities:
NQDC Plan liability19,962 — 19,962 
Contingent consideration— 60,130 60,130 
Total other long-term liabilities19,962 60,130 80,092 
Total liabilities$22,377 $60,130 $82,507 
Fair Value Measurements as of December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current Liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)The restricted investments as of December 31, 2020 and 2019 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.
There were no transfers between levels during the periods presented.
Liabilities measured at fair value using Level 3 inputs primarily consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.
Contingent consideration as of December 31, 2019$50,793 
Changes in the fair value of contingent consideration4,500 
Foreign exchange remeasurement of Euro denominated contingent consideration4,837 
Contingent consideration as of December 31, 2020$60,130 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
 12 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company's forward foreign currency exchange contracts (forward contracts) designated as hedging instruments have maturities up to two years and three months. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to three months.
The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.
Foreign Exchange ContractsDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Sell$782,327 $820,546 
Purchase$189,540 $212,348 
Derivatives not designated as hedging instruments:
Sell$98,343 $77,335 
Purchase$12,277 $30,818 
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$6,268 $19,584 
Other assets3,148 13,539 
Subtotal$9,416 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$17,551 $8,184 
Other long-term liabilities11,020 5,493 
Subtotal$28,571 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$84 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$247 $2,264 
Total Derivatives Assets$9,500 $33,592 
Total Derivatives Liabilities$28,818 $15,941 
(1)    See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.
Years Ended December 31,
20202019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,805,861 $18,122 $1,661,043 $17,672 
Operating expenses as reported$1,897,220 $(4,942)$1,804,505 $(3,453)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$115 $(5,259)
As of December 31, 2020, the Company expects to reclassify unrealized losses of $12.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 14 to these Consolidated Financial Statements.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
LEASES LEASES
The following table presents the Company’s ROU assets and lease liabilities for the periods presented.
December 31,
Lease ClassificationClassification20202019
Assets:
OperatingOther assets$46,014 $49,045 
FinancingOther assets11,095 10,389 
Total ROU assets$57,109 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$8,889 $7,451 
FinancingAccounts payable and accrued liabilities2,865 3,249 
Noncurrent:
OperatingOther long-term liabilities40,483 44,092 
FinancingOther long-term liabilities4,006 6,708 
Total lease liabilities$56,243 $61,500 
Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
2021$11,295 $3,095 $14,390 
202210,127 2,383 12,510 
20238,605 1,800 10,405 
20246,570 50 6,620 
20255,561 21 5,582 
Thereafter16,758 — 16,758 
Total lease payments58,916 7,349 66,265 
Less: Interest(9,544)(478)(10,022)
Present value of lease liabilities$49,372 $6,871 $56,243 

Lease costs associated with payments under the Company’s leases for the periods presented were as follows:
Years Ended December 31,
Lease CostClassification20202019
Operating (1)
Operating expenses$12,841 $13,026 
Financing:
AmortizationOperating expenses3,271 2,615 
Interest expenseOperating expenses448606
Total lease costs$16,560 $16,247 
(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Years Ended December 31,
Other Information20202019
Weighted average remaining lease term (in years):
Operating leases6.87.9
Financing leases2.63.3
Weighted average discount rate:
Operating leases4.9 %5.2 %
Financing leases5.2 %5.4 %
As of December 31, 2020, no leases were expected to commence that would create significant rights and obligations for the Company.
Years Ended December 31,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$10,536 $8,183 
Financing leases$450 $628 
Cash used in financing activities:
Financing leases$6,918 $5,087 
ROU assets obtained in exchange for lease obligations:
Operating leases$4,779 $9,772 
Financing leases$3,941 $3,267 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
DEBT DEBT
Convertible Notes
As of December 31, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
20202019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,312)— 
Unamortized deferred offering costs(683)— 
2027 Notes, net587,005 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,116)(6,533)
Unamortized deferred offering costs(1,744)(2,229)
2024 Notes, net488,140 486,238 
1.50% senior subordinated convertible notes matured in October 2020 (the 2020 Notes)
— 374,993 
Unamortized discount— (12,078)
Unamortized deferred offering costs— (1,033)
2020 Notes, net (1)
— 361,882 
Total convertible debt, net$1,075,145 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$627,090 $— 
2024 Notes
530,714 521,839 
2020 Notes
— 405,679 
Total fair value of fixed rate convertible debt$1,157,804 $927,518 
(1)The 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. There were no shares issued in connection with the settlement as the Company’s share price did not exceed the conversion price of
$94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
(2)The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
Interest expense on the Company’s convertible debt consisted of the following:
Years Ended December 31,
202020192018
Coupon interest$12,350 $4,907 $12,452 
Amortization of debt issuance costs1,829 2,031 3,610 
Accretion of discount on convertible notes14,682 15,917 27,602 
Total interest expense on convertible debt$28,861 $22,855 $43,664 
2027 Notes
In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense.
The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.
The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act.
2024 Notes
In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common
stock. A holder may convert fewer than all of such holder’s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million.
The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company’s existing and future senior debt, (ii) equal in right of payment to any of the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest.
In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9 million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes. In connection with the issuance of the 2024 Notes, the Company incurred $3.4 million of issuance costs.
See Note 19 to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on net income (loss) per common share.
Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the 2018 Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of December 31, 2020, there were no outstanding amounts due under the 2018 Credit Facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018.
Years Ended December 31,
Details about AOCI ComponentsConsolidated Statements of
Operations Classification		202020192018
Gains (losses) on cash flow hedges:
Forward contractsNet product revenues$18,122 $17,672 $(6,005)
Forward contractsOperating expenses(4,942)(1,819)3,958 
Total gain (loss) on cash flow hedges
13,180 15,853 (2,047)
Gain on sale of available-for-sale debt securities
Other income, net552 — — 
Income tax effect of the above
Benefit from income taxes(127)— — 
Total gain on available-for-sale debt securities
425 — — 
$13,605 $15,853 $(2,047)

The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.
Unrealized Gains (Losses) on Cash Flow HedgesUnrealized Gains (Losses) on Available-for-Sale Debt SecuritiesOtherTotal
AOCI balance at December 31, 2017(20,232)(2,722)(7)(22,961)
Impact of change in accounting principle (1)
— (586)— (586)
AOCI balance as of January 1, 2018(20,232)(3,308)(7)(23,547)
Other comprehensive income (loss) before
reclassifications		25,386 1,804 (6)27,184 
Less: gain (loss) reclassified from AOCI(2,047)— — (2,047)
Tax effect— (413)— (413)
Net current-period other comprehensive income (loss)27,433 1,391 (6)28,818 
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
reclassifications		25,266 7,122 (2)32,386 
Less: gain (loss) reclassified from AOCI15,853 — — 15,853 
Tax effect— (1,640)— (1,640)
Net current-period other comprehensive income (loss)9,413 5,482 (2)14,893 
AOCI balance at December 31, 201916,614 3,565 (15)20,164 
Other comprehensive income (loss) before
reclassifications		(23,462)976 15 (22,471)
Less: gain (loss) reclassified from AOCI13,180 552 — 13,732 
Tax effect— (100)— (100)
Net current-period other comprehensive income (loss)(36,642)324 15 (36,303)
AOCI balance at December 31, 2020(20,028)3,889 — (16,139)
(1)The amount represents the reclassification from AOCI to Accumulated Deficit due to the adoption of ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02) in the first quarter of 2018.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 31, 2020
Risks and Uncertainties [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers
there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.
Years Ended December 31,
202020192018
Total revenues by geographic region:
United States$912,375 $778,440 $696,793 
Europe518,465 509,188 436,434 
Latin America205,862 218,792 185,046 
Rest of world223,753 197,628 172,939 
Total revenues$1,860,455 $1,704,048 $1,491,212 
The following table disaggregates total Net Product Revenues by product.
Years Ended December 31,
202020192018
Net product revenues by product:
Vimizim544,257 544,345 481,977 
Kuvan457,736 463,353 433,582 
Naglazyme391,298 374,334 345,851 
Palynziq170,983 86,857 12,173 
Brineura110,192 71,997 39,889 
Firdapse1,288 22,348 21,787 
Total net product revenues marketed by the Company1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme130,107 97,809 135,097 
Total net product revenues$1,805,861 $1,661,043 $1,470,356 
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.
Years Ended December 31,
202020192018
United States$756,863 $669,171 $560,030 
Europe498,725 485,596 424,357 
Latin America205,862 218,792 184,984 
Rest of world214,304 189,675 165,888 
Total net product revenues marketed by the Company
1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme
130,107 97,809 135,097 
Total net product revenue$1,805,861 $1,661,043 $1,470,356 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Years Ended December 31,
202020192018
Customer A16 %17 %18 %
Customer B15 %13 %12 %
Customer C12 %11 %10 %
Total43 %41 %40 %
On a consolidated basis, two customers accounted for 24% and 22% of the Company’s December 31, 2020 accounts receivable balance, respectively, compared to December 31, 2019 when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of December 31, 2020 and 2019, the accounts receivable balance for Genzyme included $72.1 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Genzyme. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The outbreak of COVID-19 continues to affect economies and business around the world. The Company's global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and its business operations were impacted by COVID-19 during the year ended December 31, 2020 and the Company anticipates a continued impact due to COVID-19 on its financial results in fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.
The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.
Long-lived assets, which consist of property, plant and equipment and ROU assets are summarized by geographic region in the following table.
December 31,
20202019
Long-lived assets by geography:
United States$771,286 $773,991 
Ireland300,555 278,082 
Rest of world17,739 18,229 
Total long-lived assets$1,089,580 $1,070,302 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION
Equity Compensation Plans
Shares Available Under Equity Compensation Plans
As of December 31, 2020, an aggregate of approximately 36.7 million unissued shares was authorized for future issuance under the Company’s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan and the ESPP.
Under the 2017 Equity Incentive Plan, shares issued under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 Equity Incentive Plan that expire or are forfeited generally become available for future issuance under the 2017 Equity Incentive Plan. Shares formerly reserved for future issuance under the 2006 Share Incentive Plan were transferred to the 2017 Equity Incentive Plan and became available for issuance thereunder upon the effectiveness of the 2017 Equity Incentive Plan. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company’s stock-based compensation plans are administered by the Company’s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note 3 to these Consolidated Financial Statements for discussion regarding the valuation of equity awards.
2017 Equity Incentive Plan
The 2017 Equity Incentive Plan provides for awards of RSUs and stock options as well as other forms of equity compensation. Stock option awards granted to employees generally vest over a four-year period on a cliff basis twelve months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally ten years from the grant date. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. As of December 31, 2020, approximately 20.5 million shares were authorized and reserved for future issuance under the 2017 Equity Incentive Plan.
Employee Stock Purchase Plan
The ESPP was initially approved in June 2006, replacing the Company’s previous plan, and was most recently amended in June 2019. Under BioMarin’s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. During the year ended December 31, 2020, the Company issued 0.3 million shares under the ESPP. As of December 31, 2020, approximately 7.0 million shares were authorized and 3.4 million shares reserved for future issuance under the ESPP.
Board of Director Grants
On September 19, 2019, the Board of BioMarin approved revised compensation for the Independent Directors of the Company. On the date of the Company’s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000 ($375,000 prior to September 19, 2019), with the number of RSUs to be granted calculated based on the three-month trailing average closing price of the Company’s common stock on the Nasdaq Global Select Market. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company’s next annual meeting of stockholders.
Stock-based Compensation
Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:
Years Ended December 31,
202020192018
Cost of sales$26,246 $16,146 $13,558 
Research and development61,942 56,649 57,557 
Selling, general and administrative101,523 87,070 77,704 
Total stock-based compensation expense$189,711 $159,865 $148,819 
Stock-based compensation of $20.1 million, $20.3 million and $20.0 million was capitalized into inventory for the years ended December 31, 2020, 2019 and 2018, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold.
Restricted Stock Units
Restricted Stock Unit Awards with Service-Based Vesting Conditions
Below is a summary of activity related to RSUs with service-based vesting conditions under the plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 20193,585,384 $88.54 
Granted2,190,380 $77.13 
Vested(1,308,962)$87.57 
Forfeited(293,678)$85.17 
Non-vested units as of December 31, 20204,173,124 $83.41 
The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2020, 2019 and 2018, was $77.13, $91.28 and $84.63, respectively. The total intrinsic value of restricted stock that vested and was released in the years ended December 31, 2020, 2019 and 2018, was $109.9 million, $101.0 million and $84.5 million respectively.
As of December 31, 2020, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $245.3 million was expected to be recognized over a weighted average period of 2.6 years.
Restricted Stock Unit Awards with Performance-based Vesting Conditions
The Compensation Committee of the Board (with respect to awards to certain executive officers other than the Chief Executive Officer) and the Board (with respect to awards to the Chief Executive Officer) may grant RSUs with performance-based vesting conditions (PRSUs) to certain executive officers.
Revenue PRSUs: Although no PRSUs with vesting conditions based on revenue performance were granted during the year ended December 31, 2020, awards granted during prior periods presented were contingent upon the achievement of an annual revenue target and the earned RSUs vest over a three-year service period. The number of shares that may be earned ranged between 50% and 200% of the base RSUs, depending on the percentage of the respective annual year's Net Product Revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates achieved against the target, with a threshold achievement level of 75% of target and a ceiling achievement level of 125% of target.
Below is a summary of activity related to Revenue PRSUs under the Company's equity plan for the year ended December 31, 2020:
SharesWeighted Average Grant Date Fair Value
Non-vested units as of December 31, 2019226,884 $89.09 
Adjustment for shares earned2,272 $73.82 
Vested(126,608)$88.09 
Forfeited(3,197)$94.53 
Non-vested units as of December 31, 202099,351 $90.31 
The weighted-average grant date fair value of Revenue PRSUs was $94.53 and $83.57 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2020, total unrecognized compensation expense of $3.5 million related to Revenue PRSUs was expected to be recognized over a weighted average period of approximately 1.0 year.
Other PRSUs: Below is a summary of activity related to RSUs with vesting conditions based on other performance targets under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201944,260 $81.00 
Granted184,460 $84.17 
Vested(4,495)$73.82 
Forfeited(3,560)$78.72 
Non-vested units as of December 31, 2020220,665 $83.83 
The weighted-average grant date fair value of Other PRSUs was $84.17 and $81.00 for the years ended December 31, 2020 and 2019, respectively.
Non-vested Other PRSUs include a grant with vesting contingent upon the achievement of a three-year Non-GAAP income target and a grant with vesting contingent upon achievement of a three-year strategic goal target. The awarded PRSUs, if any, vest ratably over a three-year service period. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity and determined that attainment of each grant target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.
Also included in non-vested Other PRSUs are grants that vest contingent upon achievement of certain regulatory milestones that, for accounting purposes, were deemed not yet probable of vesting as of December 31, 2020. Therefore, as of December 31, 2020, total unrecognized compensation expense of $8.1 million related to awards deemed probable of vesting and $7.9 million related to awards not yet deemed probable of vesting. The expected weighted average period over which expense is to be recognized for the awards that are considered probable of vesting as of December 31, 2020 was 2.2 years.
Restricted Stock Unit Awards with Market-based Vesting Conditions
The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s TSR is above the 50th percentile but negative on an absolute basis.
Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201999,010 $143.92 
Granted131,350 $115.85 
Vested— $— 
Forfeited(9,370)$143.92 
Non-vested units as of December 31, 2020220,990 $127.23 
The Company utilized a Monte Carlo simulation model to determine the grant date fair value per base TSR-RSU of $112.12 using the following assumptions for the grant in March 2020: an expected term of 2.8 years, discount rate of 0.4%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. In June 2020, the Compensation Committee of the Board approved an additional grant of RSUs with market-based vesting conditions with identical terms as those granted in March 2020. The third-party valuation per base TSR-RSU of $217.65 used the following assumptions: an expected term of 2.5 years, discount rate of 0.2%, dividend yield of zero and expected volatility rate derived from historical volatilities for the Company and the members of the referenced peer group. As of
December 31, 2020, total unrecognized compensation expense of $14.1 million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.8 years.
Stock Options and Purchase Rights
Stock Options
The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2020. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Years
Aggregate
Intrinsic
Value (1)
Options outstanding as of December 31, 20197,264,235 $67.99 $146,700 
Granted891,610 $76.02 
Exercised(1,240,511)$43.87 
Expired and forfeited(85,897)$86.07 
Options outstanding as of December 31, 20206,829,437 $73.19 4.8$119,607 
Options unvested as of December 31, 20201,438,573 $81.56 8.6$11,635 
Exercisable at December 31, 20205,390,864 $70.95 3.8$107,972 
(1)The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $87.69, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 31, 2020.
The weighted-average fair value per stock option granted in the years ended December 31, 2020, 2019 and 2018, were $27.47, $36.84 and $33.40, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018, was $71.9 million, $32.5 million and $79.9 million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares.
The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:
Years Ended December 31,
202020192018
Expected volatility
36.5 – 42.2%
37.1 – 37.4%
36.8 – 38.4%
Dividend yield0.00%0.00%0.00%
Expected term
4.6 – 5.9 years
4.6 – 5.8 years
4.6 – 5.7 years
Risk-free interest rate
0.3 – 1.7%
2.2 – 3.0%
2.3 – 2.8%
As of December 31, 2020, total unrecognized compensation cost related to unvested stock options of $35.3 million was expected to be recognized over a weighted average period of 2.5 years. The net tax benefit from stock options exercised during the year ended December 31, 2020 was $4.5 million.
Stock Purchase Rights
The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:
Years Ended December 31,
202020192018
Expected volatility
30.6 – 69.2%
27.7 – 35.0%
29.7% – 35.0%
Dividend yield0.00%0.00%0.00%
Expected term
0.5 – 2.0 years
0.5 – 2.0 years
0.5 – 2.0 years
Risk-free interest rate
0.1 – 2.8%
1.2 – 2.8%
1.2 – 2.8%
As of December 31, 2020, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $18.3 million was expected to be recognized over a weighted average period of 1.4 years.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EMPLOYEE BENEFITS
 12 Months Ended
Dec. 31, 2020
Compensation Related Costs [Abstract]  
OTHER EMPLOYEE BENEFITS OTHER EMPLOYEE BENEFITS
Employment Agreements
The Company has entered into employment agreements with certain officers. Generally, these agreements can be terminated without cause by the Company upon prior written notice and payment of specified severance, or by the officer upon four weeks’ prior written notice to the Company.
401(k) Plan
The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan). Eligible employees may contribute to the 401(k) Plan up to the lesser of 60% of their current compensation or an amount up to a statutorily prescribed annual limit. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee’s eligible contributions, up to a maximum of the lesser of 6% of the employee’s annual compensation or the annual statutory contribution limit. The Company’s matching contribution vests immediately and was approximately $26.4 million, $28.5 million and $23.0 million for the years ended December 31, 2020, 2019 and 2018, respectively.
Deferred Compensation Plan
The Company amended the NQDC in the second quarter of 2019 to prohibit the diversification of deferrals of Company stock, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity and, subsequent to the 2019 amendment, changes in the fair value of Company stock held in the NQDC are no longer recognized in earnings. Other contributions held in the NQDC are classified as trading securities and recorded at fair value with the corresponding deferred compensation obligation classified as a liability. Changes in the fair value of non-BioMarin investments are recognized in earnings in the period they occur.
See Note 10 to these Consolidated Financial Statements for additional discussion on the fair value and presentation of the NQDC assets and liabilities.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESThe benefit from income taxes was based on loss before income taxes as follows:
Years Ended December 31
202020192018
U.S. Source$(162,939)$(182,112)$(128,700)
Non-U.S. Source120,617 87,301 (14,005)
Loss before income taxes$(42,322)$(94,811)$(142,705)
The U.S. and foreign components of the benefit from income taxes were as follows:
Years Ended December 31,
202020192018
Provision for (benefit from) current income tax expense:
Federal$(14,758)$5,127 $(2,660)
State and local1,201 1,331 588 
Foreign1,042 5,339 4,956 
(12,515)11,797 2,884 
Provision for (benefit from) deferred income taxes:
Federal(45,038)(58,311)(72,074)
State and local(5,321)(5,394)(994)
Foreign(838,548)(19,055)4,690 
(888,907)(82,760)(68,378)
Benefit from income taxes$(901,422)$(70,963)$(65,494)
In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s ex-U.S. regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of December 31, 2020.
The following is a reconciliation of the statutory federal income tax (benefit) expense to the Company’s effective tax rate:
December 31,
202020192018
Federal statutory income tax benefit$(8,888)$(19,911)$(29,968)
State and local taxes(3,264)(2,784)(276)
Orphan Drug & General Business Credit(44,114)(43,124)(66,451)
Stock compensation expense(1,101)239 (5,647)
Changes in the fair value of contingent consideration— (1,804)(2,361)
Foreign Source Income Subject to U.S. Tax6,266 (52)6,543 
Foreign tax rate differential (1)
(16,238)(30,639)12,583 
Section 162(m) limitation9,571 8,294 7,440 
Tax Reserves2,166 12,123 8,545 
Intra-entity transfer of assets(852,338)— — 
CARES Act carryback claim(2,201)— — 
Other1,843 (1,132)(423)
Valuation allowance/deferred benefit6,876 7,827 4,521 
Effective income tax (benefit) expense$(901,422)$(70,963)$(65,494)
(1)     For the year ended December 31, 2019, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the benefit of the valuation allowance release against the deferred tax assets of the Company’s Dutch subsidiary of $29.6 million.
The significant components of the Company’s net deferred tax assets were as follows:
December 31,
20202019
Net deferred tax assets:
Net operating loss carryforwards$30,718 $32,181 
Tax credit carryforwards532,394 508,560 
Accrued expenses, reserves, and prepaids66,889 61,807 
Intangible assets873,575 29,413 
Stock-based compensation47,011 42,873 
Lease liabilities8,991 11,470 
Inventory32,012 6,290 
Other454 575 
Valuation allowance(93,075)(86,197)
Total deferred tax assets1,498,969 606,972 
Joint venture basis difference(1,164)(993)
Acquired intangibles(1,364)(1,647)
Deferred revenue(1,517)(3,003)
Convertible notes discount— (2,364)
ROU assets(8,280)(10,258)
Property, plant and equipment(54,682)(46,642)
Total deferred tax liabilities(67,007)(64,907)
Net deferred tax assets$1,431,962 $542,065 
Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. The valuation allowance increased in 2020 due primarily to the Company’s expectation that state R&D credits will not be utilized.
As of December 31, 2020, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:
TypeAmountYear
Federal net operating loss carryforwards$4,753  2030 – 2033
Federal R&D and orphan drug credit carryforwards$566,887  2024 – 2040
State net operating loss carryforwards$182,961  2021 – 2040
Dutch net operating loss carryforwards$75,718  2022 – 2025
Not included in the table above are $124.3 million of state research credit carryovers that will carry forward indefinitely.
The Company’s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by IRC Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits.
The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement.
A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2020 and 2019, is as follows:
December 31,
20202019
Balance at beginning of period$168,748 $147,445 
Additions based on tax positions related to the current year
16,481 19,287 
(Deletions) Additions for tax positions of prior years(2,527)2,016 
Lapse of statute of limitations(138)— 
Balance at end of period$182,564 $168,748 
Included in the balance of unrecognized tax benefits as of December 31, 2020 were potential benefits of $175.1 million that, if recognized, would affect the effective tax rate. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December 31, 2020. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months.
The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from three to five years. However, carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by tax authorities.
U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. This excess totaled approximately $15.2 million as of December 31, 2020, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER COMMON SHARE
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER COMMON SHARE NET INCOME (LOSS) PER COMMON SHAREPotentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, the Company's common stock held by the NQDC and contingent issuances of common stock related to the Company's convertible debt.
The following table sets forth the computation of basic and diluted income (loss) per common share (common shares in thousands):
Years Ended December 31,
202020192018
Numerator:
Net income (loss), basic$859,100 $(23,848)$(77,211)
Add: Interest on convertible notes8,313 — — 
Less: gain on the Company's common stock held by the NQDC— — (710)
Net income (loss), diluted$867,413 $(23,848)$(77,921)
Denominator:
Weighted-average common shares outstanding, basic180,804 179,039 177,061 
Effect of dilutive securities:
Options to purchase common stock1,543 — — 
Common stock issuable under the 2027 notes2,874 — — 
Common stock issuable under the 2024 notes3,970 — — 
Unvested RSUs1,938 — — 
Common stock potentially issuable for ESPP purchases353 — — 
The Company's common stock held by the NQDC196 — 207 
Weighted-average common shares outstanding, diluted191,678 179,039 177,268 
Net income (loss) per common share, basic$4.75 $(0.13)$(0.44)
Net income (loss) per common share, diluted$4.53 $(0.13)$(0.44)

In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income (loss) per common share as they were anti-dilutive (in thousands):
Years Ended December 31,
202020192018
Options to purchase common stock5,287 7,264 7,364 
Common stock issuable under the 2020 Notes— 3,983 3,983 
Common stock issuable under the 2024 Notes— 3,970 3,970 
Unvested RSUs2,235 3,956 3,404 
Common stock potentially issuable for ESPP purchases314 587 435 
The Company's common stock held by the NQDC— 205 — 
Total number of potentially issuable shares7,836 19,965 19,156 
The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as the Company’s closing stock price on December 31, 2019 and 2018 did not exceed the conversion price of $94.15 per share for the 2020 Notes. There is no similar capped call transaction associated with the 2024 Notes or 2027 Notes. See Note 13 to these Consolidated Financial Statements for information on the Company’s convertible debt.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.4
LICENSE AND COLLABORATION AGREEMENTS
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS LICENSE AND COLLABORATION AGREEMENTSIn October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0 million, a minority 15% equity ownership interest in the licensee,
and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and sales milestones are met by the licensee.
The Company evaluated the design and purpose of the third-party licensee and determined that it is a variable interest entity (VIE), as the equity-at-risk is insufficient to support the licensee’s operations. The Company has concluded that it is not the primary beneficiary of the VIE as the Company does not have the power to direct the activities of the VIE that most significantly impact its performance. The Company is accounting for the minority equity investment at cost, less impairment, if any, adjusted for observable price changes, as it does not exercise significant influence over the operations of the licensee. Other than providing the licensee with specified transition services, the Company has no other involvement with the operations of the VIE as of December 31, 2020. As a result, the Company's loss exposure is limited to the value of the equity investment of $8.1 million which is included in Other Assets on the Company’s Consolidated Balance Sheets as of December 31, 2020.
In July 2017, the Company executed a license agreement and a settlement agreement with Sarepta Therapeutics (Sarepta) that provide Sarepta with global exclusive rights to the Company’s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under these agreements, Sarepta may pay certain additional regulatory and commercial milestone fees for exons 51, 45, 53 and possibly on future exon-skipping products to the Company if certain development and sales milestones are achieved. Additionally, the Company receives from Sarepta royalties based on 5% of net sales in the U.S. through the end of 2023 and 8% of net sales in the EU and in other countries, where certain of the Company’s patents exist, through September 30, 2024. The Company retained the right to convert the license to a co-exclusive right in the event it decides to proceed with an exon-skipping therapy for DMD.
On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to Kuvan and Palynziq from Merck Serono, with the exception of Kuvan in Japan. Previously, the Company had exclusive rights to Kuvan in the U.S. and Canada and Palynziq in the U.S. and Japan. Pursuant to the A&R Kuvan Agreement, if future sales milestones are met, the Company is obligated to pay Merck Serono up to a maximum of €60.0 million, in cash, which was an estimated fair value of $73.6 million as of December 31, 2020. Pursuant to the Pegvaliase Agreement, the Company paid Merck Serono €125.0 million in cash when the Palynziq development milestones were achieved.
In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to Firdapse, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of Firdapse in North America. In January 2020, the Company completed the sale of worldwide rights to Firdapse to a third party. The Company retained the rights to receive the royalties from Catalyst. See Note 6 to these Consolidated Financial Statements for further information about the Firdapse sale.
In September 2007, the Company licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the Kuvan new drug application. The Company receives royalties on net sales of the product in Japan.
The Company is engaged in R&D collaborations with various other entities. These provide for sponsorship of R&D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.
Contingent Payments
As of December 31, 2020, the Company was subject to contingent payments totaling approximately $662.8 million upon achievement of certain development and regulatory activities and commercial sales milestones if they occur before certain dates in
the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $73.6 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from Merck Serono and $237.7 million related to programs that are no longer being developed.
As of December 31, 2020, the Company recorded $60.1 million of contingent liabilities on its Consolidated Balance Sheet, all of which was long-term. See Note 3 and Note 10 to these Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
The Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are included as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients, certain inventory related items and certain third-party R&D services. As of December 31, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $142.8 million. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.
Under certain of the Company’s lease agreements, the Company is contractually obligated to return leased space to its original condition upon termination of the applicable lease agreement. The Company records interest expense to accrete the asset retirement obligation liability to full value and depreciates each retirement obligation asset, both over the term of the associated lease agreement. As of December 31, 2020 and 2019, the balance of the asset retirement obligation liability was $3.7 million and $3.0 million, respectively. See Note 3 to these Consolidated Financial Statements for further information on the Company's fair value measurements.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.
New Accounting Pronouncements On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.Effective January 1, 2020, the Company adopted FASB ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the previous other-than-temporary impairment model. The adoption of this standard had no impact on the Company’s Financial Statements.
Use of Estimates
Use of Estimates
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly
uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
Cash and Cash Equivalents Cash and Cash EquivalentsThe Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents.
Marketable Securities
Marketable Securities
The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations.
All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income, Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.
Non-Marketable Equity Securities Non-Marketable Equity SecuritiesThe Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income, Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment.
Inventory
Inventory
Commercial Inventory
The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations.
Inventory Produced Prior to Regulatory Approval
When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing
application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&D).
Property, Plant And Equipment
Property, Plant and Equipment
Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&D and Selling, General and Administrative (SG&A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&D projects with no alternative future uses are expensed as incurred and recorded to R&D in the Consolidated Statements of Operations.
Leasehold improvementsShorter of life of asset or lease term
Building and improvements
20 to 50 years
Manufacturing and laboratory equipment
5 to 15 years
Computer hardware and software
3 to 7 years
Office furniture and equipment5 years
Vehicles5 years
Land improvements
10 to 20 years
LandNot applicable
Construction-in-progressNot applicable
Leases
Leases
Effective January 1, 2019, the Company adopted Accounting Standards Codification (ASC) Topic 842, Leases. The amended guidance required balance sheet recognition of lease right-of-use (ROU) assets and liabilities by lessees for leases classified as operating leases. The Company adopted ASC Topic 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption through a cumulative adjustment to Accumulated Deficit.
The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Impairment
Impairment
The Company assesses its goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable.
Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded.
Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Impairment charges that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Long-lived Asset Impairment
The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&A in the Consolidated Statements of Operations. Impairment charges related to finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations.
Revenue Recognition
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC Topic 606, the Company performs the following five steps:
(i)identification of the promised goods or services in the contract;
(ii)determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii)measurement of the transaction price, including the constraint on variable consideration;
(iv)allocation of the transaction price to the performance obligations based on estimated selling prices; and
(v)recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account.
Net Product Revenues
In the U.S., the Company’s commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues.
For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Genzyme
and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known.
Revenue Reserves
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government rebates, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known.
Government Rebates: The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves.
Sales Returns: The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material.
Other Incentives: Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on Brineura, Kuvan or Palynziq therapy. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue.
Royalty and Other Revenues
Royalties: For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone payments: At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal
would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Research and Development
Research and Development
R&D costs are generally expensed as incurred. These expenses include contract R&D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs and R&D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval.
Convertible Debt
Convertible Debt
For non-conventional convertible debt that may be settled entirely or partially in cash, the Company separately accounts for the liability and equity components by allocating the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. The liability component is presented net of any discounts and issuance costs. For conventional convertible debt that may only be settled with common shares, the Company reports debt, net of any discounts or issuance costs, on the Consolidated Balance Sheets.
The Company recognizes discount accretion and debt issuance cost amortization using the effective interest method and is reported in Interest Expense on the Consolidated Statements of Operations.
Net Income (Loss) Per Common Share
Net Income (Loss) Per Common Share
Basic net income (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.
Stock-Based Compensation
Stock-Based Compensation
The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&D or SG&A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur.
Restricted Stock Units
The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed.
Stock Options and Purchase Rights
The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock
options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period.
The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.
Income Taxes
Income Taxes
The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances.
The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.
Foreign Currency
Foreign Currency
For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in SG&A in the Consolidated Statements of Operations.
Derivatives and Hedging Activities
Derivatives and Hedging Activities
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&A in the Consolidated Statements of Operations.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the
market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques:
•Income approach, which is based on the present value of a future stream of net cash flows
•Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
The Company’s fair value methodologies depend on the following types of inputs:
•Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)
•Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs)
•Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)
The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets.
The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of long-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of the contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations.
See Notes 5, 10, 11, 13, 19 and 20 to these Consolidated Financial Statements for further information on the nature of these financial instruments.
Segment Information
Segment Information
The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Schedule Of Property, Plant And Equipment Estimated Useful Lives
Leasehold improvementsShorter of life of asset or lease term
Building and improvements
20 to 50 years
Manufacturing and laboratory equipment
5 to 15 years
Computer hardware and software
3 to 7 years
Office furniture and equipment5 years
Vehicles5 years
Land improvements
10 to 20 years
LandNot applicable
Construction-in-progressNot applicable
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCIAL INSTRUMENTS (Tables)
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2020 and 2019, respectively:
December 31, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$370,325 $— $— $370,325 $370,325 $— $— 
Level 2:
Money market instruments
264,833 — — 264,833 264,833 — — 
Corporate debt securities
413,137 3,261 (8)416,390 — 220,551 195,839 
U.S. government agency securities
265,298 1,555 (1)266,852 14,000 192,488 60,364 
Asset-backed securities31,659 85 (2)31,742 — 3,189 28,553 
Foreign and other
549 168 — 717 — — 717 
Subtotal
975,476 5,069 (11)980,534 278,833 416,228 285,473 
Total
$1,345,801 $5,069 $(11)$1,350,859 $649,158 $416,228 $285,473 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair
Value		Cash and Cash Equivalents
Short-term
Marketable Securities (1)
Long-term
Marketable Securities (2)
Level 1:
Cash
$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments
173,100 — — 173,100 173,100 — — 
Corporate debt securities
518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities
209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other
549 145 (1)693 — — 693 
Subtotal
901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total
$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company’s long-term marketable securities mature between one and five years.
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The change in the carrying value of Goodwill was as follows:
December 31,
20202019
Beginning balance $197,039 $197,039 
Less: disposition(840)— 
Ending carrying value$196,199 $197,039 
Schedule of Intangible Assets
Intangible Assets, Net consisted of the following:
December 31,
20202019
Finite-lived intangible assets$644,087 $652,734 
Less: Accumulated amortization(226,816)(196,154)
Net carrying value$417,271 $456,580 
Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets
The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2020:
Net BalanceAverage Remaining Life
Acquired intellectual property$350,275 6.9 years
Repurchased royalty rights19,687 2.9 years
Technology transfer46,657 Not applicable (1)
Other652 
0.5 - 3.4 years
Total$417,271 
(1)The technology transfer intangible asset has not yet been placed into service.
Schedule of Future Amortization Expense of Finite-Lived Intangible Assets As of December 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:
Fiscal YearAmount
2021$61,963 
202261,939 
202361,311 
202455,036 
202535,759 
Thereafter94,606 
$370,614 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of Property Plant and Equipment Net
Property, Plant and Equipment, Net, consisted of the following:
December 31,
20202019
Building and improvements$761,560 $725,906 
Manufacturing and laboratory equipment414,439 366,951 
Computer hardware and software189,740 167,554 
Land90,418 90,418 
Leasehold improvements55,134 51,324 
Furniture and equipment40,223 38,569 
Land improvements7,412 7,349 
Construction-in-progress109,140 111,897 
1,668,066 1,559,968 
Accumulated depreciation(635,595)(549,100)
Total property, plant and equipment, net$1,032,471 $1,010,868 
Years Ended December 31,
202020192018
Depreciation expense$88,169 $89,285 $90,375 
Depreciation capitalized into inventory$44,492 $37,481 $25,227 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY (Tables)
 12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Schedule Of Inventory
Inventory consisted of the following:
December 31,
20202019
Raw materials$76,673 $74,442 
Work-in-process308,286 349,978 
Finished goods313,589 255,855 
Total inventory$698,548 $680,275 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities consisted of the following:
December 31,
20202019
Accounts payable and accrued operating expenses$191,429 $240,981 
Accrued compensation expense165,023 192,467 
Accrued rebates payable$65,526 57,163 
Forward foreign currency exchange contracts17,798 10,448 
Accrued royalties payable17,155 30,797 
Lease liability11,754 10,700 
Accrued income taxes9,661 3,195 
Value added taxes payable9,562 8,395 
Deferred revenue152 13,037 
Other4,488 3,438 
Total accounts payable and accrued liabilities$492,548 $570,621 
Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts
The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2020, 2019 and 2018, were as follows:
Balance at
Beginning
of Period
Provision for Current Period SalesPayments
Balance at
End of
Period
Year ended December 31, 2020:
Accrued rebates$57,163 $113,165 $(104,802)$65,526 
Reserve for cash discounts$1,889 $17,191 $(17,364)$1,716 
Year ended December 31, 2019:
Accrued rebates$43,116 $91,748 $(77,701)$57,163 
Reserve for cash discounts$1,197 $15,335 $(14,643)$1,889 
Year ended December 31, 2018:
Accrued rebates$36,472 $67,843 $(61,199)$43,116 
Reserve for cash discounts$1,055 $12,474 $(12,332)$1,197 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2020 and 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 13 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2020 and 2019.

Fair Value Measurements as of December 31, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$2,415 $— $2,415 
Other assets:
NQDC Plan assets19,962 — 19,962 
Restricted investments (1)
4,487 — 4,487 
Total other assets24,449 — 24,449 
Total assets$26,864 $— $26,864 
Liabilities:
Current liabilities:
NQDC Plan liability$2,415 $— $2,415 
Other long-term liabilities:
NQDC Plan liability19,962 — 19,962 
Contingent consideration— 60,130 60,130 
Total other long-term liabilities19,962 60,130 80,092 
Total liabilities$22,377 $60,130 $82,507 
Fair Value Measurements as of December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current Liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)The restricted investments as of December 31, 2020 and 2019 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.
Liabilities Measured at Fair Value Using Level 3 Inputs
Liabilities measured at fair value using Level 3 inputs primarily consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration.
Contingent consideration as of December 31, 2019$50,793 
Changes in the fair value of contingent consideration4,500 
Foreign exchange remeasurement of Euro denominated contingent consideration4,837 
Contingent consideration as of December 31, 2020$60,130 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)
 12 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Forward Foreign Currency Exchange Contracts Outstanding The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.
Foreign Exchange ContractsDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Sell$782,327 $820,546 
Purchase$189,540 $212,348 
Derivatives not designated as hedging instruments:
Sell$98,343 $77,335 
Purchase$12,277 $30,818 
Fair Value Carrying Amount of Derivative Instruments
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationDecember 31, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$6,268 $19,584 
Other assets3,148 13,539 
Subtotal$9,416 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$17,551 $8,184 
Other long-term liabilities11,020 5,493 
Subtotal$28,571 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$84 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$247 $2,264 
Total Derivatives Assets$9,500 $33,592 
Total Derivatives Liabilities$28,818 $15,941 
(1)    See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
Effect of Derivative Instruments The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented.
Years Ended December 31,
20202019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,805,861 $18,122 $1,661,043 $17,672 
Operating expenses as reported$1,897,220 $(4,942)$1,804,505 $(3,453)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$115 $(5,259)
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Schedule Of Lessee Lease Assets And Liabilities
The following table presents the Company’s ROU assets and lease liabilities for the periods presented.
December 31,
Lease ClassificationClassification20202019
Assets:
OperatingOther assets$46,014 $49,045 
FinancingOther assets11,095 10,389 
Total ROU assets$57,109 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$8,889 $7,451 
FinancingAccounts payable and accrued liabilities2,865 3,249 
Noncurrent:
OperatingOther long-term liabilities40,483 44,092 
FinancingOther long-term liabilities4,006 6,708 
Total lease liabilities$56,243 $61,500 
Schedule of Maturities of Finance Lease Liabilities
Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
2021$11,295 $3,095 $14,390 
202210,127 2,383 12,510 
20238,605 1,800 10,405 
20246,570 50 6,620 
20255,561 21 5,582 
Thereafter16,758 — 16,758 
Total lease payments58,916 7,349 66,265 
Less: Interest(9,544)(478)(10,022)
Present value of lease liabilities$49,372 $6,871 $56,243 
Schedule of Maturities of Operating Lease Liabilities
Maturities of lease liabilities as of December 31, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
2021$11,295 $3,095 $14,390 
202210,127 2,383 12,510 
20238,605 1,800 10,405 
20246,570 50 6,620 
20255,561 21 5,582 
Thereafter16,758 — 16,758 
Total lease payments58,916 7,349 66,265 
Less: Interest(9,544)(478)(10,022)
Present value of lease liabilities$49,372 $6,871 $56,243 
Schedule of Lease Cost
Lease costs associated with payments under the Company’s leases for the periods presented were as follows:
Years Ended December 31,
Lease CostClassification20202019
Operating (1)
Operating expenses$12,841 $13,026 
Financing:
AmortizationOperating expenses3,271 2,615 
Interest expenseOperating expenses448606
Total lease costs$16,560 $16,247 
(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
Years Ended December 31,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$10,536 $8,183 
Financing leases$450 $628 
Cash used in financing activities:
Financing leases$6,918 $5,087 
ROU assets obtained in exchange for lease obligations:
Operating leases$4,779 $9,772 
Financing leases$3,941 $3,267 
Schedule of Other Information
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Years Ended December 31,
Other Information20202019
Weighted average remaining lease term (in years):
Operating leases6.87.9
Financing leases2.63.3
Weighted average discount rate:
Operating leases4.9 %5.2 %
Financing leases5.2 %5.4 %
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT (Tables)
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Summary of Senior Subordinated Convertible Obligations The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
20202019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,312)— 
Unamortized deferred offering costs(683)— 
2027 Notes, net587,005 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,116)(6,533)
Unamortized deferred offering costs(1,744)(2,229)
2024 Notes, net488,140 486,238 
1.50% senior subordinated convertible notes matured in October 2020 (the 2020 Notes)
— 374,993 
Unamortized discount— (12,078)
Unamortized deferred offering costs— (1,033)
2020 Notes, net (1)
— 361,882 
Total convertible debt, net$1,075,145 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$627,090 $— 
2024 Notes
530,714 521,839 
2020 Notes
— 405,679 
Total fair value of fixed rate convertible debt$1,157,804 $927,518 
(1)The 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. There were no shares issued in connection with the settlement as the Company’s share price did not exceed the conversion price of
$94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of the 2020 Notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
(2)The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 3 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
Summary of Interest Expense on Debt
Interest expense on the Company’s convertible debt consisted of the following:
Years Ended December 31,
202020192018
Coupon interest$12,350 $4,907 $12,452 
Amortization of debt issuance costs1,829 2,031 3,610 
Accretion of discount on convertible notes14,682 15,917 27,602 
Total interest expense on convertible debt$28,861 $22,855 $43,664 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Amounts Reclassified out of Accumulated Other Comprehensive Income The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018.
Years Ended December 31,
Details about AOCI ComponentsConsolidated Statements of
Operations Classification		202020192018
Gains (losses) on cash flow hedges:
Forward contractsNet product revenues$18,122 $17,672 $(6,005)
Forward contractsOperating expenses(4,942)(1,819)3,958 
Total gain (loss) on cash flow hedges
13,180 15,853 (2,047)
Gain on sale of available-for-sale debt securities
Other income, net552 — — 
Income tax effect of the above
Benefit from income taxes(127)— — 
Total gain on available-for-sale debt securities
425 — — 
$13,605 $15,853 $(2,047)
Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI
The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.
Unrealized Gains (Losses) on Cash Flow HedgesUnrealized Gains (Losses) on Available-for-Sale Debt SecuritiesOtherTotal
AOCI balance at December 31, 2017(20,232)(2,722)(7)(22,961)
Impact of change in accounting principle (1)
— (586)— (586)
AOCI balance as of January 1, 2018(20,232)(3,308)(7)(23,547)
Other comprehensive income (loss) before
reclassifications		25,386 1,804 (6)27,184 
Less: gain (loss) reclassified from AOCI(2,047)— — (2,047)
Tax effect— (413)— (413)
Net current-period other comprehensive income (loss)27,433 1,391 (6)28,818 
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
reclassifications		25,266 7,122 (2)32,386 
Less: gain (loss) reclassified from AOCI15,853 — — 15,853 
Tax effect— (1,640)— (1,640)
Net current-period other comprehensive income (loss)9,413 5,482 (2)14,893 
AOCI balance at December 31, 201916,614 3,565 (15)20,164 
Other comprehensive income (loss) before
reclassifications		(23,462)976 15 (22,471)
Less: gain (loss) reclassified from AOCI13,180 552 — 13,732 
Tax effect— (100)— (100)
Net current-period other comprehensive income (loss)(36,642)324 15 (36,303)
AOCI balance at December 31, 2020(20,028)3,889 — (16,139)
(1)The amount represents the reclassification from AOCI to Accumulated Deficit due to the adoption of ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02) in the first quarter of 2018.
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2020
Risks and Uncertainties [Abstract]  
Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.
Years Ended December 31,
202020192018
Total revenues by geographic region:
United States$912,375 $778,440 $696,793 
Europe518,465 509,188 436,434 
Latin America205,862 218,792 185,046 
Rest of world223,753 197,628 172,939 
Total revenues$1,860,455 $1,704,048 $1,491,212 
Disaggregates of Total Net Product Revenues from External Customers by Product
The following table disaggregates total Net Product Revenues by product.
Years Ended December 31,
202020192018
Net product revenues by product:
Vimizim544,257 544,345 481,977 
Kuvan457,736 463,353 433,582 
Naglazyme391,298 374,334 345,851 
Palynziq170,983 86,857 12,173 
Brineura110,192 71,997 39,889 
Firdapse1,288 22,348 21,787 
Total net product revenues marketed by the Company1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme130,107 97,809 135,097 
Total net product revenues$1,805,861 $1,661,043 $1,470,356 
Disaggregates of Total Net Product Revenues Based on Patient Location
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.
Years Ended December 31,
202020192018
United States$756,863 $669,171 $560,030 
Europe498,725 485,596 424,357 
Latin America205,862 218,792 184,984 
Rest of world214,304 189,675 165,888 
Total net product revenues marketed by the Company
1,675,754 1,563,234 1,335,259 
Aldurazyme net product revenues marketed by Genzyme
130,107 97,809 135,097 
Total net product revenue$1,805,861 $1,661,043 $1,470,356 
Total Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Years Ended December 31,
202020192018
Customer A16 %17 %18 %
Customer B15 %13 %12 %
Customer C12 %11 %10 %
Total43 %41 %40 %
Summary of Non-Monetary Long-Lived Assets by Geographic Region
Long-lived assets, which consist of property, plant and equipment and ROU assets are summarized by geographic region in the following table.
December 31,
20202019
Long-lived assets by geography:
United States$771,286 $773,991 
Ireland300,555 278,082 
Rest of world17,739 18,229 
Total long-lived assets$1,089,580 $1,070,302 
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Expense
Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows:
Years Ended December 31,
202020192018
Cost of sales$26,246 $16,146 $13,558 
Research and development61,942 56,649 57,557 
Selling, general and administrative101,523 87,070 77,704 
Total stock-based compensation expense$189,711 $159,865 $148,819 
Summary of Restricted Stock Unit Activity
Below is a summary of activity related to RSUs with service-based vesting conditions under the plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 20193,585,384 $88.54 
Granted2,190,380 $77.13 
Vested(1,308,962)$87.57 
Forfeited(293,678)$85.17 
Non-vested units as of December 31, 20204,173,124 $83.41 
Below is a summary of activity related to Revenue PRSUs under the Company's equity plan for the year ended December 31, 2020:
SharesWeighted Average Grant Date Fair Value
Non-vested units as of December 31, 2019226,884 $89.09 
Adjustment for shares earned2,272 $73.82 
Vested(126,608)$88.09 
Forfeited(3,197)$94.53 
Non-vested units as of December 31, 202099,351 $90.31 
Below is a summary of activity related to RSUs with vesting conditions based on other performance targets under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201944,260 $81.00 
Granted184,460 $84.17 
Vested(4,495)$73.82 
Forfeited(3,560)$78.72 
Non-vested units as of December 31, 2020220,665 $83.83 
Below is a summary of activity related to RSUs with market-based vesting conditions under the Company's equity plan for the year ended December 31, 2020:
Shares
Weighted
Average
Grant Date
Fair Value
Non-vested units as of December 31, 201999,010 $143.92 
Granted131,350 $115.85 
Vested— $— 
Forfeited(9,370)$143.92 
Non-vested units as of December 31, 2020220,990 $127.23 
Summary of Stock Option Activity
The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2020. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Years
Aggregate
Intrinsic
Value (1)
Options outstanding as of December 31, 20197,264,235 $67.99 $146,700 
Granted891,610 $76.02 
Exercised(1,240,511)$43.87 
Expired and forfeited(85,897)$86.07 
Options outstanding as of December 31, 20206,829,437 $73.19 4.8$119,607 
Options unvested as of December 31, 20201,438,573 $81.56 8.6$11,635 
Exercisable at December 31, 20205,390,864 $70.95 3.8$107,972 
(1)The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $87.69, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 31, 2020.
Stock Option Valuation Assumptions
The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows:
Years Ended December 31,
202020192018
Expected volatility
36.5 – 42.2%
37.1 – 37.4%
36.8 – 38.4%
Dividend yield0.00%0.00%0.00%
Expected term
4.6 – 5.9 years
4.6 – 5.8 years
4.6 – 5.7 years
Risk-free interest rate
0.3 – 1.7%
2.2 – 3.0%
2.3 – 2.8%
Employee Stock Purchase Plan Valuation Assumptions
The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows:
Years Ended December 31,
202020192018
Expected volatility
30.6 – 69.2%
27.7 – 35.0%
29.7% – 35.0%
Dividend yield0.00%0.00%0.00%
Expected term
0.5 – 2.0 years
0.5 – 2.0 years
0.5 – 2.0 years
Risk-free interest rate
0.1 – 2.8%
1.2 – 2.8%
1.2 – 2.8%
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Benefit from Income Taxes Based on Loss Before Income Taxes The benefit from income taxes was based on loss before income taxes as follows:
Years Ended December 31
202020192018
U.S. Source$(162,939)$(182,112)$(128,700)
Non-U.S. Source120,617 87,301 (14,005)
Loss before income taxes$(42,322)$(94,811)$(142,705)
Schedule of Components of Provision for (Benefit From) Income Taxes
The U.S. and foreign components of the benefit from income taxes were as follows:
Years Ended December 31,
202020192018
Provision for (benefit from) current income tax expense:
Federal$(14,758)$5,127 $(2,660)
State and local1,201 1,331 588 
Foreign1,042 5,339 4,956 
(12,515)11,797 2,884 
Provision for (benefit from) deferred income taxes:
Federal(45,038)(58,311)(72,074)
State and local(5,321)(5,394)(994)
Foreign(838,548)(19,055)4,690 
(888,907)(82,760)(68,378)
Benefit from income taxes$(901,422)$(70,963)$(65,494)
Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate
The following is a reconciliation of the statutory federal income tax (benefit) expense to the Company’s effective tax rate:
December 31,
202020192018
Federal statutory income tax benefit$(8,888)$(19,911)$(29,968)
State and local taxes(3,264)(2,784)(276)
Orphan Drug & General Business Credit(44,114)(43,124)(66,451)
Stock compensation expense(1,101)239 (5,647)
Changes in the fair value of contingent consideration— (1,804)(2,361)
Foreign Source Income Subject to U.S. Tax6,266 (52)6,543 
Foreign tax rate differential (1)
(16,238)(30,639)12,583 
Section 162(m) limitation9,571 8,294 7,440 
Tax Reserves2,166 12,123 8,545 
Intra-entity transfer of assets(852,338)— — 
CARES Act carryback claim(2,201)— — 
Other1,843 (1,132)(423)
Valuation allowance/deferred benefit6,876 7,827 4,521 
Effective income tax (benefit) expense$(901,422)$(70,963)$(65,494)
(1)     For the year ended December 31, 2019, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the benefit of the valuation allowance release against the deferred tax assets of the Company’s Dutch subsidiary of $29.6 million.
Schedule of Components of Net Deferred Tax Assets
The significant components of the Company’s net deferred tax assets were as follows:
December 31,
20202019
Net deferred tax assets:
Net operating loss carryforwards$30,718 $32,181 
Tax credit carryforwards532,394 508,560 
Accrued expenses, reserves, and prepaids66,889 61,807 
Intangible assets873,575 29,413 
Stock-based compensation47,011 42,873 
Lease liabilities8,991 11,470 
Inventory32,012 6,290 
Other454 575 
Valuation allowance(93,075)(86,197)
Total deferred tax assets1,498,969 606,972 
Joint venture basis difference(1,164)(993)
Acquired intangibles(1,364)(1,647)
Deferred revenue(1,517)(3,003)
Convertible notes discount— (2,364)
ROU assets(8,280)(10,258)
Property, plant and equipment(54,682)(46,642)
Total deferred tax liabilities(67,007)(64,907)
Net deferred tax assets$1,431,962 $542,065 
Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards
As of December 31, 2020, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows:
TypeAmountYear
Federal net operating loss carryforwards$4,753  2030 – 2033
Federal R&D and orphan drug credit carryforwards$566,887  2024 – 2040
State net operating loss carryforwards$182,961  2021 – 2040
Dutch net operating loss carryforwards$75,718  2022 – 2025
Schedule of Reconciliation of Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2020 and 2019, is as follows:
December 31,
20202019
Balance at beginning of period$168,748 $147,445 
Additions based on tax positions related to the current year
16,481 19,287 
(Deletions) Additions for tax positions of prior years(2,527)2,016 
Lapse of statute of limitations(138)— 
Balance at end of period$182,564 $168,748 
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER COMMON SHARE (Tables)
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings per Common Share
The following table sets forth the computation of basic and diluted income (loss) per common share (common shares in thousands):
Years Ended December 31,
202020192018
Numerator:
Net income (loss), basic$859,100 $(23,848)$(77,211)
Add: Interest on convertible notes8,313 — — 
Less: gain on the Company's common stock held by the NQDC— — (710)
Net income (loss), diluted$867,413 $(23,848)$(77,921)
Denominator:
Weighted-average common shares outstanding, basic180,804 179,039 177,061 
Effect of dilutive securities:
Options to purchase common stock1,543 — — 
Common stock issuable under the 2027 notes2,874 — — 
Common stock issuable under the 2024 notes3,970 — — 
Unvested RSUs1,938 — — 
Common stock potentially issuable for ESPP purchases353 — — 
The Company's common stock held by the NQDC196 — 207 
Weighted-average common shares outstanding, diluted191,678 179,039 177,268 
Net income (loss) per common share, basic$4.75 $(0.13)$(0.44)
Net income (loss) per common share, diluted$4.53 $(0.13)$(0.44)
Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income (loss) per common share as they were anti-dilutive (in thousands):
Years Ended December 31,
202020192018
Options to purchase common stock5,287 7,264 7,364 
Common stock issuable under the 2020 Notes— 3,983 3,983 
Common stock issuable under the 2024 Notes— 3,970 3,970 
Unvested RSUs2,235 3,956 3,404 
Common stock potentially issuable for ESPP purchases314 587 435 
The Company's common stock held by the NQDC— 205 — 
Total number of potentially issuable shares7,836 19,965 19,156 
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail)
 12 Months Ended
Dec. 31, 2020
Leasehold improvements  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, estimated useful life Shorter of life of asset or lease term
Building and improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 20 years
Building and improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 50 years
Manufacturing and laboratory equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 5 years
Manufacturing and laboratory equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 15 years
Computer hardware and software | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 3 years
Computer hardware and software | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 7 years
Office Furniture and Equipment  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 5 years
Vehicles  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 5 years
Land improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 10 years
Land improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life, (in years) 20 years
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
Segment
tranche
Significant Accounting Policies [Line Items]  
Number of tranches in offering period | tranche 4
Number of reportable segment 1
Number of operating segments 1
Employee Stock Purchase Plan  
Significant Accounting Policies [Line Items]  
Span of offering period 2 years
Aldurazyme | Minimum  
Significant Accounting Policies [Line Items]  
Payment received as percentage of net product sales 39.50%
Aldurazyme | Maximum  
Significant Accounting Policies [Line Items]  
Payment received as percentage of net product sales 50.00%
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 1,345,801 $ 1,161,152
Gross Unrealized Gains 5,069 4,713
Gross Unrealized Losses (11) (80)
Aggregate Fair Value 1,350,859 1,165,785
Cash and Cash Equivalents 649,158 437,446
Short-term Marketable Securities 416,228 316,361
Long-term Marketable Securities $ 285,473 $ 411,978
Maximum    
Schedule of Available-for-sale Securities [Line Items]    
Short-term marketable securities maturity period 1 year 1 year
Long-term marketable securities maturity period 5 years 5 years
Minimum    
Schedule of Available-for-sale Securities [Line Items]    
Long-term marketable securities maturity period 1 year 1 year
Quoted Price in Active Markets For Identical Assets (Level 1) | Cash    
Schedule of Available-for-sale Securities [Line Items]    
Cash $ 370,325 $ 259,347
Cash aggregate fair value 370,325 259,347
Cash and Cash Equivalents 370,325 259,347
Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 975,476 901,805
Gross Unrealized Gains 5,069 4,713
Gross Unrealized Losses (11) (80)
Aggregate Fair Value 980,534 906,438
Cash and Cash Equivalents 278,833 178,099
Short-term Marketable Securities 416,228 316,361
Long-term Marketable Securities 285,473 411,978
Level 2 | Money Market Instruments    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 264,833 173,100
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Aggregate Fair Value 264,833 173,100
Cash and Cash Equivalents 264,833 173,100
Short-term Marketable Securities 0 0
Long-term Marketable Securities 0 0
Level 2 | Corporate Debt Securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 413,137 518,523
Gross Unrealized Gains 3,261 3,575
Gross Unrealized Losses (8) (12)
Aggregate Fair Value 416,390 522,086
Cash and Cash Equivalents 0 0
Short-term Marketable Securities 220,551 233,294
Long-term Marketable Securities 195,839 288,792
Level 2 | U.S. Government Agency Securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 265,298 209,633
Gross Unrealized Gains 1,555 993
Gross Unrealized Losses (1) (67)
Aggregate Fair Value 266,852 210,559
Cash and Cash Equivalents 14,000 4,999
Short-term Marketable Securities 192,488 83,067
Long-term Marketable Securities 60,364 122,493
Level 2 | Asset-backed Securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 31,659  
Gross Unrealized Gains 85  
Gross Unrealized Losses (2)  
Aggregate Fair Value 31,742  
Cash and Cash Equivalents 0  
Short-term Marketable Securities 3,189  
Long-term Marketable Securities 28,553  
Level 2 | Foreign and Other    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 549 549
Gross Unrealized Gains 168 145
Gross Unrealized Losses 0 (1)
Aggregate Fair Value 717 693
Cash and Cash Equivalents 0 0
Short-term Marketable Securities 0 0
Long-term Marketable Securities $ 717 $ 693
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCIAL INSTRUMENTS - Additional Information (Detail) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Measurements, Recurring | Strategic Investment    
Schedule of Available-for-sale Securities [Line Items]    
Strategic investments fair value $ 10.5 $ 6.2
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 197,039 $ 197,039
Less: disposition (840) 0
Goodwill, ending balance $ 196,199 $ 197,039
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 31, 2020
Goodwill And Intangible Assets [Line Items]          
Gain (loss) on disposition of other assets   $ 59,495,000 $ 25,000,000 $ 50,000,000  
Finite-lived intangible assets   644,087,000 652,734,000    
Accumulated amortization   226,816,000 196,154,000    
Goodwill impairment charge   $ 0      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Firdapse          
Goodwill And Intangible Assets [Line Items]          
Consideration received         $ 67,200,000
Gain (loss) on disposition of other assets $ 59,500,000        
Increase (decrease) in goodwill (800,000)        
Finite-lived intangible assets 32,200,000        
Accumulated amortization $ 31,600,000        
Medivation          
Goodwill And Intangible Assets [Line Items]          
Milestone payments received     $ 25,000,000.0 $ 50,000,000.0  
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]    
Finite-lived intangible assets $ 644,087 $ 652,734
Less: Accumulated amortization (226,816) (196,154)
Intangible assets, net $ 417,271 $ 456,580
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Net Balance $ 417,271
Acquired intellectual property  
Finite-Lived Intangible Assets [Line Items]  
Net Balance $ 350,275
Average Remaining Life (in years) 6 years 10 months 24 days
Repurchased royalty rights  
Finite-Lived Intangible Assets [Line Items]  
Net Balance $ 19,687
Average Remaining Life (in years) 2 years 10 months 24 days
Technology Transfer  
Finite-Lived Intangible Assets [Line Items]  
Net Balance $ 46,657
Other  
Finite-Lived Intangible Assets [Line Items]  
Net Balance $ 652
Other | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Average Remaining Life (in years) 6 months
Other | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Average Remaining Life (in years) 3 years 4 months 24 days
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2021 $ 61,963
2022 61,939
2023 61,311
2024 55,036
2025 35,759
Thereafter 94,606
Finite-Lived Intangible Asset $ 370,614
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 1,668,066 $ 1,559,968
Accumulated depreciation (635,595) (549,100)
Total property, plant and equipment, net 1,032,471 1,010,868
Building and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 761,560 725,906
Manufacturing and laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 414,439 366,951
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 90,418 90,418
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 189,740 167,554
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 55,134 51,324
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 40,223 38,569
Land improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 7,412 7,349
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 109,140 $ 111,897
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 88,169 $ 89,285 $ 90,375
Depreciation capitalized into inventory $ 44,492 $ 37,481 $ 25,227
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY - Schedule of Inventory (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 76,673 $ 74,442
Work-in-process 308,286 349,978
Finished goods 313,589 255,855
Total inventory $ 698,548 $ 680,275
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY - Narrative (Details) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Inventory [Line Items]    
Inventory $ 698,548,000 $ 680,275,000
Pre-Launch Valoctocogene Roxaparvovec    
Inventory [Line Items]    
Inventory 0 $ 29,200,000
Inventory valuation reserves $ 87,200,000  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable and accrued operating expenses $ 191,429 $ 240,981
Accrued compensation expense 165,023 192,467
Accrued rebates payable 65,526 57,163
Forward foreign currency exchange contracts 17,798 10,448
Accrued royalties payable 17,155 30,797
Lease liability 11,754 10,700
Accrued income taxes 9,661 3,195
Value added taxes payable 9,562 8,395
Deferred revenue 152 13,037
Other 4,488 3,438
Total accounts payable and accrued liabilities $ 492,548 $ 570,621
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accrued rebates      
Supplemental Balance Sheet Information [Line Items]      
Balance at Beginning of Period $ 57,163 $ 43,116 $ 36,472
Provision for Current Period Sales 113,165 91,748 67,843
Payments (104,802) (77,701) (61,199)
Balance at End of Period 65,526 57,163 43,116
Reserve for cash discounts      
Supplemental Balance Sheet Information [Line Items]      
Balance at Beginning of Period 1,889 1,197 1,055
Provision for Current Period Sales 17,191 15,335 12,474
Payments (17,364) (14,643) (12,332)
Balance at End of Period $ 1,716 $ 1,889 $ 1,197
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets remeasured $ 0 $ 0
Liabilities remeasured 0 0
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 24,449,000 19,456,000
Fair value of financial assets, Total 26,864,000 20,633,000
Fair value of other non-current liabilities 80,092,000 67,081,000
Fair value of financial liabilities, Total 82,507,000 68,258,000
Fair Value, Measurements, Recurring | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 2,415,000 1,177,000
Fair value of other non-current liabilities 19,962,000 16,288,000
Fair Value, Measurements, Recurring | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 60,130,000 50,793,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 24,449,000 19,456,000
Fair value of financial assets, Total 26,864,000 20,633,000
Fair value of other non-current liabilities 19,962,000 16,288,000
Fair value of financial liabilities, Total 22,377,000 17,465,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 2,415,000 1,177,000
Fair value of other non-current liabilities 19,962,000 16,288,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 0 0
Fair value of financial assets, Total 0 0
Fair value of other non-current liabilities 60,130,000 50,793,000
Fair value of financial liabilities, Total 60,130,000 50,793,000
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 0 0
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 60,130,000 50,793,000
Fair Value, Measurements, Recurring | NQDC Plan assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 2,415,000 1,177,000
Fair value of other non-current assets 19,962,000 16,288,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 2,415,000 1,177,000
Fair value of other non-current assets 19,962,000 16,288,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 0 0
Fair value of other non-current assets 0 0
Fair Value, Measurements, Recurring | Restricted Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 4,487,000 3,168,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 4,487,000 3,168,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets $ 0 $ 0
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) - Contingent Payment
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Contingent consideration, beginning balance $ 50,793
Changes in the fair value of contingent consideration 4,500
Foreign exchange remeasurement of Euro denominated contingent consideration 4,837
Contingent consideration, ending balance $ 60,130
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
Derivatives Designated As Hedging Instruments  
Derivative [Line Items]  
Maturity of derivatives 2 years 3 months
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Maturity of derivatives 3 months
Foreign Currency Derivatives  
Derivative [Line Items]  
Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions $ (12.2)
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail) - Foreign exchange contracts - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Derivatives Designated As Hedging Instruments | Sell    
Derivative [Line Items]    
Notional amount $ 782,327 $ 820,546
Derivatives Designated As Hedging Instruments | Purchase    
Derivative [Line Items]    
Notional amount 189,540 212,348
Not Designated as Hedging Instrument | Sell    
Derivative [Line Items]    
Notional amount 98,343 77,335
Not Designated as Hedging Instrument | Purchase    
Derivative [Line Items]    
Notional amount $ 12,277 $ 30,818
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Derivative [Line Items]    
Derivative asset, fair value $ 9,500 $ 33,592
Derivative liability, fair value 28,818 15,941
Derivatives Designated As Hedging Instruments | Level 2    
Derivative [Line Items]    
Derivative asset, fair value 9,416 33,123
Derivative liability, fair value 28,571 13,677
Derivatives Designated As Hedging Instruments | Level 2 | Other Current Assets    
Derivative [Line Items]    
Derivative asset, fair value 6,268 19,584
Derivatives Designated As Hedging Instruments | Level 2 | Other Assets    
Derivative [Line Items]    
Derivative asset, fair value 3,148 13,539
Derivatives Designated As Hedging Instruments | Level 2 | Accounts Payable and Accrued Liabilities    
Derivative [Line Items]    
Derivative liability, fair value 17,551 8,184
Derivatives Designated As Hedging Instruments | Level 2 | Other Long-Term Liabilities    
Derivative [Line Items]    
Derivative liability, fair value 11,020 5,493
Not Designated as Hedging Instrument | Level 2 | Other Current Assets    
Derivative [Line Items]    
Derivative asset, fair value 84 469
Not Designated as Hedging Instrument | Level 2 | Accounts Payable and Accrued Liabilities    
Derivative [Line Items]    
Derivative liability, fair value $ 247 $ 2,264
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]      
Net product revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
Operating expenses as reported 1,897,220 1,804,505 1,614,736
Product      
Derivative Instruments, Gain (Loss) [Line Items]      
Net product revenues 1,805,861 1,661,043 $ 1,470,356
Derivatives Designated As Hedging Instruments | Operating expenses | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash Flow Hedging Gains (Losses) Reclassified into Earnings (4,942) (3,453)  
Derivatives Designated As Hedging Instruments | Product | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash Flow Hedging Gains (Losses) Reclassified into Earnings 18,122 17,672  
Not Designated as Hedging Instrument      
Derivative Instruments, Gain (Loss) [Line Items]      
Gains (Losses) Recognized in Earnings $ 115 $ (5,259)  
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Schedule of ROU Assets and Lease Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Assets:    
Operating $ 46,014 $ 49,045
Financing 11,095 10,389
Total ROU assets 57,109 59,434
Liabilities:    
Operating, Current 8,889 7,451
Finance, Current 2,865 3,249
Operating, Noncurrent 40,483 44,092
Finance, Noncurrent 4,006 6,708
Operating And Finance Lease Liability $ 56,243 $ 61,500
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Schedule of Maturities of Lease Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Operating    
2021 $ 11,295  
2022 10,127  
2023 8,605  
2024 6,570  
2025 5,561  
Thereafter 16,758  
Total lease payments 58,916  
Less: Interest (9,544)  
Present value of lease liabilities 49,372  
Financing    
2021 3,095  
2022 2,383  
2023 1,800  
2024 50  
2025 21  
Thereafter 0  
Total lease payments 7,349  
Less: Interest (478)  
Present value of lease liabilities 6,871  
Total    
2021 14,390  
2022 12,510  
2023 10,405  
2024 6,620  
2025 5,582  
Thereafter 16,758  
Total lease payments 66,265  
Total lease payments (10,022)  
Operating And Finance Lease Liability $ 56,243 $ 61,500
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Schedule of Lease Cost (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Lease Cost    
Total lease costs $ 16,560 $ 16,247
Operating expenses    
Lease Cost    
Operating 12,841 13,026
Amortization 3,271 2,615
Interest expense $ 448 $ 606
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Schedule of Other Information (Detail)
Dec. 31, 2020
Dec. 31, 2019
Weighted average remaining lease term (in years):    
Operating leases 6 years 9 months 18 days 7 years 10 months 24 days
Financing leases 2 years 7 months 6 days 3 years 3 months 18 days
Weighted Average Discount Rate [Abstract]    
Operating leases 4.90% 5.20%
Financing leases 5.20% 5.40%
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Schedule of Supplemental Cash Flow Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash used in operating activities:    
Operating leases $ 10,536 $ 8,183
Financing leases 450 628
Cash Flow, Financing Activities, Lessee [Abstract]    
Financing leases 6,918 5,087
Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]    
Operating leases 4,779 9,772
Financing leases $ 3,941 $ 3,267
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT - Additional Information (Detail)
 1 Months Ended 12 Months Ended
May 31, 2020
USD ($)
$ / shares
Oct. 31, 2018
USD ($)
Aug. 31, 2017
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 15, 2018
$ / shares
Debt Instrument [Line Items]            
Carrying value of equity component       $ 1,100,000,000    
1.25% Senior Subordinated Convertible Notes Due in May 2027            
Debt Instrument [Line Items]            
Carrying value of equity component       $ 600,000,000 $ 0  
Debt instrument, interest rate, stated percentage, per annum       1.25%    
Debt Instrument, unamortized discount       $ 12,312,000 0  
1.25% Senior Subordinated Convertible Notes Due in May 2027 | Senior Subordinated Notes            
Debt Instrument [Line Items]            
Debt instrument, aggregate principal amount $ 600,000,000.0          
Conversion rate of shares 7.2743          
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares $ 137.47          
Proceeds from Issuance of Secured Debt $ 585,800,000          
Debt Instrument, unamortized discount 13,500,000          
Debt issuance costs $ 700,000          
0.599% Senior Subordinated Convertible Notes Due in August 2024            
Debt Instrument [Line Items]            
Carrying value of equity component       $ 495,000,000 495,000,000  
Debt instrument, aggregate principal amount     $ 495,000,000.0      
Debt instrument, interest rate, stated percentage, per annum       0.599%    
Conversion rate of shares     8.0212      
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares     $ 124.67      
Debt Instrument, unamortized discount     $ 9,900,000 $ 5,116,000 6,533,000  
Debt instrument percentage of face value     98.00%      
Principal amount on conversion rate     $ 1,000,000      
Net proceeds from offering debt     481,700,000      
Repurchase of note principal amount       100.00%    
Debt issuance costs       $ 3,400,000    
1.50% Senior Subordinated Convertible Notes Due in October 2020            
Debt Instrument [Line Items]            
Carrying value of equity component       $ 0 374,993,000  
Debt instrument, interest rate, stated percentage, per annum       1.50%    
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares           $ 94.15
Debt Instrument, unamortized discount       $ 0 $ 12,078,000  
Principal amount on conversion rate     $ 1,000      
The 2018 Credit Facility            
Debt Instrument [Line Items]            
Debt issuance costs   $ 1,000,000.0        
Maximum borrowing capacity   $ 200,000,000.0        
Outstanding amount       $ 0    
The 2018 Credit Facility | Minimum            
Debt Instrument [Line Items]            
Percentage of commitment fees payable on undrawn amount   0.15%        
The 2018 Credit Facility | Minimum | LIBOR Rate            
Debt Instrument [Line Items]            
Debt instrument interest rate percentage   1.00%        
The 2018 Credit Facility | Minimum | Base Rate            
Debt Instrument [Line Items]            
Debt instrument interest rate percentage   0.00%        
The 2018 Credit Facility | Maximum            
Debt Instrument [Line Items]            
Percentage of commitment fees payable on undrawn amount   0.35%        
The 2018 Credit Facility | Maximum | LIBOR Rate            
Debt Instrument [Line Items]            
Debt instrument interest rate percentage   1.95%        
The 2018 Credit Facility | Maximum | Base Rate            
Debt Instrument [Line Items]            
Debt instrument interest rate percentage   0.95%        
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT - Summary of Senior Subordinated Convertible Obligations (Detail)
 12 Months Ended
Oct. 15, 2020
USD ($)
d
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
May 31, 2020
USD ($)
$ / shares
Oct. 15, 2018
$ / shares
Aug. 31, 2017
USD ($)
$ / shares
Debt Instrument [Line Items]              
Convertible notes   $ 1,100,000,000          
Convertible Notes, net of unamortized discount and deferred offering costs   1,075,145,000 $ 486,238,000        
Short-term convertible debt, net   0 361,882,000        
Total convertible debt, net   1,075,145,000 848,120,000        
Total fair value of fixed rate convertible debt   1,157,804,000 927,518,000        
Repayments of convertible debt   $ 374,991,000 0 $ 374,953,000      
1.25% Senior Subordinated Convertible Notes Due in May 2027              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage, per annum   1.25%          
Convertible notes   $ 600,000,000 0        
Unamortized discount   (12,312,000) 0        
Unamortized deferred offering costs   (683,000) 0        
Convertible Notes, net of unamortized discount and deferred offering costs   587,005,000 0        
Total fair value of fixed rate convertible debt   $ 627,090,000 0        
1.25% Senior Subordinated Convertible Notes Due in May 2027 | Senior Subordinated Notes              
Debt Instrument [Line Items]              
Unamortized discount         $ (13,500,000)    
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares         $ 137.47    
0.599% Senior Subordinated Convertible Notes Due in August 2024              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage, per annum   0.599%          
Convertible notes   $ 495,000,000 495,000,000        
Unamortized discount   (5,116,000) (6,533,000)       $ (9,900,000)
Unamortized deferred offering costs   (1,744,000) (2,229,000)        
Convertible Notes, net of unamortized discount and deferred offering costs   488,140,000 486,238,000        
Total fair value of fixed rate convertible debt   $ 530,714,000 521,839,000        
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares             $ 124.67
1.50% Senior Subordinated Convertible Notes Due in October 2020              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage, per annum   1.50%          
Convertible notes   $ 0 374,993,000        
Unamortized discount   0 (12,078,000)        
Unamortized deferred offering costs   0 (1,033,000)        
Short-term convertible debt, net   0 361,882,000        
Total fair value of fixed rate convertible debt   $ 0 $ 405,679,000        
Repayments of convertible debt $ 375,000,000.0            
Common stock, shares, issued to converting holders (in shares) | shares 0            
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares           $ 94.15  
Measurement period | d 25            
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT - Summary of Interest Expense on Debt (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Schedule Of Interest Expenses [Line Items]      
Total interest expense on convertible debt $ 29,309 $ 23,460 $ 43,664
Convertible Senior Notes      
Schedule Of Interest Expenses [Line Items]      
Coupon interest 12,350 4,907 12,452
Amortization of debt issuance costs 1,829 2,031 3,610
Accretion of discount on convertible notes 14,682 15,917 27,602
Total interest expense on convertible debt $ 28,861 $ 22,855 $ 43,664
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Net product revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
LOSS FROM OPERATIONS (36,765) (100,457) (123,524)
Other income 7,148 6,945 2,205
Benefit from income taxes (901,422) (70,963) (65,494)
NET INCOME (LOSS) 859,100 (23,848) (77,211)
Product      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Net product revenues 1,805,861 1,661,043 1,470,356
Amount Reclassified from AOCI (Gain) Loss      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Benefit from income taxes (127) 0 0
Total gain on available-for-sale debt securities 425 0 0
NET INCOME (LOSS) 13,605 15,853 (2,047)
Amount Reclassified from AOCI (Gain) Loss | Gains (losses) on Cash Flow Hedges      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
LOSS FROM OPERATIONS 13,180 15,853 (2,047)
Amount Reclassified from AOCI (Gain) Loss | Gains (losses) on Cash Flow Hedges | Forward contracts      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Operating expenses (4,942) (1,819) 3,958
Amount Reclassified from AOCI (Gain) Loss | Gains (losses) on Cash Flow Hedges | Product | Forward contracts      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Net product revenues 18,122 17,672 (6,005)
Amount Reclassified from AOCI (Gain) Loss | Gain (Loss) on Sale of Available-for-Sale Debt Securities      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Other income $ 552 $ 0 $ 0
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance $ 3,122,381 $ 2,967,940 $ 2,808,663
Other comprehensive income (loss) before reclassifications (22,471) 32,386 27,184
Less: gain (loss) reclassified from AOCI 13,732 15,853 (2,047)
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent (100) (1,640) (413)
Net change in unrealized holding gain (loss), net of tax (36,303) 14,893 28,818
Ending Balance 4,106,002 3,122,381 2,967,940
Unrealized Gains (Losses) on Cash Flow Hedges      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance 16,614 7,201 (20,232)
Other comprehensive income (loss) before reclassifications (23,462) 25,266 25,386
Less: gain (loss) reclassified from AOCI 13,180 15,853 (2,047)
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 0 0 0
Net change in unrealized holding gain (loss), net of tax (36,642) 9,413 27,433
Ending Balance (20,028) 16,614 7,201
Unrealized Gains (Losses) on Cash Flow Hedges | Cumulative Effect, Period of Adoption, Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     0
Unrealized Gains (Losses) on Cash Flow Hedges | Cumulative Effect, Period of Adoption, Adjusted Balance      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     (20,232)
Unrealized Gains (Losses) on Available-for-Sale Debt Securities      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance 3,565 (1,917) (2,722)
Other comprehensive income (loss) before reclassifications 976 7,122 1,804
Less: gain (loss) reclassified from AOCI 552 0 0
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent (100) (1,640) (413)
Net change in unrealized holding gain (loss), net of tax 324 5,482 1,391
Ending Balance 3,889 3,565 (1,917)
Unrealized Gains (Losses) on Available-for-Sale Debt Securities | Cumulative Effect, Period of Adoption, Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     (586)
Unrealized Gains (Losses) on Available-for-Sale Debt Securities | Cumulative Effect, Period of Adoption, Adjusted Balance      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     (3,308)
Accumulated Gain Loss from Other      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance (15) (13) (7)
Other comprehensive income (loss) before reclassifications 15 (2) (6)
Less: gain (loss) reclassified from AOCI 0 0 0
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 0 0 0
Net change in unrealized holding gain (loss), net of tax 15 (2) (6)
Ending Balance 0 (15) (13)
Accumulated Gain Loss from Other | Cumulative Effect, Period of Adoption, Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     0
Accumulated Gain Loss from Other | Cumulative Effect, Period of Adoption, Adjusted Balance      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     (7)
Accumulated Other Comprehensive Income (Loss)      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance 20,164 5,271 (22,961)
Ending Balance (16,139) 20,164 5,271
Accumulated Other Comprehensive Income (Loss) | Cumulative Effect, Period of Adoption, Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance $ 0 0 (586)
Ending Balance   $ 0 0
Accumulated Other Comprehensive Income (Loss) | Cumulative Effect, Period of Adoption, Adjusted Balance      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning Balance     $ (23,547)
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Concentration Risk And Geographic Information [Line Items]    
Number of operating business segment | Segment 1  
Accounts receivable, net $ 448,351 $ 377,404
Customer    
Concentration Risk And Geographic Information [Line Items]    
Accounts receivable, net $ 72,100 $ 60,200
Geographic Concentration Risk | Net Product Revenue | Minimum    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 10.00%  
Credit Concentration Risk | Accounts Receivable Balance | Customer One    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 24.00% 24.00%
Credit Concentration Risk | Accounts Receivable Balance | Customer Two    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 22.00% 16.00%
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue from External Customer [Line Items]      
Total revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
United States      
Revenue from External Customer [Line Items]      
Total revenues 912,375 778,440 696,793
Europe      
Revenue from External Customer [Line Items]      
Total revenues 518,465 509,188 436,434
Latin America      
Revenue from External Customer [Line Items]      
Total revenues 205,862 218,792 185,046
Rest of world      
Revenue from External Customer [Line Items]      
Total revenues $ 223,753 $ 197,628 $ 172,939
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue from External Customer [Line Items]      
Net product revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
Vimizim | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 544,257 544,345 481,977
Kuvan | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 457,736 463,353 433,582
Naglazyme | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 391,298 374,334 345,851
Palynziq | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 170,983 86,857 12,173
Brineura | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 110,192 71,997 39,889
Firdapse | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 1,288 22,348 21,787
Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Marketed by Company      
Revenue from External Customer [Line Items]      
Net product revenues 1,675,754 1,563,234 1,335,259
Aldurazyme | Marketed by Genzyme      
Revenue from External Customer [Line Items]      
Net product revenues 130,107 97,809 135,097
Product      
Revenue from External Customer [Line Items]      
Net product revenues $ 1,805,861 $ 1,661,043 $ 1,470,356
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]      
Net product revenues $ 1,860,455 $ 1,704,048 $ 1,491,212
United States      
Disaggregation of Revenue [Line Items]      
Net product revenues 912,375 778,440 696,793
Europe      
Disaggregation of Revenue [Line Items]      
Net product revenues 518,465 509,188 436,434
Latin America      
Disaggregation of Revenue [Line Items]      
Net product revenues 205,862 218,792 185,046
Rest of world      
Disaggregation of Revenue [Line Items]      
Net product revenues 223,753 197,628 172,939
Product      
Disaggregation of Revenue [Line Items]      
Net product revenues 1,805,861 1,661,043 1,470,356
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse      
Disaggregation of Revenue [Line Items]      
Net product revenues 1,675,754 1,563,234 1,335,259
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | United States      
Disaggregation of Revenue [Line Items]      
Net product revenues 756,863 669,171 560,030
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Europe      
Disaggregation of Revenue [Line Items]      
Net product revenues 498,725 485,596 424,357
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Latin America      
Disaggregation of Revenue [Line Items]      
Net product revenues 205,862 218,792 184,984
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Rest of world      
Disaggregation of Revenue [Line Items]      
Net product revenues 214,304 189,675 165,888
Marketed by Genzyme | Aldurazyme      
Disaggregation of Revenue [Line Items]      
Net product revenues $ 130,107 $ 97,809 $ 135,097
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) - Customer Concentration Risk - Net Product Revenue
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Concentration Risk [Line Items]      
Concentration risk, percentage 43.00% 41.00% 40.00%
Customer A      
Concentration Risk [Line Items]      
Concentration risk, percentage 16.00% 17.00% 18.00%
Customer B      
Concentration Risk [Line Items]      
Concentration risk, percentage 15.00% 13.00% 12.00%
Customer C      
Concentration Risk [Line Items]      
Concentration risk, percentage 12.00% 11.00% 10.00%
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Revenue from External Customer [Line Items]    
Total long-lived assets $ 1,089,580 $ 1,070,302
United States    
Revenue from External Customer [Line Items]    
Total long-lived assets 771,286 773,991
Ireland    
Revenue from External Customer [Line Items]    
Total long-lived assets 300,555 278,082
Rest of world    
Revenue from External Customer [Line Items]    
Total long-lived assets $ 17,739 $ 18,229
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Millions
 1 Months Ended 12 Months Ended
Sep. 19, 2019
Sep. 18, 2019
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share based awards, authorized (in shares)         36.7    
Stock-based compensation expense capitalized to inventory         $ 20,100,000 $ 20,300,000 $ 20,000,000.0
Weighted-average fair value per option granted (in dollars per share)         $ 27.47 $ 36.84 $ 33.40
Total intrinsic value of options exercised         $ 71,900,000 $ 32,500,000 $ 79,900,000
Net tax benefit from stock options exercised         $ 4,500,000    
Employee Stock Purchase Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share based awards, authorized (in shares)         7.0    
Shares reserved for future issuance (in shares)         3.4    
Options to purchase shares of common stock, percentage         85.00%    
Span of offering period, in years         2 years    
Maximum percentage of qualified compensation to be used for purchase         10.00%    
Maximum payroll deductions         $ 25,000    
Shares issued under the employee stock purchase plan (in shares)         0.3    
Unrecognized compensation cost related to unvested awards         $ 18,300,000    
Unrecognized compensation cost expected to recognized over weighted average period, in years         1 year 4 months 24 days    
Dividend yield         0.00% 0.00% 0.00%
Employee Stock Purchase Plan | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expected term         6 months 6 months 6 months
Employee Stock Purchase Plan | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expected term         2 years 2 years 2 years
Stock Option              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost related to unvested awards         $ 35,300,000    
Unrecognized compensation cost expected to recognized over weighted average period, in years         2 years 6 months    
Dividend yield         0.00% 0.00% 0.00%
Stock Option | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expected term         4 years 7 months 6 days 4 years 7 months 6 days 4 years 7 months 6 days
Stock Option | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expected term         5 years 10 months 24 days 5 years 9 months 18 days 5 years 8 months 12 days
Unvested RSUs | Independent Director | Common Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period, years 1 year            
Initial equity grant value $ 400,000 $ 375,000          
Average closing price of common stock, trailing period 3 months            
Restricted Stock With Service Based Vesting Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share)         $ 77.13 $ 91.28 $ 84.63
The total intrinsic value of restricted stock vested and released         $ 109,900,000 $ 101,000,000.0 $ 84,500,000
Unrecognized compensation cost related to unvested awards         $ 245,300,000    
Unrecognized compensation cost expected to recognized over weighted average period, in years         2 years 7 months 6 days    
Restricted Stock Unit Awards with Performance-Based Vesting Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share)         $ 73.82 $ 94.53 $ 83.57
Unrecognized compensation cost related to unvested awards         $ 3,500,000    
Unrecognized compensation cost expected to recognized over weighted average period, in years         1 year    
Award vesting service period         3 years    
Percentage of threshold achievement         75.00%    
Percentage of ceiling achievement         125.00%    
Restricted Stock Unit Awards with Performance-Based Vesting Conditions | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Percentage of, number of shares may earned         50.00%    
Restricted Stock Unit Awards with Performance-Based Vesting Conditions | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Percentage of, number of shares may earned         200.00%    
Restricted Stock Unit Awards with non-Revenue based Performance Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share)         $ 84.17 $ 81.00  
Unrecognized compensation cost expected to recognized over weighted average period, in years         2 years 2 months 12 days    
Award vesting service period       3 years      
Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares earned range       50.00%      
Restricted Stock Unit Awards with non-Revenue based Performance Conditions | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares earned range       200.00%      
Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Probable Of Vesting              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost related to unvested awards         $ 8,100,000    
Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Not Probable Of Vesting              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost related to unvested awards         7,900,000    
March 2019 Base Restricted Stock Unit Awards With Market Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost related to unvested awards         $ 14,100,000    
Unrecognized compensation cost expected to recognized over weighted average period, in years         1 year 9 months 18 days    
Award vesting service period         3 years    
Ceiling achievement level         100.00%    
Expected term     2 years 6 months 2 years 9 months 18 days      
Discount rate     0.20% 0.40%      
Dividend yield     0.00% 0.00%      
Exercise price (in dollars per share)     $ 217.65 $ 112.12      
March 2019 Base Restricted Stock Unit Awards With Market Conditions | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares earned range         0.00%    
Annual shareholder return multiplier         50.00%    
March 2019 Base Restricted Stock Unit Awards With Market Conditions | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares earned range         200.00%    
2017 Equity Incentive Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares reserved for future issuance (in shares)         20.5    
2017 Equity Incentive Plan | Stock Option              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period, years         4 years    
Initial time period vesting requirements         12 months    
Contractual term of stock option awards, years         10 years    
2017 Equity Incentive Plan | Restricted Stock With Service Based Vesting Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period, years         4 years    
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 189,711 $ 159,865 $ 148,819
Cost of sales      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 26,246 16,146 13,558
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 61,942 56,649 57,557
Selling, general and administrative      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 101,523 $ 87,070 $ 77,704
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail) - $ / shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Restricted Stock With Service Based Vesting Conditions      
Shares      
Shares, Non-vested units beginning balance (in shares) 3,585,384    
Shares, Granted (in shares) 2,190,380    
Shares, Vested (in shares) (1,308,962)    
Shares, Forfeited (in shares) (293,678)    
Shares, Non-vested units ending balance (in shares) 4,173,124 3,585,384  
Weighted Average Grant Date Fair Value      
Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share) $ 88.54    
Weighted Average Grant Date Fair Value, Granted (in dollars per share) 77.13 $ 91.28 $ 84.63
Weighted Average Grant Date Fair Value, Vested (in dollars per share) 87.57    
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) 85.17    
Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share) $ 83.41 $ 88.54  
Restricted Stock Unit Awards with Performance-Based Vesting Conditions      
Shares      
Shares, Non-vested units beginning balance (in shares) 226,884    
Shares, Granted (in shares) 2,272    
Shares, Vested (in shares) (126,608)    
Shares, Forfeited (in shares) (3,197)    
Shares, Non-vested units ending balance (in shares) 99,351 226,884  
Weighted Average Grant Date Fair Value      
Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share) $ 89.09    
Weighted Average Grant Date Fair Value, Granted (in dollars per share) 73.82 $ 94.53 $ 83.57
Weighted Average Grant Date Fair Value, Vested (in dollars per share) 88.09    
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) 94.53    
Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share) $ 90.31 $ 89.09  
Restricted Stock Unit Awards with non-Revenue based Performance Conditions      
Shares      
Shares, Non-vested units beginning balance (in shares) 44,260    
Shares, Granted (in shares) 184,460    
Shares, Vested (in shares) (4,495)    
Shares, Forfeited (in shares) (3,560)    
Shares, Non-vested units ending balance (in shares) 220,665 44,260  
Weighted Average Grant Date Fair Value      
Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share) $ 81.00    
Weighted Average Grant Date Fair Value, Granted (in dollars per share) 84.17 $ 81.00  
Weighted Average Grant Date Fair Value, Vested (in dollars per share) 73.82    
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) 78.72    
Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share) $ 83.83 $ 81.00  
Restricted Stock Unit Awards with Market Conditions      
Shares      
Shares, Non-vested units beginning balance (in shares) 99,010    
Shares, Granted (in shares) 131,350    
Shares, Vested (in shares) 0    
Shares, Forfeited (in shares) (9,370)    
Shares, Non-vested units ending balance (in shares) 220,990 99,010  
Weighted Average Grant Date Fair Value      
Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share) $ 143.92    
Weighted Average Grant Date Fair Value, Granted (in dollars per share) 115.85    
Weighted Average Grant Date Fair Value, Vested (in dollars per share) 0    
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) 143.92    
Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share) $ 127.23 $ 143.92  
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Shares    
Shares, Options outstanding beginning balance (in shares) 7,264,235  
Shares, Granted (in shares) 891,610  
Shares, Exercised (in shares) (1,240,511)  
Shares, Expired and forfeited (in shares) (85,897)  
Shares, Options outstanding ending balance (in shares) 6,829,437  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Weighted Average Exercise Price, Outstanding beginning balance (in dollars per share) $ 67.99  
Weighted Average Exercise Price, Granted (in dollars per share) 76.02  
Weighted Average Exercise Price, Exercised (in dollars per share) 43.87  
Weighted Average Exercise Price, Expired and forfeited (in dollars per share) 86.07  
Weighted Average Exercise Price, Outstanding ending balance (in dollars per share) $ 73.19  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]    
Shares, Options unvested (in shares) 1,438,573  
Shares, Exercisable (in shares) 5,390,864  
Weighted Average Exercise Price, Options unvested (in dollars per share) $ 81.56  
Weighted Average Exercise Price, Exercisable (in dollars per share) $ 70.95  
Weighted Average Remaining Years, Options outstanding 4 years 9 months 18 days  
Weighted Average Remaining Years, Options unvested at December 31, 2020 8 years 7 months 6 days  
Weighted Average Remaining Years, Exercisable at December 31, 2020 3 years 9 months 18 days  
Aggregate Intrinsic Value, Options outstanding $ 119,607 $ 146,700
Aggregate Intrinsic Value, Options unvested at December 31, 2020 11,635  
Aggregate Intrinsic Value, Exercisable at December 31, 2020 $ 107,972  
Closing price of common stock (in dollars per share) $ 87.69  
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail) - Stock Option
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility, minimum 36.50% 37.10% 36.80%
Expected volatility, maximum 42.20% 37.40% 38.40%
Dividend yield 0.00% 0.00% 0.00%
Risk-free interest rate, minimum 0.30% 2.20% 2.30%
Risk-free interest rate, maximum 1.70% 3.00% 2.80%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term 4 years 7 months 6 days 4 years 7 months 6 days 4 years 7 months 6 days
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term 5 years 10 months 24 days 5 years 9 months 18 days 5 years 8 months 12 days
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.20.4
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail) - Employee Stock Purchase Plan
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility, minimum 30.60% 27.70% 29.70%
Expected volatility, maximum 69.20% 35.00% 35.00%
Dividend yield 0.00% 0.00% 0.00%
Risk-free interest rate, minimum 0.10% 1.20% 1.20%
Risk-free interest rate, maximum 2.80% 2.80% 2.80%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term 6 months 6 months 6 months
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term 2 years 2 years 2 years
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EMPLOYEE BENEFITS - Additional Information (Detail) - BioMarin Retirement Savings Plan - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Company's contribution to match employees contribution 60.00%    
Employee contribution of their current compensation 100.00%    
Employer contribution of maximum percentage over employee's annual compensation 6.00%    
Company's contribution from employment commencement $ 26.4 $ 28.5 $ 23.0
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
U.S. Source $ (162,939) $ (182,112) $ (128,700)
Non-U.S. Source 120,617 87,301 (14,005)
Loss before income taxes $ (42,322) $ (94,811) $ (142,705)
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Benefit from income taxes      
Federal $ (14,758) $ 5,127 $ (2,660)
State and local 1,201 1,331 588
Foreign 1,042 5,339 4,956
Current income tax expense, total (12,515) 11,797 2,884
Provision for (benefit from) deferred income taxes:      
Federal (45,038) (58,311) (72,074)
State and local (5,321) (5,394) (994)
Foreign (838,548) (19,055) 4,690
Deferred income tax expense (benefit), total (888,907) (82,760) (68,378)
Benefit from income taxes $ (901,422) $ (70,963) $ (65,494)
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Income Tax Contingency [Line Items]      
Deferred tax assets $ 1,432,150   $ 549,422
Unrecognized tax benefits that would affect the effective tax rate if recognized 175,100    
Undistributed earnings of foreign subsidiaries $ 15,200    
Ireland      
Income Tax Contingency [Line Items]      
Deferred tax assets   $ 835,100  
Minimum      
Income Tax Contingency [Line Items]      
Income tax statute of limitations period 3 years    
Maximum      
Income Tax Contingency [Line Items]      
Income tax statute of limitations period 5 years    
State      
Income Tax Contingency [Line Items]      
Research credit carry forward $ 124,300    
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Contingency [Line Items]      
Federal statutory income tax benefit $ (8,888) $ (19,911) $ (29,968)
State and local taxes (3,264) (2,784) (276)
Orphan Drug & General Business Credit (44,114) (43,124) (66,451)
Stock compensation expense (1,101) 239 (5,647)
Changes in the fair value of contingent consideration 0 (1,804) (2,361)
Foreign Source Income Subject to U.S. Tax 6,266 (52) 6,543
Foreign tax rate differential (1) (16,238) (30,639) 12,583
Section 162(m) limitation 9,571 8,294 7,440
Tax Reserves 2,166 12,123 8,545
Intra-entity transfer of assets (852,338) 0 0
CARES Act carryback claim (2,201) 0 0
Other 1,843 (1,132) (423)
Valuation allowance/deferred benefit 6,876 7,827 4,521
Benefit from income taxes (901,422) (70,963) $ (65,494)
Valuation allowance 93,075 $ 86,197  
Dutch      
Income Tax Contingency [Line Items]      
Valuation allowance $ 29,600    
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred Tax Assets, Gross [Abstract]    
Net operating loss carryforwards $ 30,718 $ 32,181
Tax credit carryforwards 532,394 508,560
Accrued expenses, reserves, and prepaids 66,889 61,807
Intangible assets 873,575 29,413
Stock-based compensation 47,011 42,873
Lease liabilities 8,991 11,470
Inventory 32,012 6,290
Other 454 575
Valuation allowance (93,075) (86,197)
Total deferred tax assets 1,498,969 606,972
Deferred Tax Liabilities, Gross [Abstract]    
Joint venture basis difference (1,164) (993)
Acquired intangibles (1,364) (1,647)
Deferred revenue (1,517) (3,003)
Convertible notes discount 0 (2,364)
ROU assets (8,280) (10,258)
Property, plant and equipment (54,682) (46,642)
Total deferred tax liabilities (67,007) (64,907)
Net deferred tax assets $ 1,431,962 $ 542,065
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Federal  
Income Tax Contingency [Line Items]  
Net operating loss carryforwards $ 4,753
Federal R&D and orphan drug credit carryforwards 566,887
State  
Income Tax Contingency [Line Items]  
Net operating loss carryforwards 182,961
Federal R&D and orphan drug credit carryforwards 124,300
Dutch | Foreign  
Income Tax Contingency [Line Items]  
Net operating loss carryforwards $ 75,718
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Balance at beginning of period $ 168,748 $ 147,445
Additions based on tax positions related to the current year 16,481 19,287
(Deletions) Additions for tax positions of prior years (2,527) 2,016
Lapse of statute of limitations (138) 0
Balance at end of period $ 182,564 $ 168,748
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Numerator:      
Net income (loss), basic $ 859,100 $ (23,848) $ (77,211)
Add: Interest on convertible notes 8,313 0 0
Less: gain on the Company's common stock held by the NQDC 0 0 (710)
Net income (loss), diluted $ 867,413 $ (23,848) $ (77,921)
Denominator:      
Weighted average common shares outstanding, basic (in shares) 180,804 179,039 177,061
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Weighted average common shares outstanding, diluted (in shares) 191,678 179,039 177,268
Net loss per common share, basic (in usd per share) $ 4.75 $ (0.13) $ (0.44)
Net loss per common share, diluted (in usd per share) $ 4.53 $ (0.13) $ (0.44)
Stock Option      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 1,543 0 0
Common stock issuable under the 2027 Notes      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 2,874 0 0
Common stock issuable under the 2024 Notes      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 3,970 0 0
Unvested RSUs      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 1,938 0 0
Common stock potentially issuable for ESPP purchases      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 353 0 0
The Company's common stock held by the NQDC      
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]      
Effect of dilutive securities 196 0 207
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 7,836 19,965 19,156
Stock Option      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 5,287 7,264 7,364
Common stock issuable under the 2020 Notes      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 0 3,983 3,983
Common stock issuable under the 2024 Notes      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 0 3,970 3,970
Unvested RSUs      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 2,235 3,956 3,404
Common stock potentially issuable for ESPP purchases      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 314 587 435
The Company's common stock held by the NQDC      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares) 0 205 0
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Convertible Senior Notes Due 2020    
Earnings Per Share [Line Items]    
Debt instrument, convertible, conversion price, per share (in dollars per share) $ 94.15 $ 94.15
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.20.4
LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail)
$ in Thousands, € in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2019
USD ($)
Jul. 31, 2017
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2020
EUR (€)
Mar. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net product revenues     $ 1,860,455   $ 1,704,048 $ 1,491,212    
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones     662,800          
Firdapse | Disposal Group, Disposed of by Sale, Not Discontinued Operations                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalties on net product sales               7.00%
Royalties on net product sales               10.00%
Merck Serono                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones     73,600          
Exclusive Licensing Agreement For Tralesinidase Alfa                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net product revenues $ 3,000              
Investment in equity     8,100          
Exclusive Licensing Agreement For Tralesinidase Alfa | Variable Interest Entity, Not Primary Beneficiary                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Minority equity ownership 15.00%              
A&R Kuvan Agreement | Merck Serono | Maximum                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Business acquisition contingent consideration potential cash payments upon achievement of sales milestone | €             € 60.0  
Pegvaliase Agreement | Merck Serono                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Business acquisition, cash paid | €       € 125.0        
United States                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net product revenues     $ 912,375   $ 778,440 $ 696,793    
Sarepta Therapeutics | United States | License Agreement And Settlement Agreement                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalties receivable percentage of net sales   5.00%            
Sarepta Therapeutics | EU and Other Countries | License Agreement And Settlement Agreement                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalties receivable percentage of net sales   8.00%            
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Commitments and Contingencies [Line Items]      
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   $ 662.8  
Contingent consideration   60.1  
Purchase commitment for the next five years   142.8  
Asset retirement obligation   3.7 $ 3.0
Merck Serono      
Commitments and Contingencies [Line Items]      
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   73.6  
Early Stage Development Program | Third Party      
Commitments and Contingencies [Line Items]      
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones $ 235.0    
Completed Programs | Merck Serono      
Commitments and Contingencies [Line Items]      
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   $ 237.7  
EXCEL 116 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ϛ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�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

-8?20$3;8T.P M6BP^0"X99K>]9!:GTKQ]@FCP]UZCGU@3]]K^H_GJOJ M#_'GOBB;F\%+VQX^7E\WFQ>USYI_50=5ZE=V5;W/6OVT_GK='&J5;9L7I=I] M<3T>#NWK?9:7@\^?WLZUJJ_IDZI5FS:O2GVP._"8J^_-S]>[I^);WN3/>9&W M?]T,^K\+-1#[O,SW^=]J>S,8#D3S4GU_J.K\[ZILLR+9U%51W Q&QQ<>5=WF MFW\<3CK(-'MN^B-M]AQG&N1F8 _U"7=YW;3]._KS9YKQF])O/CY[;:N[O&A5 MO\_-J=1G^+:_(U^CB\/1Z#^+'^?\)8[7;Y1BVJS>M>E>TQCK4J M.L"R>_R"K28CX:H_YOJ%VM_VC(P\ M49A$@;_P4KD0MU[@A7,ID@PQ M:?<]1/WWD!-TN*B60S8K;-G1]JP?A>(/PP2>-UGS(4#DEFQ&R9^RA:_,9V29$;-F M_/!1TT3Q$P5"1ADQ*R59KU9!GPJZ[1EECK[2=Q'%1$X9,4OESO-C\>@%:RF6 MTDMTW_V/#$$V&3'K9"%C_U%WSX^2YF_?!!_DXIYB(I^,F(42Z-!)H[Y&!ADS M&V0A;VE>CI$FQLR:T'Y8+]=!7[-$Z8.,^](TE@\R3/15I9AP3,*LB5CJ[F,M M?Q?S6"[\5$.&G=[>"AB*B80Q9A9&U^VF3WT(=?QZN+Y3/F:$T0"1,<;,QCA> M:+E?R!5C=E?H $J1>O\UR;VSP* N\V.N:(\.YC::0STL:861M=W/ST MIRMT.G2;7#5T(@399'+)\8@Q@)\@T4R817.V MT!=7::8QFM\H)?+,A-DSN.*GGIG V2]FS\"27UQ13.29";-G?A3]9Z\S4LR$ M63&P^C>3!EEGPFR==ZK_MW!23&2=";-UX"C C":RSH39.H'*&M6<;8O(,Q-F MSW3#@7-04V25*;-5X+C N*139)4I^RP7&!>8F$@K4V:MP'&!B8FT,F76"BV\ MS[9(N)C"+!-8@9LQ1&:9LIL%E6,3BHG,,F6?_D*84XJ)S#+EGOXZ6S5^$(D^ M]_:UH)C(+%-FL[R'Z6VWN7XSQ42FF3*;!E:W1@I9R#T6LWLP)DTA"[G'8G8/ MQJ0I9"'W6)<$VC6CK+9B,+V=QK.^>JWI+,9&% M''8+G6+Z9:MJU;1"_GF@&]D=9"&'V4)XCI@ZW4$6L>7&14<6ZU*.;Z6%0&5;9]^TV%M]^#^/P_4$L#!!0 M ( AZ6E)CQ!%*W0( %P[ : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'/-V[UNXD 81N%;0;Z V/,_LPJIMDF[R@T@8B *8(2]VN3N%Y$"WM$6 MVT0^%1HC/HYU;VW6Q/=_/:)X>[V#J"W4[T=0&^G>CN WJYZ6 +0VZG>#J"W4[T=0&^G M>CN WD[U=@"]G>KM 'H[U=L!]/:JMP?H[55O#]#;J]X>H+=7O3U ;U\][ ;H M[55O#]#;J]X>H+=7O3U ;Z]Z>X#>7O7V +V#ZAT >@?5.P#T#JIW .@=5.\ MT#NHW@&@=ZC^K 3H'53O - [J-X!H'=0O0- [Z!Z!X#>4?6. +VCZAT!>D?5 M.P+TCJIW!.@=5>\(T#NJWA&@=ZPVFP#TCJIW!.@=5>\(T#NJWA&@=U*]$T#O MI'HG@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U4[P30.U6;!0%Z)]4[ ?1.JG<" MZ)U5[PS0.ZO>&:!W5KTS0.^L>F> WEGUS@"]L^J= 7IGU3L#],ZJ=P;HG:O- MW@"]L^J= 7H7U;L ]"ZJ=P'H753O M"[J-X%H'=1O0M [Z)Z%X#>1?4N +V+ MZET >A?5NP#T+M5A'8#>IJN/ZP#\-EUU8*?[3L''Z7/?C[>BKW45\)U>3Y?/ M]K?OORZ_+M:WX4IT>Y\Q/OT%4$L#!!0 ( AZ6E)_X$/,6P( $TY 3 M 6T-O;G1E;G1?5'EP97-=+GAM;,W;RV[;,!"%X5?O2R@5HD1H-7*#_QH)-_$5-6'ZLX)M=D848]#<$-8AU.-Y.;Z MD]M5]UU8?3[&GWT[#MMD=IU/5A^?-IZRMDDU35U;5R&NBX>A^2UE_9R0QI/+ M'K]O)W\5-R3BS833RI\#GL]]?7#SW#9N=5O-X4O5QUWBV D?'COGT_,EWNAQ MW.W:VC5C?=_'(ZF?9EC5^>00;]@]?'_[X]Q/BSS\&)Y7'[' MO\[XM?X[^U"0/C)('SFD#PWIPT#ZL) ^"D@?):0/N:$T0A%54DB5%%,E!55) M45526)445R4%5DF155%D5119%45619%54615%%D5159%D5519%4463.*K!E% MUHPB:T:1-:/(FE%DS2BR9A19,XJL&476G")K3I$UI\B:4V3-*;+F%%ESBJPY M1=:<(FM.D5539-44635%5DV155-DU119-45639%54V35%%D-159#D=509#44 M60U%5D.1U5!D-119#4560Y'54F2U%%DM159+D=529+4462U%5DN1U5)DM119 M"XJL!476@B)K09&UH,A:4&0M*+(6%%D+BJP%1=:2(FM)D;6DR%I29"TILI84 M64N*K"5%UI(B:TF156XHM,K-_[3U^S@>_G'\\DS[JAU>\L7R+\J;GU!+ 0(4 M Q0 ( AZ6E('04UB@0 +$ 0 " 0 !D;V-0 M&UL4$L! A0#% @ "'I:4E1K5Y[O *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ "'I: M4IEEI2*3-('I & 5&@ & M@($." >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I: M4BA,0EI28\"@2TP& !4& & @($)& >&PO=V]R:W-H M965T&UL4$L! A0#% @ "'I:4L-%+O>#! 9P\ !@ M ("!BQX 'AL+W=OEI2R/!J.]H' !^ M*0 & @(%H)@ >&PO=V]R:W-H965T&UL M4$L! A0#% @ "'I:4J3)QHEU"@ PRP !@ ("!>"X M 'AL+W=OEI2BHB" 9H& W#P &0 M@($4/P >&PO=V]R:W-H965T5% !X;"]W;W)K&UL4$L! A0#% @ "'I:4IE:;RY6 P (@< !D M ("!P6X 'AL+W=OEI2 2>;0XT& #L#P &0 @(%.<@ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ "'I:4A(.-(/; P _P< !D ("!T'\ M 'AL+W=OEI2S? W M!PP& !8#0 &0 @('B@P >&PO=V]R:W-H965T&UL4$L! A0#% @ M"'I:4LRZ+*]E!0 *@\ !D ("!MHX 'AL+W=OEI2T)99%;P% !]#@ &0 @($) MK@ >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4LHZUH<0$P *S\ !D M ("!^KX 'AL+W=OEI2AW<[-54% !Z# &0 @(%!T@ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ "'I:4OQR"OR'!0 U X !D ("!P>4 'AL M+W=OEI2,1TU3F,) M #1%@ &0 @(%_ZP >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I: M4N/:_V6!+0 P)H !D ("!#/P 'AL+W=OEI2V0]T^MD" #O!0 &0 M @('$*0$ >&PO=V]R:W-H965T39R@0 *8+ 9 " @=0L 0!X;"]W;W)K M&UL4$L! A0#% @ "'I:4JYN'EJ:! B0L M !D ("!U3$! 'AL+W=OEI22?_ !(P# ^!P &0 @(&F-@$ M>&PO=V]R:W-H965TL])> M@0( !T% 9 " @6DZ 0!X;"]W;W)K&UL4$L! A0#% @ "'I:4H2C]N"-! @PH !D M ("!(3T! 'AL+W=OEI2%\'+CC(% #&#@ &0 @('E00$ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ "'I:4@/D?R[P!0 "A( !D ("!\4P! 'AL+W=O MEI2C!H7$&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4NTE M78.C!@ *1( !D ("!45\! 'AL+W=OEI2:V42H<<' "$%@ &0 M @($K9@$ >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4@V)%^C&! ? P !D M ("!;'EI2(E79%/,# "F% &0 @(%I? $ >&PO M=V]R:W-H965T%(=#-P, M $* 9 " @9. 0!X;"]W;W)K&UL4$L! A0#% @ "'I:4HWRY$QT" IS !D ("! M 80! 'AL+W=OEI2 M08C#KEL" >!0 &0 @(&LC $ >&PO=V]R:W-H965T&UL4$L! A0#% M @ "'I:4B)^$S<&! % X !D ("!!9(! 'AL+W=OEI25?H6"R<$ Q$@ &0 M@(&TGP$ >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4D$NX)6 @ 308 !D M ("!]:8! 'AL+W=OEI2C/ ]3E0" O!@ &0 @(&LJ0$ >&PO=V]R M:W-H965T+RP, )<+ M 9 " @3>L 0!X;"]W;W)K&UL M4$L! A0#% @ "'I:4BJX&G72 P [0P !D ("!.; ! M 'AL+W=OEI2!A$L MG'4& "4+@ &0 @(%"M $ >&PO=V]R:W-H965TC-CY@( .H& 9 M " @>ZZ 0!X;"]W;W)K&UL4$L! A0#% @ M"'I:4J@LRH+X @ _@< !D ("!"[X! 'AL+W=OX&@;J P MYPT !D ("!G\@! 'AL+W=OEI2-CG/B&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4A[R(ING @ ;@< !D M ("!V=0! 'AL+W=OEI28."%VX " ",!P &0 @(&WUP$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ "'I:4@'9B,4:!P 5B8 !D ("!L-T! 'AL M+W=OEI212^ ET4& M N( &0 @($!Y0$ >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I: M4BBAEAQ!!0 RQ8 !D ("!Z.X! 'AL+W=OEI2'>6NA,0' <+@ &0 M @(%@] $ >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4D(3P1:D P 7PP M !D ("!*0 " 'AL+W=OEI2$YQGF;D$ #[% &0 @($$! ( M>&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4N)FA2@+ P I0L !D M ("!< X" 'AL+W=OEI2:OOL%OD" 4"0 &0 @(&R$0( >&PO=V]R:W-H965T M(4 @!X;"]W;W)K&UL4$L! A0# M% @ "'I:4E>("4AD P D0L !D ("!F2 " 'AL+W=O MEI2+P&^RH8& #V M)0 &0 @($T) ( >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4D\I M]9:2 P >PX !D ("!(S " 'AL+W=OEI2"I^@Z'X# Z#@ &0 M @('L,P( >&PO=V]R:W-H965T&UL4$L! A0#% @ "'I:4KDL.TW& @ :P< !D M ("!##L" 'AL+W=OEI2L*9(6*H# "3# &0 @($)/@( >&PO M=V]R:W-H965TI! @!X;"]W;W)K&UL4$L! A0#% @ "'I:4G6T!*@J!0 =A( !D ("! MI44" 'AL+W=OEI2 M&AC21I$$ N$ &0 @($&2P( >&PO=V]R:W-H965T&UL4$L! A0#% M @ "'I:4L7HJ:EI2'7\$"PL& #C&@ &@ M@(&V8@( >&PO=V]R:W-H965TEI2?W^&D;4# @#0 &@ @('Y: ( >&PO=V]R:W-H965T MEI2A2L[GW<" ^#@ #0 M @ 'F; ( >&POEI28\012MT" !<.P &@ M @ 'I=P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " (>EI2?^!#S%L" !-.0 $P @ '^>@( 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 ;0!M /0= "*?0( ! end XML 117 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 118 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 119 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 453 583 1 false 136 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.bmrn.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101101 - Disclosure - NATURE OF OPERATIONS AND BUSINESS RISKS Sheet http://www.bmrn.com/role/NATUREOFOPERATIONSANDBUSINESSRISKS NATURE OF OPERATIONS AND BUSINESS RISKS Notes 9 false false R10.htm 2102102 - Disclosure - BASIS OF PRESENTATION Sheet http://www.bmrn.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 10 false false R11.htm 2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 11 false false R12.htm 2108104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 12 false false R13.htm 2109105 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 13 false false R14.htm 2113106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 14 false false R15.htm 2120107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 15 false false R16.htm 2124108 - Disclosure - INVENTORY Sheet http://www.bmrn.com/role/INVENTORY INVENTORY Notes 16 false false R17.htm 2128109 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION Notes 17 false false R18.htm 2132110 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 18 false false R19.htm 2136111 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Notes 19 false false R20.htm 2142112 - Disclosure - LEASES Sheet http://www.bmrn.com/role/LEASES LEASES Notes 20 false false R21.htm 2149113 - Disclosure - DEBT Sheet http://www.bmrn.com/role/DEBT DEBT Notes 21 false false R22.htm 2154114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Notes 22 false false R23.htm 2158115 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Notes 23 false false R24.htm 2166116 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION Notes 24 false false R25.htm 2174117 - Disclosure - OTHER EMPLOYEE BENEFITS Sheet http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS OTHER EMPLOYEE BENEFITS Notes 25 false false R26.htm 2176118 - Disclosure - INCOME TAXES Sheet http://www.bmrn.com/role/INCOMETAXES INCOME TAXES Notes 26 false false R27.htm 2185119 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE NET INCOME (LOSS) PER COMMON SHARE Notes 27 false false R28.htm 2190120 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS Sheet http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS LICENSE AND COLLABORATION AGREEMENTS Notes 28 false false R29.htm 2192121 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 29 false false R30.htm 2203201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 30 false false R31.htm 2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 31 false false R32.htm 2310302 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.bmrn.com/role/FINANCIALINSTRUMENTS 32 false false R33.htm 2314303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS 33 false false R34.htm 2321304 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT 34 false false R35.htm 2325305 - Disclosure - INVENTORY (Tables) Sheet http://www.bmrn.com/role/INVENTORYTables INVENTORY (Tables) Tables http://www.bmrn.com/role/INVENTORY 35 false false R36.htm 2329306 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Tables http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION 36 false false R37.htm 2333307 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS 37 false false R38.htm 2337308 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Tables http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES 38 false false R39.htm 2343309 - Disclosure - Leases (Tables) Sheet http://www.bmrn.com/role/LeasesTables Leases (Tables) Tables 39 false false R40.htm 2350310 - Disclosure - DEBT (Tables) Sheet http://www.bmrn.com/role/DEBTTables DEBT (Tables) Tables http://www.bmrn.com/role/DEBT 40 false false R41.htm 2355311 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Tables http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS 41 false false R42.htm 2359312 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Tables http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION 42 false false R43.htm 2367313 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables) Tables http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION 43 false false R44.htm 2377314 - Disclosure - INCOME TAXES (Tables) Sheet http://www.bmrn.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.bmrn.com/role/INCOMETAXES 44 false false R45.htm 2386315 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables NET INCOME (LOSS) PER COMMON SHARE (Tables) Tables http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE 45 false false R46.htm 2406401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail) Sheet http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail) Details 46 false false R47.htm 2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) Sheet http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) Details 47 false false R48.htm 2411403 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Details 48 false false R49.htm 2412404 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Detail) Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail FINANCIAL INSTRUMENTS - Additional Information (Detail) Details 49 false false R50.htm 2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) Details 50 false false R51.htm 2416406 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) Details 51 false false R52.htm 2417407 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) Details 52 false false R53.htm 2418408 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail) Details 53 false false R54.htm 2419409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail) Details 54 false false R55.htm 2422410 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail) Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail) Details 55 false false R56.htm 2423411 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail) Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetail PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail) Details 56 false false R57.htm 2426412 - Disclosure - INVENTORY - Schedule of Inventory (Detail) Sheet http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail INVENTORY - Schedule of Inventory (Detail) Details 57 false false R58.htm 2427413 - Disclosure - INVENTORY - Narrative (Details) Sheet http://www.bmrn.com/role/INVENTORYNarrativeDetails INVENTORY - Narrative (Details) Details 58 false false R59.htm 2430414 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail) Details 59 false false R60.htm 2431415 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail) Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail) Details 60 false false R61.htm 2434416 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail) Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail) Details 61 false false R62.htm 2435417 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) Details 62 false false R63.htm 2438418 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail) Details 63 false false R64.htm 2439419 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail) Details 64 false false R65.htm 2440420 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail) Details 65 false false R66.htm 2441421 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail) Details 66 false false R67.htm 2444422 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail LEASES - Schedule of ROU Assets and Lease Liabilities (Detail) Details 67 false false R68.htm 2445423 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail LEASES - Schedule of Maturities of Lease Liabilities (Detail) Details 68 false false R69.htm 2446424 - Disclosure - LEASES - Schedule of Lease Cost (Detail) Sheet http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail LEASES - Schedule of Lease Cost (Detail) Details 69 false false R70.htm 2447425 - Disclosure - LEASES - Schedule of Other Information (Detail) Sheet http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail LEASES - Schedule of Other Information (Detail) Details 70 false false R71.htm 2448426 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Detail) Sheet http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail LEASES - Schedule of Supplemental Cash Flow Information (Detail) Details 71 false false R72.htm 2451427 - Disclosure - DEBT - Additional Information (Detail) Sheet http://www.bmrn.com/role/DEBTAdditionalInformationDetail DEBT - Additional Information (Detail) Details 72 false false R73.htm 2452428 - Disclosure - DEBT - Summary of Senior Subordinated Convertible Obligations (Detail) Sheet http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail DEBT - Summary of Senior Subordinated Convertible Obligations (Detail) Details 73 false false R74.htm 2453429 - Disclosure - DEBT - Summary of Interest Expense on Debt (Detail) Sheet http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail DEBT - Summary of Interest Expense on Debt (Detail) Details 74 false false R75.htm 2456430 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Details http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 75 false false R76.htm 2457431 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Details http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 76 false false R77.htm 2460432 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail) Details 77 false false R78.htm 2461433 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Details 78 false false R79.htm 2462434 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail) Details 79 false false R80.htm 2463435 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Details 80 false false R81.htm 2464436 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Details 81 false false R82.htm 2465437 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail) Details 82 false false R83.htm 2468438 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail) Details 83 false false R84.htm 2469439 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) Details 84 false false R85.htm 2470440 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail) Details 85 false false R86.htm 2471441 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail) Details 86 false false R87.htm 2472442 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail) Details 87 false false R88.htm 2473443 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail) Sheet http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail) Details 88 false false R89.htm 2475444 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Detail) Sheet http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail OTHER EMPLOYEE BENEFITS - Additional Information (Detail) Details 89 false false R90.htm 2478445 - Disclosure - INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail) Details 90 false false R91.htm 2479446 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail) Details 91 false false R92.htm 2480447 - Disclosure - INCOME TAXES - Additional Information (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail INCOME TAXES - Additional Information (Detail) Details 92 false false R93.htm 2481448 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 93 false false R94.htm 2482449 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail) Details 94 false false R95.htm 2483450 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail) Details 95 false false R96.htm 2484451 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail) Sheet http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail) Details 96 false false R97.htm 2487452 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 97 false false R98.htm 2488453 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 98 false false R99.htm 2489454 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 99 false false R100.htm 2491455 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail) Sheet http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail) Details 100 false false R101.htm 2493456 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) Sheet http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) Details 101 false false All Reports Book All Reports bmrn-20201231.htm bmrn-20201231.xsd bmrn-20201231_cal.xml bmrn-20201231_def.xml bmrn-20201231_lab.xml bmrn-20201231_pre.xml bmrn-20201231xexx211.htm bmrn-20201231xexx231.htm bmrn-20201231xexx311.htm bmrn-20201231xexx312.htm bmrn-20201231xexx321.htm exhibit1032.htm bmrn-20201231_g1.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 122 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bmrn-20201231.htm": { "axisCustom": 0, "axisStandard": 41, "contextCount": 453, "dts": { "calculationLink": { "local": [ "bmrn-20201231_cal.xml" ] }, "definitionLink": { "local": [ "bmrn-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bmrn-20201231.htm" ] }, "labelLink": { "local": [ "bmrn-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bmrn-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bmrn-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 870, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 13, "http://www.bmrn.com/20201231": 3, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 20 }, "keyCustom": 79, "keyStandard": 504, "memberCustom": 57, "memberStandard": 76, "nsprefix": "bmrn", "nsuri": "http://www.bmrn.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.bmrn.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - BASIS OF PRESENTATION", "role": "http://www.bmrn.com/role/BASISOFPRESENTATION", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2491455 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail)", "role": "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i965edcb332f94097bc9f0f92e2a0e7af_I20190331", "decimals": "2", "lang": "en-US", "name": "bmrn:RoyaltyRateLowerLimit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "bmrn:ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2493456 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)", "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109105 - Disclosure - FINANCIAL INSTRUMENTS", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - INVENTORY", "role": "http://www.bmrn.com/role/INVENTORY", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132110 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136111 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142112 - Disclosure - LEASES", "role": "http://www.bmrn.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149113 - Disclosure - DEBT", "role": "http://www.bmrn.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158115 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2166116 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2174117 - Disclosure - OTHER EMPLOYEE BENEFITS", "role": "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS", "shortName": "OTHER EMPLOYEE BENEFITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176118 - Disclosure - INCOME TAXES", "role": "http://www.bmrn.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2185119 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE", "shortName": "NET INCOME (LOSS) PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2190120 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS", "role": "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS", "shortName": "LICENSE AND COLLABORATION AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2192121 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - BASIS OF PRESENTATION (Policies)", "role": "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - INVENTORY (Tables)", "role": "http://www.bmrn.com/role/INVENTORYTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333307 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343309 - Disclosure - Leases (Tables)", "role": "http://www.bmrn.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - DEBT (Tables)", "role": "http://www.bmrn.com/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355311 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359312 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2367313 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2377314 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.bmrn.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2386315 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables", "shortName": "NET INCOME (LOSS) PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ic9541e66d7034b3db61ee97b11951985_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail)", "role": "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bmrn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ic9541e66d7034b3db61ee97b11951985_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bmrn:NumberOfTranchesInOfferingPeriod", "reportCount": 1, "unique": true, "unitRef": "tranche", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)", "role": "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bmrn:NumberOfTranchesInOfferingPeriod", "reportCount": 1, "unique": true, "unitRef": "tranche", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "icc868817f807452abe329b31a496f90a_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Detail)", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail", "shortName": "FINANCIAL INSTRUMENTS - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "icc868817f807452abe329b31a496f90a_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i7f2506d63f0242758a4f64a33f62a4ee_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i31e40a7392a6474c99abc22ede9bf739_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfOtherAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense of Finite-Lived Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail)", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Property Plant and Equipment Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail)", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetail", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426412 - Disclosure - INVENTORY - Schedule of Inventory (Detail)", "role": "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail", "shortName": "INVENTORY - Schedule of Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - INVENTORY - Narrative (Details)", "role": "http://www.bmrn.com/role/INVENTORYNarrativeDetails", "shortName": "INVENTORY - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i9842fd29f6044f64bb1462bd2ec10740_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430414 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "if739f4fd6b54456abd7f826f436dc9a7_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431415 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail)", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "idf78a08ec78040e59d74f56eeae0259c_I20171231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i17cd4e5db28540cfab73f87aca622cf5_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail)", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i17cd4e5db28540cfab73f87aca622cf5_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i552cb1f768234e34ad68f2b3b409d270_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail)", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail", "shortName": "FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value Using Level 3 Inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i552cb1f768234e34ad68f2b3b409d270_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ie27f03bb6b19449bb6eb36d1c5abe960_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeRemainingMaturity1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ie27f03bb6b19449bb6eb36d1c5abe960_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeRemainingMaturity1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "if8327dd5caaa48b3b45b9b973e525ec4_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "if8327dd5caaa48b3b45b9b973e525ec4_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivative Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Effect of Derivative Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i22f8b721ac3d47bdbe16f3d1fcf89d5f_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444422 - Disclosure - LEASES - Schedule of ROU Assets and Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail", "shortName": "LEASES - Schedule of ROU Assets and Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445423 - Disclosure - LEASES - Schedule of Maturities of Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail", "shortName": "LEASES - Schedule of Maturities of Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - LEASES - Schedule of Lease Cost (Detail)", "role": "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail", "shortName": "LEASES - Schedule of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ie16eac72fbf24bb9a83f7625af3a4c85_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ie16eac72fbf24bb9a83f7625af3a4c85_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - LEASES - Schedule of Other Information (Detail)", "role": "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail", "shortName": "LEASES - Schedule of Other Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information (Detail)", "role": "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail", "shortName": "LEASES - Schedule of Supplemental Cash Flow Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451427 - Disclosure - DEBT - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "shortName": "DEBT - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i4a2052480e8a4b44b50f35b92f8c655a_I20200531", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - DEBT - Summary of Senior Subordinated Convertible Obligations (Detail)", "role": "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail", "shortName": "DEBT - Summary of Senior Subordinated Convertible Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453429 - Disclosure - DEBT - Summary of Interest Expense on Debt (Detail)", "role": "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail", "shortName": "DEBT - Summary of Interest Expense on Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "iba8ac2e85357473eb67326a10fdaa968_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456430 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i20d2f3bde43a4c7d9a4c48d1077dbab9_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i7f2506d63f0242758a4f64a33f62a4ee_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457431 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460432 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i0f3d2003ebfa4c06bc36f096e197422b_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461433 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462434 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues from External Customers by Product (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i15baafd4b025411f9fdac62382d1144f_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463435 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i1fb4a5e54bcc4f51a24d0a58f10290d2_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i9279e274aeb242ea99cd25d183f46006_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464436 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i9279e274aeb242ea99cd25d183f46006_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465437 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Summary of Non-Monetary Long-Lived Assets by Geographic Region (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468438 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469439 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "iacba8cb0062e459293ddb1a2423390e6_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470440 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Restricted Stock Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i20d5208a2511496ba043ff9973344481_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i7f2506d63f0242758a4f64a33f62a4ee_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471441 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i7f2506d63f0242758a4f64a33f62a4ee_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i1c1869b592e24342a67b807c5a858c94_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472442 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Stock Option Valuation Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i1c1869b592e24342a67b807c5a858c94_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i1edad6d6430b40a7a299e65f376f3a53_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473443 - Disclosure - EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail)", "role": "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "shortName": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Employee Stock Purchase Plan Valuation Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i1edad6d6430b40a7a299e65f376f3a53_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ic1ba2f0bb8794075bc37d8e4759a26da_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475444 - Disclosure - OTHER EMPLOYEE BENEFITS - Additional Information (Detail)", "role": "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail", "shortName": "OTHER EMPLOYEE BENEFITS - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ic1ba2f0bb8794075bc37d8e4759a26da_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - NATURE OF OPERATIONS AND BUSINESS RISKS", "role": "http://www.bmrn.com/role/NATUREOFOPERATIONSANDBUSINESSRISKS", "shortName": "NATURE OF OPERATIONS AND BUSINESS RISKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478445 - Disclosure - INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail", "shortName": "INCOME TAXES - Benefit from Income Taxes Based Loss Before Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479446 - Disclosure - INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail", "shortName": "INCOME TAXES - Components of Provision for (Benefit from) Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2480447 - Disclosure - INCOME TAXES - Additional Information (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "shortName": "INCOME TAXES - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481448 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "shortName": "INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2482449 - Disclosure - INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail", "shortName": "INCOME TAXES - Components of Company Net Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ib26d6cb662f844969329db0cb42c3124_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i3da3edd5f8464fa9a3724c72258cb960_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483450 - Disclosure - INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail", "shortName": "INCOME TAXES - Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i3da3edd5f8464fa9a3724c72258cb960_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i7f2506d63f0242758a4f64a33f62a4ee_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2484451 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail)", "role": "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail", "shortName": "INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i31e40a7392a6474c99abc22ede9bf739_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2487452 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2488453 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Anti-Dilutive Common Stock Excluded From Computation of Basic and Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "ied9c8a7152374b43a395b00160e32481_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i24e239d5d78b4db0a105be7831a56514_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2489454 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20201231.htm", "contextRef": "i24e239d5d78b4db0a105be7831a56514_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } } }, "segmentCount": 136, "tag": { "bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.25% Senior Subordinated Convertible Notes Due in May 2027", "label": "1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]", "terseLabel": "1.25% Senior Subordinated Convertible Notes Due in May 2027" } } }, "localname": "A125SeniorSubordinatedConvertibleNotesDueInMay2027Member", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "domainItemType" }, "bmrn_AAndRKuvanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A&R Kuvan agreement.", "label": "A And R Kuvan Agreement [Member]", "terseLabel": "A&R Kuvan Agreement" } } }, "localname": "AAndRKuvanAgreementMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_AccruedGovernmentAndOtherRebates": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Government And Other Rebates", "label": "Accrued Government And Other Rebates", "terseLabel": "Accrued rebates payable" } } }, "localname": "AccruedGovernmentAndOtherRebates", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_AccruedRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued rebates.", "label": "Accrued Rebates [Member]", "terseLabel": "Accrued rebates" } } }, "localname": "AccruedRebatesMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "domainItemType" }, "bmrn_AccumulatedGainLossFromOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated gain (loss) from other.", "label": "Accumulated Gain Loss From Other [Member]", "terseLabel": "Accumulated Gain Loss from Other" } } }, "localname": "AccumulatedGainLossFromOtherMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "bmrn_AcquiredIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired intellectual property.", "label": "Acquired Intellectual Property [Member]", "terseLabel": "Acquired intellectual property" } } }, "localname": "AcquiredIntellectualPropertyMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "label": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "terseLabel": "Accounting impact of NQDC Plan Change" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "negatedTerseLabel": "Common stock held by the NQDC" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_AllowancesForReserveForCashDiscountsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allowances For Reserve For Cash Discounts [Member]", "terseLabel": "Reserve for cash discounts" } } }, "localname": "AllowancesForReserveForCashDiscountsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "domainItemType" }, "bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "label": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "terseLabel": "Annual shareholder return multiplier" } } }, "localname": "AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_AverageClosingPriceTrailingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average closing price trailing period.", "label": "Average Closing Price Trailing Period", "terseLabel": "Average closing price of common stock, trailing period" } } }, "localname": "AverageClosingPriceTrailingPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bmrn_BiomarinRetirementSavingsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioMarin retirement savings plan.", "label": "Biomarin Retirement Savings Plan [Member]", "terseLabel": "BioMarin Retirement Savings Plan" } } }, "localname": "BiomarinRetirementSavingsPlanMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business acquisition contingent consideration potential cash payments upon achievement of sales milestone.", "label": "Business Acquisition Contingent Consideration Potential Cash Payments Upon Achievement Of Sales Milestone", "terseLabel": "Business acquisition contingent consideration potential cash payments upon achievement of sales milestone" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CollaborativeArrangementMinorityEquityInvestmentInLicense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Minority Equity Investment in License", "label": "Collaborative Arrangement, Minority Equity Investment in License", "terseLabel": "Investment in equity" } } }, "localname": "CollaborativeArrangementMinorityEquityInvestmentInLicense", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issuable for employee Stock Purchase Plan [Member]", "label": "Common Stock Issuable To Employee Stock Purchase Plan [Member]", "terseLabel": "Common stock potentially issuable for ESPP purchases" } } }, "localname": "CommonStockIssuableToEmployeeStockPurchasePlanMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_CompletedProjectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Completed Project.", "label": "Completed Project [Member]", "terseLabel": "Completed Programs" } } }, "localname": "CompletedProjectMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Line Items]", "terseLabel": "Concentration Risk And Geographic Information [Line Items]" } } }, "localname": "ConcentrationRiskAndGeographicInformationLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Table]", "terseLabel": "Concentration Risk And Geographic Information [Table]" } } }, "localname": "ConcentrationRiskAndGeographicInformationTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk and segment reporting disclosure.", "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]", "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION" } } }, "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" ], "xbrltype": "textBlockItemType" }, "bmrn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Payment", "label": "Contingent Payment [Member]", "terseLabel": "Contingent Payment" } } }, "localname": "ContingentPaymentMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ConvertibleSeniorNotesDueTwentyTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible senior notes due twenty twenty.", "label": "Convertible Senior Notes Due Twenty Twenty [Member]", "terseLabel": "Convertible Senior Notes Due 2020", "verboseLabel": "Common stock issuable under the 2020 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Senior Notes Due Two Thousand Twenty Four [Member]", "verboseLabel": "Common stock issuable under the 2024 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Due Two Thousand Twenty Seven", "label": "Convertible Senior Notes Due Two Thousand Twenty Seven [Member]", "terseLabel": "Common stock issuable under the 2027 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandTwentySevenMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 1", "label": "Customer One [Member]", "terseLabel": "Customer A", "verboseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 3", "label": "Customer Three [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 2", "label": "Customer Two [Member]", "terseLabel": "Customer B", "verboseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers.", "label": "Customers [Member]", "terseLabel": "Customer" } } }, "localname": "CustomersMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_DebtInstrumentConvertibleWeightedAverageMeasurementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Weighted Average Measurement Period", "label": "Debt Instrument, Convertible, Weighted Average Measurement Period", "terseLabel": "Measurement period" } } }, "localname": "DebtInstrumentConvertibleWeightedAverageMeasurementPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "integerItemType" }, "bmrn_DebtInstrumentPercentageOfFaceValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument percentage of face value.", "label": "Debt Instrument Percentage Of Face Value", "terseLabel": "Debt instrument percentage of face value" } } }, "localname": "DebtInstrumentPercentageOfFaceValue", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities related to joint venture basis difference.", "label": "Deferred Tax Liabilities Related To Joint Venture Basis Difference", "negatedLabel": "Joint venture basis difference" } } }, "localname": "DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Right-Of-Use Assets", "negatedLabel": "ROU assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_DeferredTaxLiabilityRelatedToConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liability related to convertible notes.", "label": "Deferred Tax Liability Related To Convertible Notes", "negatedLabel": "Convertible notes discount" } } }, "localname": "DeferredTaxLiabilityRelatedToConvertibleNotes", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_DepreciationExpenseCapitalizedIntoInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation expense capitalized into inventory during the reporting period.", "label": "Depreciation Expense Capitalized Into Inventory", "terseLabel": "Depreciation capitalized into inventory" } } }, "localname": "DepreciationExpenseCapitalizedIntoInventory", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_EarlyStageDevelopmentProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Early Stage Development Program", "label": "Early Stage Development Program [Member]", "terseLabel": "Early Stage Development Program" } } }, "localname": "EarlyStageDevelopmentProgramMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings per share line Items.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim", "label": "Effective Income Tax Rate Reconciliation, CARES Act Carryback Claim", "negatedTerseLabel": "CARES Act carryback claim" } } }, "localname": "EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount", "label": "Effective Income Tax Rate Reconciliation, Intra-Entity Transfer Of Assets, Amount", "terseLabel": "Intra-entity transfer of assets" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_EmployeeContributionOfTheirCurrentCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee contribution of their current compensation", "label": "Employee Contribution Of Their Current Compensation", "terseLabel": "Employee contribution of their current compensation" } } }, "localname": "EmployeeContributionOfTheirCurrentCompensation", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ExclusiveLicensingAgreementForTralesinidaseAlfaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive Licensing Agreement For Tralesinidase Alfa", "label": "Exclusive Licensing Agreement For Tralesinidase Alfa [Member]", "terseLabel": "Exclusive Licensing Agreement For Tralesinidase Alfa" } } }, "localname": "ExclusiveLicensingAgreementForTralesinidaseAlfaMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_FairValueInputsRevenueMultipleCeilingAchievementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value inputs revenue multiple ceiling achievement percentage.", "label": "Fair Value Inputs Revenue Multiple Ceiling Achievement Percentage", "terseLabel": "Percentage of ceiling achievement" } } }, "localname": "FairValueInputsRevenueMultipleCeilingAchievementPercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_FairValueInputsRevenueMultipleThresholdAchievementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value inputs revenue multiple threshold achievement percentage.", "label": "Fair Value Inputs Revenue Multiple Threshold Achievement Percentage", "terseLabel": "Percentage of threshold achievement" } } }, "localname": "FairValueInputsRevenueMultipleThresholdAchievementPercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement", "terseLabel": "Foreign exchange remeasurement of Euro denominated contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets, Amortization Not Commenced, Net", "label": "Finite-Lived Intangible Assets, Amortization Not Commenced, Net", "totalLabel": "Finite-Lived Intangible Asset" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FirdapseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Firdapse", "label": "Firdapse [Member]", "terseLabel": "Firdapse" } } }, "localname": "FirdapseMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign government and other debt securities.", "label": "Foreign Government And Other Debt Securities [Member]", "terseLabel": "Foreign and Other" } } }, "localname": "ForeignGovernmentAndOtherDebtSecuritiesMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "bmrn_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Line Items]", "terseLabel": "Goodwill And Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_GoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Table]", "terseLabel": "Goodwill And Intangible Assets [Table]" } } }, "localname": "GoodwillAndIntangibleAssetsTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax rate reconciliation changes in fair value of contingent consideration.", "label": "Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration", "terseLabel": "Changes in the fair value of contingent consideration" } } }, "localname": "IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_IncomeTaxRateReconciliationSection162Limitation": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax rate reconciliation section 162 limitation.", "label": "Income Tax Rate Reconciliation Section162 Limitation", "terseLabel": "Section 162(m) limitation" } } }, "localname": "IncomeTaxRateReconciliationSection162Limitation", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_IncomeTaxRateReconciliationTaxReserves": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax rate reconciliation tax reserves.", "label": "Income Tax Rate Reconciliation Tax Reserves", "terseLabel": "Tax Reserves" } } }, "localname": "IncomeTaxRateReconciliationTaxReserves", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_IncomeTaxStatuteOfLimitationsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax statute of limitation period.", "label": "Income Tax Statute Of Limitations Period", "terseLabel": "Income tax statute of limitations period" } } }, "localname": "IncomeTaxStatuteOfLimitationsPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bmrn_IndependentDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Independent director.", "label": "Independent Director [Member]", "terseLabel": "Independent Director" } } }, "localname": "IndependentDirectorMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_IntangibleAssetAmortizationAndContingentConsideration": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.", "label": "Intangible Asset Amortization And Contingent Consideration", "terseLabel": "Intangible asset amortization and contingent consideration" } } }, "localname": "IntangibleAssetAmortizationAndContingentConsideration", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "bmrn_LeaseRightOfUseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Right Of Use Assets", "label": "Lease Right Of Use Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "LeaseRightOfUseAssetsAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LeasesLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases Liabilities", "label": "Leases Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LeasesLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating And Finance Leases Other Information Table", "label": "Lessee Operating And Finance Leases Other Information Table [Table Text Block]", "terseLabel": "Schedule of Other Information" } } }, "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating And Finance Leases Other Information Table", "label": "Lessee Operating And Finance Leases Other Information Table [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "bmrn_LicenseAgreementAndSettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement and settlement agreement.", "label": "License Agreement And Settlement Agreement [Member]", "terseLabel": "License Agreement And Settlement Agreement" } } }, "localname": "LicenseAgreementAndSettlementAgreementMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_LongTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term marketable securities maturity period.", "label": "Long Term Marketable Securities Maturity Period", "terseLabel": "Long-term marketable securities maturity period" } } }, "localname": "LongTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_MaturityOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity Of Lease Liabilities", "label": "Maturity Of Lease Liabilities [Abstract]", "terseLabel": "Maturity of Lease Liabilities" } } }, "localname": "MaturityOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_MaximumPayrollDeductions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum payroll deductions.", "label": "Maximum Payroll Deductions", "terseLabel": "Maximum payroll deductions" } } }, "localname": "MaximumPayrollDeductions", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_MedivationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medivation.", "label": "Medivation [Member]", "terseLabel": "Medivation" } } }, "localname": "MedivationMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_MerckSeronoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck Serono.", "label": "Merck Serono [Member]", "terseLabel": "Merck Serono" } } }, "localname": "MerckSeronoMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_MilestonePaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments received.", "label": "Milestone Payments Received", "terseLabel": "Milestone payments received" } } }, "localname": "MilestonePaymentsReceived", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonqualified deferred compensation plan assets.", "label": "Nonqualified Deferred Compensation Plan Assets [Member]", "terseLabel": "NQDC Plan assets" } } }, "localname": "NonqualifiedDeferredCompensationPlanAssetsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonqualified deferred compensation plan liability.", "label": "Nonqualified Deferred Compensation Plan Liability [Member]", "terseLabel": "NQDC Plan liability" } } }, "localname": "NonqualifiedDeferredCompensationPlanLiabilityMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_NumberOfTranchesInOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Tranches In Offering Period", "label": "Number Of Tranches In Offering Period", "terseLabel": "Number of tranches in offering period" } } }, "localname": "NumberOfTranchesInOfferingPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "bmrn_OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One point five zero percent senior subordinated convertible notes due in October twenty twenty.", "label": "One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member]", "terseLabel": "1.50% Senior Subordinated Convertible Notes Due in October 2020" } } }, "localname": "OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "domainItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liabilities Payments Due", "label": "Operating And Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Total" } } }, "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_OperatingAndFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability", "label": "Operating And Finance Lease Liability", "terseLabel": "Operating And Finance Lease Liability", "totalLabel": "Operating And Finance Lease Liability" } } }, "localname": "OperatingAndFinanceLeaseLiability", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail", "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability, Current", "label": "Operating And Finance Lease Liability, Current", "terseLabel": "Lease liability" } } }, "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due", "label": "Operating And Finance Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due After Year Five", "label": "Operating And Finance Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Next Twelve Months", "label": "Operating And Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Five", "label": "Operating And Finance Lease Liability Payments Due Year Five", "terseLabel": "2025" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Four", "label": "Operating And Finance Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Three", "label": "Operating And Finance Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Two", "label": "Operating And Finance Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Undiscounted Excess Amount", "label": "Operating And Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Right Of Use Asset", "label": "Operating And Finance Lease Right Of Use Asset", "totalLabel": "Total ROU assets" } } }, "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherAssetsCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other assets current fair value disclosure.", "label": "Other Assets Current Fair Value Disclosure", "verboseLabel": "Fair value of other current assets" } } }, "localname": "OtherAssetsCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherAssetsNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other assets noncurrent fair value disclosure.", "label": "Other Assets Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current assets" } } }, "localname": "OtherAssetsNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherComprehensiveIncomeLossOtherNetOfTax": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive income loss other net of tax", "label": "Other Comprehensive Income Loss Other Net Of Tax", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeLossOtherNetOfTax", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherInformationLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Information Lease Liability", "label": "Other Information Lease Liability [Abstract]", "terseLabel": "Other Information" } } }, "localname": "OtherInformationLeaseLiabilityAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other liabilities current fair value disclosure.", "label": "Other Liabilities Current Fair Value Disclosure", "verboseLabel": "Fair value of other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other liabilities noncurrent fair value disclosure.", "label": "Other Liabilities Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_PaymentReceivedAsPercentageOfNetProductSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment received from sale of a product as percentage of worldwide net product sales.", "label": "Payment Received As Percentage Of Net Product Sales", "terseLabel": "Payment received as percentage of net product sales" } } }, "localname": "PaymentReceivedAsPercentageOfNetProductSales", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable", "label": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable", "negatedTerseLabel": "Investment in convertible note" } } }, "localname": "PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_PegvaliaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pegvaliase agreement.", "label": "Pegvaliase Agreement [Member]", "terseLabel": "Pegvaliase Agreement" } } }, "localname": "PegvaliaseAgreementMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_PreLaunchValoctocogeneRoxaparvovecMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "label": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "terseLabel": "Pre-Launch Valoctocogene Roxaparvovec" } } }, "localname": "PreLaunchValoctocogeneRoxaparvovecMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "domainItemType" }, "bmrn_PrincipalAmountOnConversionRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal amount per note used in conversion rate.", "label": "Principal Amount On Conversion Rate", "terseLabel": "Principal amount on conversion rate" } } }, "localname": "PrincipalAmountOnConversionRate", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ProceedsFromSaleOfNonfinancialAssets": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale Of Nonfinancial Assets", "label": "Proceeds From Sale Of Nonfinancial Assets", "terseLabel": "Proceeds from sale of nonfinancial assets" } } }, "localname": "ProceedsFromSaleOfNonfinancialAssets", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_ProductFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 5 [Member]", "label": "Product Five [Member]", "terseLabel": "Firdapse" } } }, "localname": "ProductFiveMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 4 [Member]", "label": "Product Four [Member]", "terseLabel": "Vimizim" } } }, "localname": "ProductFourMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 1 [Member]", "label": "Product One [Member]", "terseLabel": "Aldurazyme" } } }, "localname": "ProductOneMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 7 [Member]", "label": "Product Seven [Member]", "terseLabel": "Palynziq" } } }, "localname": "ProductSevenMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product six.", "label": "Product Six [Member]", "terseLabel": "Brineura" } } }, "localname": "ProductSixMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 3 [Member]", "label": "Product Three [Member]", "terseLabel": "Kuvan" } } }, "localname": "ProductThreeMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product 2 [Member]", "label": "Product Two [Member]", "terseLabel": "Naglazyme" } } }, "localname": "ProductTwoMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductsExcludingProductOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Products excluding product one.", "label": "Products Excluding Product One [Member]", "terseLabel": "Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse" } } }, "localname": "ProductsExcludingProductOneMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_RepurchasedRoyaltyRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchased royalty rights.", "label": "Repurchased Royalty Rights [Member]", "terseLabel": "Repurchased royalty rights" } } }, "localname": "RepurchasedRoyaltyRightsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of world" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestrictedInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investments.", "label": "Restricted Investments [Member]", "terseLabel": "Restricted Investments" } } }, "localname": "RestrictedInvestmentsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestrictedStockWithServiceBasedVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock with service based vesting conditions.", "label": "Restricted Stock With Service Based Vesting Conditions [Member]", "terseLabel": "Restricted Stock With Service Based Vesting Conditions" } } }, "localname": "RestrictedStockWithServiceBasedVestingConditionsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right Of Use Assets Obtained In Exchange For Lease Obligations", "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "terseLabel": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_RoyaltiesReceivablePercentageOfNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties receivable percentage of net sales.", "label": "Royalties Receivable Percentage Of Net Sales", "terseLabel": "Royalties receivable percentage of net sales" } } }, "localname": "RoyaltiesReceivablePercentageOfNetSales", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_RoyaltyAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty and other.", "label": "Royalty And Other [Member]", "terseLabel": "Royalty and Other Revenues" } } }, "localname": "RoyaltyAndOtherMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "domainItemType" }, "bmrn_RoyaltyRateLowerLimit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty rate lower limit.", "label": "Royalty Rate Lower Limit", "terseLabel": "Royalties on net product sales" } } }, "localname": "RoyaltyRateLowerLimit", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_RoyaltyRateUpperLimit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty rate upper limit.", "label": "Royalty Rate Upper Limit", "terseLabel": "Royalties on net product sales" } } }, "localname": "RoyaltyRateUpperLimit", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_SareptaTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sarepta Therapeutics.", "label": "Sarepta Therapeutics [Member]", "terseLabel": "Sarepta Therapeutics" } } }, "localname": "SareptaTherapeuticsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]", "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block]", "terseLabel": "Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of estimated accrued rebates and reserve for cash discounts.", "label": "Schedule Of Estimated Accrued Rebates And Reserve For Cash Discounts Table [Text Block]", "terseLabel": "Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts" } } }, "localname": "ScheduleOfEstimatedAccruedRebatesAndReserveForCashDiscountsTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfInterestExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expenses.", "label": "Schedule Of Interest Expenses [Line Items]", "terseLabel": "Schedule Of Interest Expenses [Line Items]" } } }, "localname": "ScheduleOfInterestExpensesLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfInterestExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expenses table.", "label": "Schedule Of Interest Expenses [Table]", "terseLabel": "Schedule Of Interest Expenses [Table]" } } }, "localname": "ScheduleOfInterestExpensesTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Lessee Lease Assets And Liabilities Table", "label": "Schedule Of Lessee Lease Assets And Liabilities Table [Table Text Block]", "terseLabel": "Schedule Of Lessee Lease Assets And Liabilities" } } }, "localname": "ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]", "terseLabel": "Schedule Of Property, Plant And Equipment Estimated Useful Lives" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based compensation arrangements by share based payment award equity instruments other than options restricted stock units.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Line Items]", "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based compensation arrangements by share based payment award, equity instruments, other than options, restricted stock units.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Restricted Stock Units [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "bmrn_SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior subordinated notes repurchased percentage of principal amount.", "label": "Senior Subordinated Notes Repurchased Percentage Of Principal Amount", "terseLabel": "Repurchase of note principal amount" } } }, "localname": "SeniorSubordinatedNotesRepurchasedPercentageOfPrincipalAmount", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior unsecured revolving two thousand eighteen credit facility.", "label": "Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]", "terseLabel": "The 2018 Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "terseLabel": "Shares earned range" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Discount Rate", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRate", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award initial time period vesting requirement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Initial Time Period Vesting Requirement", "terseLabel": "Initial time period vesting requirements" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialTimePeriodVestingRequirement", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options nonvested aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options unvested at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options unvested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Years, Options unvested at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award performance percentage.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Performance Percentage", "terseLabel": "Percentage of, number of shares may earned" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "label": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "terseLabel": "Ceiling achievement level" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term marketable securities maturity period.", "label": "Short Term Marketable Securities Maturity Period", "terseLabel": "Short-term marketable securities maturity period" } } }, "localname": "ShortTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_SpanOfOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Span of offering period.", "label": "Span Of Offering Period", "terseLabel": "Span of offering period, in years", "verboseLabel": "Span of offering period" } } }, "localname": "SpanOfOfferingPeriod", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency", "terseLabel": "Issuances under equity incentive plans, net of tax" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares", "terseLabel": "Issuances under equity incentive plans, net of tax (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "bmrn_StrategicInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic investment.", "label": "Strategic Investment [Member]", "terseLabel": "Strategic Investment" } } }, "localname": "StrategicInvestmentMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of operating loss and tax credit carryforwards.", "label": "Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block]", "terseLabel": "Summary of Expiration of not Utilized Net Operating Loss and Tax Credit Carryforwards" } } }, "localname": "SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Fixed Assets", "terseLabel": "Increase (decrease) in accounts payable and accrued liabilities related to fixed assets" } } }, "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease, Intangible Assets", "terseLabel": "Increase (decrease) in accounts payable and accrued liabilities related to intangible assets" } } }, "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_SupplementalBalanceSheetInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental balance sheet information", "label": "Supplemental Balance Sheet Information [Line Items]", "terseLabel": "Supplemental Balance Sheet Information [Line Items]" } } }, "localname": "SupplementalBalanceSheetInformationLineItems", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "stringItemType" }, "bmrn_SupplementalBalanceSheetInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental balance sheet information.", "label": "Supplemental Balance Sheet Information [Table]", "terseLabel": "Supplemental Balance Sheet Information [Table]" } } }, "localname": "SupplementalBalanceSheetInformationTable", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "stringItemType" }, "bmrn_SupplementalCashFlowLeaseInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Cash Flow Lease Information", "label": "Supplemental Cash Flow Lease Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowLeaseInformationAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_TechnologyTransferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology Transfer", "label": "Technology Transfer [Member]", "terseLabel": "Technology Transfer" } } }, "localname": "TechnologyTransferMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bmrn_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third party.", "label": "Third Party [Member]", "terseLabel": "Third Party" } } }, "localname": "ThirdPartyMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions", "label": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions [Member]", "verboseLabel": "March 2019 Base Restricted Stock Unit Awards With Market Conditions" } } }, "localname": "TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen base restricted stock unit awards with revenue based vesting conditions.", "label": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Revenue Based Vesting Conditions [Member]", "terseLabel": "Restricted Stock Unit Awards with Performance-Based Vesting Conditions" } } }, "localname": "TwoThousandNineteenBaseRestrictedStockUnitAwardsWithRevenueBasedVestingConditionsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandSeventeenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen equity incentive plan.", "label": "Two Thousand Seventeen Equity Incentive Plan [Member]", "terseLabel": "2017 Equity Incentive Plan" } } }, "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Based Vesting Conditions [Member]", "terseLabel": "Restricted Stock Unit Awards with Market Conditions" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketBasedVestingConditionsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions [Member]", "terseLabel": "Restricted Stock Unit Awards with non-Revenue based Performance Conditions" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsNotProbableOfVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Not Probable Of Vesting", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Not Probable Of Vesting [Member]", "terseLabel": "Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Not Probable Of Vesting" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsNotProbableOfVestingMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsProbableOfVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Probable Of Vesting", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Non Revenue Based Vesting Conditions, Probable Of Vesting [Member]", "terseLabel": "Restricted Stock Unit Awards with non-Revenue based Performance Conditions, Probable Of Vesting" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithNonRevenueBasedVestingConditionsProbableOfVestingMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.", "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions", "terseLabel": "(Deletions) Additions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Discount Rate", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted Average Discount Rate [Abstract]" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term (in years):" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.", "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]", "terseLabel": "0.599% Senior Subordinated Convertible Notes Due in August 2024" } } }, "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20201231", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "country_NL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NETHERLANDS", "terseLabel": "Dutch" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r455", "r456", "r459", "r460", "r641" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r455", "r456", "r459", "r460" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r57", "r126" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r143", "r152", "r243", "r383", "r384", "r385", "r424", "r425" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r143", "r152", "r243", "r383", "r384", "r385", "r424", "r425" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r143", "r152", "r243", "r383", "r384", "r385", "r424", "r425" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r143", "r152", "r243", "r383", "r384", "r385", "r424", "r425" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r226", "r311", "r315", "r597" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r341", "r343", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r594", "r598" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail", "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r341", "r343", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r594", "r598" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail", "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r226", "r311", "r315", "r597" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r221", "r311", "r313", "r551", "r593", "r595" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r221", "r311", "r313", "r551", "r593", "r595" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r330", "r341", "r343", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r594", "r598" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail", "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r330", "r341", "r343", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r594", "r598" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail", "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r222", "r223", "r311", "r314", "r596", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r222", "r223", "r311", "r314", "r596", "r627", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r227", "r539" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued operating expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable Balance" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r20", "r228", "r229" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r115" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premium on investments (accretion of discount)" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r15", "r17", "r405", "r562", "r580" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 10.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r9", "r42" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r276" ], "calculation": { "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r68", "r457" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "verboseLabel": "Gains (losses) on Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r68", "r79", "r457" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r60", "r68", "r71", "r457" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r61", "r62", "r63", "r68", "r71" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Available-for-Sale Debt Securities", "verboseLabel": "Gain (Loss) on Sale of Available-for-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r65", "r67", "r68", "r582", "r603", "r606" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r508", "r509", "r510", "r511", "r512", "r514" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r68", "r71", "r140", "r141", "r142", "r458", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r140", "r141", "r142", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r345", "r347", "r390", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r347", "r378", "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r92", "r114", "r517" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail": { "order": 3.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of discount on convertible notes" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r87", "r114", "r519" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r114", "r519" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r238", "r331" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetRetirementObligation": { "auth_ref": [ "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligation", "terseLabel": "Asset retirement obligation" } } }, "localname": "AssetRetirementObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r204", "r213", "r219", "r242", "r455", "r459", "r504", "r560", "r579" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Lease Classification" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r54", "r124", "r242", "r455", "r459", "r504" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r488" ], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Fair value of financial assets, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r236" ], "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r237" ], "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r234", "r246" ], "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r231", "r235", "r246", "r565" ], "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r233", "r246" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term Marketable Securities", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r233", "r246" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term Marketable Securities", "verboseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r348", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r468", "r473" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r340", "r342", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r113", "r448" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Non-cash changes in the fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r443", "r444", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r443", "r445" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r33", "r610", "r611" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r33", "r116" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash aggregate fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r117", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r109", "r116", "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r109", "r507" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Financing Activities, Lessee [Abstract]", "terseLabel": "Cash Flow, Financing Activities, Lessee [Abstract]" } } }, "localname": "CashFlowFinancingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash used in operating activities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r449", "r450", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "LICENSE AND COLLABORATION AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockIssuedEmployeeStockTrust": { "auth_ref": [ "r326" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.", "label": "Common Stock Issued, Employee Stock Trust", "negatedLabel": "Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)" } } }, "localname": "CommonStockIssuedEmployeeStockTrust", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; \u00a0\u00a0 181,740,999 and 179,838,114 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "auth_ref": [ "r328", "r329", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]", "terseLabel": "OTHER EMPLOYEE BENEFITS" } } }, "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationRelatedCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation Related Costs [Abstract]", "terseLabel": "Compensation Related Costs [Abstract]" } } }, "localname": "CompensationRelatedCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r74", "r76", "r77", "r85", "r570", "r589" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r84", "r94", "r569", "r588" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r189", "r190", "r226", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r189", "r190", "r226", "r501", "r502", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r189", "r190", "r226", "r501", "r502", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r189", "r190", "r226", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r186", "r189", "r190", "r191", "r501", "r503" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r189", "r190", "r226", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r300", "r301", "r312" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r311", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r311", "r319" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r16", "r563", "r581" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "totalLabel": "Total convertible debt, net" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Short-term convertible debt, net", "totalLabel": "Short-term convertible debt, net" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Total fair value of fixed rate convertible debt" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Long-term convertible debt, net", "totalLabel": "Convertible Notes, net of unamortized discount and deferred offering costs" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of Senior Subordinated Convertible Obligations" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r331", "r338", "r608" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r89", "r124", "r242", "r504" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r88" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Operating expenses as reported", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r125", "r420", "r431" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r129", "r420" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r420", "r431", "r433" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current income tax expense, total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Benefit from income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r125", "r420", "r431" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r187", "r226" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Common stock, shares, issued to converting holders (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r561", "r563", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument interest rate percentage" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r289", "r563", "r578" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Carrying value of equity component", "verboseLabel": "Convertible notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price, per share (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r45", "r293", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate of shares" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r518", "r520" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage, per annum" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r46", "r127", "r293", "r295", "r296", "r297", "r517", "r518", "r520", "r576" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r517", "r520" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized discount", "terseLabel": "Debt Instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r122", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Convertible Debt" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "totalLabel": "Total gain on available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]", "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.", "label": "Deferred Compensation, Share-based Payments [Member]", "terseLabel": "Company Stock Held By NQDC" } } }, "localname": "DeferredCompensationShareBasedPaymentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r421", "r431" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r37", "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r421", "r431" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r125", "r421", "r431", "r432", "r433" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "totalLabel": "Deferred income tax expense (benefit), total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Provision for (benefit from) deferred income taxes:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r53", "r253" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "negatedLabel": "Unamortized deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r421", "r431" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred Tax Assets, Gross [Abstract]" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r414" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r414" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r417", "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r417", "r418", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Federal R&D and orphan drug credit carryforwards", "verboseLabel": "Research credit carry forward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses, reserves, and prepaids" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r413" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r400", "r414" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.", "label": "Deferred Tax Liabilities, Tax Deferred Income", "negatedLabel": "Deferred revenue" } } }, "localname": "DeferredTaxLiabilitiesTaxDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESComponentsofCompanyNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Company's contribution from employment commencement" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Company's contribution to match employees contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Employer contribution of maximum percentage over employee's annual compensation" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r114", "r274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r114", "r201" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r55", "r58", "r471", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative asset, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r55", "r58", "r471", "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative liability, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gains (Losses) Recognized in Earnings" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r469", "r472", "r476", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r466", "r469", "r476", "r479", "r480", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Forward foreign currency exchange contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Remaining Maturity", "terseLabel": "Maturity of derivatives" } } }, "localname": "DerivativeRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r462", "r464", "r465", "r466", "r467", "r474", "r476", "r481", "r483", "r485" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r122", "r130", "r462", "r464", "r466", "r467", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives and Hedging Activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated As Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregates of Total Net Product Revenues Based on Patient Location" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r273", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r86", "r150", "r151", "r152", "r153", "r154", "r161", "r164", "r170", "r171", "r172", "r176", "r177", "r571", "r590" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share, basic (in usd per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, BASIC (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r86", "r150", "r151", "r152", "r153", "r154", "r164", "r170", "r171", "r172", "r176", "r177", "r571", "r590" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share, diluted (in usd per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, DILUTED (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r122", "r173", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r507" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation expense" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation expense capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost expected to recognized over weighted average period, in years" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Net tax benefit from stock options exercised" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares": { "auth_ref": [ "r392" ], "calculation": { "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between cost and fair value added or subtracted from paid-in capital, arising from contribution of shares to an ESOP or commitments-to-release ESOP shares.", "label": "Employee Stock Ownership Plan (ESOP), Gain (Loss) on Transactions in Deferred Shares", "terseLabel": "Less: gain on the Company's common stock held by the NQDC" } } }, "localname": "EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Manufacturing and laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r140", "r141", "r142", "r147", "r155", "r157", "r180", "r243", "r292", "r298", "r383", "r384", "r385", "r424", "r425", "r508", "r509", "r510", "r511", "r512", "r514", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Strategic investments fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r488", "r489", "r490", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r488", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r488", "r500" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r489", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r488", "r489", "r491", "r492", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r331", "r332", "r337", "r338", "r489", "r540" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0Price\u00a0in Active Markets For Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r331", "r332", "r337", "r338", "r489", "r541" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "verboseLabel": "Significant\u00a0Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r489", "r542" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r493", "r496" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r493", "r496" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value Using Level 3 Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Financial assets remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Changes in the fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Contingent consideration, ending balance", "periodStartLabel": "Contingent consideration, beginning balance", "terseLabel": "Liabilities remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSLiabilitiesMeasuredatFairValueUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r122", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r524", "r530", "r538" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r526", "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r522", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r522" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r522" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r525", "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r521" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r524", "r530", "r538" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r535", "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r534", "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r268" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: Accumulated amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 6.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r269" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 1.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r269" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 5.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r269" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 4.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r269" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 3.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r269" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail": { "order": 2.0, "parentTag": "bmrn_FiniteLivedIntangibleAssetsAmortizationNotCommencedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r263", "r264", "r268", "r270", "r552", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r268", "r556" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r263", "r267" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r268", "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Balance" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Average Remaining Life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r115", "r505", "r506" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign exchange loss (gain)" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r122", "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r331", "r477" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts", "verboseLabel": "Foreign Currency Derivatives" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Forward\u00a0contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r114" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of nonfinancial assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r114" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Gain on sale of nonfinancial assets", "terseLabel": "Gain (loss) on disposition of other assets" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r254", "r256", "r559" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r122", "r259", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r114", "r255", "r258", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment charge" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Less: disposition" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r466", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r128", "r434" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S. Source" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r81", "r204", "r212", "r215", "r218", "r220", "r557", "r567", "r573", "r591" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r128", "r434" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Non-U.S. Source" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r128", "r204", "r212", "r215", "r218", "r220" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESBenefitfromIncomeTaxesBasedLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r82", "r114", "r202", "r241", "r566", "r586" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in the loss of BioMarin/Genzyme LLC" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r405", "r410", "r412", "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r403", "r411", "r416", "r429", "r435", "r437", "r438", "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r156", "r157", "r203", "r401", "r430", "r436", "r592" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "weight": -1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Benefit from income taxes", "totalLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/INCOMETAXESComponentsofProvisionforBenefitfromIncomeTaxesDetail", "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r78", "r122", "r397", "r398", "r411", "r412", "r415", "r422", "r628" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance/deferred benefit" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign tax rate differential (1)" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Federal statutory income tax benefit" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Stock compensation expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Foreign Source Income Subject to U.S. Tax" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State and local taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r402" ], "calculation": { "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "Orphan Drug & General Business Credit" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r111", "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r166", "r167", "r172" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Effect of dilutive securities" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r262", "r266" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r80", "r200", "r516", "r519", "r572" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Total interest expense on convertible debt" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r93" ], "calculation": { "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Coupon interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Summary of Interest Expense on Debt" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r163", "r165", "r172" ], "calculation": { "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The after-tax amount of interest recognized in the period associated with any convertible debt.", "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "Add: Interest on convertible notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r108", "r110", "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest, net of interest capitalized into fixed assets" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORY" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r27", "r251" ], "calculation": { "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r51" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/INVENTORYNarrativeDetails", "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r52", "r122", "r179", "r247", "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r29", "r251" ], "calculation": { "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r51", "r138", "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r28", "r251" ], "calculation": { "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r248" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory reserves, net of stock-based compensation" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r91", "r199" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r536", "r538" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r537" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r124", "r214", "r242", "r456", "r459", "r460", "r504" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r124", "r242", "r504", "r564", "r584" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43", "r124", "r242", "r456", "r459", "r460", "r504" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r488" ], "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Fair value of financial liabilities, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r16", "r563", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Percentage of commitment fees payable on undrawn amount" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR Rate" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Summary of Non-Monetary Long-Lived Assets by Geographic Region" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Purchase" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r46", "r287" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofInterestExpenseonDebtDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Instruments" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r181", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF OPERATIONS AND BUSINESS RISKS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NATUREOFOPERATIONSANDBUSINESSRISKS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r109", "r112", "r115" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r72", "r75", "r83", "r115", "r124", "r146", "r150", "r151", "r152", "r153", "r156", "r157", "r168", "r204", "r212", "r215", "r218", "r220", "r242", "r504", "r568", "r587" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss)", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "NET INCOME (LOSS)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r150", "r151", "r152", "r153", "r161", "r162", "r169", "r172", "r204", "r212", "r215", "r218", "r220" ], "calculation": { "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss), basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r163", "r169", "r172" ], "calculation": { "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income (loss), diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r144", "r145", "r148", "r149", "r158", "r159", "r160", "r244", "r245", "r320", "r321", "r322", "r323", "r386", "r426", "r427", "r428", "r553", "r554", "r555", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "EU and Other Countries" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESAdditionalInformationDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "verboseLabel": "Number of operating business segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r68" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "verboseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Furniture and Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "verboseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r204", "r212", "r215", "r218", "r220" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r531", "r538" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r522" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r522" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r522" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r527", "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r521" ], "calculation": { "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r535", "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r534", "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]", "terseLabel": "Available-for-sale debt securities:" } } }, "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Cash flow hedges:" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r61", "r62", "r65" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "Net change in unrealized holding gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r65" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "totalLabel": "Net change in unrealized holding gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r60", "r65" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented." } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Unrealized holding gain (loss) arising during the period, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r65", "r69" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented." } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r65", "r69", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Cash Flow Hedging Gains (Losses) Reclassified into Earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "terseLabel": "Reclassifications to net loss, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r73", "r76", "r79", "r84", "r292", "r508", "r513", "r514", "r569", "r588" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r73", "r76", "r453", "r454", "r457" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Net change in unrealized holding gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r65", "r69", "r70", "r239" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "terseLabel": "Less: reclassifications to net income (loss), net of tax impact of \u00a0\u00a0 $(127), $0 and $0, respectively." } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "auth_ref": [ "r66", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "negatedLabel": "Reclassification, tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r453", "r454", "r457" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r61", "r65" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized holding gain (loss) arising during the period, net \u00a0\u00a0 of tax impact of $(227), $(1,640) and $(413), respectively." } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r62", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "negatedLabel": "Unrealized holding gain (loss) arising during the period, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r468", "r484" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r115" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Long-Term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESFairValueCarryingAmountofDerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "weight": 1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other income, net", "verboseLabel": "Other income" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r96", "r100", "r131" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r95", "r97", "r232" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchase of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r98", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Business acquisition, cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r348", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r102" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible senior subordinated note offering, net" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from offering debt" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from Issuance of Secured Debt" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r101", "r382" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercises of awards under equity incentive plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r103", "r107", "r131" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Principal repayments of financing leases" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r96" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities and sales of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r280", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r122", "r272" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property, plant and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r275" ], "calculation": { "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r277", "r585" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r34", "r122", "r277", "r629", "r630" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant And Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r277" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r275" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life, (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "durationItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase commitment for the next five years" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r68" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "verboseLabel": "Less: gain (loss) reclassified from AOCI" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Amount Reclassified from AOCI (Gain) Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayments of convertible debt", "verboseLabel": "Repayments of convertible debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r394", "r642" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r122", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested RSUs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r298", "r387", "r583", "r602", "r606" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r140", "r141", "r142", "r147", "r155", "r157", "r243", "r383", "r384", "r385", "r424", "r425", "r599", "r601" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r197", "r198", "r211", "r216", "r217", "r221", "r222", "r226", "r310", "r311", "r551" ], "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net product revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r123", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r533", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r533", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r9", "r38" ], "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Value added taxes payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Marketed by Company" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Marketed by Genzyme" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r189", "r226" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Product Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONAdditionalInformationDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r68", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule Of Shares Excluded From Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Provision for (Benefit From) Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "terseLabel": "Compensation Related Costs [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/OTHEREMPLOYEEBENEFITSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Components of Net Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r469", "r476", "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effect of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value Carrying Amount of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Earnings per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r347", "r377", "r389" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalNetProductRevenuesfromExternalCustomersbyProductDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONSummaryofNonMonetaryLongLivedAssetsbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Disaggregates of Total Net Product Revenues from External Customers by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r263", "r267", "r552" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofNetBookValueandEstimatedRemainingLifeofFiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r263", "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Summary of Forward Foreign Currency Exchange Contracts Outstanding" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Benefit from Income Taxes Based on Loss Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule Of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INVENTORYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentNetDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r348", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r354", "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Employee Stock Purchase Plan Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock Option Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r410", "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r186", "r189", "r190", "r191", "r501", "r503" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Total Net Product Revenue Concentrations Attributed to Largest Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy": { "auth_ref": [ "r122", "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for not readily marketable securities, valuation methods and significant assumptions used to determine fair value, restrictions on the investment and reasons investments are not readily marketable, including securities that are not registered, investments in nonpublic entities.", "label": "Securities Owned Not Readily Marketable, Policy [Policy Text Block]", "terseLabel": "Non-Marketable Equity Securities" } } }, "localname": "SecuritiesOwnedNotReadilyMarketablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r122", "r205", "r206", "r207", "r208", "r209", "r210", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorSubordinatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A senior subordinated note is a bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior subordinated debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors. However senior subordinated notes are junior to Senior Notes and Senior bond holders.", "label": "Senior Subordinated Notes [Member]", "terseLabel": "Senior Subordinated Notes" } } }, "localname": "SeniorSubordinatedNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail", "http://www.bmrn.com/role/DEBTSummaryofSeniorSubordinatedConvertibleObligationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r113" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award vesting service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period, years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Shares, Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per RSU granted (in dollars per share)", "verboseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Shares, Non-vested units ending balance (in shares)", "periodStartLabel": "Shares, Non-vested units beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Non-vested units ending balance (in dollars per share)", "periodStartLabel": "Weighted Average Grant Date Fair Value, Non-vested units beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Shares, Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum percentage of qualified compensation to be used for purchase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share based awards, authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares, Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares, Expired and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Expired and forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "verboseLabel": "Shares, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per option granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r356", "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Options outstanding ending balance (in shares)", "periodStartLabel": "Shares, Options outstanding beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending balance (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r346", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r122", "r348", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing price of common stock (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "The total intrinsic value of restricted stock vested and released" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Contractual term of stock option awards, years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r374", "r388" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONStockOptionValuationAssumptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Years, Exercisable at December 31, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Shares, Options unvested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Years, Options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Options to purchase shares of common stock, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail", "http://www.bmrn.com/role/INCOMETAXESSummaryofExpirationofnotUtilizedNetOperatingLossandTaxCreditCarryforwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r50", "r140", "r141", "r142", "r147", "r155", "r157", "r180", "r243", "r292", "r298", "r383", "r384", "r385", "r424", "r425", "r508", "r509", "r510", "r511", "r512", "r514", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESEffectofDerivativeInstrumentsDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r140", "r141", "r142", "r180", "r551" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "The Company's common stock held by the NQDC" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAntiDilutiveCommonStockExcludedFromComputationofBasicandDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Initial equity grant value" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r292", "r293", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible notes, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r292", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares issued under the employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r292", "r298", "r359" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Shares, Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r50", "r292", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible notes, net" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r292", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Retirement of treasury stock" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r292", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r292", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r24", "r25", "r124", "r230", "r242", "r504" ], "calculation": { "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONAdditionalInformationDetail", "http://www.bmrn.com/role/EQUITYCOMPENSATIONPLANSANDSTOCKBASEDCOMPENSATIONEmployeeStockPurchasePlanValuationAssumptionsDetail", "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r48", "r299" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r331", "r574" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r395", "r439", "r577", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed earnings of foreign subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r396", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would affect the effective tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r182", "r183", "r184", "r185", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r132", "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Provision for Current Period Sales" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r136" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Payments" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r132", "r133", "r134", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r132", "r133", "r134", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONScheduleofEstimatedAccruedRebatesandReserveforCashDiscountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Minority equity ownership" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LICENSEANDCOLLABORATIONAGREEMENTSAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r163", "r172" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r161", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=75028277&loc=d3e19833-108362" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244533&loc=d3e17042-113922" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121573983&loc=d3e28200-109314" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r487": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r515": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "820", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r643": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r644": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r645": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r646": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r647": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r648": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r649": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r650": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r651": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 123 0001048477-21-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001048477-21-000008-xbrl.zip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
  •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

    AY(RAMAEVZ-FJ,7:\BEC+9+L/M[1L MX_&6E42$I;=^H]?_B NM/Q>B#!O5#Y,!'XPR,P*&ORV)SH0T(<@S$?.<9*_H MC^)"Z]@^Q;FPJT6^HTJ;8-C'?%7\,J\NCLVHNZS"H&!^IQ$?KSGH,Z2#M MN*/<->. V K79V2*P3_Q,*CD\'G0JB1'+H)/SIF.1X;*11^2')P;7M/"1<9* M]%2+-7/(<#UV\. 9HR)%PPK8BVE5Y8%F1%(3+Q+3)86@.ZVB<%6;*Q_=76J9 MQ]KC8^%;3".6TZ#!_\5+0'J">%>ABC3K'T7B]8:L"C3U&[? MTH2*#.&FHF,9L8,F_$.04G:JAQ3Y%7'&ZS\\-N,#N]4RO-VF[*UPSJX^KP:O M@,U5S_"V;XMBMU@VS5N-"(C*1Q>K(+(JAL^$@*)%*G13J3$#D9>F]S%X@"*4 MG58W-"E+ D#A 6B#L,IA(L$H4$ N46C^^*(# 8D>7]%N0F4XKR3K06?=67-3 M%PX+73 0MX3B&+A!@@UJ#H55K7?!QK(FZC5/0R*-[);WQ+1*[<1F\-@I$D;_ M<1AN[[ZS15HW.[*;0Q#MJEBC%+4NJ-K,)BPX-3A=V8OF%'4ZXEZQ/;_$GI$F MTG@XN*#]%I^?Z]+Z8$WKGPN7)0A-0H8A$EZLH,4_Z*6S-"=>DLY+!R*E*:&R M;2QLI(VD'&BU4Y'.!$SL;3.LV5IK:-H&[^771EJ);G$/D3<3*9:I->;NA7^F MZE=*[A#6JNV0X4% "0MU86!-;+D_B:= U-MZZIU67PE6GP@^)H*;U#OBAZ3@ M;NTKFYH?$<;AH0K3I*^4S<4I[,U6S8TM6HPU#6X4NQ1\/IUXJAZ'4DYQ&=:T MA7H="[?)PN3DCBP[1]FY[_[@!W\4)B1&4[Q]B0<4:JE%?96#$:Q;M2%BJ15_ M&1[L< ;UQ::-D!C:[&7'&K!3XJU4>V_ETV);[K<2SYR!Y7'\6_8GFEKF$[G% M:(Q68//QCVRAL9U<$H],Z2 ZL!1O<"1-+_+ORXG2PESNNO))Q61-E4?0_ M*5."42Q<$P'=,E#%/>=;XUTXQ('22NQVM)^": U\3S?&!;<#K._?X8 0-B M".N* ( R&^2.')+JI([9E7U MG2\3Z7;BRV%7]XLV_[4DAV'Q0Y$+X^+78;WW%//V93AA7@=?>\T?@'R'OOLE M,?*U BEA"AX)?MTM1RP"\<.%X@>T> .G6:[ZY*!A@*KLFH40 T M'I=:,-"!U"7DH6N_)L1 %$5[JHO,+KJTXJ?XT M!1*7(F(08+!(5G[]G.UN("A1,B61$J;>Z<@2"=SEW'//^CR<'X,%\_3]HIY+ MC=BJ%]G).-F[@4S,21A)Q7H=/0K_W*'HIIG&PBR46.)X(79\4N6;[E<*)WC7 MCS5H_&719NUF&#>_T_8G[&"8;9JHB%>C9/C=,G-K;-TN6W>3)8EU0Z-M-_@I MNU3DZ>'#\%4HCSH/J JW7S$O++XK(96P;J>P MCGRZ'4(L_$NWN[E>N[YF%V=FQ/^T[\&S( .[")/*)."PAA?[\>EQG'?=F,%R[>$FV%32 MKXP!K"GN!<>[WK1@4Z-.BHJ*K?#5TFP$PX>KDEXI@Z$N&VE(2.A*-E1QNB"# M0]'S0 'NXYCHH>$JT!=^AFD,G1A<,%4;N_ ".#D:$ V+!O=IAJ'D*A6ZP40M M:G34=9*H0J8\#YE_51A0\4(YVZ]OI&9MA:A*F\ M9F=[(6>7A.AMN89.*.A>NSGTL,7B@1$MY64K*$&AN&Z+BL?X,B$L[0W1?[]3 MO)12O#-X6,G'@[HU9F')1\_TZE/>6&R/D$/>^LZ$CTQ2&.CY53WK$D%;"K:VNS'LY$:L0)V"D>[MY M3M1(14^@+@X,L^B_,'8\1C'1.";-8E#+.H&+-H3#3["6-1A+/JG4NDBRR;2D MJB1.SY@PY?V'=^9#F8X]HY,*!M0^Q#3W9D@5,U:P%(A=1I(RC+,9S@,,E(IQ M$[W";@$N]?%BI9]U!,=3(E"E$/8T"Z@6J;E2J@;&5,*\QW3?2 HPS%N-)_9% M77E )UG:] ;WH"Q>J'$NO9 M3#$@)<'B*>?L,/4WJ> A =XM>GE=3'*_ZWGJF/.-0[Y0G"NAD1+2HNX?E2+1 M2(SZIAG)%":*.K_0P:BX1 3>N/]I^]5/NPS!,D<"BT\CR/07M92-&09H$WJ3 M4]!)M'1V0_!X"'^BN:F]4@RK ?01=?%(EA 3-X:K.:!LL:V[==O9>!N&52I' MTW#DWF*_)\3Y8->4J66H"+#,$9>I*.S../5977:;,+0C[+*6V5K>&1L^Z M;>!>BM:O(C+^J_0?W_ -*738#\/&08=YM>+2$'TB]@#H:"YUML4HI-A11)VN0(QAB7X' MPQ+K?92.-/,;6PE9@82@B_"+"B=7VV=3W$"A Z):/]0IQUSY..CU^_ID4_X( MRY^T4R8"X'8?< ,!13JQ>$*Y2!>6<^2J"^_+I :C*09)$5H0+*;^)2XH?%1UF5W MA 2@(4"$OG231>)"5]BZ .34P(ZP]%!U(9>$3L! 258 MVD"!1VK*L-"B\'+FWR5UR %KO!\1>.>*B'") =,?CHEUD]+I!M;Z"S5/)M7V M9U.%!.(JP102UF/S&S0V'!5P%H*4,S=IKM7#:T"K=-,AVYFW+LDD-)A''=LZ M[6IR:R[B5RB3IU+ M\&9F@,2F5/I0+X9E? ^7KU8C@N*).M$'WU-3XOOC8X/ZE//9B,WYR4'*L%JB053"8)'-#I9>)*:9K)?32%F4574EI4K%HR:?3 MT(#^F4]@UA:GR6T[9A\Y&:!3V8(! +O#.U<4IH8DF&94SGH98O-.TYCEB'&> M'4=R#7ZA2!(;2+PJLGS>6X@/Z;^?@[V\/G&1-EL6!,N(.; M@SF1P#8^?SZVW1S*I,-=3XK$:9I=Z+@9JT]Y)IJO"38,E6J!.B5-Q_%UW6>K MVS!I0%+][Z G+Q@4:GUR# A7@QOO':XZUJB$7 @?F:@P@>N!MHM1BSR)*KCY MKW <0MO>)QCC#"CN8:=0: B3P1I'V;&M==T=?1MK,"C-Z:&+>S-U 8,PB[3TOG1/(U'B"U!V-Q2V*8=CQ%&#%IO\]+TQ=[70ZKH L1R6EZ$1BLO\0X>,$XC-IG$T/T0R MPIQQ2G)9''V2VE3>[*87+ #A)34X%P3*W2$7]?$V36B<^Q%K4VC(QR%F.JAN*Q"3 R3SV_(H5#R7D^+.-@]5,UF MDX5=8 Z^.%!JE$$#]>ZTH6M+%WNH+Q3%::%0SEO6MIQS/JA;B;5 MRPK"&/&8F+(HKD)-G-7)&A,!FZ$;[E@EX_?*CJ3TF4U9D:V%L=H;@> =WAJI MK3*YTW5;U.;2(UHXZEF$"]S^<4=4+=UWRKMK""PI,:O#>,5>Y MD .,!69ACJ]*(V\D!"WH"E2]KN2U4[Y)%8W74F:R5L,")?2 S6)TG L0(1?$ M_-=W:3UN?IWYI]N)]6[5 ;WN_""*:'*9+@>!:]!A\VD%8U1,LB0B. XJR"B\ M AD]%K"&RD*^T'$O;ODRXRX38@<9MIRVH*V5W$4T7]%!NU4W)+! UHVKT)U, M!7%V7*W&4JQ@.0T0>\*/4JFO:E25 M)5@:%P@+(Z%'VOWY=OWQ;$^$:XGT@F6YI/N&L8F$')]H3 ==*$5<%N. MHW :GB]9!]QNXBWK@G1U76PCN1PP\T,;"_:D8T2"JP<%7ZKR\*,ZA I*/V@< M" T5VA%L5*DPM$%N+5!2FC1_5TA-G/WV\G^B^&?] -'8G8?[@1P+MS/-3'C3HD_B14ITSMQW MYOK O)!D$ Q6D25YE-;)V-=QKJNLQF,"S;^YF6HH*UU'$#)T)Q>KQ<6L M*B6$%.:$XJCQ^I>1'!UN>NXU0(=M#="3K@%Z2&$B!$A'_TIF3=0)!>CJH)$Z MVHZ1@.1"P.S,V::P\5"";4T: A^%5MZBCE4=C<],8^HW *6Y9_11(^O4?AQ\ MLAU#'R_Q;IW$,Y05K)@Z8_9H6/ UNP$78\$QU 03L\F%(J)C0.2@06 M1!JC;SK^%M^&R'.H,/\F8!6,39!4&V+#X2+@<&WVKKXDY'NF&:7RX-Y$CF.7 MOYC*UJ14CKAAX/LYXS4Z\'"%AOJ ?R&6LNX(DKBYE#> \"#ZB&7H'64Z">N2 M/"+B* V2UYE+4?B@\;";X$0HT*UA4)1&&-!TX"8^^T/K7JW O9KG0?88INN) MWI?MFG_[FMO4/(?0P"'CPE.//GUQ*[*?Q6SW9L7GX3Q71;W"P5U^32G-$"RF M@,*E&:VSSAG@*"[:<_+/H2:6]7MM=$-/ \= N\TKV&8'CZ96-(?&1)IA6XS@ MYCB97OJ84R>(9U8:4WCOAE=2MU6K:6[W; 5[IHN0#)<4YS,('"&@ZG4=-L\N M(T)F]R$,P+(I$]E50]A57F9!#6_#UFY&JA@A#P<8E\/L0H =XH+P?8*W8I 4 MNGG>9=V&4AMA,'!< 3&0ECA*Z*;0(::C=A52H9'3[V MZ1Q&1BI1=* L#6$0*."<:HH1M[SDDJV: M8886K4ZL<5;90A_W.VR&V)Q;KD M89Z%4;O:*UAM@XW,K3;H!8 !496FJ%_515[S.[3+OX+E][#]E8^UQ3TS(T8U M8UA1;CYO]&KFG;4D* (!J\$?_U"SY: XM@RPDFT%V,:+MOE$ MLB$X;N.V#M ?N3*8=V:JL+_#/,8"K.$?7V78#@]_>AWG[&MN1B;80\]@"Q?7 MA&_[PG;5$$: :WG!F)&N4G*OJ+\OLJ2"7WCWD.VZTF#LDG&R*/G2DUC6TKFT MSEBV57I*"7XI=,P26*5>6X((1G".0F.7>J.P;5]5JL%/)-8(%(0ZHZE#GOD*+U1M M]M+^0S2E]$*/IY1ZKU1$P25G 2US+;.;@GP+D;5#53\.$\W9'!>)"FD^EA^( ML$JE@H0R &CJ,"J?A45S^J0UH')Y-3/0SA+%%S*]KE-/XW58"WB,X52U."+N M1HZR0A(7$=;0EC5-95IL#.HC5F:F-J4@;-D:E$/BGS?QT"Y7G?[HNLZ#(:J+ MNG2$.7L_3R2!5X6N'1FJJTRRL\+-;5M40;$(#3%98.=)-L1B;V-Q:>U**3\) M[R#[5F16D'+W4LLSQMZN.Z7[T<50*1W^11#WWLM.CMNST29>=/C+R M0"I %OIX?LA*C?44Q7@LV*8P99,$!D-()6/F+> KQ34VK8\NOP+UBWQP$2$# M(=P(U7[@FTL#Y$+O[>@:>E+DEUBJ'JE9;IKC%A7*;8:QRLP-[H(S-T3.=(2W M6_]BX08(VS+Y##[_@B[L'0N!O%-IB#W?),O5#'_'&&]FJ N .' [PSAAHZ-F M^\YMD0^C1S?VC6(0JJ88(>.;HD87IDW42PGGA&8H:;?*.=6 MV#[6<%97PMU;P,DOQE?R!L,\TJE'IA8]$'8B<[RQN>)-C7*R@?+;K"R.85&V ML4F=B+7)?"[<3"'C1&E8+K9T8M9^0@Z#7J M!B>:-FG1BJ.G[JZHKK1KV()"5SHGY+@)-Z+= @$UYE@;68*\#[65M?9:TS<, M?9F_7<8C-ZH)2[<7SHHO#M4@6JCQ^##"RE"(HU2,3Z*74%>"AU.FQA1,>/[6 M\(K<)>OQ,2BI,S)=US)5!$7$6BA+B7T%C.LD8?,9QW(R"6-TJEF)H5?E8G3" MBN5B[^;B)?^1Y4[]\'RH12#$!,++'95IU"AIJ]A?A&%#.")T4JUCPW>1?X]M! M.!! A<+UAGB0^OXO=!S$%)K*,.#"C"QL9V?1U"\HS 2PDIQ;@%0 M]F.58SLB7P*TM0X]"/O9V#1O(S+UB)[FCL%QCCG Y>Q]?<&XE?S:&V!.IG0CRC=].UH.L;OT[? V2Q""^@*=4! 7. A/1 MFM*5D#.SJW]V7+K)B\Q:/MV:-L062-V#B3>_41$"V:#2\_!<8#A#-UXP'>+! M, U9N ;.DO3W_D$&:I8[\:Y12(V_,ENFEK%+25)#1&XV.LGU/[E2#+TD\ \= MA%W",\&Y1VK QG!;K*ORFA0'0W&Q7)8YW$BA,"-\;/Z"!K\3AB2K9QW8SEK- M@!,HUK%/-YLRBMK-M]"!F+>UR)+-$>HM\%F?PWB'24\V"@: MF6X7:G)2$3D+-1\7AUI1,BDS!AC\J07.6T4E0GK%:"8FDQ9/:9DI &2V*!A2 M9UJIJ9F&:A(FX[869$4[L'#9\>Q@'F(TD7LY!K\O1B\MJM".OV0_FG91-)51 M5 Y8CB@K?,:K.'L?YG%JD<#K.K3=U?O>52=]2\%1XY UW#;SNU@0Z@P5)%0Y M.HIDKTKX@!T0K:Q_E"Z*$R>J\PMX=(MT>><6T2&1G&MNE9?!M:N &,'21$=1 M>##;R@Y9AYC-U/0I>!M*#W.*/03=M?SDT#:'8 (AKJOT=C< MJ^54#PG#8_]H M9X?XOT052J7^5XFFT*=DOQB/A388S1![<,F;TQZ?.'I2WZ8M?_>(UE*5-^CA M>5=D&=\2?M:4EIJ#M,'7%(XC!'RBX(!4#B9(4DE%MKD$#>:D62Y<=DSF5_:Y M5]7L]=JJFK:JYM[RNP0F6B^.'0"6#/,Z:6+^#S+N=J'=95O#S.[EC "&8BEZ]^L+^5K]+$3 M=C68M4Y=O)-JD&K3HLA&,3U )S%%W7(])"M4TQ3F7A0.^9,NP$PS?&"54S;, MW C.! SC-,^\W^X;9P)-238%/9Z\1!&V2W%@=E MFZO$TM2H<,*E=XF/UNPYMPH%2?JD&DEJM0O77-2U%XU/MG0^-@#K4EPQ;61& M4PA43)\4&;]F%3FI'J=.9@*!Y3V"+2H?$?$UH(_@9")QBR25[W@N2B8NQ.5= M<"XZNJ+-#8"C1+$V:*C OBG>JX?L&5M.^0)&N-,RUOQ'DD)FG&13LHC5YGZ] MEI>[U4)4 M-[2&N0F.ZWZFJ&%5.K(D'2D$X&X2.!(7%*:H/,6&&=TD*XRK4R!7JQ2$XDGD M'C13]J/2.*MWHK'/[(QC@C4W'X!CE0H? MM"BHN0[DS9"'5\HXA+0-6!=%('L@%*,8%>48F<52O83$NIN:8@1W4>CJR'$A M)RJ\B!&=,5WB /U9P?NH%,N^L,/P<83R47NWV3XR+6V?MM38B4@ATY53?^/( MD"5*,C$:4^\+YG8>2VD YQ!B%T:>V_M20ZJNCPU1D*) 8"I][/":P2V?8[\6 M&@)TT^:*.L6YWI+L%"PZHX8LF%+>#=@?N'ZX#,/!U&PHGW2HN.H&63 =K+;* M= DZ?Y')G%EAR\SDJ;U0.Z]-U'EV'.NIA9FN F M[S@F?,P\.5/"[9]E7.3D/-I VCE1OTR+@T.@9Y_N#M388$.7.]-K);WN&-F) MI0K%$U-J.E'=0 IM=!H7;%XGL][A<^@]+52GK<*EIYA:,!BD=-\)94+'?[?, M%G=@_>@BK\'7EGN3K\RB0>')58B_Y?MVW2;7?"V<-B&X6I9C6RRS M,6$4QEJE/--O -55H2CX:,2/F>4V)@'+9II46\QSWRF'-Y)1(@$)";YS:_+\ M$R[=D7++*BDN0N;PSI1[+OC"P=81*3PV)9 :'\0RFW8LR:3P(OF#!1M$FY%B M(#"1BQ$,^D A!X.+RA*F@-,/=,^]AM['9\93&H+.%#9S>8+;$MK:4 ]#F3Y+ M6@.#Z_"YD7S*HEK;5?"?8QL\J8X^ HV+ 6RNLQ!D* %;A__%:D[!^14R4>D3 M=5>$T>K! NOX)+U,9=C13^WPDR(&2C<=J845*G,YEY:UQU]^F1JYN,A/)K;I MUUF&!:2L RT:)CERN72Y$E>*]>,=JW).7BC&Y@!PUYN\5$%3N=4+6;\73>5LJ"!T"D6#K]R5SH9Z^?S)YZB%8J@54<=,L8LLBR\W.D/'*5JM):.J%;]ZK):BZ;]PC'_,!01 *'KJ9,XQK MT.L?H$E*@!9X[,"J2KA[-/@5)GY22;_9?[(A)P^W?CWYS_&+CGD(V;)NR$L7 MNDL@A_)R>@W=+E8/C4@:MNB#.4/F.C7"]5)0_!2HHPA#AEOVB0@X@=>.KGQQ M/F4S=A_S&=Z&K_/J'.?SHB.V'GW1!LR9_U6/HT*(CK_,.%+22-J'13\*YK'U MX>,OQ0M'[T2Z8P,'PM@]QB[&W]G':0!?39,!>R=AAPH,"HQY:X8QN)$E\?U) MJ-K/.!C@ZCM\G733Q#I4ZS01T=[")G*G $M4)4/3*QS2ITW$@3YN!!ZL7!4F M+.-&WN%+HK(=4:L)(5=HY%D*+F\.8G^,.9=/2/L\YM>_T2BB9QKA[QAC)?", MD^-/;\[X7UKR8/'>TT4^ !%F&!,S&CT//XRHI^**H?,)%\\;-M/=];H/1V<8 M,4_X-?%8MR1=XODFXG!D.:'0+$.#2, (BU>DWE>/O2N<4^WGMD2E(V&<*X98BJ'A6T12D?HF4'E6Z"9, M)DX)P-P9DYANO7IS>O8"?\VM9^1TA++WV/"0Z@*0CPZM(EF5YJ"=9-O&VJ.7 MO'8LXJV/;TY>OW 2.3$:8&2Z%D%BZTO>5$B!"8M_DDVG,05Y6"[Q^_HNRZEE MF[MG8170EA;])_%+ U]>HT@W0.=2BN)\3!ZMF=ZMW8KV>X21T@LZ-.!B(RD& MV-?B[&AT?BI;(F >;"?7UWUXD8G>Y6QJ4=D.4-X$CBS!9S'H0V$. X",N:$+ MUKR,7EWJB;A?%1 IR/R126^$:AWR:+C=_G8OJ*WV)T+6G-?/H_> &DY_ 0$[>("^/QT*"Q<79, MR>5X)&7JH'$$CJ;)*+7D797]5HFKDO$3O4BK+Y!3KL/20^]R3)1CJAI^4ATZ^76!F"]Q!V MBO\H+3*FGWH"4BS6O2GTK)NE4@$!PG#%+@/OF;PZ+IPQ19;:FI(/]DXTGZ%G M"M](6)H':Q?&O8ZO_)IN>2$:(_9]O)0X?LJ>A5/]N8Y- B17_K2CK*(8D7A+ MC?NOBSW,:MN5]E;-M<,ZIF'?WYK:^\@4)XA<6^Y EAA8Y0G']V+=1^K9RUC/ MD"44#8[\+;N%:]]ILI"7525K9D@WQ[EL8F1,S,](F*EA&@EUP8+IZQ#,#)O4 M1BR%L+PAZH926N50MY<$7=$S+PR;X44) M7H^#G*$=YOJV\T1MZ,TE%J'P/@=%+-:(XU/1E&(Z^B( P?B<5P!7R M*Y$D*UJ&8H#_CK^BH>26]-;X!50\'N.]:L!?+?J]]ML)YNEG/9 SZF55!.!1 M4#@!\4:Y!*^Q ,N;4S.A&'P&1O4EI>;:A*>!,0>^&(D2O8/MN<@7TJ'S0!%- MY@'$=^9J6J4B0QTIO&/>2) 0^1?EKY7N$Q@+($]&Y HC)?<'QKU"RO-: ?9] M.MW8WY'\$K?K(QG:3)_]T 66C_+JO./T'VAJ#3GHY.QQR$.O=^-QTUB<[Q5V MF$OC.O\C!G?KLPF:7+]K+(\L"(Y<=FSX#.:?GDM"']\CQ6\$.I2)CE-+O"D> MLQF"?K\%Y#&-T+ 1:J8O*B<34X1C2A /L[P;_)1=*@I62!&PFMD;P_F@##0/ M+],@A0EDE[C;''= FVADVG'2"Z+*=L6%9F:RE%8>9%.'Q$.J-UU"Z;Y++COI MXAIKE:P702HC.'M_)4?%7P-OXA_))M=CUZ!/N(08B*.!(%:1BQ-H>(?'_L/< M6X8TO;]=SNV.4D?LG9?*U(N3@K@R%A;B63CKW@W>4PR=HX0<1Q//A%1.$8/& M#7-M)5\K,!T!/]0UHJ9]R#V4DO[E_*)S3DQ=6:[BZ;#*"]M5S+G%#BT@&;_> MK0BG46T,MKDLGZ1<$?YJ_CKPE=4HOHB3X"U][(0_1D%4C8747#%+8F*UL02_ MZ"!(HYR$FH=*_U%1"X(S'LGWLZZK[;_= 7J@?1,#5C>\!;6D?8$!K#9.H__J M68C1^<8GTT,7O(!*I@MW)GC2*^D(%L'N=+%;,X969KV)LB&B4:Y%N,- M_%-UM7@1:JZ0UL0V+6\T@;N]<"MN)^%0D8N)]9=9RA$ KO2>GI.0MRKXBG .]H/MGYZ=WJ,V32T@O&-R: M+[KFI42,K(1B-%'BUJAQ'E81(V_9 \]H-Z6^(/VT")>B\M&NR8'_2EP=T,*,CJ5,):0U='@W=$%5Z<':7A5PFQ:1DA8J3$ M5-2R\5\CE2#,.;>:VN-34W8R=_+@L 0#Q5/TWV8H,D_(^*;R+Z))Q3>JYG-WIZ?')<;,<4G=!87IRB1Z5G"Y=-K><-07W+I8B M>F8;BRP;.U@&?3RO8],L2&!,*J<*(!O^$C(DE-A$1>?*5B;IQ]%^,[#A2(_< MM\RH.<:I?IIR>XWQ3^':-FD@LTBZDZ*P74J."TB*1?=L$62C[L+1QVY.%IUP M"%THH>\@W[RZ&(F M:(Y:XWL'RCGII$(G;&&&B^^S3@>I%G=%F>=K#+ZFFH> M:"%_M:CZ7G(,)?-$LW?+]XZEE!03.3$>D:E@C'F. "ES^#.OIKG+O+MGBG%3 M,M>I,DMDEJ#;.I@O-=4.&B8)O3 0+OA4(8DI'8RH1U/1O,2B9>MOL6O;(5$_ MS]E2191I8[<:AY?">QB+E$R>_V:$NXVX\IP"_WQ>=06)G MCS@8>/S'[\K@R M?";QJ%#]R/U"%108/]^ L)= M36$'3F4_J5;HY.24K!L.#&?9%Z?0[#]A6F&Y=9^+-WAM\0O!.>67G8>/Y.&% MU(BBV\T JX1K.M(%!7#S*U;><2Z7!5&?&A'J(#PAKJE;3=3T02[L[(BGSR&2 M"(O'$RIUL9]CVM5)=GG-6ZE6I-!5]C1%*@4DR#7W YAJ3]*/'U-9YB@^B"?7%YP.T0!+,53([^ M?D>7-(>IHT%-4^ZBG21E4&!#05Q,%BWHJ54\Q^8YP.C"R_\(M$@:Y!W C)_,2YK7FTA2.N_JKK'MY,I]6#M,"BMU!C M?KY-PJF+K]W&<\["4:T7 S=K53R2&@ZK/BE\12%/G9S+I%NWF2!)E_U)GR_K M?1O"6;NTRF((6'-3?#)V"59[[G^_?W#$[F.JH3AU6^IK7$9'L)QO;OWX^O33 M"T\5O?DI\P%J7U)>UAS,)6#&_A[UG[3:QG Q;A.<:W,,CI M\?!\I\)3^8XPUE&QOQNZ4#JUY=V*+WB0?M0:(2[&5VY>SBU;(<-0*&13UCAE'6H'4Q(Q\;PS?, +-@O1M'!X):B.6M="S:T% MG7A=[3:O1FR*M\&=E928! %0+N'+^;5ES,S@P. H;C=[@E72!#CO1P&ZP=EE M7/X%5P0#'M@B0YW%TWW=W,IW:DQB,+NKE"!]R1(G9R/-4AV$*!TMJOOG9EK^ MSZE>F%8+O(N=_=V7X%_!ZQ+)BN[^@Z$B4@PP2?@BY_X19PMPM-H#BG2KY Q7 MR4EF6(S!FH#4MDD:8,78"_1J^,]W(BQD@F^0>4TK9HO2C>@TE21)';@4M_&E MME#*735%T2U^=#TG";).KW?$K>.U7#&@")8IUJKFF1=%^H -,H(W'HJA&WL> MA5='RDU@4;A-:)[>EW/35>]/IAM\3,U)!84U#:5.01X7:E1X&KU#F\QQU+R\ M<8E(P(@<><%A-I[WF2Y9/7$"KR<)@GL4P=;9R4GQHE8V87!E_U,5&K>(WO)9 M&'L0AA/6B'4&54LRNQ71V?U9P;93CFJB)'ZA GP-X9N!B'#L0[/HN=6SQ3+" M83;>U7?1],V'TP55G#%Q;20M30%;C=78IB30E6^5I%6,Z1_ZCX'$< ^ M9EX"".'4..'S'4F F+IZ ME4;ZA-/2&@XOKZ@0:_8EA%U>ZDL/7\V-M)_YZ)"98K/DN.*2@2'(LDN;]_^Y M=N/5#1G/"Q_;AWM0.SK.AX\S/N9U 3^?J1[/=8I%P'R13)TNUB+;EAM5=-GG MG^G]6GUMQ5W5=>8<4E6M'AQ=7O1$!F@;+Y[[>4:Y]BR_#/-(WX_ZY(FT$HSI M",69,3'AB^?$N,O$BOH<=6X*D\LZ-MB, 9DR31N+H9*W#-LXI4 'GTV+A-'\ M/6TSUJSVAG[OIM%P/)\ZGA.%^&%N#P.A@>BH?'F)U5JHHQ4JH/-XBIZ79BZ1 MXEVGVT,\XK^4K7-D_\<: >[']5J7WCIJ_B!*ILF,;**&Z?3T;COL9G.5%"PY M?$G"%M-*R+4* QKEF=C-]56E^BU>#'>P)##(%H8'ARY,=L6QG@,+GA+V]8S_ M28]UZQ*LZ>I@N7XDZ"_S^J*:8:E(X887F)(V%(P;1<50N/E>O)Y[3OTYDB5' M)K2)3 R%U=/6O6R$2CYSTCN2_)KO([!;[5P\7$"$$L,+(?Y[O>= RYFI;G!: M"&U7Q\*4E45'-+DJNFF]LO602^!2XB/UJK+B>IN!E&B5$R((X%]-K@K$]4V# M4RZ! \>G0A61*JY?E<$5EF*-JNR',9;"8,V+P/]0?7Q""$$,OR? 2)1R-1%8 M6=V9),Q.WI]Y1@"&[?0PZOX--SZC0ZF'#&Y8I/AP<,:.0I)(\D!(P!21*P@9 M;8:(*;#N]*\9+'#(_^!- L!)$-,\ZPK("MWS#!,OB<>$N[P1MCI/L)]D&G MMO1T*8F@>JU.L@DWKGBG-D5NI3'S]V?QJ&%']/)@W5-L8;< ME^-.,-(%5?Q7C:)9,#H*O&^B"I; HO2>)LP^W'.!'/;*U,F*]W$SC0=2X!5DE&PA\D]BD7-%GUP97TLKY4^>P)L*4;+XQ7 M^SV2=&0X=Q\3@BO!Y@QUK%&Q>LEVL30Y:'(KP%?>I727PZLLLX[Y_"D_)/C1 M ,O YT[];J+WGI3I>Z;VH4\NBIK_#8>$8^MT\NG]\0L8 49I4T:OT;ON#8/0U RPA<0I9:+&?1U]T"0$?"S%#S^-Q*4L) M;J\US]CD\%I;O&WM.!7E5"P DH0 :RQUJ$!UOW,W^"7^HBX%YX-QDN8O"Y% M[)U.7?-RG(TJD^YJ-._H739.1A'6A9?'IWKYEBW*BENI#:G(%20P#:W7R)"1FVKQ?53/+(#$$ W]?$^HAJCA9:]M%O&+SB3F'7 MSBZDHS^7$3H5N"':Z;$&539(*DZ*1J47<&>DY@;@ZAFYATQ]C0;NJS7W3-&T MFR6J=K[I;VZ[OCF/(JMVP;ULFU8^A7CY!5OH:(OKR([_+%;.AN3ZRL3AT1;1 MMMO*GN,K-%3AU1Z2;Q)ACL6$4YM*B#VQC M(RSO[$*\+NZ28SS8L2ZG35RB4L?@]-KUFIKO9/?LA<,J8$@MJ+Z[(T),5C[] MWCLV-;A8!X_&('@Y>VL!$]C9KDF'>:J+8MOMSP>*D[K\C M19#8TE>#R-0BYV9 HG :G@NZ)OXGBHOS+.?8"*D8.'V9]$:YQ=7F>T@M74K# M,"'IXC/HO1.E@98$I(J1KS0T6\>E=%AP;.D>P6YNRH8RRC57.;K+$#JP=Z8J MVP)!TW$3C]C^DJR[@MHO0^H8-@$95.C/O01JIRV!:DN@5@44-&]D&[4VJM"R M3UQDJ@MN3YZ&O/8CO204?J+EB8![\[@*(:Q,5$:>D+58O_C4;ISM4"!D@)Y%% M%T^?,8TJSO>R_JP.)Y2XD$7MLPXH>[?NPCH%-=C1/@P3H1=C4YN]?SUZXVB; MRA_*@6&A_Y#35RD6[5-,3!EBU@8UN)ZE6>FF M&;"[[>(]ZAVE(ACS,%YTBQW?L+PAMV6%N95MO3UL+\M %UB;TK7=T"M,TZU) M#]?\&>F3WI$YX9N7+@>;A!&E]/*9>6C\B:&R9624JFW@KZ#>>,]0=NJNF/1G MH5#@ALTK/-=\Y[2!P%]A(L3AI)A_++>'EHQK.^(V6]PH;*XQ%$0-\[U44AUZ MC:X%YR,_-WP)BR\S;7V+8'%,76L*H=TNB84,7D0WY%,ND,GAU.C8/EB7F0 W> SK5>44RF+I MU;:QMA+"TV$YMUG776M!&!AD+.\+E^9ON3K!C F M$5(3 #%ERNPN%QVA?- A8XZ%8&C3Z%C4VQZ3 RI^9G]"]*&8K^DIW&7-HLDM M":YPBBC"7/.P*/.*WWQ;F5T@KQ2V*,MP].6;1%?X&N<(<>YEK;T[;7Z]YQ?; M$/"^L?8GGBWL#Y$6X$PX/B(VW>YVW+'>\&//RZ*&WT V>59'] M'.5?W9H4T].),7@,SY95I''+,9S[E;K?!8J$YNFF\"^J!/, >P1-$F[IR.<\'2B;-7!H(,]B(JS.#&X?Z'N:/J<94 M)4%1T@20N_QKPN\RMM06^KLLLC)X!N@&)XMTO@,^,XD+[OSD0\6W4%EBTSXGTN."6(5 X.A <>48^--Q MH;R>#0:6P\^I$E.I7D8:X]G#K"1J(2N^[WZUEU\N@3O.,>CD#-9MH!&B99AB MI46&HT83G)"[%\S21S?%]17MI1?WNG,DXUITG Q*NZ.YM)0\N&9R*Z]D!L2+WB<6'J MX.9(*4T_'?71>8USPG$:3C%Y6;"3YAPUKVG0/72Z!ZT!T)F]*;&EH4L'XKI_XTYX3W4#K+!M!1=9@KW"+&R.3TT=4O<2/U- M1I8'[/ME !1*)2^ MZ-B66C6$N< U8YD7"3E+ ]"]18\457, M,+-]KEX8-!10(CY3$2I[IA-2#FX?CZ&CJ_-1R^/M4)2ZP0B;A-B_JS5Y%74@ M/:YS86(\,E1-"36?[UC^L5!F3)6#=50;0 TU_75MKTF8ZX?16H=N!- C"/;P MEYGRE(%N,EV&Y/O--;H F3*"&%PP'C;&SS/CAK%IA.&.VFW.^EW'IL12;K / M& >!VA4:SP[->[YD67K8';GJ^-B_3DM[1^CVG+H(7:KB&$OZ7II5>5&%7-.P M$'E]KF3;/,:I3-/'R7[5\P:]<(P;Z5,YEB5J&Y;;-^K7L'FDOK,%"UYTDHNY M+7#5Q%A+GC.SP#'28WKEJ?%\;AMY!S5;I @G+1O;@4328L".,M]7@R/HN,/^ M#KLV>J>NG9M!TDPWP]!+*X;&K>?+PZU)LLOSW(M0=MLBE+8(964P+H:P1"K= MT-B>\C7");N4WNPX&'Z">:9CCZ:NSES5"ZAH' CF9UE0$J*!4N5L;X?87M!! M,-8\PW82;P&--^Q$PP144YOWB(NN_ RN4>-,J!F.I,B$XG%NE(+;_J"?'$77)$4 !&NEHF ". MHO'F&QX=NDC8RE]JU63<16MRI+X'-E#LQT-F#-9[\685?E!/+@ L< M[&VTZ4=&UN00DMPTBPI;1VB:*V):#L[G"S!L!V_9@3 MXSH(.R9@?TU5O?AMM833$K43G.KY$5X4:(5D#]'>%LX9AB042^89XTIO)VT\52 M:TGZ@"N"K7.CC(:49U]#V+D+,.-'UOWQ"B!LS;BN2\>*#:I35%Z4P5$$BU_" MN"+D$UE64V<9";C8!Y8[@\/S%BM*P);-@E>@A CH.,5^,P:O=([6.$0_[:], M]PWC\_R(:H,B%NAH_1"J8.O8^%FC;)-+39!E9")+O)AK)QVRNKEG-?I(HZD@;C M?)2KHYQO1!TGF*"(FPSK]C*_)YWSR-C.W1&]2>PGJ8&TJ-41N3$!N1P;7F,> MM2$Y)1O#:3:)'/:M67:)#GQ5-<(N3&LK6K&[E6MK)M!WNS3?737/BX\2(LIHGD8RG;CQJ[=S)IU[6_" MD^G/8BS9UB6:0HQ5Y[KL\Z4]C:603C4<EF(<&"Q"/;#%H$ M5I'90KW(MK=JG$T0;;[J_-XAQ"\5@D>'VV_.>Q<<&I]4S=U-R9S$H+0C!PY7 MPOZR=$:X+J@YU,7-U07:^I,BJL1\QE)*WR,X$!%)"TA1&*WG<3S@6"S'MOVP MR]XTKM)Z4(0:5C0CI5!*424B!;H)A(K';44#I2&O[%!\NG WH>:-PC$+9N', M$G&6NBELK!>0=#3WA.IG,G>3.05V:W3'?W0N!!3DBUB;7;='(#IE+A49%4W1 M1_VDRD@[+RW)D6*GBA$(XKQ&8E3.APRT MU-% CH5Y&EPIEWI+-!7\.":W!2%'U/&;%H9M':&GF8 M0U37O5F(56S($.D;Z\H&9FT:J8?__OYYYWW5N<=\4Q MQM&_OKLY13@8?'>_R=JFO;IVWP\?.!%6JND__];?[[WLOT*66T&;(&SF\9@0 M"3EMN@':\P-<*/=VN):4I[WOUG5_!UU$W*("+W7C?HHVH(5:IRW&&,K8HN^2 M;2#QJ2*8Y^GC*+T-^G%(2@IZ"D9^D17!*!'H^M=@7N!@P"03M0IK+GKEZ*A[ MN+>/JJ7,X?]'^O&B=;JD=;XOH_F_[>QU=WJ#A7_N=?MW_-M>_^A.W[QNL/U^ M=[=_L"&#W;B5'2PWV.])Q%C,0%Q1\O_UWNN_]X[D^ON!^+E0KL]Y)QEMZ/:7US==9G/MJ9JW& M]WKNG"^CVY%*'DO[TVA;1C<:CWOCT4LQ8\@(G)7HC<=1H(>^1C?"G-G(J@5Y M4<-QJ!*GU,C^TJV]6>( +ERD&T_F8(4+W0L:EIL(V1Y_O7=[!YV=7H^-Z/J* MKE+4: UZRZ_ O>SJDS\^)P:X#] ]+O7#&P'- MB_T1?50Y.1B*,*W3WL)NCHV^0",+VZA3S]%8"KD*>VC0N"SKK#\'1SLWZL_[ MTX0/8& ^G.J22M!2_(.3H_6J:>^NTS;5$[E')72CFE];J=':2:*$*U!2 M]VHS;HQ:Z^UT#NYJ%FZHY;?VLN[P2R%BQR2KEHI"/-:BK8N&'/0&.T_+(IN$ MZ9 *4*R+#(;_ET[P#I/':?1,33'067NM*;:"E7S?&EK?9&A]3RG"-<_!_\X M/2/!03#<0))E17S*<^;$-IC, D4W18*+7)M<+ XUR^M"ZJ!=ZCUAZC1U[[KN MS"EMUI"_TJ#",,!4(/S8U0*'-U4+W%O_^4W5 CO=X!=U#B;P*58:$W'=9A2! M?$R#,S4KF?ERL,?Y^PXV%U<8Q")V^PG9.0D6"X^24#ASA/H'$;4O0Q":&,EG M708!E*J32:S&P9NO:E01P! ;3SG_\13$2W"AQL'O69Y$A,7C4:>]KL%.X_?L MXWZ+B;--/P8_P&]\:XJ2Y8VZGMUG4G]-Q7EP^)A"7#[S(:,*T-3^&0$1W&Y3 MI);!@@I+HBKL0&>:!+S?VQHR2-"@MQ6^T/6C9XQJ@N?SC:[Q/^87](]V=KGI MA1KFL)*?7Z2+94NB.J+ M5^9FB%Q/J7JU__V VX_I7SMV\$591;B.!+2NHGIMI'#RR1/PPTMV_)KW8R.T M?9Y 8\-0.FZ#5$=PD^40.!K3[-G;U\=2:8O-#-+F2W^!526UCJ4W#FV2A7FT MD@!/)9Q7D#-BA"3J1D::9%)B(6Z:Y6K[CRHZ-P=FEA6E_8UN/ND@N!9(L[HJ M9+[!6$GG*]P\\@\+W"MLX^]24_ C>H(!J?#P3.#0&@G#=8>99C'A^1WG0_5' M5%#U;83UM[_"+?3/OPUV>B_/#?<++!^A!O&$049X"?S?:34#'Y\R]*)=(CB] M;]4P)TI0&%R_$T1PC\XT$/(BQ4";&:DQ%8H"F^9.'!TSS@!(Q M&55.29/)>2YL9[+Q_X-G[R)&>&(NU\4MO_X<<6\\XI )0%Y<(,FQAO/7D^7V M%OC(\2R/DP#I3W'2U+;AL5;PB2>2!^D7#)!]LM3D"@QB26R!\7F6RZ3;EB+%M/JGC"M#IL\X8=4-:>(1?WNW9U5Y\':JLX]4)W4DD-WXB=A M,TY+8X-A/3W<<6_^K"B^]@G5#9GOV>B+>"3O$?A>$ W>43=?<"I=.703\W<= MRWLCM/)'P4L@0%"8+%[X2 *N(O$TB*3H:CK,$HTI^NK]IP\")JJ)D3^$113^ M&?S(3;QG!)L@*[X9#5X:Q#C%!%,P"V-&%J9V2$+<),8-X=CPUDNLFRACJ]N@ M\V"C%K/*>X_0$/IW#WFL>%GH,3]@-W \6N),,8$UV" )2SUVIA@2^ V3_=\1 MHI.])6HBQ1VOW/D4UHMV$#FN$/N(G8+FK@0-$Y$S:,8,+7,Q=\5!%731_^6* M'?C#)\6D("FVNT_!J]_^7\83A4^=2/]\[3.'VS]OB,P\'6UYJTZFQUWTG^C6 MVHQE/2:1T$ZUM+V)HTFN?Z[X..TKM#=G%4Y53[Q0BT_R8A[/)NNSGPGDLTQ\&-@8JQ@C)M"-M M5E#$1=L5AH/)"6023),.9J+!%A>%!C.0)W+#>YP:1F\"F0$;GN. @BJ!7&4< M,R0HGR_*,76<]]EXZ0Z'XC@2A"!6G"EAW'7O^#G*+AS'[++P MD2G"U('IP(F^BK/W&.#S3FO'M3(Q0H9.O@K>P=2^FFY\^3,\P"'GH(_@]A75 M5%_@S@MA!'\'G[?;ZP42PAIBQ#UUF% 1\2J+'*0>_^O&M.L((RC'U>HV=M$UX+%Y;Y##*7E+22^5.(IF%KY" [S-$^WT07J M#W;Z_^^\W_UC=OY=$";EHC_YJF.OUYM]?>FW;N.YJ'=?HZSPG^7([!_!%_%P M+7P\K2?^'[C&YVOBB:7).^WMD3)"(D9C0[6@A MLQ;>;C=*@^VTKP,3W%/G/5_;O3NUWN]V]P_V5M[*?=@][._<2]OY83O6#1GK M47?G\&Y/;<=Z@PP,%O_U#B@)FU:FV-Q-C!K]"==F+IST_G.<],%SG/3AJS'W^]OTFO8ML)> MR],&8&BE]JE)[<%1MW?8"FTKM)LDM(=[W?Z@%=I6:#=*:/O=0:MI6Z'=+*'M M=0_ZK="V0KM10KNSOD*[Z9@5S44J2Z T;.#I6'W6/\S6'W8/ M#]JM?XY;O]OO]G?:K7^.6[]S<%/@H]WZ)[KUAP?=W=UVZY_AU@\.^MW]^]_Z M)YN675PX_RV F!LHZ,O-:PU/P+>D5CM=+52M<]&5YW+P]JQ:L5KR7B64>/:->O!.2YY0;' MWNE#?P'N!GJWV_ONW]_><#TX:!NNUZ#A^M$@X?:[@KN@(AP[Y? ),,0BM[X. MRW#AB5TGK T$LH(O7@@Z<:'G-7+GY< T8YNWA6$G9 >-Q8[@5D4-W2K0P%;4 M07PD:-/]0P,ZT?S"89A(X[I2I>!'>%S>YKGZB4?!.,^FC+!<1?$U6W-F)Q/. M9H((K))"71)8$'7)QT5PG*85?'H>7>MGPJ]]@$7K'^C)[:]HN?J']>?2HBV_ M8 P9@!W?C$-VXTK]2I@IEL.]8!S%RX$#':9A<%3)D5@85B)&SZS"<[Q(]V;!J.2._<$M((G\P%/1(6 MA3#502++S%MRFD)_CR%FKEU] G"H$'J=%#0A6R'[ D%"$V;$-+P*0@8-+PW M2PV@W-V]&2(/$EPV[=X/=])P>[O+6C9S\ #?W0\]W=_G(MR[=MK[X'%OIVL.U@9;#[#])F/SBX:SDCG/D'\6D.EVI<_2_= M_6_F[OZ'9A]?;K1;[]( GI7PS:N^CM2,,9%G2/6#:(ED>;RX/4/Y;>CE%I7/ MWC9+O%Z20):L7K@5O'6O.U@B/M(0+L"%W1YT#^>1DQ#:C9W,K7[3'M]RO]PM M>\[[#HY+N^_?^)S;QE/7:/"5]5PNUI0/N58^,L\# ME8NM;)K+@95X88 S+T3TT0\1_;",Y-RZS6BE7+[?\HQVA,]ZA L'>;O^->R&K*FA]XT/W.X7ZO>WW1W=TR MO#R1!RYF;[=\F2T_Z.UV[Z-=L=WRM=WRW:-^]SX:EMHM7]LMW^GO=/?;+7]. M6][O[W>O+T+]YBU?D;NY]@8IT213KAEYE--BH6FZVF+&-9'S%54R/KPQ>W1P MPS6WXCK&&Y7A>M3(MF+U;6(%!O.#-B:U8O4@UCM# Z[ MU^.2M&+5BM6MQ>IHT'LTL7HRT>Y?LJ+@:F);G]O&O!]VT%L[^]W#%VU,Y%GL M-4)6[+6;_4PV>[#3;O:SV6QPGMJ]?AY[?=C;Z>[>VV:O-*:]VUT_J_,TSRYB M:M;"0O2MH4K5."[)#GU!].A3%93AUP>*<;<-^]]^((YZ_<4'HH6":"7KSI)U MT._V6L%Z]'UX>H*UO[?8-F\%JQ6L;^'S:9&16N&Z'ZTUZ/46!POO'Q3I*<2\ M/Z@2J5?1R=A*LJ)8QH_;0!E?=U$^W#OJ7L_&TW_>"@.V@W_9EM>K]_L-A];W?]B>[Z_D[O?L_ZTZ_Z1B,U=HU4B]?2"89A M$8_:V/AFN&R[W8.61* 5KGM2M;UN?Z>-8C[Z/CQ%P=IM$WJ/OP]/4;#V%];) MM(+5"M;=RVB[AX^3*7Y2D?&%3D<4(\U U ;+'\>)V&NI?9_CQE]KX+>;_F0W M?;'QW6[ZD]WTQ89QN^E/=-/!:.UO2J0+NAAV[I89\6IR M[6#;P6X ->3:L8-M%B/D&M(^K@FMU:"W#A1@&[!0_:-U6*@-6:O#C5VKEH9O M_9?K49CX[M/-68*,[U68A.E(!6<3I;M@^/I5[\SZ#U 9+G=^W7<^X/#]Q]T7%H5: M:+*V?81K)O1[G3K)Q$G64ICH+(ZE<99'J19J8I.D*JR#9P_ MCB/=.]AKT8Z?Y=ZC-]GN_+/<^9W>VE6WMSO_0,FR@]WN];"?[=X_S;W?/]QY MJ":,IQ@R_UA.5!XD67J^7:I\&F1#&,BUQ-2M![=F)P!UWX,RL[?Q@>W@UV6RM=K73='=S@*4"8M-*UIM*U=Q,X01LWO[%8IRBS MT9=)ED0J+_Z'2M#+JS9H_CB)H'[O)ERA-HCR-/=^I],?/$3E8;OWZ[?W@\[1 M_D';9?),]_ZP=]A6FS_3O3_8WW\ =*UF_"+]!H$HHH[+ 8Q;WKB->_O#SK[> M\#B-5%K^L+W#($8/L4@#9M0TD!T/]$Y_!09[W=X I_Q)C54>E%GPS[\=#@:] ME^_#-#Q7V)SY/T7P.BY&55'$64J-F\=IF%P5<1%DX^!MG(;I"(84G&1I%)?Z M,Y]4424E?>3C3.4<\:>']P]L_!^,L#W!F^"CX2&2'#%_.JCS(^$7I>9#+ MVW& EC12HXR%[P?PH56.GX*!A(\[@&"2 MJ_&_OOM;W#O8V1E$_;W1X<%P-^P?#'L[1[OAWLYA+]K=C<;A_SL +Y?@UD#$ MX?B5W$H=_KMIPQ;KQ.]N@_56^]**)7 .(((D\'\K4 >P.%>.MGD=EF&P5:5A M!4=>12]N&K><.GQA_4IP+X"'UO__S:J@F&15$H%6"B/0<@HT69)DEZBHZ%(K M@ADH+!@<_@9UE)ET\*=9F-PJU,RJ6U!JHRS]HTI'I)5\&\8&;XU#>G!\ #C7D;I0 M23;#J07PX/@"+@Q5=!\=D!$T=K?'6ONVB(R[^]V#W=W5H]OUN[N]^X'BNP?X MR':P]SG8P<. '/:?#,CAKV!QJ. ]?&Y2!&_@)HP6:IBU@3KL!.KK2('/:#@- M"2RJ$RRR"5:RZ4\'7^P]7C+LG+O0EM\XX6>P+='8:V^< ^4/7H-(ZB1#V0YV=P6^\'_N^V\K->J'#M(-<37^\^3\AU50XY M^(G@KZX41^_AY[*:3,?#CWNO-[B7EC SDP?.<;4[OW1-R^#H7MJ"VIU?^YT_ MV+\7],1VY]=^Y_<>0ML_V8:P#ZK$V'@V5<%6DA7%(K;DU98CKX]XKZ@<^>$G M=-A_V%KW933A>M2ZM\+U[<3I8$@-ODD5M(+5"E;#A X.=Q^6,[V5KF_O\@*:S?]:6[Z M;G?G/HKTVXU?]XV'PWX?P$;/-8[E&B]1C/7\41O:V@PS'@R>-K35"M(P8=6N)ZT<-UH'&Y09.LQZA;[1\O4+=ZBYNTY??0)U+-^0[5> MJPO73!?";Q^6P**]:9^1=.T<'K09RE:Z[DMW[?() M\#;?_2@1NKW][EZ;]GQFF[YST-UM-_UY;?K>WKT T+8;O^X;WW^(C7^>N>[K M"O5:@WW-SL%6K[O3UMD__CX\1<$:]%O!>O1]>'*"!0JKC5^UPG5?PM5[Q-#[ MDPM?+5\"N>$"O^YR?:V9U_JX3W;3%YM@[:8_S4V'@]Y&M)[GQM]@NJS,0EF: M6^,Q@=0?AK]B^[Z8*Y:@JUB,^OT\>"CV>XMY*'",[?WTY> M<8#BWDQ>T42C<.W).7Q8,@642]8;!]W GA)B9CEXN;JSLBR1A*H1,-SC^@1;[U__,YS.7AZ_"&*D:B@5 F^C"INH9$8$ 4@) MH9#P =DK2WP4:H9FK@?\JV6O&>D!P![+:_ MLSR[B/$MQ&!05+-90K,C2@)\ M@G!1#/G=3002G=L1,M!3<2[A"!Q%V-FE("I+L]&D<%'64^"JUGE1-F# M# N:PN%:'>O0,= KW,H?#G%87I=X_7D*K=X-W:3 +\6ZM MDC#O!)$/6)X9E&Y7\3@7[D6=I M>!'G%6PG+(R:QJ..'CY*[\G'W]Z]WNX?F;_"5W!/I_!,/##)51!&<.L7"G\: MCQ4^&[9T6!5P&HJB#P,U91=[X95#;(%Y[P;G"G%+"F*#V49 MEPE,2R1 S^ 7F8$]17J?>.2SF0ISF%5)SQHJ4,DI?GX9R>:=MHO1"9+X"VQK MDK@KY.] )RC@C5_@22AUA99F//3+V$A;59K 6L'2BA[ [Y':C$!<$.R?])2TZGLJ U]F:)$TKP MIB":E_E]9>J9FY49$= ,E4HM)0X\&=5C'L&G%=/T?$Y)O]+WX*[XW#WKO@C. M50IR0"=XA--$10[?JY@;:):#DHMGR!BT]>/Q\>D+$FV46R$0XC?AHX+7R/N2 MXX//7K]HL"R7-*;VOULOX^8CZ#54J7:$P7F2#4%&AC'W8:^_*%+(&=TN_HN'<);&,?P9 M1 :T1ES(&:*I+4VQ1$*T3D*%.@A7!&S8.,-= -N4[Y "9"BG/=7B8V;+>PZ7 M#6J/8 1/I=W@I5;FWPOVG:BL4)K(DH0W780L;%H@NL$QV)I36*8K[=TV#*(C MU\(=MV$%UH5SYAW;UG"'/]C4-X(MS3/- MUY,H[6,^FX3I>H[M=5Z=K^?(WGP=)>"47X MN:X#G,4D%M#BW=[I]O'K]5,+AA_3*3L4YPX17ZM%2(NLIYRMLVI[17Z@4W&^5J-K M5%%RVID-C\RAH+9%GID8:+9&[=FW=E5*T2;7 M0QZR=N@XB:H\_.N*"G?#/$OC"!;I1;"$G_?X](VW6E)3EO$@Z_K^](RCEN_N M]U TO?VNAX('O+6S_ V[EB+0'#1YX'-%6G&^YKU=PW8-'WT-5QN1?> )OC2;P MVCA2RRCA>[VM-T!MG_[\>9.T]MZ:^ /KK@/6Q%Q=]V7ZD)7!\6R6P B&B6I7 MZYG9[Q_"\T3B3>=A4E1@N!=+W1I/RW0W\:'?-B] M/\LS?CEU7L[Z:U MYQ_8' V3J_2O^,]@:Z;.+V <<-ZW9W_._GIQSPF=5:JFK8/UMU+79L,WR?^H M-;:OZ]ZNA>(:] 9[K4%]TQKM]-HUNF7\;J,]CM_B:?Q7/ VV%/;YDK\1A,EL M\@P3!C8K_=NQKUC7_R+8.GR6;@>*^P+-7]MA'Q8%L=G7.4&IX)10I9I15['#1ULUH8&/ZDP*2FKW<69.]?-O4+?R^&F6S++DJPM%H$N9QE"&\X3@,](Q(I4D*L#:FBS%WG"59S$B!,RR<56,XI3VHKR:J6 0;&'E MR<;NQ]XZ[\=LHM*KY(LJL[2"UP9;IS]_WMB5WE_GE6[6-K^)NOEM<_7-P1JM M>AA521G,X'XFQ!M"(''BCYNVM(=KM+3+7I^_!;^BUCZ6:_2WX\6"+2_>14?\ M"<-']FN!!.=_[P<)LF%:X_&*!866-%*CC)MQ?B# ' Z=_-_P<0<03'(U_M=W M?[L91NK@NW__2N@L(,XG&0(A(MI"^.];MSXU86\^O/PU0U/=*Y0DXM[%::6B MQ:?\42>_]2X-X%D)C1;&[F*0N9AM!.YVB>AK@M X-Z--PV.:0S[*TNWS#*&F MIN$?")IE$>00WN@\#Z?%?0$A]0?KB(2T,^CN[^]N"@3.8??PX*X#:I&0KAML MKWNT?[?'/L)@#[H'@[W'1$*ZKQ12<[OO>])5@H04G!C\MSG%\X!CBE/0D$9Y M/B]\@.56Z%?0_JI<.XM@$;A4NW-F=<@^>AP0I^4&Z.1,VOUK*";\W.[>(V'; M+;<"9R4X8RNI]=Q@&(C?PB0;E=DH0USI(,^^AK,PO\@NU!R=[T/72FWPHIXA MS*X*?E+3;#:)DS@,CC=U-=>B3(*]W_^J8F/12=IE?&K+>*(1L4\G6%>X$]SF M)EEO]?5;5F1Y7"*Z^AH42C[8M(]'DRR-\FR6A 6H[.=5B78KW=#.^XG,^YN4 MV(9"&;QZ_R'8Z1T\]A6XWHMT^O/G1S<2UOT(_5*="C[<17%%([)=5)56F8&XXS2Y4XG$!"ME.L*4G^"+050%$L2=,?PI^F4UC M86G2''1!2,>'%N@RRY.(R ZY:E8]4T0FF68$$?<3PAG29^13' M!*N)ST0FRSRO9ER:4%2C">:SIW%1J$C7A&'M:5486L$(]NA*14YA4U&&>W7"J7R"\TJQD90D;F\;/L?9JP#SD*XP+/-;T$FWF(-"\ 2(&+)QR)?"Y MR,R$:Z1H?YAG< ([#^MK&!3Y&_%XC&221#P/HIYX6 _BH(^QW2,Q/:4X0!Q+CQ'DIQ&-N)%=)#$ MXH3<7?C?ZVD/+RJ&.7Q4)=" M6'K$S2?4M%.#I5LY/^DR:N_1%?DK?;J=3._=F(4?@=S/*@R0.[!/+NO,9U;[ MXGF,+HC]$3\S1[06S.(9=41J#89:B@X_2'VLB/I/J#SA^<,X-;H%'T<:.64% M!0H)#IVN-(+3.OJSBHO82B1RUJ8@S)-XAI6[>)"1#3FH2!?H.1%I*^_)/"?A M@U$2OL(CC_50H5ME]45=V:5UM'Q/MJEQYT-8YG&5*S!E@E,UHREMG7PXY7>,)G$2P=W*9S+TPJ =FA0:>W2^ M>>!LZL4%@D'"I8)# ?U43/""0;)D!1_3.LOB0DO [J<6^[O\M,G)<9F9P% MFYMP3)-U.0KA)@B2#+8#+8LJF:B&7"'Y*3Y+' M/47GBIFV23)'.3D?\$0Q.7Z$^PZ&^QLHI1%QLT[ PSB?:.9JF ,;Q_!TN5/P M+C .0!>>0Z),!='$A4OWWM[ 68])QJ:^77=-YDV3I?5R5M=;(;S =@[MPX1L M'!Y6I: !99I-KR#>]I'"RTVV578F!8-=OSL;@B1>\(&>X447T3J:M\-YN61/ M(@=/9LHN$1QHM4VKPM()HPO328H"]%KB/O !)?QF6I^+B\ M1Z,K3AT63/KU3ZC<@\\4;?CI/=PDV2Q&MA\TQ=@[8Z>%"8KPI_]48+M:1YCJ MV^">JX\?OD\-)/K2E#'CO5!O04N*H!W7VOE@ /!Q8-%_(:KK36SC)DE M"9DE;:Q+4KDI.1\92)_"( NY1V'.D1H)-)S^]";,$_*][=W5_WY@;UW]8KS. MJ?R)'94KQ^="V<1<"*+11&APJQ0<_YSC*:?P6' ^E(FT%.%8P3U'0I,4<@'P M,>"7>F,T%XMW697R4)!1G!\X.)G\UA$\ID?79J:>ARNZ2-]7(>MVQ)X2AB@Z MYC$HZ/K;XQ!>!;;!Z(LG[["^\EQX"'B 137\@X)39@ZDB42UF\66B:+KQC=D M;!G508$A87OI^K^X>\I:5=XV@(*I,'K#[B[\%"=@1MQ=:;=GSKHV"\O^*,K4 M[[_$P_@?V(!%9Q&L3XQ%S-G%8#U2:U/-+K:F[L(W-SDXOD T,LU3HW&AXPE4 M>#=Q"N]8>OL[NTU'4(RX"(,',&B01-(IUPY3QSIFB:+[50R:G"T-^.HXPV#) M-MI?K]'Z-C<'#T!.S"Q7VWCQQN.8/44*71AS%Z?*9C09G*\2I7 ;@T^HE;:. M7WUZH>U'THJW&3^><7@K*#D,X.<*CB8\!AZ)5^WA[C_$U(;?/?=VX4&M,KIM M%V[;A=MVX:?2+KP6SAU=6Q0G=&XU^27<85<)9O5&DNX)?GOW[IV3-Z6;9;=[ M&&QA9!Q&#-?[BV"H[PHUBXL,;#KTE?F6@IM"XRJB@==SOMKK]EZ08U;82YVL M4WI)6+NO./X V]+O#^8L[S!(,PR@E&C]IG*1PW2TGVG'X(1(T!;D> L[>3(L M-OA1#G*L_#&ZP8?.7Z%@\70&\42YLV!3G#8^P=/ MFM9P>YPKQ6EHLO!+>GV:9]A=.]^_?6% M.[%)&)&HAN@81O@2C&"Z:Z.^PL%AA9U@>@:'O3O !3A['>SN=?XS[[).%<[K#HH3-6B? %_?7317N-X3C@R3;4I>,GW#&I<2 M/JSYY5S=D:LI!Y9)F^044*2*!X(\(/L>\PRP$@H+(L+151?]%3KC!_->-KXS MQRLBI)53)N^/&^KN)[X;]W2H5$JF-$T@4>0BF\"MJ&L>/P781U6)/ZC.C>LA MVI1$AD5A0**PU^L>-8E"$'H2S[X&:V_[E,%N=Y>>,CCJ#LQ3^KO=@VN>@O,A M8; YZH9U]7,'((KR5G07X$D]YRC3H5U\^6R$@A0A^IS&.%T,HBB)'[W-,@ZF M!-XF!#:HGTK$J[2@VY$\H8E0-IS')%D>U[74GL20J M=C%[@;*&8IHD#=<7U0+HV-A4*;$C,-Y#^0J*II+[K-]&S\O5GQ5&FV@XDS#W MAVI+?;3G'_MQ 5-^5%*X59<'#;'8RTD=O3>QZ^.JG&1Y_!>OG)?U?'\,JZBC M8(X=(D=-<]WKD#0(US'H0UB8K3?OCU_4TAA_PA#QCL;S >,$.4Q),.&/<&=, M^97PE9DW7%PW^%311IE6%-D=[.UQ9/>Z8)(#^GV*AV.:)6I4)6I!Q,BY!?!6Q1LU5_@>J3;IZB=2)BG*P> C(P:- M"%2.Z&F@C:-+6H88HITJS'S%Q92+NN#7,8I /+[B."F(4!Q5&!<>9ZNQ'%M) M,Y)FJ&Q(U#["':SS^->4:5">'6TBC%NB!960LPUR\.H7TIDFITVV0O@UGE93 M+H6BV(..M9F7OS,5&-X6UZ.4F%" I^_W@NDYUVYT,:=U@:50.DJOWT;O0"G< M=3\MUY16TJ>?WIV]IQLAQNNJ?_0/*BEMBG?^62'#$1P!>3L^'FV)T81*R,(( M/H%FFJD3A3_J^6V(DV.V(R[HV(UTW2?[,V"BX%5^2G5R*08V=$P$C4U_FSID M/E*R!>3'%FXL?,0YI7)R3CCO]WK!/_]VM+?_$O31][]0^N@K& V,_*5C.UVS MOJB_3M_\>,6%JF1-8!D?HH(1-FP(=SMZS2'6X<1AD%SA]JL42?4($LSZ0U0B MG6(MJI9Q_AA[#G%9<8Y'XNIXOW*RE*L(,!Y'6FL45B+BF .[ @,QF6D?8YA% M]$VN1X^RRQ07I+TW5Y41W>G+O5DE5[8B::C.\7[\\'H;+BRL+#K7Y]Y4E)63 M.(_\Q,E<,6DGD'=TFJ](^![86"6G),[C3&%A?WM5K6QS]VASFW8136DZ@9?A ME3%NX/.4'E\58%R!__#Z"EZ%44IR BA<$G%5,-:/Q2R M01E/J?L #2_;7 "31WM/ FNUH YY)R;G3F$E&\5FWT#6J]4W*Q#)'V_.NL_9 M\/4"23>DY-1^%2QBI'[ $:/MIS/])NW<#\(2C+E2(VT@%!)B$L7N.L" OUL M=C6G("0QEIPXU+'?BO]A,SC@!Q0;Q]R33^NI3,]5=O]=RR M<8*\WH]5";;*EXWHE^!"-W8.J>O [3089Z.JT/U66-YOVY$RJDP!)ZT0^0&[ M/:DBM_N"FAV4B4BX#1:FK8+S^OH;U:P,ORC]X7F!*[K!6X[EY6X-OHOENO7I MG^%T]A*<5!BJ3G[0[+A KMY,P;4/NDGJ(N3>"%U0872TOBEXKOI8D ^Z8*@2 M4W6&"3\E5S[PK"P#J7([OBF<8[P.+L.<='$8I!752 N#! @E!O_G!F>Z]NJ6 MAW282)@*/?YKZQIE$?@DJPJ][Q!]LJ7/X*-*M$B(NR5+2<*PBI-H.ZO*^HYF M.9A_.G:V4"GJ#[B^*;=ECDCPX<*?^RP.),5&&Z=1SE9E+F?Z/?IZ_SY!>>+% MJ'=JCOW67]/()P:&7 FF:4BE%W&>,=,0IR,*VXSI;1V_+7+ZIW0?I[S3?97; M%,A*#B4"G$+WW+EWJ60.Z![]N;J A9167).OHLQX5)DJ<"_ZD60%C8//&.;- M$W@[7\3..8RG$OP(V'@\C[EC.%?4>RK?YO!P&$]9/*8QA>BX,5;"W+7WT3=J M*@5_RF.%C2MVE\ZY5T WB*)C:Y9)6Z.4ZF]6Q<^]4FFGK51J*Y7:2J4G7*ET M#_[$LLW+; <2IH![T^ERB7"49P(I,?*N3>XTHSYYIR4^'+*KYT2=R1_,PJ3H M&*P(YPZG],G-EWA(> ,S??'ZW??$KSMX$8?;,3K"X!C2_H*O^ 6]E> 8+B^XV?&3! 0!MV%L M82#P'@53F*JD/.N=V@)",$ F^#'T;G,:$'\\0TD[M]2(LQSSH^>4V\0BDD+W M?^M6 /-,ZV)?9'@ITM;$E, :8!)5GE.*5:08V[L0O. <\W<&1[]@?TTGET# M(Q\IQ):@0A8*0<.(*.R(NUZ6:CHK/0M"\KUQ\<7 3>BG;8:E[U@X$XEPS#F8 M[-]Q5$1 +$*=DS8V39R.\Q",L&I$;;2TQA0D5-)^K[ZJ486]3&PJD9??Y LO MMVZ':Q"EZ#DWPD\(>X)_OA'B85W97GX&=8#G,DMIHT45-<-_Z$ %0^A@8A&A MJAZ?RN7HJ'NXMW\7)I?]0?=H<"_,(+O]^Z$Q.6H'VU^.>F=)4-N%:&W]O4V" MA_\OU?J]F4.'N@O.[S( =BN%1'[XY4(]OEH(U84KLAG+T3]JE\-=CL/'P):] MSYDVXSG^2J@@.D97%X&;IK>T%N@%:[L"?[^_2;N3S?&5CS_;?N=P'VYFQE.^ MMYGC7V^Y JL$7+WS/)Z?S&Z P![T=KN]%0ML*ZVMM-Z/M.X>];N#=9366YLP M8_I_ZV_"G"#:&Q80A\DM+)B&V3V)(]0TKS4\*'N#W>[.+8])LT#>J^JNO7)I MU=U*UZ-.:&?OZ-8V;BM=K70M*5W]O M:W@>]@>'W?[=3-X-]\,"_A@YZ![T/I7K73=CTX^ M['6/6NEJI>M^I*NWV]UMO?>5K^N/1'N04AB>^?Y22Q6&U&WEK O#IR]:;^NQ]^'I"=8 ?/E6L!Y]'YZ>8.WU'DFPGJP'_XJQ6!D"-$Y'V11! M$[^V*?9-,72WCGK][N[RAZ)UH5K)6E*R#OJWT;:M8+6"M:1@[>_=QO%X5+=\ MI-0F7.,?5*EO[RU$N[B%D30_PR=Q%IKFM89GX1"<\%MGU1N%\GX=)O^5RSM, MK70]KB>^TSW\)EW0"E8K6(VVX4%W\"B"15?X]]0JOGEM^$@QZW)2X[7]CJ]M MC2=%**/*:_#EZP%A<0F7(-2\TPQXA4V=!,;-='U(NAZ691X/*P9,N[%SOP4C MO1F,M,8E3E#3BR(GSD8X &@"1B:0*O2\,@^W$><$<6=R&/"8$0PUA NBHR2) M&I45HXK-X/=7 1T1PMQ R.4\+B8$GQU'<9A?$93)4)6(]DV')\@N4Y47DWBF M86JN?2I!C$^R2Q\YA;$A$#B% 2.8.B (<;IF&>#Q?S_OV->R0#Y4[#F,$ M3DPJI0>BIYP+J=&B0;UL 9Y7(,"18NF-@GK][9RT,B^2 <\,-49N@2"T H!Y M+0\I\PQ@GPX\(L(C$R;C4*!!45,E\0A?'3%A$$&#;R-&D>$A'8/\@21Z;"G] MHY?X]%88[D6;,9U]8SZ7Y,)*B::8BHD-A?" F&::$\)O83,1W 4?C-?52T:? M(GRG;#Q&AI/A57ND5WJDP=AB@"MB59O;KK\?@K%FU#+L$6(^I6667R&@6'Y. M^*HC;$N,]*ZY@*L(S2HH7]<?]\XB, ; !-;OV 0,!@GB-@FN%Z(NX?( M*U$0#F'M-F.M/B+4=%A,.O2_ 5(%@308M#H7O:Y$D!.8W=_[W=U@*-HN_/_L MO7MSVSBR/OQ56-GL>9TJ6:.[Y&1WJCS)9$[.[DSR2^92YZ]3$ E9W%"DAB#M M:#[]V]T 2%"B+I1EB9)QZM1L;),@T#=T-]!/$VW+(ZE&(8Z"USH[O-:^(9A! M:K\S]068&O220+[EMJD:-QEP:H8IGD)0?*< T7$U$^"O[E*?@>49*J#Q$'TA M4AQ;@3'.\/X5J,-7C0Y/ 3,U?^+C)$=!''/JM4&8ZNB[4_GF M4M,$A?R<8V4V: &YJZ,QE27N)H])R9#DU+2(YC*A+IJ"8+97U^-.(]6V*J6> MGM3Y- ?V7R/#V)"M(,+ C7D:N]1#2\*L%[F+;\CI" [<(3EI.H9%R5$+/ZDE M-9Q_%]CWELUQCT%D6_B"FQ_U'V4OV^!8M8^]E[WXWK2QN=#E*,&*>T7Y=Q4! M8TW $E/J>_]\L1V'N=]YL<7^'AX*-TI ,TJ<(>$@]W'X$ M5VR6M4OXG]2[FTGDZ#/82#Z0KP'6GBP"\/0M6 '$WJ =--<::J^:-8EA+OK% M9 C(+A&,\D^WMY^DG4AC-,R)WH#C-."ZK\6=:M]+?ODL#>YTKUI\\$NFN_3T MCQK&]BV8--7S\XJ>^_'M*V5OOE);Y70V5^;K/YKZ$K4UX\QS!YWO6=!Y"SIO M0>=/LOC+!)V7B/'P,?+YV7)3,8* S[UJ>1+P';4J' MB#HS003EQYR\9HH"QMJKS4<"RN51E-F%A0)[W6V*W#)C^\N:,X/[1F#]=.SA M8%8A4K#D:*#DP8L?N^E,)+B)PS1NY2&#AKZ6G0 \'P,+!Z<4RU0E!642 #Z? MK!Q4/DP8_<:,"FT(SB.V_I6B%X1R_T:H_T!$F:.GOC9*C%;;&E!LZ1%C,:<; M4S];]9/6AT*?@W*8<8HD,_N7T:ZA\,=]ZMDN(].&(?U9=I&4B]H>(V,;Q1:! MC?S\(D$ZE70;,_N,N9%(5.0L*V85)Q]E9+R;9/A*[ MW_HSB(!OA8-+(7G+W^7W47#/5'U ML\FC.D7>FL\^E3D:7(9PC SL[!U4;8;Z0'RVY_55OP9-!)89GAJ3)3CH8 ML;A_ICYFR3^$"3;>1O_JMECJ:^E^&+J_)??@#GT2M.N^I]PE2^A#&!4Z&ONU M4-U69W_HOXWC)>GX[90!U#D][0)M]$LHI@VC1$F.!9[R=U@/=9'^ =_?B$3*!YO/DG40PX$%\-*8_;68<2/- M\, S C+LOB@;+:// S:3K&'WIMG_.Q*ZW_H[AH,/41R I^1Q2OX9@Q)..9[W M?&%A-/&=GWA(O[]2_WA5/*"6C]]'03K#'MRR8WPQ'BU5>=6;N! $&O%L(8%, M.;A<9BE)@[W=]=:A;^;BG>0XEVF=:UL5LDS:]54"GW8?>2E-=ZY'H<=$B''= M%X905,BF%'LF\4JO)Q3N$^LYRR0AI?R*N@'2 ,D#YSLN0*1\*JI+UQI M"T")S%ZVV)E7;=J-NW3="6L=0WNB"4CZ*. M:&0U#VQ:$T[^O;K)ISH=_P6;F>Q)DF>411LEBFD M/*22C4 M:!\!KT6P)"4-B,8!-C^6$::T\;C!T08!.Z76I*P[=5-?"I+W42E15(<+9<>7 M%W7*:F3F2P\V&\^2.%DX-/._/5<*R*NT!37$[:9<];!G/!X,27=(WU]5AXAT M+QA&\_0E: _("R-@8<3S--9_+-UR,.6-CEIUB"--FMS<]"5ID5)_\"<+"N?)==;;0UU\Y6T<2N=>^2T4\QX%9VY>^)=M7HI< MY1;5V:Y;:F=2L4L5Y<)M&79=T4(W3A2P\\K(DP9QAT6VH[QF0V\G"!3B; M$-H(W#V-Z$EG9K.[#!13RZ-AO1;C&H"\.V.<-,]X,HT\X-:=S_.[,*F\?IZ) M>GXY0CE^V>48HCF>G8&+BD_>@8SK,EU7D6#IVLQ_1P_P];BQ'#D:T:]QEAV4 M19/KY?297$WMVZNI]FJJO9IZH5=3E3FZJ2'DR"3"K0"W+,)- >]AAB5I?_'\ M4"%+'B^5GZD,]9@%^R$ME%Y:AHL!JN?FL-F2)E%AOJGQU9^;]*H,UOZYU6SO^;=^>[37FYLFVVXW>ZWU?[:3?4:3[>PT[!8WX,?1*]6)?@-6U3=%Q&;5'7_W?5TA^K4&U.Y@YL5 M6BNT)X9$[H'45H:NM0)K!?9$KL$>G0R/);07VQ9IO4??OMG+H]_2JB0;HU.- M>*5:6A/!';4NH'OP)3*F?3.JW'/" MC]UEJQY0#Q6Q@L[CLCP6+6M@\0SFW/]+EA=)M&I=BN6RT*.[>UC9K,L3.!4] MCK/;WK/L[J>^2*[NC>NJX!RZ;KGY MX0U'7/I?TU"$)DC'7-Q1O@,9??9$$$?(ZH4L#_4XA^E= 9?O.,A MX>IDDD<"[0?J(EEQV*4!-@9]""> 3%NJ$A MC*3* Z>/ELJ$^F)4@KNB[\=]F8*=.!>DK*>"_3NY)=!->C+ @SMS<4POSL\7 MI]K=Y0U[#"\(5J5-ZUH4X:L/GY04OD+A_H]";9(P,_1!6:[!X!05Z?5&B_ZU![5_%;*WK+#EIEZP[?.ML WEE4'994.*I?:CQ4054 M)VZ46LNH7/IR(._@P\@]A6P8;@9I*/6!>ZO*D,?W2NM\@FZYDW5YAEY9#AZ M@VH+)U+#UE$6P)'=LFV)#T3PV!=?5U)/][ZA+H2XD,7!+$#(!85U"S%=DK?M M"A?:TB4(L94H9^-,@MC,#<^@OF2A+I8I"]+UK$<@>4\. I L^708YVJ/+O=U M(8@M-Y@N..9)\XH?@J8'#=E_JH.,4C5$9M6@(UC0/;V#0+WM%4#=A M2DV"$_I &%BJ)YN"_HAR6!<8JX" 04U.7(JFIRJ#Y<(($@=$HK4B% :20J(V M(DO0C3T/B?M#$A>D(F.&0>'Q0N4RM+-7%#79L2.\"W2+(WPL!1;*/!GVI%ZB M59XGT+\W8Y'E45#LN2=HH/S+#6HEG$^2.BYA*B/(6Y1KZ,T,ZD<'@^?&%6.= MU+];Z\CU6AWQ8T&,4[U,B?820BB1%E..C$-FW"C_'GDQ#+P^I5WUS$\)59J+SS#7"_>A '2?I M4"8!_X&G@G-I3!/5>"B56)99EUNE(<6-M5\!UJOO:6SH1V*II.M MW9 17^1Y/0SC2]FU.7/W@.D>#[-V.TC:8[)WSP2L:&#!BBQ8D04KNE"PHB?J M+?V8LX?'M+XYN:?V96U.VNC20B!\>2BF,_+:*S##K:+_A.&LFY/' K-#K8H M8(G"D,O3.'*\L9%$/B;Y.]EAYJJ39GQ@"?0^\=79'3/35]?RK%/V.Y7)$$8' M96X $>:]FKBQWVM/AY)=3>='?%H=SSU(>$(AO;^2XXGULX.W(M>G#]"BLP:, MA?.6W!&$^>&G>':)P/@6$^N_H\\5C:' CF\:BLD;,%J^MXW<=-[FL6=%(F!W M6M,_-,!)HY!3!(Q7>.9T@#1/$_-XI.B0FOE)=@;?B$)UT*/C!FI, '* %Y)4QXA\.#U4)C>JF:5D@03&OJ7^[!A[ M+AJ8=! RQ%^>E=QFR55=@W"I&L$J(J(R&23/D>^O9=3O[ ^/)P$4+(ZVL@LF7Z3ZYF@170[V-6GZ!6 MM"!Y*3Z.,GKG\)#)H!U>5G8*41C7#6S>-S [.^ C^F8D+A5^A/W&\S5&L;2P M7DE_F7$4?97/X R,%FA&P_&2WN(2YKJA&V0P0_ S+&%])V%+#HAN)T&8B$RC M7)[\>-GR"VE3><5(W[L"7?;%M'PBV=4DLU=6R5CD]D@7AAO]IO7A#C43CZCI M!S7X55W<2R::&_J0"%CH46Q8F&(S/KS^*6U]9/1A^C#1%_3R]^C2$?406453 M;B#!<7'K]Q=J#Z@V;N..+?ZZ9#$%9P.?*:.P.H+0.R+3G:8Q>00C:;_E7*Q+ M+E"&&CN4V,-[:&:J3RL)+E,G;(3T9 I-G[&G6OFSV;6U4A6)).R\P!=QNYL@ M:8. W4]Y1EGQQ7M9CD_,:Z[;EA*\K+X_F1_F&L\F_^4*>.0/; O8@\]1@!E!PYFC_ M50OZ,B^5>?<\1OM?L"9QGCPIV*Z\Y5&C MM'^YS.:6Q[DX;MXR;UY F#09)2_G\V\,[PU1WI_2O,8S1M& :I''G)>C;K_9 MUJF3HMW3CQO'RY2S3V)VC51#LZE:U)G;)#S _0+4KEI "'@2:J@$6J,#S': M% P^?,]G\4+N]C08K6A XL.+6^R&_ M+7^BD"TOL>_9YECP!&A0\U1,.U!&:[Y-ZU4+@Y&,OE)+Q_7J'#C+ZDB+M9J! M-P_DU$(*U1_2F(6+XH#4J):^K4ZJR0"F,=A HY\''DOX\H$'%IM'RG@Q$4/! MG.BYBN7U*1B3XE2-;53>6ULALV1LUAPRF>I&AXKQN(BLPVYV$;7: M3IX/S4[<']"]?[[8GJCN]U\< M/4K:TA48<[F4-% W&#[%8,9Q/RTBNM9YA_O"N?,+L-OIZ=P$WL@ RQU2?F,K M.U7YV"0%9?&X<&-_KI4UEO0Q^T07Z"-;V&$VA'3%5'(_5KM' [T9F$MCXS8B M6ZMDL\NVS6=_[#9MUVN=7%B(C1NI$IASWK*_+UH*6O-?*\AKKUWNEVVUV M._NUQ]C\M^YPOS>W--UXFLGVVST[63O9IYILMUNW1C'M?CUZ86S=(#/L.H%M M, SPNBQF?YK.($=X]"1]@?;M_5$74=BUR\B/!P)'G;F>U[ BZFR0AG?S7(MX\W1XB6B MU:^$WZ.N-2S%JK;#0C5:/K,."XW1 #SMFO98L&)KQ7:-V Y;O6;+BJT5V_,2 MV]Y-N]FQ8ENZCNGY]?MK?:.TA*>]]/E\W<2X5V;X=1$A >=ZAT^Z]>:Z!(Y,X0- M><^4K>7,T^K,S> "VA!>(F>N1H/FS3GW6+M$IK1')^]/9M-)WW_YB=RDVP.X M2<_0TQ]VA[9%?2TY,QBUFC>6,W7D3.NDS= M9];GQPG93%\M&=,;[7L3 MPS+F:=-)PV;/9I/JQ9-.]6-JFTTZ.!=^0L0S<)OPG\O;^<9^N%7-ZUVE42RC8Z.D]QO MVSQ"[9@RJ!096*8D5Y<=;K-4>74C%4) MJQ*7JQ+#X1[92JL25B4N5B5&HT[ELC&K%U8O+ETO^MW*-7NU40M*3'Q'[::^ MWZ._U4E[>'U,8\?HXZ6[\BXXBQU>WCM&]CE^8,)Y:<2"JL-AF[##2P=2?V^:1^U;+YKYMW MC5_M3T8=[.>Q#QP ^CE,]XZOW*W,Z$UV2%;1,-4ZR7V*(^PV['PN;2MP7LWD MEM>RJ9^<\XB%PKKJUU&NWQD\24>Y)^G.U6NM__-C6HGMUZ!LRV0[_:>@K)WL MN4UVL)O,VHYR%3K*.;@IVVYR!^DFM^FDJBXR\-A6<"&7; MQ]GV_VD51T[C'$8VV1G:&=XU!E>[(7HW_V9 M_Y<_>XKKSX^^G%8/"NV>5"];5QW3XKU+P+*STE5?Z3K_WAM6NNHI7;U1YY1U MX%:Z+EJZ6I4OH5K9LK*U:W.24VZ+%PM@\:_TGH5/FM2XH*+B7K\Z\KLM]SX* M9P9[WU6RG'E:SG2[S8'E3 TY<]5O#BUL1;UXTKFQL!5/<:K#[@+VUV+&GR)/ MNY,F?0%9J(ODS/ 2\H,7R9E>WW8?JB5GVL,+2'I>(F,ZHU.>I%UL M4N<3"Q;A7_Z?-J^SJWUHV_:ZM>0,]G"UC*DA8]J=RNWN+6..HC&VLU,]&0-Q MV^6W/CX!(FD,OTIC9C,[.QKN=JNRY;;!T%$,Q"577*&$!=I9< M!2B8L?@K1TBV\8(@V=XBWE^X.$55\FZX)Q>AEM567$.%;3<&PW[E"Z>5EEWS M:BXKK>5U8L]=[H-O#2F^JGMX><7%D83W_F)AWO76SW'DZIN=>R,^B7F+I$S M-\-35F1:QFQ0F;Y5F5IRIGL)1Z.7R)BK[K#9/@.GY1CN/ MHT<--;K=&+7VKCH^!%'.(ZZW>G#Q>C 85*_AM'I@]>#2]* W;.U;4V_UP.K! MI>A!KV>](JL%SUT+;JI?R:N!%E3IW7N*GJDTS.X=874+I4ZKT(>WT%MJ2TO; MDW:!Q0Z^?NC&G FN6_BN=(7=O4DQ$RMDH,;%1@O@)(G]<9K(!ZHW <9^SDH. MK]$BO1XND_#ZV#3\K[^-.IU!IH5'^FZ1"MU.<]3'96MXH-=$VXRUR(0BZ1ER M:NR'+,%FT-%$I[2<21S-G%F$C9OA;T!1>-.=^OP>/N;,F!\F/&2AR\%H"/P5 M-H<.^4/^M!_ZB0\_P-]@#C&;+U"R<#J_-;\T@5HWO3>6U8]GM49'*&'U.GV# M[> AF6IVA"EU% 7>&[QS6!" +-R!5(@W6YL^6SYMYU-^PKY5*1-_AFJ#'%%& M>)(&$S\(9D!&?$ =O6]@C)I/KX]< 0U%]7X=\X!AT_:\<39VWS7>4CMN*W^% MC6'GAWFM?66EN^$Q&3P8%0E@_G<:ZRG,V1V_'@.QOUZS"V$*\^*XH MRB#':G"2W.4%KUW69')@^2&2>MR-8K+*K\%UXS$^!1-AIYV ,XWYY)\O_N:W MAMUNQVOWW=%PW&/MX;C5O>FQ?G?4\GH];\+^;PA>!35[!RE^&^%ND8A_?,>^ M7RNQZP3I^W^,X^^JOW9@^2OW^WYF(<@6:B6:FO;PC7#>^<)-A<#=%+?$VQ!V M8N$+),-['W=,^"82Q"/]HF<^ M5]C_]4.>0T&>D,X>OOXS=6-U?F0B(=',/85?HAC^<3N#F;OL#;@*$-V!C[ MSD\$A OCA742'L]-#?\@F0DF>#LSZ4'8U$7B)RFXZ\@VP:3AQ;_I(9UQ"HXZ M%^3=_0\+4Q8O*%Q[@Z]8YCV>>=1HIR+GR&B"320+*B]9HND,@%?W?D(ATTPE#08U64M1\N= U6 M=1:Y&D,P4^(=4GK+:4-5X^3T]XM M[-DQNUV;4&8C/SZ$CLOC!)PZ\ ;3$!;*1<,1J3M%-PU^6Y#$AG,7W?,XG-%& M,0\8.($!K :<.?A[Y$$PIZ48(H9,2\@B*;^CZ6#$D1,1Z"[T(/G@>A@7R# F M!8.MR!>8AJ7!\/?(JX0[PK\+_0E,#OXD9T$V4O[K'C@H_5M81)3&V97W\^#. M'TBZQ'?].:Z4<',^_O[AW34$6C %C\^ X \@>LZ4W7-RZ%7.U?$A!@/1A(5/ M4LJKE,9U0!0(R]O(ZAD+T;H0D91@@]N/"1D/6(6DQY#NWF?PTB05E#5%3\%Q M8=K$=V<:B3E&S Y8J$0%!M_![\&V,6?*69!,71P1AI]PRC&SH.G@0,#\PWI MM @&C5DHT]S">8!X!&M$79@ BQ>YJ,LQ9&9"KX\EL*89;Q#E"]$168M(<+%" MLF0*;^&D9KX0LN TCZ)@9OAF$(FD.)[' [9 ^X(R30H@$K#Y4H\*L16Q.X1W M8U2,F(/6SKG7=+YP*2"Q+[XZ$^ ]O$C&MO7FUU*Y@1<##]@.A));"_-@4,'Q M7Y,)1^&!=>FL6T.E;N2"\S0_+FF2'0RX^F" OMQ^@Q*B)O$9Y_6>YB7RO[I! MZLG([Q,LU_G0<#XD?.:T;Z5I\(5S&X8IC/R9S\''07E^'\7P0.OZ7T0;M.L) M21+R#?[$:I5&VF9[S>18 S6 1(."IY)L&BZ87$D08Q_%=HEC0,G84&V96TG1 M-2Q$TYU6TP'+0C9CS,'YF,<?E1$D!M:%#AI&!(8P V M K1 V5NU C%E*J];*F%:#_"!XL;H+QV,)DV,@4>Y9$,'JW B)Z<31-P;BU-NV_4_0Q>+?YI' 31RT;09DGNDX M'58(SX,KE,8Q#X%/H*Y3W.P<$$YTY'(G%GF/$2&I?BKXAG=1N6-&FUD$^ZQW MAZ0'><+'5%@,#1#).14D=^^_). M[BW%CX!(;4T2&]P$9JF/ZPLB="O4Q5->/*;2_WCC^0*\V<5K/R0NT$O+5T!! M)/);%V0G:R?[9)/M[#3LEN+LK17R[?[*LR6U ?(.RC$OQ:\<)A+S_IRLY3O+H8WEH5)NLN]O?6KW>7T?^H@>^2\G]+LM\%N0RRA L MN78@U^AIC$2M%]U1I=7WHJG+6782FTNC0_MFE0Y%>:@. C>9M"9N51"X&=W% M.V8QV15%U[&,L-': WBYZLJ?'.^IJ&>[-Y6P M8GN>8GO3K8YI:X76"NUIVW??[-'ZR0JM%=I3H]=:2VN%]JR$MM>JC!!S+)G= M,9EW7J'BZEG3VOQ!IW2I=496'?8Z6[;MI[-E%1!LSX:0-(')\UY1'E6,YZ59NP#+6TUPVK&Y6O&/F#35C.L9ER\9NP!/VWUPNK% MQ>O%'H#4M=&+NL-2;P4BPMR +NV9;*MNP>H?G4@09?G\/(\O0?RP-E-6EG@I M5;M)M.?0RR&>TW#"[J.8:D;&"^=EI]OL:I1 >O)EI]<<9;_!0BON8D42EEZI M>J5"[7A>WL^$X9"6K/\3L+S]H M.&^!+;.Q+X$?;N,[CK5YK/GLT567P,LMNJI%5[7HJA>%KGKR30LKDE75[_]+ ML;(U49@#P#GX1:!_?B<7E\9823R.TL3Y619'8ZVP44$L2X-U;?!PY]I@HR 8 M_UB^8\JZ:;+S$LKD$8 84J[^DXK$GRQ.B[WX.5JP0!4L?Z1]_O/RL<*9N4)Z M148Q/U6/.S'] ;T#SN(0"ZIE ;1T?W)(&H'.I4<4@3EQD4183RU!_"0F!9"6 MAX+C6[ 5@INJ?VXJ&JY^6_]"?3JK*-=E]VJ(#!(#<0*# -PC%-PY8E'%BDLQ M%A('A.J"X#!"1"8)\X,P !%A4-8X4ZDQGU:FKDT^@ M2?4K33Z!BM2D+OG)5EY^H+ \%IS.7SXTEWM'AR>.(43=U[O>>I,!C1W*<0?QM9?]B9;_7?9(R<2O[5O9K+_N=QZ+I6=FW MLG^FLM^N'NA;V;>R?Q&RW^DTVV@D^Y,>ZD$PVZIY0 MV]>LCV=6;R8KO98KV4RVO64)UK\FV#0TGC&7IZ0/5 09=*/_=J MN=]G5O;V'B:*E5Q(F%\B;'B;-2S/B_)EAU%./25ET1H]?4\U#D0HV6'VERA! M>NL"2>82/<,%(@:\C4)2=*I6RTMVOR3P"]F5CG8F _D$M2K%E+M#,; V,W#:*%I6R:JGRC3;%U*1\YQK4TQ:< MOL4>S2!U$D0:^:>[F?X48]ODGVFR9\&YXE)4J:=P8O:0=0;'+K*@C%$8\D"V M9)7%F-+T2& -%X81*X6<>8ME+?/8PIW'I#*Z4I6:Q0JNAM#%INJOJ WF//+? MJB_*)LW%#^7%HHW"KE!\B@9HT!JP4#5&9:66Q]_4#]C5/$!UGJ%IT^7X#-;5N@F3\8!K.,=%ZK.&^PH MV=E[%J3:K #O[ZN5QM;.8UCI%IS.<+OZB\N6P:LJI_> .U(YN9Q=6P,/:ED; M;#L#V\G:R=K.P!6KV*7#]R77JLEO;%/B4NE*3XML+ M:#KQ+-%>SQ3,]0 M(RX%Q=B*[1F)[>/[.5BQK0$CGYO8/K[9@A7;&C#RF8GM MHSLA6*&M 1N?F= ^NDW!$WP/JLB4[D=FCX>(9*47?Q[G?JU\#4]!KCBSGGR'G(?3JG$MC[?IQ_5/)%:BUAUN; MJO%+%ESG?NS#O9.CCQ2GHZWP[T]1^GZ1HC#:-^%H1>'R1&'/C(@5A0L3A:MA MLU<90G&K%-1CT[="L*L0M)J=PPM!3197E(*=Z@5K<=5_I=Z$ZMED2185#:Y4 M Z[4K;T<#9N=K ,KC)771.A*B1B[4WJR"2R-:O2\F\?\.F!IZ$ZQA")RD\B- M[GB(O=6^,?CT?73/76-,+!S#$HLTD+5N(3#>G]-H1M6;K"UC@>/!EQ:BZ93Y MYAM6Z7%-B97U3H%\68F-3DL72B!F_C><)E;B<.R6I*@@A^K6>15=Z< M1852:?%C48RVU#NR)(G]<9KH IQP,^W]W0#%B*M8+8?).\L"#>^[,X'/3 MW47IM(5[G[F Q6#SY!#OSP-#HSG669X%VS[_%YO-W[PCWH6D!JK*K+SX#AD5 MF^OU\O4:G2(=%_Y&]:S*IL!@U[+1-!9C92-@Y9Z?R!+7I0ZB65UM7M*W/-=< M&;-9@QUV89%4\$M5;OH'D:0>U>[E58?/O)'UL%4D@&UD;1M9'^G^N&UD?;Q& MULD;SI_4XWI!1?]Q)"TYC)'&( *\H:K#]6X X_CW MJC [+])6'8$S5UK659_%E@R>U(QT@_;!Y4UO#+L=3LN?$'0$;LBKE !_W8@I M@.A!X(PY[GU8>0YL\"3IF7,'6UJ(?_ CV=D9!D1GWH]B&.DO?(A/X*7$+"IW M?9J [SJPQ3.JH!^SL2S?QU@B=5TNQ"0-3/>@X4@' )P!-&A I8;#[ID?D*6; MIK!FN66S.;I>Z"3 ^EW%2LESX0.1&88MH0 J*'5O.G]P#1#!@H!P07S^8-:\ M.W-_SI'4>HT%QT4D+$G%>O^E@:H8?X%>A"/X#6J"K^<2I@'>)\A%EQ)DH% ML(9+A &N".6B^V^(3KF],*+K**:?R$* #(%YF#:$],@& (% M,]W.9!HAK28F_>&&RAK\'25CH#4UK# M@,\9/35Z3I:@.5O4B^7M@BRE0,H @1,3$F-76(NR)=82YZ+;V0\S8//?NL/] MWMR"1/ TD^VW>W:R=K)/-=EN]RCH&<\*:"/;["S:A@7FL$@3%IC# G-88(X: M G.XG%=O:'C\*PR%PSCX%YYXEQS)5;KE4ESZ[F60\KT#HWW7YQKX8U=8*F#T9:"'"NJ5E3K(:JC_I9" M82NJ5E3K(:KM=CVM:N78LKRQ;?UDZ_=(T*T(C^\51YZ\P_$)1+3;VE*#?> V MQ_L9S>?(F3T:%UK.',4#N=D"6&$9;2?]];1W; M4V31=ZL5725=G06SW1[LZZ'7*&2\2,[<="K[I98SQSF!:3>'9\^91W.C'EM MY61*W5,F5\-!V$YU?+&-.ESH[6VJ9Q:\J6S MK4FT9#R.'C54YD%G[]L:AR!)S"RM.!J-*A2!V(5P"K 92E >[0O0L(IE6"G M;O)J9J?HJD7#[-[TN;3A^EETY/N5FA_F7<_7=U7&Y<6^X%[%QF&X3%B4%IMK MM!^R+["Y[NMC+QS;S'8&F=(: M3(*'@2T\SMNHJAY["T< 0[TWZ_M<6W;MR:YDY697UKB25&4>1W1ULU;XLO-C&D=SSDI;>5IF'IR9NBFIR< 5 MG!##3"J>%EGY0PR?3F,&HR4P&OY6<=9R[.G4KZSWK,%%5?_\QD$KZ5,_YV@R M$3QQQ@O+E0-P)<3FQ[DB48\DD6"_\:QQM=[ R(- +JWX'&@%7W8&S:YN8P_L M6E"3ZQGS.'7/Y^1^^!^Z"?2*!PZK-CFD.C[+'NUB*>CHM!JK M5DZ_[>4,1 89_##Z,"-AL?=QO+%S5L[!AZD/$>-#UM>;OJB>I(&0=;&2*/U6 M?7A2.A@N-R'W=!*PP*B3JE-L4PC&_B! M("4MW[3' EEN>F_PJY:O!^?K:O"]Q$#\X3JSB>B=.BZP@KK6BPWA/DG)?=9X M0C'1ND8GBO(WZ-=FU5(?[_61!9'P,01Y33+BW_,WJL4VI7?-MU0^M)6_PL8B M"M)D_2LK#4F/R DILL+7KNLR>3 PD(D!A/W?$#P"3+ZCV_P6/@BR(?[Q'?M^K<2N M$Z3O_S&.OZO^VH'EK]Q;^YF%(%NX.Z)=:0_?".>=+]Q44&R/IO0V9,%"^ +) M\-X/6>C"-Y$@'ND7/?.9BS1(Z)&/X'43S85SI?U=[U4]%W_U(=3!&,W]M^:7 MIO,.O#D6BP:X?2Z?)YBAC+!6XP'\/<<#V@216%F1W4.>++&ODXP-BKL@EH* MRV5SBD?^8CHQ598B&?,[%7 M" 8)Y0/8R&?S(%IP?JUE)DMTZCA=T/!XOCMO...X\)T&>(80/D!PH#+3\CDY M&X@]KB'4F_$8;9Z6MK)$*GYFU4MM%AC#"HQQKGZB!=YN72!L8G/^[ MN"/,!7^M__$&MH%YP!:O_9!F1R\M'^8#J7(/K-F27IBZZJ_&5W]NTI^6KB3( MOW6[S6YGM/;/K69[S[]UA_N]N6FR[?833;;?[MG)VLD^U62[W9V&W5*KL[5@ MJL*C[?[*LR6WS*3#?,SK52MN"%FU_^7@+SL_PF;@.>^XRV=C'LOK5MUV8X=2 MGT-2[G"/'I'=QA7'=3?*6JN7RNHH"GB\LDMQUR[+?!;D,J[ 67+M0*[1T]B3 M6B^ZHPIY[D53_F-'L;DT.K1O5NE0E(?JY;2326OBUA\M1 7#CZN?+:YU]\OR M\KV=C<=EW(BONN@:7GOOM;K5T<WN@\QFA=8*[4F%MM.S M0FN%]KR$%D&EKV/JJ-:'$EF=\P7UE:0E@[5#I%?Z)2NOLY(8-UN M;PM@Q-.9MPLD9^=F6^6U)6<5(9Z<4 ?*\;JQ=6+ZQ>%/6BU7OD(:/5"ZL7EZ<7_4'E9II6+:Q:7+I:# >5 M&Y/41BWJ#LBXN6BF>(-,..-%5K'TP&..=8ZR:D9LA;%0:QRL+M%6T#ROT@D[ M63M96T%C*VAL!8VMH+$5-&=!+EM!8RMH#EE!L[XA7;^>YZN?_O6;\TGCW5[] M*[UG$L1& XVL=,K8APY[MJ)X+JF.JHNN82:CW1E63V547/>3)_"LT#XSH>T. MJU_ZMD)KA?:D0ML>;;FH9X76"FW-A/;JICG:%=<:,/!YB6N-36SED'1# M?_::AJ0_?_IBA*2W@9?&[*_%C#><7]A=0/^D$/5W?^;_Y<_VBU"7R++#U?.= M2%OK.^FMZKW -TC/4UG;Y\B9]DWE0,1RYCB^N60YOO>1K2AT=.: MBI.&1I8QZTN1+5]JR9=]<(DM8X[ F,$IDV_/(,?S$5MZV@3/CJ=:-EJM)5_: MU7%O+&..M*U6]7 +1]$EXA'#HTE20YW>JQW>0:ER'E4[5AV>A3KLU6C/JH-5APM5AWU:^%EUL.IPF>JP M?Q+>:H/5ADO3AGW:#M9"&W:"+#X6/C$-\]J'X-]W"T1?@2OK:-@VT.79G,7< M8,X5O\-B9<>!9RA(_"O'O811>__;E'7 BC&9^2!]E M@CB1[X;.P'Q/;F69#] M#TXT@\4O-S%#\ID,F:1)&G-G#I^)/($0Y*8R@/2#P(()Q-<"EH;NU GY@X8M ME]01Z7P>Q?1\E,;.71"-05/&J8!I"1K23QPPS0_U(5YE.]B^6;:#H[JLY11V MT/]+JLY>YG#C,/ I0YY0HUU8I!^F,/1OS2]-G#F0@]Z"L7[\S1A.22B, J]J M+,G:R-SA[210!KF%ZCGA7"JC,HS:A#HK)A3>RPB,V@IZF4S7$TG-LH?'&/-( M^,BOUS2H?\_SW@ (,&Z\I9RM5OX*&X-?E2;K7UE!:STF^8>=(@',_TYC/84Y MN^/78^#1UVLV@1F^9L$#6X@7WQ7%"F1*#3Y$L5I>\-IE32:'7984:' N8#LD M'H!OS&-\"B;"3CL!9QKSR3]?_,UO#;O=CM?NNZ/AN,?:PW&K>]-C_>ZHY?5Z MWH3]WQ"4@W9ST.FW\$&0#?&/[]CW:R5VG2!]_X]Q_%WUUPXL?^4;S,\L!-F: MP7?_ZV^C3GOX1CCO?.&F(C-TMR'8,^&3:7L/'DI(!@\(XOF)?N8S&6]ZY"-L MZ$1SX5QE!O15/1=_]2%T8*R 9@MS)S/_#MN4Q. !@\O&(?0"^Q?AY:P''ZRA M![0)(K&RHFTF_K1>Q(

    •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